Annexure- 7

Annexure IV

The financial details and capital evolution of the transferee/resulting and transferor/demerged companies for the previous 3 years as per the audited statement of Accounts

Name of the Company: Privi Speciality Chemicals Ltd.

(Rs. in Crores)

	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year
	2024-25	2023-24	2022-23
Equity Paid up Capital	39.06	39.06	39.06
Reserves and surplus	1,062.13	881.42	783.41
Carry forward losses	-	-	-
Net Worth	1,101.19	920.48	822.48
Miscellaneous Expenditure	-	-	-
Secured Loans	845.26	879.13	403.70
Unsecured Loans	2.50	9.00	-
Tangible Fixed Assets- Net of Deprecitation with Capital WIP	991.92	969.93	1,023.78
Income from Operations	2,038.34	1,712.06	1,577.84
Total Income	2,056.25	1,733.68	1,599.44
Total Expenditure	1,802.38	1,601.70	1,568.17
Profit before Tax	253.87	131.98	31.27
Profit after Tax	189.30	97.88	22.47
Cash profit	314.92	223.13	133.09
EPS	48.46	25.06	5.75
Book value per share	10.00	10.00	10.00

For Privi Speciality Chemical Limited

Ashwini Saumil Shah
Company Secretary

PRIVI SPECIALITY CHEMICALS LTD. * 400 710. * Navi Mumbai * REGD. OFFICE

PRIVI BIOTECHNOLOGIES PVT. LTD.

The financial details and capital evolution of the transferee/resulting and transferor/demerged companies for the previous 3 years as per the audited statement of Accounts

Name of the Company: Privi Biotechnologies Private Limited.

(Rs. in Crores)

	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year
	2024-25	2023-24	2022-23
Equity Paid up Capital	36.27	36.27	36.27
Reserves and surplus- Share premium	-	-	-
Revaluation Reserve	7.46	7.46	7.46
Carry forward losses	-19.40	-11.58	-11.29
Net Worth	16.87	24.70	24.98
Miscellaneous Expenditure	-	-	-
Secured Loans	-	-	-
Unsecured Loans	-	-	-
Tangible Fixed Assets- Net of Deprecitation with Capital WIP	13.89	15.93	16.78
Income from Operations	4.80	5.55	6.23
Total Income	6.15	9.03	7.32
Total Expenditure	13.61	8.95	8.44
Profit before Tax	-7.47	0.08	-1.13
Profit after Tax	-7.58	-0.14	-1.02
Cash profit	-5.27	2.27	1.25
EPS	-2.09	-0.02	-0.28
Book value per share	10.00	10.00	10.00

For Privi Biotechnologies Private Limited

Ashwini Saumil Shah
Company Secretary

PRIVI BIOTECHNOLOGIES PVT LTD

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN: U24110MH2021PTC358857

Regd. Office: Ground Floor, Privi House, A-71, TTC, Thane Belapur Road, Near Kopar Khairane Railway Station, Navi Mumbai - 400 710. India | Tel.: +91 22 27783040 | Fax: +91 22 27783049

Annexure IV

The financial details and capital evolution of the transferee/resulting and transferor/demerged companies for the previous 3 years as per the audited statement of Accounts

Name of the Company: Privi Fine Sciences Pvt. Ltd.

(Rs. In Crores)

Particulars	As per last Audited Financial Year	1 year prior to the last Audited Financial Year	2 years prior to the last Audited Financial Year
	2024-25	2023-24	2022-23
Equity Paid up Capital	233.83	204.89	0.01
Reserves and surplus- Share premium	11.57	0	0
Carry forward losses	-36.82	-2.28	-0.04
Net Worth	208.58	202.61	-0.03
Miscellaneous Expenditure	0	0	0
Secured Loans	16.87	24.38	0
Unsecured Loans	34.51	40.51	50.45
Tangible Fixed Assets- Net of Deprecitation with Capital WIP	166.93	162.04	21.86
Income from Operations	48.25	4.73	0
Total Income	52.15	8.07	0.62
Total Expenditure	86.12	7.81	0.66
Profit before Tax	-33.97	0.26	-0.04
Profit after Tax	-34.55	-2.24	-0.04
Cash profit	-21.68	1.23	0.01
EPS	-1.48	-0.11	-39.99
Book value per share	10	10	10

For Privi Fine Sciences Private Limited

Ramesh Kathuria
Company Secretary

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE Navi Mumbai - 400 710

Works : Plot No. C-39 & C-39 Part, MIDC, Lote - Parshuram Industrial Area, Tal. Khed, Dist. Ratnagiri - 415 722, (Mah.), India.
Tel.: 9359031328, 8999138530

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Independent Auditor's Report

To the Members of Privi Speciality Chemicals Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Speciality Chemicals Limited (the "Company") which comprise the standalone balance sheet as at 31 March 2025, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2025, and its profit and other comprehensive loss, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition	
See Note 2(xvi), 20 and 37 to standalone financial statements	
The Key Audit Matter	**How the matter was addressed in our audit**
The Company's revenue is derived primarily from sale of products. The principal products of the Company comprise of aroma chemicals. Revenue from sale of goods is recognized on transfer of the products to the customer. The Company uses a variety of shipment terms	We applied the following audit procedures in this area to obtain sufficient appropriate audit evidence:- • Assessed the appropriateness of Company's accounting policies relating to revenue recognition as per the applicable accounting standard.

across its operating markets and this has an impact on the timing of revenue recognition. The performance obligations in the contracts may be fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on contract terms. There is a risk that revenue could be recognised at a time which is different from transfer of control especially for sales transactions occurring on and around the reporting period. Also, there is a risk of recognizing fictitious revenue throughout the year. In view of this and since revenue is a key performance indicator of the Company, we have identified timing of the revenue recognition as a key audit matter.	• Obtained an understanding of the Company's sales process and evaluated the design and implementation of key internal controls in relation to the timing of revenue recognition. We also tested the operating effectiveness of such controls for a sample of transactions and also of controls over revenue recognised on and around the reporting period. • For a sample of sale transactions selected using statistical sampling, performed detailed testing and in particular examined whether these are recognised in the period in which control is transferred. This included examination of the terms and conditions as per customer orders, such as shipping terms, transporter documents and customer acceptances. • Tested on a sample basis, specific revenue transactions recorded around the year end date to check whether revenue has been recognised in the correct reporting period by examining the underlying documents. • Tested sample using statistical sampling approach for journal entries for revenue recognised during the year, selected based on specified risk-based criteria, to identify unusual transactions. • Evaluating the Company's disclosures in the standalone financial statements in respect of revenue recognitions. (Refer Note 37 of standalone financial statement)

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true

BSR & Co. LLP
14th Floor, Central B Wing, North C Wing, Nesco IT Park, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2 A. As required by Section 143(3) of the Act, we report that:

   a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

   b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matter stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

   c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

   d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

   e. On the basis of the written representations received from the directors as on 1 April 2025 and 2 April 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164(2) of the Act.

   f. the modification relating to the maintenance of accounts and other matters connected therewith are as stated in the paragraph 2A(b) above on reporting under Section 143(3)(b) of the Act and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

   g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

   a. The Company has disclosed the impact of pending litigations as at 31 March 2025 on its financial position in its standalone financial statements - Refer Note 34 to the standalone financial statements.

   The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts –

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Refer Note 18 to the standalone financial statements.

c. The following are the instances of delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

Financial Year	AGM Date	Dividend to be paid withing 30 days from AGM Date	Unclaimed dividend amount	Due Date of Transfer to IEPF (7 years)	Remarks
2016-17	11 August 2017	10 September 2017	Rs 1.31 lakhs	16 September 2024	Unclaimed dividend not transferred to IEPF account as of date

d (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 41(a)(vii) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 41(a)(viii) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend.

As stated in Note 38 to the standalone financial statements, the Board of Directors of the Company has proposed final dividend for the year which is subject to the approval of the members at the ensuing Annual General Meeting. The dividend declared is in accordance with Section 123 of the Act to the extent it applies to declaration of dividend.

f. Based on our examination which included test checks, the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except for the instances mentioned below:

i. At the application level for certain fields / tables relating to all the significant financial processes

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

where audit trail was enabled from 9 November 2024.

ii. The feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes.

For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit. Additionally, the audit trail has been preserved by the Company as per the Statutory requirement for retention to the extent log generated>

A. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar

Partner

Membership No.: 113959

ICAI UDIN:25113959BMLXBN1455

Place: Mumbai

Date: 03 May 2025

BSR & Co. LLP
14th Floor
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The inventory, except goods-in-transit and stocks lying with third parties, has been physically verified by the management during the year.For stocks lying with third parties at the year-end, written confirmations have been obtained and for goods-in-transit subsequent evidence of receipts has been linked with inventory records. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company except as follows:

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

Quarter	Name of bank	Particulars	Amount as per books of account (Rs in lakhs)	Amount as reported in the quarterly return/ statement (Rs in lakhs)	Amount of difference (Rs in lakhs)	Whether return/statement subsequently rectified
Jun-24	Refer Note-1	Trade Receivables and Inventories	99,356.84	98,562.42	794.42	No
Sep-24	Refer Note-1	Trade Receivables and Inventories	99,459.93	1,01,687.90	(2,222.97)	No
Dec-24	Refer Note-1	Trade Receivables and Inventories	109,531.33	107,579.72	1,951.61	No
Mar-25	Refer Note-1	Trade Receivables and Inventories	112,343.25	111,639.77	703.48	No

Refer note 14 of the standalone financial statements.

Note: 1 The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd., IDFC bank, ICICI Bank Ltd, Standard Chartered Bank.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments, provided guarantee or security or granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, limited liability partnerships or any other parties during the year. Accordingly, provisions of clauses 3(iii)(a) to 3(iii)(f) of the Order are not applicable to the Company.

(iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, the Company has neither made any investments nor has it given loans or provided guarantee or security and therefore the relevant provisions of Sections 185 and 186 of the Companies Act, 2013 ("the Act") are not applicable to the Company. Accordingly, clause 3(iv) of the Order is not applicable.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its manufactured goods and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

carried out a detailed examination of the records with a view to determine whether these are accurate or complete.

(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion, the undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Income-Tax, Duty of Customs which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in lakhs- net of amount paid under protest*)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
The Income Tax Act, 1961	Income Tax	237.34	AY 2014-15	CIT Appeals	None
The Income Tax Act, 1961	Income Tax	202.79	AY 2017-18	ITAT	None
The Income Tax Act, 1961	Income Tax	268.79	AY 2018-19	CIT Appeals	None
The Income Tax Act, 1961	Income Tax	331.76	AY 2020-21	ITAT	None
The Income Tax Act, 1961	Income Tax	542.64	AY 2021-22	CIT Appeals	None
The CustomsAct , 1962	Custom Duty, Fine and Penalty	90.54	FY 2011-12 and 2012-13	Office of the Commissioner of Customs,	None

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

Name of the statute	Nature of the dues	Amount (Rs. in lakhs- net of amount paid under protest*)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
				Mumbai	
The Custom Act 1962	Custom Duty, Fine and Penalty	961.97	FY 2017-18 and 2018-19	Office of the Commissioner of Customs, Nhava Sheva	None
The Custom Act 1962	Custom Duty, Fines and Penalty	261.94	FY 2017-18	Office of the Commissioner of Custom House-Kandla	None
Maharashtra, Good and Service tax act 2017 (MGST Act 2017)	GST, Interest and penalty	90.87	FY 2019-20 and FY 2020-21	Deputy Commissioner of State Tax. Raigad Maharashtra	None

*Protest deposit paid amounting to Rs. 307.31 lakhs. Further, interest, penalty and fines has been considered to the extent mentioned in the demand orders.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

defined under the Act.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under the Act).

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) During the course of our examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in annual report is expected to be made available to us after the date of this auditor's report.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
ICAI UDIN:25113959BMLXBN1455

Place: Mumbai
Date: 03 May 2025

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park 4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Speciality Chemicals Limited ("the Company") as of 31 March 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2025, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2025 *(Continued)*

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar

Partner

Membership No.: 113959

ICAI UDIN:25113959BMLXBN1455

Place: Mumbai

Date: 03 May 2025

Privi Speciality Chemicals Limited

Standalone Balance Sheet

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

	Note	As at March 31, 2025	As at March 31, 2024
Assets			
Non-current assets			
Property, plant and equipment	3	93,563.23	95,334.72
Capital work-in-progress	3	5,628.57	1,658.58
Right of use assets	4 a	3,407.56	3,777.31
Other Intangible assets	4 b	930.42	834.61
Intangible assets under development	4 b	1,386.82	1,008.56
Financial assets			
Investments	5	6,170.54	6,163.14
Other financial assets	6	1,808.64	1,656.56
Income tax assets (net)		1,512.94	2,343.19
Other non-current assets	7	3,544.22	1,349.42
Total non-current assets		1,17,952.94	1,14,126.09
Current assets			
Inventories	8	72,267.11	60,282.56
Financial assets			
Trade receivables	9	40,076.14	36,108.27
Cash and cash equivalents	10	4,058.45	1,575.08
Bank balances other than cash and cash equivalents	11	6.79	444.78
Other financial assets	6	629.74	-
Other current assets	7	12,352.44	6,333.96
Total current assets		1,29,390.67	1,04,744.65
TOTAL ASSETS		2,47,343.61	2,18,870.74
EQUITY AND LIABILITIES			
EQUITY			
Equity share capital	12 a	3,906.27	3,906.27
Other equity	12 b	1,06,213.00	88,141.61
Total equity		1,10,119.27	92,047.88
LIABILITIES			
Non-current liabilities			
Financial liabilities			
Borrowings	13 a	27,913.38	38,350.20
Lease liabilities	13 b	274.12	820.04
Provisions	15	2,254.17	1,778.96
Deferred tax liabilities (net)	16	2,221.95	2,355.03
Total non-current liabilities		32,663.62	43,304.23
Current liabilities			
Financial liabilities			
Borrowings	14	56,862.93	50,462.91
Lease liabilities	13 b	542.84	373.86
Trade payables			
a) Total outstanding dues of micro enterprises and small enterprises	17	1,243.11	1,275.87
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	17	39,269.08	27,060.55
Other financial liabilities	18	6,045.94	2,339.34
Other current liabilities	19	316.42	509.16
Provisions	15	280.40	198.92
Current tax liabilities (net)		-	1,298.02
Total current liabilities		1,04,560.72	83,518.63
Total liabilities		1,37,224.34	1,26,822.86
TOTAL EQUITY AND LIABILITIES		2,47,343.61	2,18,870.74
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2	-	-

The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 03, 2025

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited
CIN : L15140MH1985PLC286828

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 03, 2025

Privi Speciality Chemicals Limited

Standalone Statement of Profit and Loss

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2025	Year ended March 31, 2024
INCOME			
Revenue from operations	20	2,03,834.26	1,71,206.12
Other income	21	1,790.47	2,161.63
TOTAL INCOME (I)		2,05,624.73	1,73,367.75
EXPENSES			
Cost of materials consumed	22	1,14,132.73	93,197.62
Changes in inventories of finished goods and work-in-progress	23	(3,574.49)	5,442.38
Employee benefits expense	24	7,515.05	6,544.46
Finance costs	25	8,379.31	9,502.36
Depreciation and amortisation expenses	26	12,667.94	12,195.37
Power and fuel expense	27	15,183.00	13,802.14
Other expenses	28	25,934.28	19,485.74
TOTAL EXPENSES (II)		1,80,237.82	1,60,170.07
Profit before tax		25,386.91	13,197.68
Tax expenses:			
Current tax		6,563.27	3,080.18
Deferred tax (Credit) / Charge		(106.61)	329.01
Tax expense		6,456.66	3,409.19
Profit for the year (III)		18,930.25	9,788.49
Other comprehensive income			
Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans		(104.08)	15.81
Income tax related to items that will not be reclassified to profit or loss		26.47	(4.08)
Total other comprehensive (loss) / income for the year (IV)		(77.61)	11.73
Total comprehensive income for the year (III + IV)		18,852.64	9,800.22
Earnings per equity share: nominal value of share Rs.10/- each Basic and diluted (Rs.)	36	48.46	25.06
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 03, 2025

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited
CIN : L15140MH1985PLC286828

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 03, 2025

Privi Speciality Chemicals Limited

Standalone Statement of Cash Flows

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2025	Year ended March 31, 2024
A	**Cash flow from operating activities**		
	Profit before tax	25,386.91	13,197.68
	Adjustment for:		
	Depreciation and amortisation expenses	12,298.19	11,635.31
	Amortisation of right of use assets	369.75	560.06
	(Gain) on write-back of financial liabilities (refer note 21)	(54.92)	-
	Sundry balances written off	11.53	0.78
	Unrealised foreign exchange (gain) / loss (net)	1,963.92	(680.84)
	Interest income	(14.08)	(29.38)
	Finance cost	8,379.31	9,502.36
	Loss on sale of property, plant and equipment (net)	18.53	25.60
	(Gain) on disposal of Other Intangible assets	(63.78)	-
	(Gain) on sale of investments (net)	(1.01)	(8.70)
	Allowance for expected credit loss and credit impariment	41.20	-
	Operating cash flow before working capital changes	48,335.55	34,202.87
	Movements in working capital		
	(Increase) in trade receivables	(4,009.07)	(4,659.48)
	(Increase) / Decrease in inventories	(11,984.55)	14,213.69
	(Increase) / Decrease in other current and non current assets (non financial assets)	(6,556.61)	2,769.78
	(Increase) / Decrease in financial assets	(781.82)	(149.37)
	Increase / (Decrease) in trade payable	12,175.77	(1,435.87)
	Decrease / (Increase) in financial liabilities	36.45	(882.02)
	Decrease / (Increase)in non financial liabilities and provisions	219.89	(5,231.44)
		(10,899.94)	4,625.29
	Cash generated from operations	37,435.61	38,828.16
	Income taxes paid	(7,031.04)	(2,649.71)
	Net cash generated from operating activities [A]	30,404.57	36,178.45
B	**Cash flow from investing activities**		
	Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital creditors	(15,127.05)	(10,261.43)
	Proceeds from sales of property, plant & equipment and Other Intangible assets	344.96	2.65
	Investment in subsidiaries	-	(1,020.00)
	Investment in structured entity	-	(499.50)
	Fixed deposit placed	-	(32.83)
	Proceeds on maturity of Fixed deposit	356.72	7.30
	Interest received	14.08	29.38
	Net cash (used in) investing activities [B]	(14,411.29)	(11,774.43)
C	**Cash flow from financing activities**		
	Proceeds from Non-current borrowings	14,900.00	17,400.00
	Repayment of Non-current borrowings	(25,716.76)	(15,987.10)
	Current borrowings (net)	6,771.79	(15,530.33)
	Payment of lease liabilities including interest on lease	(463.26)	(558.40)
	Dividend paid	(781.25)	-
	Interest paid	(8,220.11)	(9,178.38)
	Net cash (used in) financing activities [C]	(13,509.59)	(23,854.21)
	Net increase in cash and cash equivalents (A+B+C)	2,483.69	549.81
	Cash and cash equivalents at the beginning of the year	1,575.08	1,025.27
	Exchange differences on translation of foreign currency cash and cash equivalents	(0.32)	-
	Cash and cash equivalents at end of the year (refer note 10)	4,058.45	1,575.08

Standalone Statement of Cash Flows *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Note B : Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital creditors during the year.

Note C : Reconciliation of net debts

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2024	1,193.90	38,350.20	50,462.91
Loan/ lease taken during the current year	-	14,900.00	6,771.79
Repayment during the current year	-	(25,716.76)	-
Current maturities of long term debt (refer note 13 a)	-	379.94	(379.94)
Interest accrued but not due on borrowings	-	-	8.17
Interest on lease liabilities	86.32	-	-
Payment against lease liabilities	(463.26)	-	-
Closing balance as on March 31, 2025	816.96	27,913.38	56,862.93

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2023	1,354.99	40,370.49	62,560.05
Loan/ lease taken during the current year	276.59	17,400.00	-
Repayment during the current year	-	(5,809.30)	(25,708.13)
Foreign exchange gain or loss	-	115.18	(198.34)
Current maturities of long term debt (refer note 13 a)	-	(13,726.17)	13,726.17
Interest accrued but not due on borrowings	-	-	83.16
Interest on lease liabilities	120.72	-	-
Payment against lease liabilities	(558.40)	-	-
Closing balance as on March 31, 2024	1,193.90	38,350.20	50,462.91

Note D : For Corporate social responsibility related spends, refer note 42

Material accounting policies **2**

The accompanying notes forms an integral part of the standalone financial stateme **3 to 43**

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 03, 2025

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited
CIN : L15140MH1985PLC286828

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 03, 2025

Privi Speciality Chemicals Limited

Standalone Statement of Changes in Equity

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	March 31, 2025	March 31, 2024
Balance at the beginning of the current reporting year	3,906.27	3,906.27
Changes in Equity Share Capital due to prior year errors		
Restated balance at the beginning of the current reporting year	3,906.27	3,906.27
Changes in equity share capital during the current year		
Balance at the end of the current reporting year	3,906.27	3,906.27

B. Other equity

	Reserves and Surplus			
	General reserve	Retained earnings*	Capital Reserve (refer note 12(b))	Total
Balance as at April 01, 2023	35,573.76	42,766.63	1.00	78,341.39
Profit for the year	-	9,788.49	-	9,788.49
Other comprehensive income / (loss) (net of tax)	-	11.73	-	11.73
Total comprehensive income for the year	35,573.76	52,566.85	1.00	88,141.61
Balance as at March 31, 2024	35,573.76	52,566.85	1.00	88,141.61
Profit for the year	-	**18,930.25**	-	**18,930.25**
Other comprehensive (loss) (net of tax)	-	**(77.61)**	-	**(77.61)**
Total comprehensive income for the year	-	**18,852.64**	-	**18,852.64**
Contribution and distribution to the owners				
Dividend of Rs 2.00 per share for the year ended March 31, 2024 (including dividend distribution tax) (refer note 38)	-	**(781.25)**	-	**(781.25)**
Balance as at March 31, 2025	**35,573.76**	**70,638.24**	**1.00**	**1,06,213.00**

* The Balance arising out of remeasurement of defined plans is adjusted against the available retained earnings.

Notes to the standalone financial statements **3 to 43**
Material accounting policies **2**
The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached
For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 03, 2025

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited
CIN : L15140MH1985PLC286828

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

D. B. Rao
Executive Director
DIN: 00356218

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 03, 2025

Privi Speciality Chemicals Limited

Notes to the Standalone Financial Statements

for the-year ended March 31,2025

(Currency: Indian Rupees in Lakhs)

1 General Information

Privi Speciality Chemicals Limited ('PSCL or 'the Company') incorporated on 25 May 1985 under the provisions of the Companies Act, 1956 is a public company domiciled in India. The Company is having register office at A-71, Privi House, Thane Belapur Road, TTC, Navi Mumbai-400710, Maharashtra, India. The Company is primarily engaged in the manufacture and export of aroma chemicals and in the trading of chemicals. The Company's manufacturing units are located at Mahad and Jhagadia. The equity shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Ltd.

2 Material accounting policies

This note provides a list of the material accounting policies adopted by the Company in the preparation of standalone financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of Compliance

These Standalone Financial Statements of the Company comprising the Balance Sheet as at March 31, 2025, Statement of Profit and Loss (including other comprehensive income), Statement of Changes in Equity, and Cash Flow Statement for the year ended March 31, 2025, and a summary of material accounting policies and other explanatory information have been prepared by the Company in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the 'Act'), other relevant provisions of the Act and guidelines issued by the Securities and Exchange Board of India.

The standalone financial statements were authorised for issue by the Company's Board of Directors at their meetings held on May ,03 2025.

i. Basis of preparation and Presentation

Basis of Preparation

The financial statements have been prepared on a historical cost basis, except for the following assets and liabilities:

(i) Derivative Financial Instruments measured at fair value. (refer note no. 18)

(ii) Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments)

(iii) Employee's Defined Benefit Plan as per actuarial valuation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

2. Material accounting policies *(continued)*

i. Basis of preparation and Presentation (Continued)

Functional and Presentation Currency

The standalone financial statements are presented in Indian Rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates. All values are rounded to the nearest lakh, unless otherwise stated.

ii. Use of estimates, judgements, and assumptions

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of income, expenses, assets and liabilities, Actual results may differ from these estimates and assumptions.

Estimate and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised prospectively.

The Company has identified the following areas where significant judgements, estimates and assumptions are required. Further information on each of these areas and how they impact the various accounting policies are described below and in the relevant notes to the financial statements.

Financial reporting results rely on the estimate of the effect of certain matters that are inherently uncertain. Future events rarely develop exactly as forecast and the best estimates require adjustments, as actual results may differ from these estimates under different assumptions or conditions. Estimates and Judgments are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. The Management believes that the estimates used in preparation of these financial statements are prudent and reasonable. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. "revisions to accounting estimates are accounted for prospectively.

Judgements:

In the process of applying the Company's accounting policies, management has made the following judgements, which have the most significant effect on the amounts recognized in the financial statements.

a. Lease term, whether the Company is reasonably certain to exercise extension options – (refer note 4 a)

Assumptions and estimation uncertainties

Information about judgements in applying accounting policies, as well as estimates and assumptions that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are included in the following notes:

(a) Measurement of defined benefit obligations for key actuarial assumptions - refer note 31

(b) Recognition of deferred tax assets – Note 16

BSR & Co. LLP 14th Floor, Central D Wing and North C Wing, Nesco IT Park 4, Nesco Centre, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai

2. Material accounting policies *(continued)*

ii. Use of estimates, judgements, and assumptions (continued)

(c) Useful Lives of Property, Plant and Equipment, Right of use assets and Intangible Assets: Note 3 and 4

(d) Recognition and Measurement of Provisions and Contingencies: Note 34

iii. Current and non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is expected to be realised within 12 months after the balance sheet date; or

(d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the balance sheet date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is due to be settled within 12 months after the balance sheet date; or

(d) the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Terms of a liability that could, at the option of the counter party, result in its settlement by issue of equity instruments do not affect its classification. Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

The operating cycle is twelve months from the time between the acquisition of assets for processing and their realization in cash or cash equivalents.

iv. Property, Plant and Equipment ("PPE") and depreciation

I Recognition and Measurement

The cost of an item of property, plant and equipment shall be recognised as an asset if, and only if it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai

2. Material accounting policies *(continued)*

iv. *Property, Plant and Equipment ("PPE") and depreciation (continued)*

Property, Plant and equipment are measured at cost including nonrefundable taxed and import duties, which also includes capitalized borrowing costs less accumulated depreciation and any accumulated impairment losses. Cost of an item of property, plant and equipment comprises its purchase price, including import duties and non-refundable purchase taxes, after deducting trade discounts and rebates, any directly attributable cost of bringing the item to its working condition for its intended use and estimated costs of dismantling and removing the item and restoring the site on which it is located. The Company's date of transition to the standards was determined with reference to its fair value at the date.

Depreciation on additions/disposals) is provided on a pro-rata basis i.e. from/ (upto) the date on which asset is ready for use/ (disposed off).

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of Property, Plant and equipment. Any Gain or loss on disposal of an item of Property, Plant and equipment is recognized in profit or loss.

II Subsequent Expenditure

Subsequent Expenditure is capitalized only if it is probable that the future economic benefits flow to the associated with the Expenditure will flow to the entity.

Depreciation and amortization

Depreciation is calculated using the straight-line method to allocate cost of property plant and equipment, net of residual values, over their estimated useful lives as per the useful life prescribed in schedule II of the Companies Act, 2013 except in case of the following class of assets where the useful life is based on technical evaluation of the management:

Fixtures in leasehold premises are amortized over the primary period of the lease or useful life of the fixtures, whichever is lower.

Asset Class	Estimated useful life (in Years)	
	Useful life considered by the Company as per Schedule II / Technical Evaluation	Schedule II of the Companies Act, 2013
Building	33	30
Plant and Machinery	10	15
Electrical installation	10	10
Laboratory equipment's	10	10
Furniture & Fixtures	16	10
Office Equipment	10	5
Leasehold Improvement	15	15
Vehicle	10	8
Computer	6	6

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai

2. Material accounting policies *(continued)*

iv. *Property, Plant and Equipment ("PPE") and depreciation (continued)*

Depreciation and amortization (continued)

Depreciation on additions / deletions during the year is provided from the date in which the asset is ready to use to the date in which the asset is disposed of.

The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets required under finance leases are depreciated over the shorter of the lease term and their useful lives (not being greater than the useful life envisaged in Schedule II of Companies Act, 2013) unless it is reasonably certain that Company will obtain ownership by the end of lease term, in which case the depreciation rates applicable for similar assets owned by the Company are applied.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss within other gains/(losses).

v. *Intangible assets and amortisation*

Intangible assets with finite useful life are stated at cost of acquisition, less accumulated depreciation/ amortisation and impairment loss, if any. Cost includes taxes, duties and other incidental expenses related to acquisition and other incidental expenses.

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

Asset Class	Estimated useful life (in Years)
Computers Soft wares	3 to 6 Years
Rights of Sale of Products	5 Years
Development Rights	5 Years

About internally generated intangible assets:

Expenditure on research activities, undertaken with the prospect of development of new products or gaining new technical knowledge and understanding, is recognised in profit or loss as incurred.

Capital expenditure on research and development is capitalized and depreciated as per accounting policy mentioned above. Revenue expenditure is charged off in the year in which it is incurred.

Development activities involve a plan or design for the production of new or substantially improved products or processes. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai

2. Material accounting policies *(continued)*

v. Intangible assets and amortization (Continued)

and directly attributable borrowing costs (in the same manner as in the case of tangible fixed assets). Other development expenditure is recognised in profit or loss as incurred.

Intangible assets are amortised in profit or loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the asset.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

vi. Impairment of Non-financial assets

At each reporting date, the Company reviews the carrying amounts of its non-financial assets (other than biological assets. investment property, inventories, contract assets and deferred tax assets to determine whether there is any indication of impairment nt. If any such indication exists, then the asset's referable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or group of CGUs that are expected to benefit from the synergies of the combination.

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value Jess costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its Recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset's carrying a mount does not exceed the carrying amount that would have been determined, net of depreciation or amortization. if no impairment loss had been recognized.

vii. Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing. Borrowing costs include interest costs measured at EIR amortization of discounts, hedge related cost incurred in connection with foreign currency borrowings, ancillary costs incurred in connection with borrowing of funds and exchange differences arising from foreign currency borrowings (other than those

BSR & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

2. Material accounting policies *(continued)*

vii. ***Borrowing costs (Continued)***

term foreign currency borrowings) to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognised as an expense in the period which they are incurred.

viii. ***Foreign currency transactions***

Transactions denominated in foreign currency are recorded at the exchange rate prevailing on the date of transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of profit and loss of the year.

Monetary assets and liabilities in foreign currency, which are outstanding as at the balance sheet date are translated at the year-end at the closing exchange rate and the resultant exchange differences are recognized in the statement of profit and loss.

Foreign exchange differences regarded as an adjustment to borrowing costs are presented in the statement of profit and loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit and loss on a net basis within other incomes/expenses.

ix. ***Financial Instruments***

a. Financial assets

Initial Recognition and Measurement

All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset, However, trade receivables that do not contain a significant financing component are measured at transaction price.

Classification and subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortised cost

A financial asset is classified as subsequently measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

2. Material accounting policies *(continued)*

ix. ***Financial Instruments (continued)***

a. Financial assets *(continued)*

The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through Other Comprehensive Income ("FVTOCI")

A financial asset is classified as subsequently measured at fair value through Other Comprehensive Income if both the following conditions are met:

- The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

Financial assets included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in other comprehensive income (OCI). However, the Company recognizes interest income,

impairment losses & reversals and foreign exchange gain or loss in the P&L. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from equity to P&L. The Company did not have any financial assets at FVTOCI during the current year as well as previous year.

Financial assets at fair value through Profit and loss ("FVTPL")

Financial assets at FVTPL are a residual category for financial assets. Any financial assets which do not meet the criteria of categorizing it at amortised cost or at FVTOCI is classified as at FVTPL.

Financial assets included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.
- When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the

BSR & Co. LLP Chartered Accountants

REGD. OFFICE

2. Material accounting policies *(continued)*

ix. Financial Instruments (continued)

a. Financial assets *(continued)*

- extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

  Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of Financial Assets

In view of its past experience of having insignificant impairment bad debts / write-offs and based on management's estimate considering its portfolio of customers, this trend would continue for the foreseeable future, the Company has determined that significant impairment of Financial assets is not required to be recognised based on Expected Credit Loss model.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at amortised cost and financial liabilities at FVTPL. Derivative liabilities are classified as FVTPL. All financial liabilities are recognised initially at fair value. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognised in the profit or loss. Except derivative instruments, the Company has not designated any financial liability as at FVTPL.

Financial liabilities at amortised cost

All financial liabilities except for derivatives are classified as measured at amortised cost. This category includes bank and other borrowings, trade payables and other financial liabilities.

BSR & Co. LLP 14th Floor Central 5 Wing and North C Wing Nesco IT Park4, Nesco Corner, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

2. Material accounting policies *(continued)*

ix. Financial Instruments (continued)

b. Financial liabilities (continued)

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

c. Offsetting of Financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Business Model Assessment

Financial assets -Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed, and information is provided to management. The information considered includes:

the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities, or expected cash outflows or realizing cash flows through the sale of the assets.

- how the performance of the portfolio is evaluated and reported to the Company's management.
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed.
- how managers of the business are compensated- e.g., whether compensation is based on the fair value of the assets managed, or the contractual cash flows collected, and the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial Assets that are held for trading or are managed and whose performance is evaluated on a fair value basis are measured at FVTPL.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

2. Material accounting policies *(continued)*

ix. Financial Instruments (continued)

d. Derivatives

Initial recognition and subsequent measurement The Company uses derivative financial instruments, such as forward currency contracts, interest rate swaps and currency SWAPS, to hedge its foreign currency risks, interest rate risks and its long term loans, respectively. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. The purchase contracts that meet the definition of a derivative under Ind-AS 109 are recognised in the Statement of Profit and Loss.

x. Segment Reporting

An operating segment is a component of the Company that engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses that relate to transactions with any of the Company other components, and for which discrete financial information is available. All operating segments' operating results are reviewed regularly by the Company Chief Executive Officer (CEO) to make decisions about resources to be allocated to the segments and assess their performance.

The Chief Operational Decision Maker (CODM) monitors the operating results of its business Segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on

profit and loss and is measured consistently with profit or loss in the standalone financial statements. Operating segments have been identified on the basis of nature of

products / services. The Accounting Policies adopted for segment reporting are in line with the Accounting Policies of the Company. Segment assets include all operating assets used by the business segments and consist principally of fixed assets, trade receivables and inventories. Segment liabilities include the operating liabilities that result from the operating activities of the business. Segment assets and liabilities that cannot be allocated between the segments are shown as part of unallocated corporate assets and liabilities respectively. Income / Expenses relating to the enterprise as a whole and not allocable on a reasonable basis to business segments are reflected as unallocated corporate income / expenses.

xi. Cash flows

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flow. The cash flows from operating, investing and financing activities of the Company are segregated based on available information.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

2. Material accounting policies *(continued)*

xii. Cash and Cash equivalents

Cash and cash equivalent in the balance sheet and for the statement cash flow comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

xiii. Investment in subsidiaries and joint ventures

Investment in subsidiary companies and joint venture companies are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiary companies and joint venture companies, the difference between net disposal proceeds and the carrying amount are recognised in the statement of Profit and Loss.

The Company reviews its carrying value of investments in subsidiaries annually, or more frequently when there is indication for impairment. If the recoverable amount is less than its carrying amount, the impairment loss is accounted for. Determining whether the investments in subsidiaries are impaired requires an estimate in the value in use of investments. The Management carries out impairment assessment for each investment by comparing the carrying value of each investment with the net worth of each Company based on audited financials, comparable market price and comparing the performance of the investee companies with projections used for valuations, in particular those relating to the cash flows, sales growth rate, pre-tax discount rate and growth rates used and approved business plans.

xiv. Lease as a lessee

The Company has adopted Ind AS 116 effectives from April 01 2019 using modified retrospective approach. For the purpose of preparation of Standalone Financial statement, management has evaluated the impact of change in accounting policies required due to adoption of Ind AS 116 in first year of applicability.

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Company assesses whether: (i) the contact involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

As a lessee, the Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In addition, the right-

BSR & Co. LLP Chartered Accountants

REGD. OFFICE

2. Material accounting policies *(continued)*

xiv. Lease as a lessee (continued)

of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method.

The Company has used number of practical expedients when applying Ind AS 116: - Short-term leases, leases of low-value assets and single discount rate.

The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company applied a single discount rate to a portfolio of leases of similar assets in similar economic environment with a similar end date.

The Company's leases primarily comprise land and buildings and Plant and equipment. The Company leases land and buildings for warehouse facilities.

xv. Inventories

Inventories include raw materials, packing materials, fuel, consumable stores and spares and manufactured inventory. Inventory is valued at the lower of cost and net realisable value.

Cost comprises the purchase price, costs of conversion and other related costs incurred in bringing the inventories to their present location and condition. Cost of raw materials, packing materials, fuel, consumable, stores and spares are determined on the basis of Periodic moving weighted average method. Cost of finished goods and work in progress are determined using the absorption costing principle. Cost includes the cost of material consumed, labour and appropriate proportion of costs of conversion which include variable and fixed overheads.

Obsolete, defective, and unserviceable inventories are duly provided for. The comparison of cost and net realisable value is made on an item-to-item basis. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale. The net realisable value of work in progress is determined by reference to the selling prices of related finished products

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

2. Material accounting policies *(continued)*

xvi. ***Revenue Recognition***

Revenue recognition Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer i.e., when the customer is able to direct the use of the transferred goods or rendering of services and obtains substantially.

All of the remaining benefits at an amount that reflects the consideration entitled in exchange for those goods or services. The policy of recognizing the revenue is determined according to Ind AS 115 "Revenue from contracts with customers".

Sale of Goods: Revenue is recognised upon transfer of control of promised goods to customers for an amount that reflects the consideration which the Company expects to receive in exchange for those goods. Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer which is usually on dispatch/ delivery of goods, based on contracts with the customers. Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, price concessions, incentives, and returns, if any, as specified in the contracts with the customers.
Revenue excludes taxes collected from customers on behalf of the government. Accruals for discounts/incentives and returns are estimated (using the most likely method) based on accumulated experience and underlying schemes and agreements with customers. Due to the short nature of credit period given to customers, there is no financing component in the contract.

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold, and services rendered is net of variable consideration on account of various discounts and schemes offered by the Company as part of the contract

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortised cost.

Government grants

Government grants are not recognised until there is reasonable assurance that the Company will comply with the conditions attached to them and that the grants will be received. Government grants are recognised in the statement profit or loss on a systematic basis over the periods in which the Company recognises as expenses the related costs for which the grants are intended to compensate.

An export incentive is recognised in the statement of profit and loss when the right to receive credit as per the terms of the scheme is established in respect of export made, and there is no uncertainty as to its receipt.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

2. Material accounting policies *(continued)*

xvii. ***Employee Benefits***

Short Term Employee Benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus, ex-gratia etc. These are recognised as an expense at an undiscounted amount in the Statement of Profit and Loss of the year in which the related service is rendered.

Post-employment Benefits

(i) Provident Fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's.

contribution is recognised as an expense in the statement of profit and loss during the period in which the employee renders the related service.

(ii) Gratuity

The Company's gratuity benefit scheme is a defined benefit plan. The Company`s net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary usingthe projected unit credit method.

Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the assets ceiling (if any, excluding interest), are recognised in OCI. All expenses related to defined benefit plan are recognised in employee benefits expense in the Statement of Profit and Loss.

(iii) Compensated Absences

The Company provides for encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/ availment. The Company makes provision for compensated absences based on an independent external actuarial valuation carried out at the end of the year.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

2. Material accounting policies *(continued)*

xviii. Taxation

Income tax expense comprises current tax and deferred tax charge or credit.

Current Income Tax

Provision for current tax is determined as the amount of tax payable in respect of taxable income for the year in accordance with the provisions of the Income Tax Act, 1961.Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the enacted or substantively enacted tax rates and tax laws. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

"Current tax is recognised in statement of profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current tax is also recognised in other comprehensive income or directly in equity respectively. "

Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

On March 30, 2019, MCA has issued amendment regarding the income tax Uncertainty over Income Tax Treatments. The notification clarifies the recognition and measurement requirements when there is uncertainty over income tax treatments. In assessing the uncertainty, an entity shall consider whether it is probable that a taxation authority will accept the uncertain tax treatment. This notification is effective for annual reporting periods beginning on or after April 1, 2019. As per the Company's assessment,there are no material income tax uncertainties over income tax treatments.

Current tax assets and current tax liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.

Current Tax is recognised in profit or loss except to the extent that it relates to a business combination or to an item recognised directly in equity or in other comprehensive income.

Deferred Tax

Deferred tax is recognized in respect of temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be

BSR & Co. LLP Chartered Accountants

SPECIALITY CHEMICALS LTD REGD. OFFICE Mumbai - 400 710

2. Material accounting policies *(continued)*

xviii. ***Taxation** (continued)*

Deferred Tax (continued)

available to allow all or part of the deferred tax asset to be utilised, unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised either in other comprehensive income or in equity. Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

xix. ***Earnings** per share*

Basic earnings per share are calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share are the net profit for the year attributable to equity shareholders. For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares, except where the results would be anti-dilutive.

xx. ***Provisions and contingent liabilities***

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

Provision in respect of loss contingencies relating to claims litigation, assessment, fines, penalties etc. are recognized when it is probable that a liability has been incurred, and the amount can be estimated reliably.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, probably will not, require an outflow of resources embodying economic benefits, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed

BSR & Co. LLP Chartered Accountants

REGD. OFFICE

2. Material accounting policies *(continued)*

xx. Provisions and contingent liabilities (continued)

unless the possibility of outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the standalone financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic resources embodying economic benefits will arise, related income are recognized in the year in which the change occurs.

xxi. Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement

date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

***xxii.* Recent accounting pronouncements: -**

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.
For the year ended March 31, 2025, MCA has notified Ind AS – 117 Insurance Contracts and amendments to Ind AS 116 – Leases, relating to sale and leaseback transactions, applicable to the Company w.e.f. April 1, 2024. The Company has reviewed the new pronouncements and based on its evaluation has determined that it does not have any significant impact in its Standalone financial statements.

xxiii **Equity shares**

Equity shares incremental costs directly attributable to the issue of equity shares are recognised as a deduction from equity. Income tax relating to transaction costs of an equity transaction is accounted for in accordance with Ind AS 12.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency Indian Rupees in lakhs)

3 Property, plant and equipment

Description	Gross carrying amount				Accumulated Depreciation				Net carrying amount
	As at April 01, 2024	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2025	As at April 01, 2024	Depreciation for the year	Disposal / Transfer during the year	As at March 31, 2025	As at March 31, 2025
At cost :									
Building	27,997.08	1,662.18	48.47	29,610.79	3,783.89	935.40	1.48	4,717.81	24,892.98
Leasehold Improvement	608.42	9.87	-	610.29	519.78	4.06	-	523.84	86.45
Plant and equipment	1,15,030.90	8,018.11	235.29	1,22,813.72	51,274.31	9,850.70	22.34	61,102.67	61,711.05
Electrical installation	8,422.35	493.71	9.52	8,906.54	3,127.46	746.36	0.90	3,872.92	5,033.62
Furniture and fittings	267.92	3.41	-	271.33	83.58	14.31	-	97.89	173.44
Office equipment	471.15	3.25	-	474.40	243.36	35.42	-	278.78	195.62
Computers	1,197.08	88.69	-	1,285.77	811.94	141.41	-	953.35	332.42
Laboratory equipments	1,937.91	138.69	-	2,076.60	975.33	148.37	-	1,123.70	952.90
Vehicles	449.73	17.24	51.69	415.28	220.17	38.92	28.56	230.53	184.75
	1,56,374.54	10,435.15	344.97	1,66,464.72	61,039.82	11,914.95	53.28	72,901.49	93,563.23
Capital work -in- progress	1,658.58	14,405.14	10,435.15	5,628.57	-	-	-	-	5,628.57
	1,58,033.12	24,840.29	10,780.12	1,72,093.29	61,039.82	11,914.95	53.28	72,901.49	99,191.80

During the year completed capital projects Rs. 10,435.15 lakhs transferrd from Capital work-in-progress to Property, plant and equipment

a) The net carrying amount of property, plant and equipment (excluding Leasehold Improvement and Vehicles) amounting to Rs. 93,292.02 lakhs (March 31, 2024 : Rs 95334.72 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans. (refer note 13a and 14)

b) The Plant and equipment, Building and Electrical Installation includes an amount of Rs. 57.54 lakhs, Rs. 277.55 lakhs and Rs. 17.09 lakhs respectively (March 31, 2024 : Rs.443.38 lakhs, Rs. 67.18 lakhs and Rs. 14.65 lakhs respectively) that represent other incidental cost (i e borrowing cost, power and fuel, salary etc) capitalised.

c) The Company has not recognised any impairment loss during the current year (March 31, 2024 : Rs. Nil).

d) The title deeds of immovable properties as disclose above are held in name of the Company.

e) Disposal of assets consisit Building, Plant and Machinery and Electrical installation sold to subsidiary (Prigiv Specialties Private Limited) amouting to Rs. 268.57 Lakhs at WDV as at March 01 ,2025

Ageing for capital work-in-progress (CWIP) as at March 31, 2025 is as follows :

Description	Amount in Capital work-in-progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress #	5,628.57	-	-	-	5,628.57
Projects temporarily suspended	-	-	-	-	-
	5,628.57	-	-	-	5,628.57

CWIP projects in progress consists Amber fleur, Amber Gama and Dihyromyrcenol etc.for CWIP, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-25.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

3 Property, plant and equipment *(Continued)*

Description	Gross carrying amount				Accumulated Depreciation				Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2024	As at April 01, 2023	Depreciation for the year	Disposal / Transfer during the year	As at March 31, 2024	As at March 31, 2024
At cost :									
Building	25,075.20	2,921.88	-	27,997.08	2,915.63	868.26	-	3,783.89	24,213.19
Leasehold Improvement	565.20	35.22	-	600.42	516.34	3.44	-	519.78	80.64
Plant and equipment	1,05,877.67	9,153.23	-	1,15,030.90	41,986.35	9,287.96	-	51,274.31	63,756.59
Electrical installation	7,558.29	864.06	-	8,422.35	2,417.80	709.66	-	3,127.46	5,294.89
Furniture and fixtures	267.92	-	-	267.92	68.57	15.01	-	83.58	184.34
Office equipment	466.58	4.57	-	471.15	208.24	35.12	-	243.36	227.79
Computers	1,185.51	11.57	-	1,197.08	665.79	146.15	-	811.94	385.14
Laboratory equipments	1,870.60	67.31	-	1,937.91	830.36	144.97	-	975.33	962.58
Vehicles	496.95	-	47.22	449.73	197.85	41.29	18.97	220.17	229.56
	1,43,363.92	13,057.84	47.22	1,56,374.54	49,806.93	11,251.86	18.97	61,039.82	95,334.72
Capital work -in- progress	8,821.37	5,895.05	13,057.84	1,658.58	-	-	-	-	1,658.58
	1,52,185.29	18,952.89	13,105.06	1,58,033.12	49,806.93	11,251.86	18.97	61,039.82	96,993.30

During the year completed capital projects Rs. 13,057.84 lakhs transferd from Capital work-in-progress to Property, plant and equipment

a) The net carrying amount of property, plant and equipment amounting to Rs. 95,334.72 lakhs (March 31, 2023 : Rs 93,556.99 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans. (refer note 13a and 14)

b) The Plant and equipment, Building and Electrical Installation includes an amount of Rs 443.38 lakhs, Rs. 67.18 lakhs and Rs. 14.65 lakhs respectively (March 31, 2023 : Rs.1,004.41 lakhs, Rs. 269.29 lakhs and Rs. 99.75 lakhs) that represent other incidental cost (i.e borrowing cost, power and fuel, salary etc) capitalised.

c) The Company has not recognised any impairment loss during the current year (March 31, 2024 : Nil).

d) The title deeds of immovable properties as disclose above are held in name of the Company.

Ageing for capital work-in-progress (CWIP) as at March 31, 2024 is as follows :

Description	Amount in Capital-work-in progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	959.24	699.34	-	-	1,658.58
Projects temporarily suspended	-	-	-	-	-
	959.24	699.34	-	-	1,658.58

CWIP projects in progress consists Common Infrastructure and Sustained Capex at Mahad plant, Amber Extreme 2TPM, In MPP Plant, etc. For CWIP, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-24.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements ***(Continued)***

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

4 a Right of use assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount	
	As at April 01, 2024	Addition during the year	Disposal during the year	As at March 31, 2025	As at April 01, 2024	Amortisation for the year	Disposal during the year	As at March 31, 2025	As at March 31, 2025
Land	4,721.10	-	-	4,721.10	1,257.73	240.74	-	1,498.47	3,222.63
Building	634.29	-	-	634.29	323.71	129.01	-	452.72	181.57
Plant and Machinery	67.00	-	-	67.00	63.64	-	-	63.64	3.36
Total right of use assets	5,422.39	-	-	5,422.39	1,645.08	369.75	-	2,014.83	3,407.56

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.

The Company has not recognised any impairment loss during the current year (March 31, 2024 - Nil).

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount	
	As at April 01, 2023	Addition during the year	Disposal during the year	As at March 31, 2024	As at April 01, 2023	Amortisation for the year	Disposal during the year	As at March 31, 2024	As at March 31, 2024
Land	3,990.41	730.69	-	4,721.10	927.69	330.04	-	1,257.73	3,463.37
Building	1,006.13	-	371.84	634.29	465.53	230.02	371.84	323.71	310.58
Plant and Machinery #	67.00	-	-	67.00	63.64	-	-	63.64	3.36
Total right of use assets	5,063.54	730.69	371.84	5,422.39	1,456.86	560.06	371.84	1,645.08	3,777.31

Company has hired few machinery on rental basis and basis that arrangement the underlying machinery will get transferred to the Company. This assets will be capitalising under property plant and equipment.

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.

The Company has not recognised any impairment loss during the current year (March 31, 2023 - Nil).

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

140

Notes to the Standalone Financial Statements ***(Continued)***

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

4 a Right of use assets (Continued)

i) The Company has taken land on lease for a non-cancellable period ranging 3 to 99 years, Building on lease for a tenure ranging from 3-5 years and plant and machinery for 10 years.

ii) The Company leases with contract term of less than 1 year. These leases are short term leases. The company has elected not to recognise right of use assets and lease liabilities of these assets.

iii) Maturity analysis of lease liabilities– contractual undiscounted cash flows:

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Less than one year	393.48	463.26
One to five years	329.19	890.97
More than five years	-	-
Total undiscounted lease liabilities	722.67	1,354.23
Discounted lease liabilities included in the statement of financial position	816.96	1,193.90
Current lease Liabilities	542.84	373.86
Non-current lease Liabilities	274.12	820.04

iv) The weighted average incremental borrowing rate of 6.25% to 9.40% (March 31, 2024 : 6.25% to 9.40%) has been applied for measuring the lease liability.

v) The total cash outflow for leases for year ended March 31, 2025 is Rs. 463.26 lakhs (March 31, 2024 : Rs. 558.40 lakhs.)

vi) Income from sub leasing of Right to use assets is Rs. 46.52 lakh. (March 31, 2024 : Rs. 43.23 lakh) to related parties

BSR & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

4 b Other Intangible assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2024	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2025	As at April 01, 2024	Amortisation for the year	Disposal / Transfer during the year	As at March 31, 2025	As at March 31, 2025
Computer softwares	1,300.65	-	-	1,300.65	853.18	273.32	-	1,126.50	174.15
Rights of sale of products	1,546.57	337.07	63.54	1,820.10	1,172.77	109.84	55.52	1,227.09	593.01
Development rights	265.65	150.00	-	415.65	252.31	0.08	-	252.39	163.26
Total intangible assets	3,112.87	487.07	63.54	3,536.40	2,278.26	383.24	55.52	2,605.98	930.42
Intangible assets under development	1,008.56	865.33	487.07	1,386.82	-	-	-	-	1,386.82
	4,121.43	1,352.40	550.61	4,923.22	2,278.26	383.24	55.52	2,605.98	2,317.24

During the year completed capital projects Rs. 487.07 lakhs transferrd from Intangible assets under development to Other Intangible assets

Ageing for intangible assets under development as at March 31, 2025 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress #	528.26	648.56	210.00	-	1,386.82
Projects temporarily suspended	-	-	-	-	-
	528.26	**648.56**	**210.00**	-	**1,386.82**

Intangible assets under development in progress consists development of Menthol, Floravone and Indomarone etc. For Intangible assets under development, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-March-25.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2025

(Currency: Indian Rupees in lakhs)

4 b Other Intangible assets *(Continued)*

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal / #Transfer during the year	As at 'March 31, 2024	As at April 01, 2023	Amortisation for the year	Disposal / Transfer during the year	As at 'March 31, 2024	As at 'March 31, 2024
Computer softwares	1,259.20	41.45	-	1,300.65	586.73	266.45	-	853.18	447.47
Rights of sale of products	1,387.24	159.33	-	1,546.57	1,058.64	114.13	-	1,172.77	373.80
Development rights	265.65	-	-	265.65	249.44	2.87	-	252.31	13.34
Total intangible assets	2,912.09	200.78	-	3,112.87	1,894.81	383.45	-	2,278.26	834.61
Intangible assets under development	487.07	722.27	200.78	1,008.56	-	-	-	-	1,008.56
	3,399.16	923.05	200.78	4,121.43	1,894.81	383.45	-	2,278.26	1,843.17

During the year completed capital projects Rs. 200.78 lakhs transferrd from Intangible assets under development to Other Intangible assets

Ageing for intangible assets under development as at March 31, 2024 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	626.06	382.50	-	-	1,008.56
Projects temporarily suspended	-	-	-	-	-
	626.06	382.50	-	-	1,008.56

Intangible assets under development in progress consists development of Menthol, Floravone and Indomarone etc. For Intangible assets under development, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-24.

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

BSR & Co. LLP Chartered Accountants

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

5 Investments

Unquoted

	As at March 31, 2025		As at March 31, 2024	
	Number of shares	Amount	Number of shares	Amount
Investments measured at Cost:				
Equity Instruments:				
Subsidiaries:				
Face value of Rs. 10 each fully paid:				
Privi Biotechnologies Private Limited	3,62,74,728	4,271.70	3,62,74,728	4,271.70
Face value of USD 1 each fully paid:				
Privi Speciality Chemicals USA Corporation	51,000	30.61	51,000	30.61
Face value of Rs. 10 each fully paid:				
Prigiv Specialties Private Limited	1,78,50,000	1,785.00	1,78,50,000	1,785.00
Face value of Rs. 10 each fully paid:				
Total		6,087.31		6,087.31
Investments measured at amortised Cost:				
Structured entity				
Radiance MH Sunrise Ten Private Limited	49,95,000	83.23	49,95,000	75.83
Face value of Rs. 10 each fully paid:		83.23		75.83
Aggregate amount of unquoted investments		6,170.54		6,163.14
Aggregate amount of impairment in value of investments		-		-

During the previous year, the company has subscribed to the shares of Radiance Sunrise Ten Private Limited (Structured entity), for 49,95,000 equity shares of Rs. 10 each amounting to Rs. 499.50 lakhs. Investment in Structured entity initially recognised as at its fair value as per INDAS 109, subsequently it will be carried at amortised cost. The excess of the nominal value of investment over the fair value on initial recognition is recognise as prepaid expense and amortised overt the term of contractual agreement (20 years) (refer note. 40)

6 Other financial assets

(Unsecured and considered good, unless otherwise stated)

	Non-current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Security deposits *	1,727.37	1,656.56	-	-
Investments in term deposits (with remaining maturity of more than twelve months) **	81.27	-	-	-
Other receivable from related parties #	-	-	629.74	-
	1,808.64	1,656.56	629.74	-

* An amount of Rs. 433.75 lakhs (March 31, 2024 : Rs. 376 lakhs) receivable from related parties. These receivable are pertaining to security deposit given for lease hold premises (refer note 30 and below table).

Particulars	As at March 31, 2025	As at March 31, 2024
Privi Biotechnologies Private Limited	25.00	25.00
Money Mart Securities Private Limited	300.00	300.00
MM Infra & Leasing Private Limited	108.75	51.00
Total	433.75	376.00

** Note : Term deposits with no lien amounting to Rs 81.27 lakhs (March 31, 2024: Rs Nil lakhs) against which bank guarantee given to statutory authorities and vendors.

Other receivable from related parties towards the sale of assets and lease income

Particulars	As at March 31, 2025	As at March 31, 2024
Prigiv Specialties Private Limited	493.73	-
Privi Life Science Private Limited	136.01	-
Total	629.74	-

BSR & Co. LLP 1 1st Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2025

(Currency: Indian Rupees in lakhs)

7 Other non-current assets

(Unsecured and considered good, unless otherwise stated)

	Non-current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Capital advances				
Considered good	1,757.00	181.60	-	-
Considered doubtful	36.15	36.15	-	-
Less: Allowance for doubtful advances	(36.15)	(36.15)	-	-
	1,757.00	181.60	-	-
Advances other than capital advances				
Advances with indirect tax authorities	45.21	6.00	-	-
Advances with direct tax authorities	247.83	-	-	-
Prepaid expenses #	1,100.22	771.15	670.45	670.45
GST Receivable	393.96	390.67	7,299.83	2,703.02
Advances to employees	-	-	41.98	21.06
Other @	-	-	325.00	-
Advance for supply of goods and services*	-	-	4,175.18	3,099.43
Less: Allowance for doubtful advances	-	-	(160.00)	(160.00)
	3,544.22	1,349.42	12,352.44	6,333.96

Prepaid expenses include investment in structured entity amounting to Rs 407 Lakhs (March 31, 2024 : Rs. 428.42 lakhs) (refer note 5)

@ Advance paid to various parties towards proposed QIP transactions and shareholder approval is valid till 11 August 2025.
*An amount of Rs 883.75 lakhs (March 31, 2024 : Rs. 929.20 lakhs) receivable from related parties. These receivable are pertaining to advance for supply of goods and services (lease services). (refer note 30 and below table)

Particulars	Nature of transaction	As at March 31, 2025	As at March 31, 2024
Privi Speciality Chemicals USA Corporation	Advance for supply of goods and services	883.75	916.99
Privi Biotechnologies Private Limited	Advance for supply of goods and services	-	12.21
Total		883.75	929.20

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2025

(Currency: Indian Rupees in lakhs)

	As at March 31, 2025	As at March 31, 2024
8 Inventories		
(valued at lower of cost and net realisable value)		
Raw materials including goods in transit Rs.7,523.01 lakhs (March 31,2024 : Rs. 4,462.40 lakhs)	19,242.98	11,118.67
Finished goods including goods in transit Rs. 13,578.47 lakhs (March 31, 2024 : Rs. 11,843.84 lakhs)	22,170.45	22,033.85
Work-in-progress	29,662.23	26,224.34
Stores and spares	975.40	744.72
Packing material	99.83	73.61
Fuel	116.22	87.37
	72,267.11	60,282.56

i) During the year ended March 31, 2025 : Rs. 62.16 lakhs (March 31, 2024: Rs. 39.65 lakhs) was recognised as an expense for inventories carried at net realisable value.
ii) The mode of valuation of inventories has been stated in note 2 xv of significant accounting policies.
iii) Bank overdrafts, cash credit and short-term loan from bank facility are secured by first paripassu charge on inventories (including raw material, finished goods and work-in-progress) and book debts (refer note 9 and 14).

9 Trade receivables		
Trade receivables considered good- Secured		
Dues from related parties (refer note 30)	10,482.99	9,843.37
Dues from others (Other than related party)	29,593.15	26,264.90
Trade receivables credit impaired	69.04	27.84
Less: Allowance for expected credit loss and credit impairment	(69.04)	(27.84)
	40,076.14	36,108.27

Refer note 33 for information about credit risk and market risk of trade receivables.

The movement in allowance for expected credit loss and credit impariment of receivable is as follows:

Balance as at beginning of the year	27.84	27.84
Allowance for expected credit loss and credit impariment	41.20	-
Allowance for expected credit loss written off during the year	-	-
Balance as at the end of the year	69.04	27.84

Trade receivables ageing as at March 31, 2025 based on due date

Particulars	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered goo	30,453.21	9,559.90	58.42	4.61	-	-	40,076.14
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed trade receivables-credit impairs	-	-	-	19.70	21.50	22.45	63.65
(iv) Disputed trade receivables-considered good	-	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables-credit impaired	-	-	-	-	-	5.39	5.39
	30,453.21	9,559.90	58.42	24.31	21.50	27.84	40,145.18
Less:-							
Allowance for doubtful trade receivables	-	-	-	19.70	21.50	27.84	69.04
	30,453.21	9,559.90	58.42	4.61	-	-	40,076.14

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

(Currency: Indian Rupees in lakhs)

9 Trade receivables (continued)

Trade receivables ageing as at March 31, 2024 based on due date

Particulars	Not due	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered goo	26,906.87	8,910.50	210.41	80.49	-	-	36,108.27
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed trade receivables-credit impaire	-	-	-	-	-	22.45	22.45
(iv) Disputed trade receivables-considered good	-	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables-credit impaired	-	-	-	-	-	5.39	5.39
	26,906.87	8,910.50	210.41	80.49	-	27.84	36,136.11
Less:-							
Allowance for doubtful trade receivable		-	-	-	-	27.84	27.84
	26,906.87	8,910.50	210.41	80.49	-	-	36,108.27

	As at March 31, 2025	As at March 31, 2024
10 Cash and cash equivalents		
Balances with banks:-		
In current accounts	3,913.53	1,531.25
In Eumer exchange foreign currency account	125.39	26.71
Term deposits (with original maturity of less than three months)	9.44	8.87
Cash on hand	10.09	8.25
	4,058.45	1,575.08

Current accounts include dividend accounts balance Rs.9.78 lakhs (March 31, 2024: Rs.9.78 lakhs)

11 Bank balances other than cash and cash equivalents		
Margin money deposits (with original maturity of more than three months but less than twelve months)	6.79	444.78
	6.79	444.78

Note : Margin money deposit amounting to Rs.6.79 lakhs (March 31, 2024: Rs 36.49 lakhs) are pledged with banks for non cash limits and term deposit Rs.Nil lakhs (March 31, 2024: Rs.152.24 lakhs) are pledged as cash security with banks for the loans taken by the Company and Rs. Nil lakhs (March 31, 2024 Rs.256.05 lakhs) other deposits with no lien.

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

	As at March 31, 2025	As at March 31, 2024
12 a Share capital		
Authorised Share Capital		
50,010,000 (March 31 2024: 50,010,000) equity shares of Rs. 10 each	**5,001.00**	5,001.00
5,000,000 (March 31, 2024 5,000,000) preference shares of Rs. 10 each	**500.00**	500.00
Issued, subscribed and fully paid up:		
39,062,706 equity shares of Rs. 10 each (March 31 2024 : 39,062,706 equity shares of Rs.10 each)	**3,906.27**	3,906.27
	3,906.27	3,906.27

A Reconciliation of the number of equity shares

Description	As at March 31, 2025		As at March 31, 2024	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**3,90,62,706**	**3,906.27**	3,90,62,706	3,906.27
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	**3,90,62,706**	**3,906.27**	3,90,62,706	3,906.27

B Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid. Failure to pay any amount called up on shares may lead to forfeiture of the shares. On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

C Details of shareholders holding more than 5% of shares

ame of the Share holde	As at March 31, 2025		As at March 31, 2024	
	Number	%	Number	%
Vivira Investment and Trading Pvt Ltd	**1,54,95,188**	**39.67%**	1,54,95,188	39.67%
Moneymart Securities Pvt Ltd	**34,12,502**	**8.74%**	34,12,502	8.74%
Mr. Mahesh P Babani	**25,86,348**	**6.62%**	25,86,348	6.62%
Banbridge Limited	**23,83,958**	**6.10%**	23,83,958	6.10%

D Aggregate number of shares allotted as fully paid up by way of following (during 5 years immediately preceding March 31, 2024) :

(a) Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash. Nil (March 31, 2024 - Nil)

(b) Aggregate number and class of shares allotted as fully paid up by way of bonus shares. Nil (March 31, 2024 - Nil)

(c) Aggregate number and class of shares bought back: Nil (March 31, 2024 - Nil)

BSR & Co. LLP Chartered Accountants

For PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

12 a Share capital (continued)

E Shares held by promoters as at the March 31, 2025

Sr.	Promoter name	As at March 31, 2025		As at March 31, 2024		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Private Limited	1,54,95,188	39.67%	1,54,95,188	39.67%	-
2	Moneymart Securities Private Limited	34,12,502	8.74%	34,12,502	8.74%	-
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	15,48,202	3.96%	15,48,202	3.96%	-
6	Vinaykumar Doppalapudi	8,91,068	2.28%	8,91,068	2.28%	-
7	Vijaykumar Doppalapudi	8,55,006	2.19%	8,55,006	2.19%	-
8	Rajkumar Doppalapudi Rao	-				-
8	Jyoti Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
9	Seema Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
10	Snehal Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
11	Prasanna Doppalapudi Rao	-	-			-
11	Premaleela Doppalapudi	5,24,522	1.34%	5,24,522	1.34%	-
12	Sharon Doppalapudi Rao	2,45,656	0.63%	2,45,656	0.63%	-
13	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	2,32,185	0.59%	-
14	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	93,446	0.24%	-
15	MM Infra & Leasing Private Limited	79,758	0.20%	79,758	0.20%	-

Shares held by promoters as at March 31, 2024

Sr.	Promoter name	As at March 31, 2024		As at March 31, 2023		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,54,95,188	39.67%	-
2	Moneymart Securities Private Limited	34,12,502	8.74%	34,12,502	8.74%	-
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	15,48,202	3.96%	11,20,346	2.87%	1.09%
6	Vinaykumar Doppalapudi	8,91,068	2.28%	7,41,068	1.90%	0.38%
7	Vijaykumar Doppalapudi	8,55,006	2.19%	7,05,006	1.80%	0.39%
8	Jyoti Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
9	Seema Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
10	Snehal Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
11	Premaleela Doppalapudi	5,24,522	1.34%	2,74,522	0.70%	0.64%
12	Sharon Doppalapudi Rao	2,45,656	0.63%	2,45,656	0.63%	-
13	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	2,32,185	0.59%	-
14	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	93,446	0.24%	-
15	MM Infra & Leasing Private Limited	79,758	0.20%	79,758	0.20%	-

BSK & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2025

(Currency: Indian Rupees in lakhs)

	As at March 31, 2025	As at March 31, 2024
12 b Other equity		
General reserve	35,573.76	35,573.76
Capital reserve	1.00	1.00
Retained earnings	70,638.24	52,566.85
Total other equity	1,06,213.00	88,141.61

The description of the nature and purpose of each reserve within equity is as follows:

A General reserve

As per the approved scheme of arrangement (Demerger) between the Privi Organics India Limited , Privi Specialities Chemicals Limited and Privi Organics Limited during the period ended 31 March 2017, the excess of book value of assets over liabilities is treated as general reserve.

B Retained earnings

Retained earnings represent the amount of undistributed accumulated earnings at each Balance Sheet date of the Company.

C Capital reserve

As per the approved Scheme of Arrangement and Amalgamation amongst Fairchem Speciality Limited (Demerged / Transferee Company) and Privi Organics India Limited (Transferor Company). vide NCLT Mumbai order dated June 30 , 2020, all the assets , liabilities and reserve pursuant to the scheme, have been transferred at carrying amount and the difference if any being the excess is treated as capital reserve.

D The Capital management objective of the Company is to (a) maximize shareholder value and provide benefits to other stakeholders and (b) maintain an optimal capital structure to reduce the cost of capital.

For the purposes of the Company's capital management, capital includes issued equity share capital, share premium and all other equity. The Company monitors capital using debt-equity ratio, which is total debt less liquid investments and bank deposits divided by total equity.

The Company's debt equity ratio as at March 31, 2025 was as follows:

Particulars	As at March 31, 2025	As at March 31, 2024
Total Debt	84,776.31	88,813.11
Less: Cash and cash equivalents and term deposits	4,146.51	2,019.86
Net Liabilities (A)	80,629.80	86,793.25
Total Equity (B)	1,10,119.27	92,047.88
Debt - Equity Ratio	0.73	0.94

In addition, the Company has complied all the financial covenants (as at March 31, 2025) relating to the borrowing facilities that it has taken from the lenders like interest coverage service ratio, Debt to EBITDA, etc.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

13 a Non-current borrowings

	Non-current		Current maturity of long term debt (*)	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Secured:				
Term loans from banks (refer note (i))				
Term loan in Indian currency (refer note (iii) below)	27,913.38	30,272.86	12,403.57	13,045.24
Term loans in foreign currency (refer note (ii) & (iii) below)	-	676.64	692.43	676.63
Term loans from financial institutions				
Vehicle loan (hypothecated with the lender) (refer note iii below)	-	0.70	0.23	4.30
Unsecured:				
Intercorporate Loan (refer note (vi))	-	900.00	250.00	-
Loan from Directors (refer note (vii))	-	6,500.00	-	-
	27,913.38	38,350.20	13,346.23	13,726.17

(*) Amount disclosed under the head ' current borrowings (secured) ' refer note 14

i) Term loan are secured by a first mortgage on the Company's immovable properties both present and future ranking paripassu interest and a first charge by way of hypothecation of all the company's assets (save and except book debts and inventories) including movable machinery (save and except spares tools and accessories) both present and future subject to charges created in favour of the Company's bankers for inventories, book debts and other specified movable assets for securing the borrowings of working capital .

ii) Currency exposure for borrowings is exclusive of Currency swap on ICICI bank Rupee loan of Rs.4,000 lakhs are taken @64.42 per USD and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76.78 per USD and @ 75.83 per USD respectively which are classified as Indian currency loan.

iii) **Terms and repayment schedule**

Terms and conditions of outstanding borrowings are as follows:

Name of the Bank / Financial Institution	Currency	Interest Rate	Year of Maturity	Installment	Carrying amount as at March 31, 2025	Carrying amount as at March 31, 2024
Foreign Currency (External Commercial borrowing (ECB))						
Ratnakar Bank	EUR	2.75%	2026	The term loan is repayable in 24 quarterly installments of EURO 187,500.00 each starting from Apr 2020.	692.43	1,353.27
Foreign Currency-Total (A)					692.43	1,353.27
Indian Currency						
Kotak Mahindra Bank	INR	8.75%	2024	The term loan is repayable in 20 quarterly installments of Rs.250 lakhs starting from Mar 2023 .	-	5,236.80
CITI Bank	INR	9.51%	2025	The term loan is repayable in 12 quarterly installments of Rs.916 lakhs starting from Mar 2023 .	2,751.72	6,411.46
ICICI Bank	INR	7.90% - 8.60%	2025	The term loan is repayable in 20 quarterly installments of Rs.200 lakhs starting from Sep 2020 .	200.38	999.52
ICICI Bank	INR	9.25%	2028	The term loan is repayable in 15 quarterly installments of Rs.125 lakhs starting from Jun 2024. and increase by Rs.125 lakh after every year.	4,244.67	4,864.09
HDFC Bank	INR	7.90%-9.50%	2026	The term loan is repayable in 20 quarterly installments of Rs.280 lakhs starting from Apr 2021 .	1,121.07	2,235.89

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Mumbai - 400 710

Name of the Bank / Financial Institution	Currency	Interest Rate	Year of Maturity	Installment	Carrying amount as at March 31, 2025	Carrying amount as at March 31, 2024
Foreign Currency (External Commercial borrowing (ECB))						
HDFC Bank	INR	7.43% - 8.38%	2027	The term loan is repayable in 20 quarterly installments of Rs.370 lakhs starting from Jun 2022 .	2,960.00	4,440.00
HDFC Bank	INR	8.85%	2028	The term loan is repayable in 20 quarterly installments of Rs.350 lakhs starting from Jan 2024 .	5,250.00	6,650.00
HDFC Bank	INR	8.95%	2029	The term loan is repayable in 20 quarterly installments of Rs.375 lakhs starting from Sep 2024 .	6,369.27	7,487.02
HDFC Bank	INR	8.51% - 8.20%	2029	The term loan is repayable in 12 quarterly installments of Rs.350 lakhs starting from Sep 2024 .	3,850.00	-
HDFC Bank	INR	8.40%	2032	The term loan is repayable in 23 quarterly installments of Rs 217.39 lakhs starting from Aug 2026 and repayable in 22 quarterly installments of Rs.227.27 lakhs starting from Dec-2026	10,000.00	-
RBL Bank	INR	9.75%	2028	The term loan is repayable in 14 quarterly installments of Rs.357.14 lakhs starting from May 2024 .	3,569.84	4,993.30
Yes Bank (Vehicle loan)	INR	8.97%	2024	The term loan is repayable in 65 monthly installments of Rs.0.41 lakh starting from Jan-2020	0.23	5.02
Indian Currency total -B					40,317.18	43,323.10
Total Term Loan (A+B)					41,009.61	44,676.37

iv) Term loans availed have been utilized for the purpose for which the funds have been borrowed.

v) In current year Company has complied all the financial covenants with respective term loan availed from bank

vi) During the previous year Company has taken Inter corporate loan from Privi Biotechnologies Private Limited with interest rate of 7.25% p.a. Company is expcting to pay intercorporate loan within 12 months.

vii) During the previous year Company has taken unsecured loan from Directors with interest rate of 8.75% p.a. Company has repaid the entire loan during the year.

13 b Lease liabilities

i)

	Non-Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Lease liabilities	274.12	820.04	542.84	373.86
	274.12	820.04	542.84	373.86

	As at March 31, 2025	As at March 31, 2024
ii) **Amount recognised in profit or loss**		
Interest expenses on lease liabilities	86.32	120.72
Income from sub-leasing right-of-use assets presented in other income	59.12	43.23
Expenses related to short term leases	-	-
Expenses relating to leases of low-value assets, excluding short-term leases of low-value assets	-	-
iii) **Amounts recognised in statement of cash flows**		
Total cash outflow for leases	463.26	558.40

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

	As at March 31, 2025	As at March 31, 2024
14 Current borrowings		
From Banks:		
Cash credit (refer note e)	**389.65**	-
Working capital demand loan (refer note b & c)	**33,400.00**	28,584.42
Packing credit from bank (refer note d)	**9,358.52**	7,791.96
Interest accrued but not due on borrowings	**368.53**	360.36
Current maturities of long term debt (refer note 13 a)	**13,346.23**	13,726.17
Total	**56,862.93**	50,462.91

a) All the above loans except Current maturities of long term debt, are Rs 77,500 Lakh (March 2024 Rs 31,000 Lakh) fund base secured by first pari passu charge on all current assets of the Company both present and future. Balance loan of Rs. Nil lakh (March 2024 Rs.21,267 lakh) is unsecured.

b) Working capital demand loans from banks are secured by way of hypothecation of inventories both on hand and in transit and book debts and other receivables both present and future and also secured by way of second charge on fixed assets .Working capital loans carry interest rate @ 7.50% to 9.00%.

c) **Quarterly statements of current assets filed by the company with the banks are in agreement with the books of accounts except below (FY 2024-25)**

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Amount of difference	Reason for material discrepancies
Jun-24	Kotak Mahindra, RBL, SCB, HDFC, Citi, ICICI, YES, IDBI	Trade receivables and Inventories	99,356.84	98,562.42	794.42	refer note-i
Sep-24	HDFC, YES, ICICI, SCB, Citi, RBI and IDBI	Trade receivables and Inventories	99,459.93	1,01,687.90	-2,227.97	refer note-i
Dec-24	HDFC, YES, ICICI, SCB, Citi, RBI and IDBI	Trade receivables and Inventories	1,09,531.33	1,07,579.72	1,951.61	refer note-i
Mar-25	HDFC, YES, ICICI, SCB, Citi, RBI, Bajaj Finance and IDBI	Trade receivables and Inventories	1,12,343.25	1,11,639.77	703.48	refer note-i

i) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory. the related amounts are mentioned below :

Jun-24 stores and spare inventory of Rs. 794.21 Lacs and inventory of Rs.6.64 lacs and debtors of Rs.(6.42) lacs not included in quarterly statement submitted to bank

Sep-24 Stores and spare inventory of Rs. 870.50 lacs and GIT of Rs. (3160.82) lakhs not included in quarterly statement submitted to bank

Dec-24 Stores and spare inventory of Rs. 891.54 lacs and GIT of Rs. 1060.57 lakhs not included in quarterly statement submitted to bank

Mar-25 Stores and spare inventory of Rs.975.40 lacs and inventory of Rs.3.85 lacs and debtors advance 275 lacs are deducted from receivabel in quarterly statement submitted to bank

Quarterly statements of current assets filed by the company with the banks are in agreement with the books of accounts except below (FY 2023-24)

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Amount of difference	Reason for material discrepancies
Jun-23	refer note-i	Trade receivables and Inventories	1,00,585.56	1,00,969.00	-383.44	refer note-ii
Sep-23	refer note-i	Trade receivables and Inventories	98,401.60	97,349.00	1,052.60	refer note-ii
Dec-23	refer note-i	Trade receivables and Inventories	1,00,517.77	1,00,464.00	53.77	refer note-ii
Mar-24	refer note-i	Trade receivables and Inventories	96,390.83	96,925.00	-534.17	refer note-ii

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Mumbai - 400 710.

14 Current borrowings (secured) (Continued)

i) The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd., IDFC bank, ICICI Bank Ltd, Standard Chartered Bank

ii) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory, the related amounts are mentioned below :

Jun-23 unrealised gain of Rs. 161.32 lakhs, stores and spares inventory of Rs. 726.03 lakhs and Goods in transit of Rs. (1,270.79) lakhs not included in quarterly statement submitted to bank.

Sep-23 unrealised gain Rs. 281.16 lakhs, stores and spares inventory Rs. 755.33 lakhs and GIT Rs. 16.11 lakhs not included in quarterly statement submitted to bank.

Dec-23 unrealised gain Rs. 209.40 lakhs, stores and spares inventory Rs. 777.25 lakhs and GIT Rs. (932.88) lakhs not included in quarterly statement submitted to bank.

Mar-24 unrealised gain Rs. 270.21 lakhs, Stores and spares inventory Rs.744.72 lakhs and GIT Rs. (1,549.10) lakhs not included in quarterly statement submitted to

d) Packing credit in rupees carry interest rate @ 8.00% to 9.00% p.a.

e) Cash credit loan from bank carry interest rate @ 8.10% to 9.50%.

15 Provisions

	Non-Current		Current	
	As at March 31, 2025	As at March 31, 2024	As at March 31, 2025	As at March 31, 2024
Provisions for employee benefits				
Compensated absences (refer note 31)	614.98	371.63	114.16	62.91
Gratuity (refer note 31)	1,639.19	1,407.33	166.24	136.01
	2,254.17	1,778.96	280.40	198.92

16 Income tax

	As at March 31, 2025	As at March 31, 2024
Amounts recognised in profit or loss		
The major components of income tax expense for the years ended March 31, 2025 and March 31, 2024 are:		
Current income tax:		
Current income tax expenses	6,563.27	3,080.18
Deferred tax:		
Relating to origination and reversal of temporary differences	(106.61)	329.01
Income tax expense reported in the statement of profit or loss	6,456.66	3,409.19
Income tax recognised in other comprehensive income (OCI)		
Tax expense related to items recognised in OCI during the year:		
Remeasurements of defined benefit	(26.47)	4.08
Income tax related to OCI	(26.47)	4.08
Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for March 31, 2025 and March 31, 2024:		
Accounting profit before income tax	25,386.91	13,197.68
At India's statutory income tax rate of 25.17% (March 31, 2024 : 25.17%)	6,389.89	3,321.86
Non-deductible expenses for tax purposes (CSR expenses)	53.26	58.40
Others (Interest on delay payment of income tax etc)	13.51	28.93
	6,456.66	3,409.19
	6,456.66	3,409.19

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

16 Income Tax *(Continued)*

Income tax expense reported in the statement of profit and loss

Impact of tax rate change: During FY 2019-20, the Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company re-measured its Net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change was recognised in the standalone statement of profit and loss for that year.

Deferred Tax movement

	As at 1 April 2024	(Credit) / Charge in the statement of profit and Loss	(Credit) / Charge in other comprehensive income	As at March 31, 2025
Deferred tax (assets)/liabilities				-
Difference between WDV as per books and income tax for Property plant and equipm	3,308.38	163.49	-	3,471.87
Deferred asset on Right of use assets and lease Liabilities (net)	(60.58)	(26.14)	-	(86.72)
Provision for doubtful debts and advances	(54.79)	(13.74)	-	(68.53)
Expenses allowable for tax purposes when paid (Gratuity, Leave encashment and othe	(404.86)	(198.53)	(26.47)	(629.86)
Forex loss unrealised Impact (Derivative instrument)	(433.12)	(31.69)	-	(464.81)
	2,355.03	(106.61)	(26.47)	2,221.95

	As at 1 April 2023	(Credit) / Charge in the statement of profit and Loss	(Credit) / Charge in other comprehensive income	As at March 31, 2024
Deferred tax (assets)/liabilities				
Difference between WDV as per books and income tax for Property plant and equipm	2,954.74	353.64	-	3,308.38
Deferred asset on Right of use assets and lease Liabilities (net)	(24.30)	(36.28)	-	(60.58)
Provision for doubtful debts and advances	(54.79)	-	-	(54.79)
Expenses allowable for tax purposes when paid (Gratuity, Leave encashment and othe	(422.88)	13.94	4.08	(404.86)
Forex loss unrealised Impact (Derivative instrument)	(430.83)	(2.29)	-	(433.12)
	2,021.94	329.01	4.08	2,355.03

a) In respect of Deferred taxes, all items are attributable to origination and reversal of temporary differences.

b) Deferred tax benefits are generally recognized for all deductible temporary differences to the extent it is probable that taxable profits will be available against which, those deductible temporary differences can be realised.

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710.

		As at March 31, 2025	As at March 31, 2024
17	**Trade payables**		
a)	Total outstanding dues of micro and small enterprises		
	Acceptances	**252.87**	-
	Other than acceptances	**990.24**	1,275.87
b)	Total outstanding dues of creditors other than micro and small enterprises		
	Acceptances	**13,694.26**	7,101.02
	Other than acceptances		
	i) Payable to related parties : (refer note no: 30)	**3,148.44**	2,629.21
	ii) Payable to others	**22,426.38**	17,330.32
		40,512.19	28,336.42

The Company's exposure to credit and currency and liquidity risk related to trade payables are disclosed in Note 32

Information as per the requirement of Section 22 of The Micro, Small and Medium Enterprises Development Act, 2006

a)	(i) The principal amount remaining unpaid to any supplier at the end of accounting year included in trade payables	**1,243.11**	**1,275.87**
	(ii) The principal amount remaining unpaid to any supplier at the end of accounting year included in Payable for capital expenditure (refer note 18)	**1,011.80**	**345.28**
	(iii) The interest due on above	-	-
	The total of (i) & (ii)	**2,254.91**	1,621.15
b)	The amount of interest paid by the buyer in terms of section 16 of the Act, The amount of the payment made to the supplier	-	-
c)	The amounts of interest accrued and remaining unpaid at the end of financial year	-	-
d)	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the due date during the year) but without adding the interest specified under this Act.	-	-
e)	the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-

The above information has been determined to the extent such parties have been identified on the basis of information available with the Company.

Trade payables ageing as on 31-Mar-2025

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	**1,238.73**	**4.38**	-	-	-	**1,243.11**
ii) Others	**10,245.71**	**4,146.58**	**52.17**	**9.66**	**2.03**	**14,456.15**
iii) Disputed dues - MSME	-	-	-	-	-	-
iv) Disputed dues-Others	-	-	-	-	-	-
v) Unbilled dues (Provision for expenses, Vendor Finance, Goods-in transit etc)		-	-	-	-	**24,812.93**
	11,484.44	4,150.96	52.17	9.66	2.03	40,512.19

Trade payables ageing as on 31-Mar-2024

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	1,172.60	103.27	-	-	-	1,275.87
ii) Others	7,274.20	5,261.05	128.16	-	2.04	12,665.45
iii) Disputed dues - MSME	-	-	-	-	-	-
iv) Disputed dues-Others	-	-	-	-	-	-
v) Unbilled dues (Provision for expenses, Vendor Finance, Goods-in transit etc)	-	-	-	-	-	14,395.10
	8,446.80	5,364.32	128.16	-	2.04	28,336.42

	As at March 31, 2025	As at March 31, 2024
18 Other financial liabilities		
Payable for capital expenditure #	2,932.44	1,051.21
Deposits	105.25	102.25
Salaries, wages and bonus payable	748.86	675.03
Derivative Instruments (forward exchange contracts and Interest rate swaps (Refer note 13 a))	2,222.43	433.51
Interest on delayed payment of income tax	36.96	77.34
	6,045.94	2,339.34

Payable for capital expenditure includes MSME amouting to Rs. 1011.80 lakh (March 31, 2024 : Rs. 345.28 lakh)

The Company's exposure to credit and currency and liquidity risk related to the above financial liabilities are disclosed in note 33

19 Other current liabilities		
Statutory liabilities	224.34	207.24
Contract Liabilities (Advance from customer) (refer note 37)	92.08	301.92
	316.42	509.16

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2025	Year ended March 31, 2024
20 Revenue from operations		
Revenue from contracts with customers		
a) Sale of products- Manufactured Goods (refer note 29 and 37)	**2,02,891.81**	1,71,148.96
b) Export incentives	**780.24**	-
c) Other operating revenues - Scrap Sales	**162.21**	57.16
Total	**2,03,834.26**	**1,71,206.12**
21 Other income		
Interest income from fixed deposits carried at amortised cost	**14.08**	29.38
Gain on write-back of Financial liabilities measured at amortised cost	**54.92**	-
Gain on disposal of Other Intangible assets	**63.78**	-
Gain on sales of investment (net)	**1.01**	8.70
Net Gain on Foreign currency transactions	**1,224.07**	1,882.65
Interest income from Income Tax Refund	**199.32**	-
Miscellaneous income	**233.29**	240.90
	1,790.47	2,161.63
22 Cost of materials consumed		
Raw material consumed		
Opening Stock	**11,118.67**	19,655.08
Add: Purchases	**1,19,116.91**	82,078.42
Less: Closing stock	**19,242.98**	11,118.67
Consumption	**1,10,992.60**	90,614.83
Packing material consumed		
Opening Stock	**73.61**	119.71
Add: Purchases	**3,166.35**	2,536.69
Less: Closing Stock	**99.83**	73.61
Consumption	**3,140.13**	2,582.79
Total	**1,14,132.73**	93,197.62

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2025	Year ended March 31, 2024
23 Changes in inventories of finished goods and work in progress		
Closing stock:		
Finished goods	22,170.45	22,033.85
Work in progress	29,662.23	26,224.34
	51,832.68	48,258.19
Opening stock:		
Finished goods	22,033.85	25,948.48
Work in progress	26,224.34	27,752.09
	48,258.19	53,700.57
Decrease / (Increase) in inventories	(3,574.49)	5,442.38
24 Employee benefits expense		
Salaries, wages and bonus	6,629.43	5,689.73
Contribution to provident and other funds	339.62	327.78
Staff welfare expenses	546.00	526.95
	7,515.05	6,544.46
25 Finance costs		
Interest on term loans using effective interest rate measured at amortised cost	3,314.16	4,011.01
Less: Interest capitalised (refer note 3)	-	-
Net interest on term loans	3,314.16	4,011.01
Interest on working capital loans using effective interest rate measured at amortised cost	4,382.03	4,775.83
Interest on vehicle loans using effective interest rate measured at amortised cost	0.17	0.50
Loan arrangement fees amortised using effective rate of interest basis	44.09	42.76
Interest on unsecured Loans	515.58	474.20
Interest on delayed payment of income tax	36.96	77.34
Interest cost lease liability using effective interest rate measured at amortised cost	86.32	120.72
	8,379.31	9,502.36

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2025	Year ended March 31, 2024
26 Depreciation and amortisation expenses		
Depreciation on property, plant and equipment	11,914.95	11,251.86
Amortisation of intangible assets	383.24	383.45
Amortisation of right of use assets	369.75	560.06
	12,667.94	12,195.37
27 Power and fuel expenses		
Fuel	8,213.90	7,950.90
Power	6,691.08	5,633.82
Water Charges	278.02	217.42
	15,183.00	13,802.14

28 Other expenses

	Year ended March 31, 2025	Year ended March 31, 2024
Consumption of stores and spares	1,634.79	1,437.86
Job work charges	2,408.92	2,087.60
Repairs and maintenance of:		
Buildings	344.36	244.37
Plant and machinery	1,024.80	1,043.01
Others	37.23	32.55
Contract labour charges	924.31	1,196.72
Research and development expense	132.36	202.52
Pollution control expenses	1,469.57	964.40
Other factory expenses	1,529.68	1,068.06
Insurance	804.29	899.01
Postage and telephone expense	76.10	80.61
Rates and taxes	163.79	143.49
Training expenses	21.81	6.10
Payment to auditors:		
'For audit	50.06	48.00
'For limited review	30.00	27.00
'Other services*	2.16	1.20
Out of pocket expenses	3.81	1.20
Brokerage and commission	177.03	160.92
Printing and stationery	47.60	42.81
Freight outward	10,454.94	5,924.60
Selling and distribution	1,294.18	1,078.73
Legal and professional fees	1,252.02	1,048.92
Travelling and conveyance	943.73	823.42
Bank charges	163.06	157.07
CSR expenses (refer note 42)	211.59	232.01
Sundry balances written off	11.53	0.78
Allowance for expected credit loss and credit impairment	41.20	-
Loss on Sale of property, plant and equipment	18.53	25.60
Miscellaneous expenses	660.83	507.18
	25,934.28	19,485.74

* Professional services fee relating to proposed Qualified Institutional Placement (QIP) amounting to Rs.50 lakhs has been disclosed under "other current assets", hence, not included above.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements ***(Continued)***
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

29 Segment information

A. Factors used to identify the entity's reportable segments, including the basis of organisation

The Company has determined its reportable segment as "Aromatic chemicals" since the chief operating decision maker (CODM) evaluates the Company's performance as a single segment.

B. Information about reportable segments

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
Revenue from sale of products (Manufactured goods)	2,02,891.81	1,71,148.96
	2,02,891.81	1,71,148.96

C. Geographic information

The geographic information analyses the Company's revenue and non-current assets by the Company's country of domicile and other countries. In presenting the geographical information, segment revenue has been based on the geographic location of customers and segments assets were based on the geographic location of the respective non-current assets.
The product offerings which are part of the speciality chemicals portfolio of the Company are managed on a worldwide basis from India. all the non-current assets of Company are located within India. (refer note 37)

The Company publishes the standalone financial statements of the Company along with the consolidated financial statements. In accordance with Ind AS 108 - Operating Segments, the Company has disclosed the segment information in the consolidated financial statements.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

30 Related party disclosures

Details of transactions between the Company and other related party are disclosed below.

a) List of Related Parties

Promoter Group

Vivira Investment and Trading Private Limited

Subsidiary Companies

Privi Biotechnologies Private Limited

Privi Speciality Chemicals USA Corporation

Prigiv Specialties Private Limited

Enterprises owned by key management personnel or their relatives

Privi Life Science Private Limited

Privi Fine Sciences Private Limited (Privi Organics Limited amalgamated in Privi Fine Sciences Private Limited w.e.f 01.04.2021)

Moneymart Securities Private Limited

Babani Investment and Trading Private Limited

Satellite Technologies Private Limited

Prasad Organics Private Limited

MM Infra & Leasing Private Limited

Babani Bros. LLP

Pee Vee Premises LLP

Babani Buildcon LLP

Snejyo Agro LLP

Key Management Personnel (KMP)

Mr. Mahesh P. Babani	Chairman & Managing Director
Mr. D. B. Rao	Executive Director
Mr. Narayan S. Iyer	Chief Financial Officer
Mrs.Ashwini S. Shah	Company Secretary
Mr. Anurag Surana	Independent Director
Mr. Hemang Gandhi	Independent Director
Mr. Naresh Tejwani	Independent Director from October 25, 2024
Mrs. Priyamvada Bhumkar	Independent Director from October 25, 2024
Mrs. Anuradha Thakur	Independent Director upto March 31, 2025
Mr. Dwarko Topandas Khilnani	Independent Director upto March 31, 2025

Relatives of Key Management Personnel

Mahesh Purshottam Babani HUF

Mrs. Seema Mahesh Babani

Ms. Snehal Mahesh Babani

Ms. Jyoti Mahesh Babani

Mr.Vijaykumar Doppalapudi Rao

Mr.Vinaykumar Doppalapudi Rao

Mrs. Grace Vinaykumar Doppalapudi Rao

Mrs. Sharon Doppalapudi Rao

Mrs.Premaleela Doppalapudi Rao

Mr. Rajkumar Doppalapudi Rao

Mrs. Prasanna Raj Doppalapudi Rao

Mr. Rameshbabu Gokameswararao Guduru

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

b) During the year, following transactions were carried out with the related parties :

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
Transactions						
Purchase of raw materials						
Privi Life Science Private Limited	-	-	0.35	0.80	-	-
Privi Speciality Chemicals USA Corporation	9,397.56	9,948.75	-	-	-	-
Prasad Organics Private Limited	-	-	2,664.90	2,831.22	-	-
Privi Fine Sciences Private Limited	-	-	8.80	35.62	-	-
Prigiv Specialties Private Limited	170.25	-	-	-	-	-
Job work charges paid						
Privi Fine Sciences Private Limited	-	-	271.61	80.13	-	-
Prasad Organics Private Limited	-	-	81.52	-	-	-
Sale of finished goods						
Privi Speciality Chemicals USA Corporation	33,031.76	32,949.49	-	-	-	-
Privi Fine Sciences Private Limited	-	-	105.86	-		
Prasad Organics Private Limited	-	-	1,761.03	1,498.94	-	-
Prigiv Specialties Private Limited	161.44	-	-	-	-	-
Sale of Assets						
Prigiv Specialties Private Limited	268.66	-	-	-	-	-
Lease expense						
MM Infra & Leasing Private Limited	-	-	89.96	85.68	-	-
Moneymart Securities Private Limited	-	-	216.00	205.71	-	-
Privi Biotechnologies Private Limited	90.00	90.00	-	-	-	-
Technical Fees						
Privi Biotechnologies Private Limited	480.00	555.00	-	-	-	-
Lease income						
Privi Life Science Private Limited	-	-	42.66	39.87	-	-
Moneymart Securities Private Limited	-	-	1.35	1.26	-	-
MM Infra & Leasing Private Limited	-	-	1.31	-	-	-
Privi Fine Sciences Private Limited	-	-	0.60	0.90	-	-
Vivira Investment & Trading Private Limited	-	-	0.60	0.60	-	-
Prigiv Specialties Private Limited	12.00	-	-	-		
Privi Biotechnologies Private Limited	0.60	0.60	-	-	-	-
Unsecured loan taken						
Mr. Mahesh P Babani	-	-	-	-	-	6,500.00
Privi Biotechnologies Private Limited	-	-	-	-	-	900.00
Interest on unsecured loan taken						
Mr. Mahesh P Babani	-	-	-	-	470.97	438.84
Privi Biotechnologies Private Limited	41.76	35.36	-	-	-	-
Reimbursement of expense received						
Prigiv Specialties Private Limited	-	233.75	-	-	-	-
Privi Speciality Chemicals USA Corporation	54.77	53.07	-	-	-	-
Advances						
Privi Speciality Chemicals USA Corporation	883.75	916.99	-	-	-	-
Investment in shares						
Prigiv Specialties Private Limited	-	1,020.00	-	-	-	-

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

b) **During the year, following transactions were carried out with the related parties : *(Continued)***

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
Deposit Received						
Prigiv Specialties Private Limited	3.00	-	-	-	-	-
Deposit Given						
MM Infra & Leasing Private Limited	-	-	57.75	-	-	-
Managerial renumeration						
Mr. D.B.Rao	-	-	-	-		
Short Term Employee Benefits	-	-	-	-	24.00	32.67
Post Employment Benefits	-	-	-	-	-	-
Other Long Term Benefits	-	-	-	-	-	-
Mr. Mahesh P Babani						
Short Term Employee Benefits	-	-	-	-	420.00	480.00
Post Employment Benefits	-	-	-	-	-	-
Other Long Term Benefits	-	-	-	-	-	-
Mr.Vinaykumar Doppalapudi Rao						
Short Term Employee Benefits (Salary paid)	-	-	-	-	29.68	26.98
Post Employment Benefits	-	-	-	-	14.59	15.77
Other Long Term Benefits	-	-	-	-	-	-
Dividend Paid						
Mr. Mahesh P Babani	-	-	-	-	51.73	-
Mahesh Purshottam Babani Huf	-	-	-	-	35.83	-
Mr. D.B.Rao	-	-	-	-	22.41	-
Moneymart Securities Private Limited	-	-	68.25	-	-	-
Vivira Investment and Trading Private Limited	-	-	309.90	-	-	-
Mm Infra & Leasing Private Limited	-	-	1.60	-	-	-
Mahesh Purshottam Babani HUF	-	-	-	-	35.83	-
Mrs. Seema Mahesh Babani	-	-	-	-	7.80	-
Ms. Jyoti Mahesh Babani	-	-	-	-	7.80	-
Ms. Snehal Mahesh Babani	-	-	-	-	7.80	-
Mrs. Premaleela Doppalapudi Rao	-	-	-	-	5.49	-
Mr. Vinaykumar Doppalapudi Rao	-	-	-	-	14.82	-
Mrs. Grace Vinaykumar Doppalapudi Rao	-	-	-	-	4.64	-
Mr.Vijaykumar Doppalapudi Rao	-	-	-	-	14.10	-
Mrs. Sharon Doppalapudi Rao	-	-	-	-	4.91	-
Mr. Rajkumar Doppalapudi Rao	-	-	-	-	13.82	-
Mrs. Prasanna Raj Doppalapudi Rao	-	-	-	-	5.74	-
Mr. Rameshbabu Gokarneswararao Guduru	-	-	-	-	1.87	-
Sitting fees						
Mr. Anurag Surana	-	-	-	-	6.00	5.00
Mrs. Anuradha Thakur	-	-	-	-	6.00	5.00
Mr. Rajesh Budhrani	-	-	-	-	-	5.00
Mr. P.R. Barpande	-	-	-	-	-	5.00
Mr. Hemang Gandhi	-	-	-	-	5.00	1.00
Mr. Naresh Tejwani	-	-	-	-	1.00	-
Mrs. Priyamvada Bhumkar	-	-	-	-	1.00	-
Mr. Dwarko Topandas Khilnani	-	-	-	-	6.00	4.00

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

c) Outstanding balances

Particulars	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2024
Receivables /Other assets						
Privi Speciality Chemicals USA Corporation	10,451.33	9,939.01	-	-	-	-
MM Infra & Leasing Private Limited	-	-	108.75	51.00	-	-
Privi Life Science Private Limited	-	-	136.01	85.67	-	-
Moneymart Securities Private Limited	-	-	300.00	300.00	-	-
Prasad Organics Private Limited	-	-	865.09	704.58	-	-
Privi Biotechnologies Private Limited	-	37.21	-	-	-	-
Prigiv Specialties Private Limited	538.99	31.09	-	-	-	-
Privi Fine Sciences Pvt. Ltd.	-	-	5.06	-	-	-
Investments						
Privi Speciality Chemicals USA Corporation	30.61	30.61	-	-	-	-
Privi Biotechnologies Private Limited	4,271.70	4,271.70	-	-		-
Prigiv Specialties Private Limited	1,785.00	1,785.00	-	-	-	-
Trade Payables / Other Liabilities						
Privi Biotechnologies Private Limited	164.37	-	-	-	-	-
Prigiv Specialties Private Limited	203.83	-	-	-	-	-
Privi Life Science Private Limited	-	-	0.25	0.25	-	-
MM Infra & Leasing Private Limited	-	-	0.29	129.25	-	-
Moneymart Securities Private Limited	-	-	1.44	314.24	-	-
Prasad Organics Private Limited	-	-	459.03	531.81	-	-
Privi Fine Sciences Private Limited			52.97	39.06		
Privi Speciality Chemicals USA Corporation	2,270.26	1,614.60	-	-	-	-
Payable to Key Management Personal						
Mr. Mahesh P Babani (*)	-	-	-	-	21.69	13.69
Mr. D B Rao (*)	-	-	-	-	1.65	1.55
Relatives of Key Management Personnel						
Mr.Vinaykumar Doppalapudi Rao (*)	-	-	-	-	1.46	1.33
Company has provided Corporate Bank Guarantee to CITI Bank against a working capital Loan sanction to Privi Speciality Chemicals USA Corporation (formally known as Privi Organics USA Corporation) (refer note d below)	3,423.26	3,334.96	-	-	-	-

*Remuneration Net of Tax Deducted at Source

BSK & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

31 Employee benefits - post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the refer note 24 under "Contribution to provident & other funds":

	Year ended March 31, 2025	Year ended March 31, 2024
Contribution to employees provident fund	338.45	327.06
Contribution to labour welfare fund	0.66	0.16
Contribution to ESI	0.51	0.56

b) Defined benefit plans

The Company operates one unfunded post-employment defined benefit plan that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

	March 31, 2025	March 31, 2024
Amount recognised in the balance sheet in respect of Gratuity		
Present value of the defined benefit obligation at the end of the year	1,805.43	1,543.34
Fair value of the plan assets	-	-
Net liability	1,805.43	1,543.34

	As at March 31, 2025	As at March 31, 2024
Movement in present value of defined benefit obligation		
Opening Liability	1,543.34	1,456.35
Current service cost	109.01	112.61
Interest cost	110.97	108.35
Actuarial /loss	104.08	(15.81)
Benefits paid	(61.97)	(118.16)
Closing defined benefit obligation	1,805.43	1,543.34
Expense recognised in statement of profit and loss		
Current service cost	109.01	112.61
Interest on defined benefit obligations	110.97	108.35
Total	219.98	220.96
Remeasurements recognised in Other comprehensive income		
Change in financial assumptions	58.48	28.01
Change in Demographic Assumptions	-	-
Experience adjustments	45.60	(43.82)
Total	104.08	(15.81)
Total expense recognised	324.06	205.15

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD OFFICE Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

31 Employee benefits - Post-employment benefit plans *(Continued)*

b) Defined benefit plans *(Continued)*

	As at March 31, 2025	As at March 31, 2024
Principal actuarial assumptions at the balance sheet date		
Discount rate (p.a.)	7.44%	7.44%
Expected rate of salary increase (p.a.)	8.25%	8.25%
Attrition rate	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.
Mortality tables	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)

At March 31, 2025 the weighted average duration of the defined benefit obligation was 9 years (March 31, 2024 : 9 years)
The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
	March 31, 2025	March 31, 2024	March 31, 2025	March 31, 2025
Impact on defined benefit obligation due to:				
a. 1% increase	(122.81)	(106.77)	136.80	119.48
b. 1% decrease	140.25	121.94	(122.25)	(106.71)

The sensitivity analysis above has been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment for last five years

	March 31, 2025	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2021
Defined benefit obligation	1,805.43	1,543.34	1,456.35	1,371.47	1,167.16
Surplus/(deficit)	(1,805.43)	(1,543.34)	(1,456.35)	(1,371.47)	(1,167.16)
Experience adjustment on plan liabilities	45.60	(43.82)	(31.22)	90.57	11.38

Compensatory absences

The Company provides for the encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits, for future encashment. The liability is provided based on the number of days of unutilized leave at each balance sheet date on the basis of an independent actuarial valuation. Amount of Rs. 450.15 lakhs (31 March, 2024 : Rs 15.01 lakhs) has been recognised in the Standalone Statement of profit and loss of provision for long-term employment benefit.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency Indian Rupees in lakhs)

32 Financial instruments

Company has an established control framework with respect to the measurement of fair values
This includes a management has overall responsibility for overseeing all significant fair value measurements, including Level 3 fair values.
The management regularly reviews significant unobservable inputs and valuation adjustments If third party information, such as broker quotes or pricing services, is used to measure fair values, then the internal valuation team assesses the evidence obtained from the third parties to support the conclusion that these valuations meet the requirements of the applicable financial reporting framework, including the level in the fair value hierarchy in which the valuations should be classified."
Significant valuation issues are reported to Company's audit committee if any.
When measuring the fair value of an asset or a liability, Company uses observable market data as far as possible. If the inputs used to measure the fair value of an asset or a liability fall into different levels of the fair value hierarchy, then the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.
Company recognises transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred.

a. Accounting classification and fair values

The Company is exposed to the risks of changes in fair value of its financial assets and liabilities. The following table summarises the fair values and carrying amounts of financial instruments.

		Carrying value			Fair value measurement using		
As on 31 March 2025	Note	Amortised cost	Financial assets/liabilities at FVTPL	Financial assets/liabilities at FVOCI	Total carrying amount	Level 1	Level 2	Level 3
Financial assets:								
Trade receivables	9	40,076.14	-	-	40,076.14	-	-	-
Cash and cash equivalents	10	4,058.45	-	-	4,058.45	-	-	-
Bank balances other than cash and cash equivalents	11	6.79	-	-	6.79	-	-	-
Other financial assets	6	2,438.38	-	-	2,438.38	-	-	-
Financial liabilities:								
Non Current borrowings	13 a	27,913.38	-	-	27,913.38	-	27,913.38	-
Current borrowings	14	56,862.93	-	-	56,862.93	-	-	-
Trade payables	17	40,512.19	-	-	40,512.19	-	-	-
Derivatives	18	-	2,222.43	-	2,222.43	-	2,222.43	-
Lease liabilities	13 b	274.12	-	-	274.12	-	274.12	-
Other financial liabilities (other than lease liabilities)	18	3,823.51	-	-	3,823.51	-	-	-

		Carrying value			Fair value measurement using		
As on 31 March 2024	Note	Amortised cost	Financial assets/liabilities at FVTPL	Financial assets/liabilities at FVOCI	Total carrying amount	Level 1	Level 2	Level 3
Financial assets:								
Investment in equity instruments (unquoted)	5	6,163.14	-	-	6,163.14	-	-	-
Trade receivables	9	36,108.27	-	-	36,108.27	-	-	-
Cash and cash equivalents	10	1,575.08	-	-	1,575.08	-	-	-
Bank balances other than cash and cash equivalents	11	444.78	-	-	444.78	-	-	-
Other financial assets	6	1,656.56	-	-	1,656.56	-	-	-
Financial liabilities:								
Non Current borrowings	13 a	38,350.20	-	-	38,350.20	-	-	38,350.20
Current borrowings	14	50,462.91	-	-	50,462.91	-	-	50,462.91
Trade payables	17	28,336.42	-	-	28,336.42	-	-	-
Derivatives	18	-	433.51	-	433.51	-	433.51	
Lease liabilities	13 b	1,193.90	-	-	1,193.90	-	-	1,193.90
Other financial liabilities (other than lease liabilities)	18	1,905.83	-	-	1,905.83		-	

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

32 Financial instruments *(Continued)*

b. The fair value of financial instruments as referred to in note (a) above have been classified into a three categories depending on the inputs used in the valuation technique.

The categories used are as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

c. **Calculation of fair values**

The fair values of the financial assets and liabilities are defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Methods and assumptions used to estimate the fair values are consistent with those used for the year ended March 31, 2025.

(i) The fair values of the derivative financial instruments has been determined using valuation techniques with market observable inputs. The models incorporate various inputs including the credit quality of counter-parties and foreign exchange forward rates. In case the forwards are taken from banks and financial institutions, the fair value is determined using quoted forward exchange rates at the reporting date and present value calculations based on high credit quality yield curves in the respective currencies by the bankers.

(ii) The fair values of investments in mutual fund units is based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at Balance Sheet date. NAV represents the price at which the issuer will issue further units of mutual fund and the price at which issuers will redeem such units from the investors.

(iii) Loans, lease liabilities and borrowings have fair values that approximate to their carrying amounts as it is based on the net present value of the anticipated future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities.

(iv) Cash and cash equivalents, trade receivables, investments in term deposits, other financial assets (except derivative financial instruments), trade payables, and other financial liabilities (except derivative financial instruments) have fair values that approximate to their carrying amounts due to their short-term nature.

BSR & Co. LLP
14th Floor
Central Wing and
North C Wing
Nesco IT Park-1,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2025

(Currency Indian Rupees in lakhs)

33 Financial risk management

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Board of Directors has established the risk management committee, which is responsible for developing and monitoring the company's risk management policies. The committee reports regularly to the board of Directors on its activities.
The Company's risk management are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and activities.
The Audit committee oversees how management monitors compliance with the company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Audit committee is assisted in its oversight role by internal audit by external party.

The Company has exposure to the following risks arising from the financial instruments:

a. Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counter-party fails to meet its contractual obligations and arises principally from the Company's receivables from customers. The carrying amount of financial assets represent the maximum credit exposure.
The Company's exposure to credit risk is influenced mainly by the individual characteristic of each customer. However, management also consider the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which company operates.
The Company analyses credit worthiness of each new customer individually before standard payment and delivery terms are offered. The Company is monitoring economic environment in countries where it operates and is taking actions to limit its exposure to customers in those countries experiencing particular economic volatility.

The Company's exposure to credit risk for trade receivables by geographic region was as

Particulars	March 31, 2025	March 31, 2024
India	11,125.67	11,899.63
Outside India	28,950.47	24,208.64
	40,076.14	36,108.27

Expected credit loss on Trade receivables

At March 31, 2025 the ageing of trade and other receivables that were not impaired was as follows.

Particulars	March 31, 2025			
	Gross Carrying Amount	Impairment Allowances	Loss Rate	Net Carrying Amount
Neither past due nor impaired	30,453.21	-	0.00%	30,453.21
Past due 0-90 days	8,743.42	-	0.00%	8,743.42
Past due 90-180 days	816.48	-	0.00%	816.48
Past due 180-270 days	52.74	-	0.00%	52.74
Past due 270-365 days	5.68	-	0.00%	5.68
More than 365 days	73.65	69.04	93.74%	4.61
	40,145.18	69.04		40,076.14

Impairment of Trade receivables

At March 31, 2024 the ageing of trade and other receivables that were not impaired was as follows.

Particulars	March 31, 2024			
	Gross Carrying Amount	Impairment Allowances	Loss Rate	Net Carrying Amount
Neither past due nor impaired	26,906.87	-	0.00%	26,906.87
Past due 0-90 days	8,716.48	-	0.00%	8,716.48
Past due 90-180 days	194.02	-	0.00%	194.02
Past due 180-270 days	113.16	-	0.00%	113.16
Past due 270-365 days	97.25	-	0.00%	97.25
More than 365 days	108.33	27.84	25.70%	80.49
	36,136.11	27.84		36,108.27

Movement in Loss allowance measured at amount equal to life time expected credit losses for trade receivables.

Particulars	Amount
Balance as at April 01, 2023	27.84
Impairment loss recognised	-
Amounts written off	-
Balance as at March 31, 2024	27.84
Impairment loss recognised	41.20
Amounts written off	-
Balance as at March 31, 2025	69.04

The Company uses an allowance matrix to measure the expected credit loss of trade receivables. Based on the industry practices and the business environment in which the entity operates, Management considers that the trade receivables are in default (credit impaired) if the payments are more than 365 days past due.

Management believes that the unimpaired amounts that are past due by more than 30 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk and the current provision for the bad debts represents the impacted credit loss it foresees in its receivables.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

(Currency Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

a. Credit Risk *(Continued)*

Financial assets other than trade receivables are not impaired and further, there are no amounts that are past due. Management believes that the amounts are collectable in full, based on historical payment behavior.

b. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company maintains the level of its cash and cash equivalents at an amount in excess of expected cash outflow on financial liabilities. The Company also monitors the level of expected cash inflows on trade and other receivables together with expected cash outflows on trade and other payables.

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

March 31, 2025	Carrying amount	Contractual cash flows: Total	1 year or less	1-2 years	2-5 years	More than 5 years
Non-derivative financial liabilities						
Term loans from banks	41,009.38	47,763.37	15,641.53	11,735.34	16,522.22	3,864.28
Other borrowings	41,471.63	41,471.63	41,471.63	-	-	-
Trade payables	40,512.19	40,512.19	40,448.33	52.17	11.69	-
Other financial liabilities	3,823.51	3,823.51	3,823.51	-	-	-
Lease liabilities	816.96	722.67	393.48	329.19	-	-
Derivative financial liabilities						
Currency Risk	2,222.43	2,222.43	2,222.43	-	-	-
	1,29,856.10	1,36,515.80	1,04,000.91	12,116.70	16,533.91	3,864.28

March 31, 2024	Carrying	Contractual cash flows: Total	1 year or less	1-2 years	2-5 years	More than 5 years
Non-derivative financial liabilities						
Term loans from banks	52,076.37	52,076.37	13,726.17	10,292.98	21,353.23	6,769.37
Other borrowings	36,736.74	36,736.74	36,736.74	-	-	-
Trade payables	28,336.42	28,336.42	28,336.42	-	-	-
Other financial liabilities	1,905.83	1,905.83	1,905.83	-	-	-
Lease liabilities	1,193.90	1,193.90	373.86	463.26	517.11	
Derivative financial liabilities						
Currency Risk	433.51	433.51	433.51	-	-	-
	1,20,682.77	1,20,682.77	81,512.53	10,756.24	21,870.34	6,769.37

The gross inflows/(outflows) disclosed in the above table represent the contractual undiscounted cash flows relating to derivative financial liabilities held for risk management purposes and which are not usually closed out before contractual maturity. The disclosure shows net cash flow amounts for derivatives that are net cash-settled and gross cash inflow and outflow amounts for derivatives that have simultaneous gross cash settlement.

c. Currency Risk

The Company is exposed to currency risk on account of its borrowings and other payables in foreign currency. The functional currency of the Company is Indian Rupee. The Company uses forward exchange contracts to hedge its currency risk, most with a maturity of less than one year from the reporting date.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

(Currency Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at March 31, 2025 and March 31, 2024 are as below:

Particulars	March 31, 2025 USD in lakhs	March 31, 2025 EURO in lakhs	March 31, 2024 USD in lakhs	March 31, 2024 EURO in lakhs
Financial assets				
Cash and cash equivalents	1.30	0.15	0.16	0.02
Trade Receivables	333.77	4.18	277.58	14.79
	335.07	4.33	277.74	14.81
Financial liabilities				
Borrowings	-	7.50	-	15.00
Packing credit in foreign currency	45.38	-	51.61	-
Working capital demand Loan	100.47	-	39.28	-
Trade payables and other financial liabilities	120.11	8.82	89.86	0.66
Other Current financial liabilities - Derivative Instruments Currency risk*	26.06	0.08	9.39	0.05
	292.02	16.40	190.14	15.71
Net exposure	43.05	(12.07)	87.60	(0.90)

*** The exposure disclosed here is net of currency swap taken by the Company**

Currency exposure for borrowings is exclusive of Currency swap on ICICI bank Rupee loan of Rs 4,000 lakhs are taken @64.42 per USD and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76.78 per USD and @ 75.83 per USD respectively which are classified as Indian currency loan.

The Company's corporate treasury function provides services to the business, co-ordinates access to domestic financial markets, monitors and manages the financial risk relating to the operation of the Company through internal risk reports which analyse exposures by degree and magnitude of risks. These risks include market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The use of financial derivatives is governed by the Company's policies approved by the board of directors, which provide written principles on foreign exchange risk, interest rate risk, credit risk, etc.

The Corporate treasury function reports quarterly to the Company's risk management committee, an independent body that monitors risks and policies implemented to mitigate risk exposures.

d. Sensitivity analysis

A reasonably possible strengthening (weakening) of the foreign currencies against INR at March 31, 2025 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

Effect in Indian Rupees in lakhs	Profit before tax Strengthening	Profit before tax Weakening	Equity, net of tax Strengthening	Equity, net of tax Weakening
March 31, 2025				
USD (3 % movement)	110.53	(110.53)	82.71	(72.28)
EUR (3 % movement)	(33.43)	33.43	(25.02)	21.86
	77.10	(77.10)	57.69	(50.42)

Effect in Indian Rupees in lakhs	Profit before tax Strengthening	Profit before tax Weakening	Equity, net of tax Strengthening	Equity, net of tax Weakening
March 31, 2024				
USD (3 % movement)	219.11	(219.11)	163.96	(143.28)
EUR (3 % movement)	(2.44)	2.44	(1.83)	1.60
	216.67	(216.67)	162.13	(141.68)

e. Interest risk

The company is exposed primarily to fluctuation in USD SOFR rates. Interest rate risk on financial debt is managed through interest rate swaps.

The interest rate profile of the Company's interest-bearing financial instruments is as

Particulars	March 31, 2025	March 31, 2024
Fixed-rate instruments		
Financial assets (bank deposits)	97.50	-
Financial liabilities (borrowings)	-	88,813.11
Variable-rate instruments		
Financial liabilities (borrowings) *	84,776.31	-
Total borrowings	84,873.81	88,813.11

*Effect of interest rate swaps is disclosed in Note 13 a

Financial assets classified at amortized cost have fixed interest rate. Hence, the Company is not subject to interest rate risk on such financial assets

Cash flow sensitivity analysis for variable-rate instruments

A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

	Profit or loss 100 bp increase	Profit or loss 100 bp decrease	Equity, net of tax 100 bp increase	Equity, net of tax 100 bp decrease
March 31, 2025				
Variable-rate instruments	847.76	(847.76)	634.38	(634.38)
March 31, 2024				
Variable-rate instruments	-	-	-	-

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 703

Notes to the Standalone Financial Statements (Continued)
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

34 Contingent liabilities:

Claims against the Company not acknowledged as debts are below

	As at March 31, 2025	As at March 31, 2024
Income tax authorities	1,824.95	932.16
Goods and Service Tax and Custom Duty *	1,458.84	106.06

* Demand of Rs. 1458.84 lakh (Rs. 106.06 lakh March 31, 2024) was raised by Goods and Service Tax (GST) and Customs authority out of which Rs. 59.48 lakh (Rs.16.98 lakh March 31, 2024) is paid under protest, balance Rs. 1,399.36 lakhs (Rs. 89.08 lakh March 31, 2024) are unpaid as on March 31, 2025.

The claims against the Company comprise of pending litigations / proceedings pertaining to demands raised by Excise, Custom, Sales / VAT tax and other authorities / bodies. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial statements.

It is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above pending resolution of the respective proceedings as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

The Company does not expect any reimbursements in respect of the above contingent liabilities.

35 Commitments

	As at March 31, 2025	As at March 31, 2024
Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of advances of Rs.1757.00 lakhs. (March 31, 2024 : Rs. 181.60 lakhs)	6,253.28	1,699.50
Bank Guarantee	261.74	514.56
Bank Guarantee to wholly own subsidiary (refer note 30 d)	3,423.26	3,334.96
LC's issued in favour of suppliers, but the material not dispatched	1,350.90	911.91

(i) During the current year, the Company entered into a contract to purchase property, plant and equipment and patents and trademarks for March 31,2025: Rs. 23,280.75 Lakhs March 31, 2024: Rs. 8,498.42 Lakhs respectively.

36 Earnings per share

	Year ended March 31, 2025	Year ended March 31, 2024
Profit after tax attributable to equity shareholders [A]	18,930.25	9,788.49
Number of equity shares at the beginning of the year [B]	3,90,62,706	3,90,62,706
Number of equity shares outstanding at the end of the year [C]	3,90,62,706	3,90,62,706
Weighted average number of equity shares outstanding during the year [D]	3,90,62,706	3,90,62,706
Basic and diluted earnings per share of face value Rs. 10 [A]/[D]	48.46	25.06

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements (Continued)
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

37 Revenue from Contracts with Customers

(A) The Company is primarily in the business of manufacture and sale of Aroma chemicals. All sales are made at a point in time and revenue recognised upon satisfaction of the performance obligations which is typically upon dispatch/ delivery and acceptance of goods depending on the contract terms. The Company has a credit evaluation policy based on which the credit limits for the trade receivables are established, the Company does not give significant credit period (120 days) resulting in no significant financing component.

(B) **Reconciliation of revenue recognised from Contract liability:**

Particulars	As at March 31, 2025	As at March 31, 2024
Opening Contract liability	301.92	5607.18
Less: Recognised as revenue during the year	2,865.56	8,642.17
Add: Addition to contract liability during the year	2,655.72	3,336.91
Closing Contract liability	92.08	301.92

Contract liability primarily relates to advance consideration received from customers for sale of products in case of few contracts based on terms agreed. The contract liability is expected to be recognised within 12 months.

There is no contract asset as at 31 March 2025 (31 March 2024 : Nil)

(C) **Reconciliation of revenue as per contract price and as recognised in statement of standalone profit and loss:**

Particulars	As at March 31, 2025	As at March 31, 2024
Revenue from contract with customer as per Contract price	2,02,891.81	1,71,148.96
Less: Discounts and other adjustments	-	-
Revenue from contract with customer as per statement of standalone profit and loss	2,02,891.81	1,71,148.96

(D) **Disaggregation of revenue from contract with customers**

Particulars	Revenue from contracts with customers March 31, 2025	Revenue from contracts with customers March 31, 2024
India	67,466.49	53,410.11
Outside India	1,35,425.32	1,17,738.85
	2,02,891.81	1,71,148.96

(E) **Unsatisfied Performance Obligations**

The Company applies the practical expedient in Paragraph 121 of Ind AS 115 and does not disclose information about remaining performance obligations.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements (Continued)
for the year ended March 31, 2025

(Currency: Indian Rupees in lakhs)

38 Dividend on equity shares

	FY 2024-25	FY 2023-24
Dividend on equity shares declared during the previous year and paid during the year*	781.21	-
	781.21	-

*Dividends declared by the Company are based on the profit available for distribution. On May 02, 2024, the Board of Directors of the Company have proposed a final dividend of Rs. 2.00 per share in respect of the year ended March 31, 2024 and same has been paid during the year ended 31 March 2025 amounting to Rs. Rs 781.21 lakh.

Dividends not recognized at the end of reporting period

Dividends declared by the Company are based on the profit available for distribution. On May 03, 2025, the Board of Directors of the Company have proposed a final dividend of Rs. 5/- per share in respect of the year ended March 31, 2025 subject to the approval of shareholders at the Annual General Meeting, and if approved, would result in a cash outflow of approximately Rs.1,953.13/- lakh.

39 Transfer Pricing

Transactions with related parties are governed by transfer pricing regulations of the Indian Income-tax Act, 1961. The Company's international and domestic transactions with related parties are at arm's length as per the independent accountants report for the year ended March 31, 2024. Management believes that the Company's international and domestic transactions with related parties post March 2024 continue to be at arm's length and that the transfer pricing legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.

40 Investment in shares of Radiance Sunrise Ten Private Limited

The Company has been supplementing its incremental energy requirements by sourcing power from renewable sources. To this end, the Company has executed a Share Subscription and Shareholder's Agreement dated December 28, 2022 to acquire 26% stake in Radiances MH Sunrise Ten Private Limited for supply of 10 MW electricity generated through Solar Power Plant ("Solar plant") at a concessional rate with a minimum entitlement of 51% of power generated from the Solar Plant. As per the agreement , the company has subscribed 49,95,000 equity shares of ₹ 10 each of Radiances MH Sunrise Ten Private Limited during the previous year.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

41 Other Statutory Information

a) Other informations

(i) As on March 31, 2025 there is no untilised amounts in respect of any issue of securities and long term borrowings from banks and financial institutions. The borrowed funds have been utilised for the specific purpose for which the funds were raised.

(ii) The Company do not have any transactions with struck off companies.

(iii) The Company do not have any charges or satisfaction, which is yet to be registered with Registrar of Companies beyond the statutory period.

(iv) The Company is in compliance with the number of layers prescribed under clause (87) of section 2 of the Companies Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(v) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(vi) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.

(vii) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(viii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

(ix) The Company have not entered in any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax

42 Corporate social responsibility

As per section 135 of the Companies Act, 2013 a corporate social responsibility (CSR) committee has been formed by the Company. The areas for CSR activities are Education, Environment Sustainability, Health and hygiene and Disaster Management. Amount spent during the year on activities which are specified in Schedule VII of the Companies Act 2013 are as mentioned below:

Particulars	Year ended March 31, 2025	Year ended March 31, 2024
a) Amount required to be spent by the Company during the year	210.00	232.01
b) Amount approved by the Board to be spent during the year	210.00	232.01
c) Amount spent during the year		
Paid		
(i) construction / acquisition of any asset	-	-
(ii) on purpose other than (i) above	211.59	232.01
Total	211.59	232.01
d) Details of related party transactions	-	-
e) Details of unspent obligations	Nil	Nil

Details of other than ongoing project

In case of Section 135(5) of the Companies Act, 2013 (Other than ongoing project)				
Opening Balance as at April 01, 2024	Amount deposited in specified fund of Schedule VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance as at March 31, 2025
-	-	210.00	210.00	-

In case of Section 135(5) of the Companies Act, 2013 (Other than ongoing project)				
Opening Balance as at 1 April 2023	Amount deposited in specified fund of Schedule VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance as at 31 March 2024
-	-	232.01	232.01	-

Note: There are no ongoing projects as at March 31, 2025 and March 31,2024

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2025

43 Additional Regulatory Information

Ratio	Numerator	Denominator	Year ended March 31, 2025	Year ended March 31, 2024	% Variance	Reason for Variance greater than 25%
Current Ratio (in times)	Total current assets	Total current liabilities	1.24	1.25	-0.80%	
Debt - Equity ratio (in times) (net)	Debt consists of borrowings Less Cash and cash equivalents and short term investments	Total equity	0.73	0.94	-22.34%	
Debt service coverage ratio (in times)	Net profit before tax + Depreciation + Interest (EBITDA)	Debt service = Interest + Principal repayments	1.36	1.37	-0.73%	
Return on equity ratio (in %)	Net profit after tax for the year	Average Total Equity	18.73%	11.23%	66.79%	Increase due to increase in profitability during the current year
net capital turnover ratio (in times)	Revenue from operations Average	Average working capital (i.e Total current assets less Total current liabilities)	8.85	11.76	-24.74%	Decrease due to increase in Revenue from operations Average
net profit ratio (in %)	Net profit after tax for the year	Revenue from operations	9.29%	5.72%	62.41%	Increase due to increase in profitability during the current year and Increase due to increase in revenue from operation along with reduction in raw material cost during the current year
return on capital employed (in %)	Profit before tax and finance costs	Total equity + Borrowings +Deferred tax liabilities (net)	17.13%	12.39%	38.26%	Increase due to increase in profitability during the current year
Inventory turnover ratio	Revenue from operations	Average Inventory	3.08	2.54	21.26%	
Trade receivable turnover ratio	Revenue from operations	Average Trade receivable	5.35	5.07	5.52%	
Trade payables turnover ratio	Purchases	Average Trade payables	3.55	3.03	17.16%	

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 03, 2025

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited
CIN : L15140MH1985PLC286828

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 03, 2025

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Independent Auditor's Report

To the Members of Privi Speciality Chemicals Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Speciality Chemicals Limited (the "Company") which comprise the standalone balance sheet as at 31 March 2024, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including material accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2024, and its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition	
See Note 2(xvi), 20 and 37 to standalone financial statements	
The Key Audit Matter	How the matter was addressed in our audit
The Company's revenue is derived primarily from sale of products. The principal products of the Company comprise of aroma chemicals. Revenue from sale of goods is recognized on transfer of the products to the customer. The Company uses a variety of shipment terms	In view of the significance of the matter we applied the following audit procedures in this area, among others to obtain sufficient appropriate audit evidence:- • Assessed the appropriateness of Company's accounting policies relating to revenue recognition as per the applicable accounting standard.

178

across its operating markets and this has an impact on the timing of revenue recognition. The performance obligations in the contracts may be fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on contract terms. There is a risk that revenue could be recognised at a time which is different from transfer of control especially for sales transactions occurring on and around the reporting period. Also, there is a risk of recognizing fictitious revenue throughout the year. In view of this and since revenue is a key performance indicator of the Company, we have identified timing of the revenue recognition as a key audit matter.	• Obtained an understanding of the Company's sales process and evaluated the design and implementation of key internal controls in relation to the timing of revenue recognition. We also tested the operating effectiveness of such controls for a sample of transactionsand also to controls over revenue recognised on and around the year end. • For a sample of sale transactions selected using statistical sampling, performed detailed testing and in particular examined whether these are recognised in the period in which control is transferred. This included examination of the terms and conditions as per customer orders, such as shipping terms, transporter documents and customer acceptances. • Tested on a sample basis, specific revenue transactions recorded around the year end date to check whether revenue has been recognised in the correct reporting period by examining the underlying documents. • Tested sample using statistical sampling approach for journal entries for revenue recognised during the year, selected based on specified risk-based criteria, to identify unusual transactions.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

When we read the annual report, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance and take necessary actions, as applicable under the relevant laws and regulations.

Management's and Board of Directors Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting

179

frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other

matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2 A. As required by Section 143(3) of the Act, we report that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books except for the matter stated in the paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e. On the basis of the written representations received from the directors as on 31 March 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2024 from being appointed as a director in terms of Section 164(2) of the Act.

f. the modification relating to the maintenance of accounts and other matters connected therewith are as stated in the 2A(b) above on reporting under Section 143(3)(b) and paragraph 2B(f) below on reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014.

g. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a. The Company has disclosed the impact of pending litigations as at 31 March 2024 on its financial position in its standalone financial statements - Refer Note 34 to the standalone financial statements.

b. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts – Refer Note 18 to the standalone financial statements.

c. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

d (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 42(a)(vii) to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of

funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 42A(viii) to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The Company has neither declared nor paid any dividend during the year.

f. The reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is applicable from 1 April 2023. Based on our examination which included test checks, except for the instances mentioned below, the Company has used accounting software for maintaining its books of account, which has a feature of recording audit trail (edit log) facility and the same has operated throughout the year for all relevant transactions recorded in the software.

(a) In case of the accounting software used for maintaining general ledger, the audit trail (edit log) facility for data changes performed by users having privileged access.

(b) At the application level for certain fields / tables relating to all the significant financial processes.

(c) The feature of recording audit trail (edit log) facility was not enabled at the database level to log any direct data changes for the accounting software used for maintaining the books of accounts.

Further, where audit trail (edit log) facility was enabled, we did not come across any instance of audit trail feature being tampered with.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar

Partner

Membership No.: 113959

ICAI UDIN:24113959BKGPPL2810

Place: Mumbai

Date: 02 May 2024

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified in a phased manner over a period of three years. In accordance with this programme, certain property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The inventory, except goods-in-transit and stocks lying with third parties, has been physically verified by the management during the year.For stocks lying with third parties at the year-end, written confirmations have been obtained and for goods-in-transit subsequent evidence of receipts has been linked with inventory records. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company except as follows:

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

Quarter	Name of bank	Particulars	Amount as per books of account (Rs in lakhs)	Amount as reported in the quarterly return/ statement (Rs in lakhs)	Amount of difference (Rs in lakhs)	Whether return/statement subsequently rectified
Jun-23	Refer Note-1	Trade Receivables and Inventories	100,586	100,969	(383)	No
Sep-23	Refer Note-1	Trade Receivables and Inventories	98,402	97,349	1,053	No
Dec-23	Refer Note-1	Trade Receivables and Inventories	100,518	100,464	54	No
Mar-24	Refer Note-1	Trade Receivables and Inventories	96,391	96,925	(534)	No

Refer note 14 of the standalone financial statements.

Note: 1 There are multiple banks i.e. Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd., IDFC bank, ICICI Bank Ltd, Standard Chartered Bank.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has made investments in Companies during the year. The Company has not made any investment in firms, Limited Liability Partnerships or any other parties during the year. The Company has provided guarantee and security to Company during the year in respect of which the requisite information is as below.

The Company has not provided guarantee and security to firms, Limited Liability Partneships or any other parties. The Company has not granted loans and advances in the nature of loans to Companies, firms, Limited Liability Partnerships or any other parties during the year.

B S R & Co. LLP Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

Particulars	Guarantees (Rs in lakhs)	Security	Loans	Advances in nature of loans
Aggregate amount during the year				
Subsidiaries*	-	-	-	-
Joint ventures*	-	-	-	-
Associates*	-	-	-	-
Others	-	-	-	-
Balance outstanding as at balance sheet date				
Subsidiaries*	3,335	-	-	-
Joint ventures*	-	-	-	-
Associates*	-	-	-	-
Others*	-	-	-	-

**As per the Companies Act, 2013*

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made and guarantees provided, the terms and conditions are, prima facie, not prejudicial to the interest of the Company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loans are given during the year Further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loans given. Further, the Company has not given any advances in the nature of loans to any party during the year. Accordingly, clause 3(iii) (d) of the Order is not applicable.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted. Accordingly, clause 3(iii) (e) of the Order is not applicable

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans. Accordingly, clause 3(iii) (f) of the Order is not applicable

(iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and loans, guarantees and security given by the Company, in our opinion the provisions of Section 185 and 186 of the Companies Act, 2013 ("the Act") have been complied with.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its manufactured goods and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are accurate or complete.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2024 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in lakhs net of protest)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
The Income Tax Act, 1961	Income Tax	3.33	AY 2005-06	CIT Appeals	Not Yet Paid
The Income Tax Act, 1961	Income Tax	316.13	AY 2014-15	Commissioner (Appeals)	Not Yet Paid
The Income Tax Act, 1961	Income Tax	31.21	AY 2015-16	CIT Appeals	Not Yet Paid
The Income Tax Act, 1961	Income Tax	209.36	AY 2017-18	ITAT	Not Yet Paid
The Income Tax Act, 1961	Income Tax	50.67	AY 2017-18	ITAT	Not Yet Paid
The Income Tax Act, 1961	Income Tax	268.79	AY 2018-19	Commissioner (Appeals)	Not Yet Paid
The Customs Act, 1962	Custom Duty	9.52	1998-99	CESTAT	Not Yet Paid

BSR & Co. LLP Chartered Accountants

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
The Customs Act, 1962	Custom Duty	90.54	2013-14	CESTAT	Not Yet Paid

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Act.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under the Act).

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in annual report is expected to be made available to us after the date of this auditor's report.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly,

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
ICAI UDIN:24113959BKGPPL2810

Place: Mumbai
Date: 02 May 2024

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A)(g) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Speciality Chemicals Limited ("the Company") as of 31 March 2024 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2024, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2024 *(Continued)*

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
ICAI UDIN:24113959BKGPPL2810

Place: Mumbai
Date: 02 May 2024

Privi Speciality Chemicals Limited

Standalone Balance Sheet

as at March 31, 2024

(Currency: Indian Rupees in lakhs)

	Note	As at March 31, 2024	As at March 31, 2023
Assets			
Non-current assets			
Property, plant and equipment	3	95,334.72	93,556.99
Capital work-in-progress	3	1,658.58	8,821.37
Right of use assets	4 a	3,777.31	3,606.68
Other Intangible assets	4 b	834.61	1,017.28
Intangible assets under development	4 b	1,008.56	487.01
Financial assets			
Investments	5	6,163.14	5,067.31
Other financial assets	6	1,656.56	1,497.35
Income tax assets (net)		2,343.19	2,343.19
Other non-current assets	7	1,349.42	3,093.30
Total non-current assets		1,14,126.09	1,19,490.54
Current assets			
Inventories	8	60,282.56	74,496.25
Financial assets			
Trade receivables	9	36,108.27	31,448.79
Cash and cash equivalents	10	1,575.08	1,025.27
Bank balances other than cash and cash equivalents	11	444.78	418.68
Other financial assets	6	-	9.84
Other current assets	7	6,333.96	7,402.37
Total current assets		1,04,744.65	1,14,801.20
TOTAL ASSETS		2,18,870.74	2,34,291.74
EQUITY AND LIABILITIES			
EQUITY			
Equity share capital	12 a	3,906.27	3,906.27
Other equity	12 b	88,141.61	78,341.39
Total equity		92,047.88	82,247.66
LIABILITIES			
Non-current liabilities			
Financial liabilities			
Borrowings	13 a	38,350.20	40,370.49
Lease liabilities	13 b	820.04	994.77
Provisions	15	1,770.90	1,730.17
Deferred tax liabilities (net)	16	2,355.03	2,021.94
Total non-current liabilities		43,296.25	45,117.37
Current liabilities			
Financial liabilities			
Borrowings	14	50,462.91	62,560.05
Lease liabilities	13 b	373.86	380.22
Trade payables			
a) Total outstanding dues of micro enterprises and small enterprises	17	1,275.87	927.53
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	17	27,060.55	28,844.76
Other financial liabilities	18	2,339.34	7,284.18
Other current liabilities	19	509.16	5,849.86
Provisions	15	198.92	212.56
Current tax liabilities (net)		1,298.02	367.55
Total current liabilities		83,518.63	1,06,906.71
Total liabilities		1,26,822.86	1,52,044.08
TOTAL EQUITY AND LIABILITIES		2,18,870.74	2,34,291.74
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Yogesh Bahuli
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Standalone Statement of Profit and Loss

for the year ended
March 31, 2024

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2024	Year ended March 31, 2023
INCOME			
Revenue from operations	20	**1,71,206.12**	1,57,784.32
Other income	21	**2,161.63**	2,159.61
TOTAL INCOME (I)		**1,73,367.75**	1,59,943.93
EXPENSES			
Cost of materials consumed	22	**93,197.62**	1,13,322.15
Changes in inventories of finished goods and work-in-progress	23	**5,442.38**	(18,243.98)
Employee benefits expense	24	**6,544.46**	7,235.42
Finance costs	25	**9,502.36**	6,662.48
Depreciation and amortisation expenses	26	**12,195.37**	10,515.53
Power and fuel expense	27	**13,802.14**	14,713.05
Other expenses	28	**19,485.74**	22,612.16
TOTAL EXPENSES (II)		**1,60,170.07**	1,56,816.81
Profit before tax		**13,197.68**	3,127.12
Tax expenses:			
Current tax		**3,080.18**	333.81
Deferred tax		**329.01**	545.82
Tax expense		**3,409.19**	879.63
Profit for the year (III)		**9,788.49**	2,247.49
Other comprehensive income			
Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans		**15.81**	63.46
Income tax related to items that will not be reclassified to profit or loss		**(4.08)**	(17.85)
Total other comprehensive income for the year (IV)		**11.73**	45.61
Total comprehensive income for the year (III + IV)		**9,800.22**	2,293.10
Earnings per equity share: nominal value of share Rs.10/- each Basic and diluted (Rs.)	36	**25.06**	5.75
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Ltd. Navi Mumbai

Privi Speciality Chemicals Limited

Standalone Statement of Cash Flows

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2024	Year ended March 31, 2023
A	**Cash flow from operating activities**		
	Profit before tax	13,197.68	3,127.12
	Adjustment for:		
	Depreciation and amortisation	11,635.31	9,986.50
	Amortisation of right of use assets	560.06	529.03
	Gain on write-back of financial liabilities measured at amortised cost (refer note 21)	-	(2.57)
	Sundry balances written off	0.78	-
	Unrealised foreign exchange loss (net)	(680.84)	936.28
	Interest income	(29.38)	(26.15)
	Finance cost	9,502.36	6,662.48
	Loss on sale of property, plant and equipment (net)	25.60	59.44
	(Gain) on sale of investments (net)	(8.70)	(8.88)
	Operating cash flow before working capital changes	34,202.87	21,263.25
	Movements in working capital		
	(Increase) in trade receivables	(4,659.48)	(2,702.91)
	Decrease / (Increase) in inventories	14,213.69	(18,375.47)
	Decrease in other assets	2,620.41	2,349.49
	(Decrease) in trade payable	(1,435.87)	(1,013.88)
	(Decrease) / Increase in other current liabilities and provisions	(6,113.46)	5,231.32
		4,625.29	(14,511.45)
	Cash generated from operations	38,828.16	6,751.80
	Income taxes paid	(2,649.71)	(1,282.64)
	Net cash generated from operating activities [A]	36,178.45	5,469.16
B	**Cash flow from investing activities**		
	Purchase of property, plant and equipment	(10,261.43)	(14,212.51)
	Proceeds from sales of property, plant & equipment	2.65	7.67
	Purchase of investment in subsidiaries	(1,020.00)	-
	Investment in structure entity	(499.50)	-
	Fixed deposit placed	(32.83)	(23.53)
	Proceeds on maturity of Fixed deposit	7.30	122.61
	Interest received	29.38	25.18
	Net cash (used in) investing activities [B]	(11,774.43)	(14,080.30)
C	**Cash flow from financing activities**		
	Proceeds from Non-current borrowings	17,400.00	12,500.00
	Repayment of Non-current borrowings	(15,987.10)	(6,065.15)
	Current borrowings (net)	(15,530.33)	8,290.90
	Payment of lease liabilities	(560.40)	(490.11)
	Dividend paid	-	(781.25)
	Interest paid	(9,178.38)	(6,460.70)
	Net cash (used in) / generated from financing activities [C]	(23,854.21)	6,994.49
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	549.81	(1,616.65)
	Cash and cash equivalents at the beginning of the year	1,025.27	2,636.96
	Exchange differences on translation of foreign currency cash and cash equivalents	-	4.96
	Cash and cash equivalents at end of the year (refer note 10)	1,575.08	1,025.27

BSR & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

Privi Speciality Chemicals Ltd. Navi Mumbai

Standalone Statement of Cash Flows *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Note B : Purchase of Property, Plant and Equipment includes movements in capital work-in-progress (including capital advances) during the year.

Note C : Reconciliation of net debts

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2023	**1,354.99**	**40,370.49**	**62,560.05**
Loan/ lease taken during the current year	**276.59**	**17,400.00**	-
Repayment during the current year	-	**(5,809.30)**	**(25,708.13)**
Foreign exchange gain or loss	-	**115.18**	**(198.34)**
Current maturities of long term debt (refer note 13 a)	-	**(13,726.17)**	**13,726.17**
Interest accrued but not due on borrowings	-	-	**83.16**
Interest on lease liabilities	**120.72**	-	-
Payment against lease liabilities	**(558.40)**	-	-
Closing balance as on March 31, 2024	**1,193.90**	**38,350.20**	**50,462.91**

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2022	1,715.21	38,060.00	49,904.67
Loan/ lease taken during the current year	-	12,500.00	8,290.90
Repayment during the current year	-	-	(6,065.15)
Foreign exchange gain or loss	-	103.47	(46.49)
Current maturities of long term debt (refer note 13 a)	-	(10,292.98)	10,292.98
Interest accrued but not due on borrowings	-	-	177.14
Interest on lease liabilities	129.09	-	-
Payment against lease liabilities	(489.31)	-	-
Closing balance as on March 31, 2023	1,354.99	40,370.49	62,560.05

Note D : For Corporate social responsibility related spends, refer note 42

Material accounting policies **2**
The accompanying notes forms an integral part of the standalone financial statemer **3 to 43**

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051762

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Standalone Statement of Changes in Equity

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	March 31, 2024	March 31, 2023
Balance at the beginning of the current reporting year	3,906.27	3,906.27
Changes in Equity Share Capital due to prior year errors		
Restated balance at the beginning of the current reporting year	3,906.27	3,906.27
Changes in equity share capital during the current year		
Balance at the end of the current reporting year	3,906.27	3,906.27

B. Other equity

	Reserves and Surplus			
	General reserve	Retained earnings*	Capital Reserve (refer note 12(b))	Total
Balance as at April 01, 2022	35,573.76	41,254.78	1.00	76,829.54
Profit for the year	-	2,247.49	-	2,247.49
Other comprehensive income / (loss) (net of tax)	-	45.61	-	45.61
Total comprehensive income for the year	35,573.76	43,547.88	1.00	79,122.64
Contribution and distribution to the owners				
Dividend of Rs 2.00 per share for the year ended March 31, 2022 (refer note 38)	-	(781.25)	-	(781.25)
Balance as at March 31, 2023	35,573.76	42,766.63	1.00	78,341.39
Profit for the year	-	**9,788.49**	-	**9,788.49**
Other comprehensive income / (loss) (net of tax)	-	**11.73**	-	**11.73**
Total comprehensive income for the year	-	**9,800.22**	-	**9,800.22**
Contribution and distribution to the owners				
	-	-	-	-
Balance as at March 31, 2024	**35,573.76**	**52,566.85**	**1.00**	**88,141.61**
* The Balance arising out of remeasurement of defined plans is adjusted against the available retained earnings.				

Notes to the standalone financial statements **3 to 43**
Material accounting policies **2**
The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached
For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Standalone Balance Sheet

as at March 31, 2024

(Currency: Indian Rupees in lakhs)

	Note	As at March 31, 2024	As at March 31, 2023
Assets			
Non-current assets			
Property, plant and equipment	3	95,334.72	93,556.99
Capital work-in-progress	3	1,658.58	8,821.37
Right of use assets	4 a	3,777.31	3,606.68
Other Intangible assets	4 b	834.61	1,017.28
Intangible assets under development	4 b	1,008.56	487.07
Financial assets			
Investments	5	6,163.14	5,067.31
Other financial assets	6	1,656.56	1,497.35
Income tax assets (net)		2,343.19	2,343.19
Other non-current assets	7	1,349.42	3,093.30
Total non-current assets		1,14,126.09	1,19,490.54
Current assets			
Inventories	8	60,282.56	74,496.25
Financial assets			
Trade receivables	9	36,108.27	31,448.79
Cash and cash equivalents	10	1,575.08	1,025.27
Bank balances other than cash and cash equivalents	11	444.78	418.68
Other financial assets	6	-	9.84
Other current assets	7	6,333.96	7,402.37
Total current assets		1,04,744.65	1,14,801.20
TOTAL ASSETS		2,18,870.74	2,34,291.74
EQUITY AND LIABILITIES			
EQUITY			
Equity share capital	12 a	3,906.27	3,906.27
Other equity	12 b	88,141.61	78,341.39
Total equity		92,047.88	82,247.66
LIABILITIES			
Non-current liabilities			
Financial liabilities			
Borrowings	13 a	38,350.20	40,370.49
Lease liabilities	13 b	820.04	994.77
Provisions	15	1,770.96	1,710.17
Deferred tax liabilities (net)	16	2,355.03	2,071.94
Total non-current liabilities		43,304.23	45,147.37
Current liabilities			
Financial liabilities			
Borrowings	14	50,462.91	62,560.05
Lease liabilities	13 b	373.86	380.22
Trade payables			
a) Total outstanding dues of micro enterprises and small enterprises	17	1,275.87	927.53
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	17	27,060.55	28,844.76
Other financial liabilities	18	2,339.34	7,284.18
Other current liabilities	19	509.16	5,849.86
Provisions	15	198.92	212.56
Current tax liabilities (net)		1,298.02	367.55
Total current liabilities		83,518.63	1,06,906.71
Total liabilities		1,26,822.86	1,52,044.08
TOTAL EQUITY AND LIABILITIES		2,18,870.74	2,34,291.74
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Pradip Bhansali
Chairman & Managing Director
DIN: 06051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Standalone Statement of Profit and Loss

for the year ended
March 31, 2024

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2024	Year ended March 31, 2023
INCOME			
Revenue from operations	20	**1,71,206.12**	1,57,784.32
Other income	21	**2,161.63**	2,159.61
TOTAL INCOME (I)		**1,73,367.75**	1,59,943.93
EXPENSES			
Cost of materials consumed	22	**93,197.62**	1,13,322.15
Changes in inventories of finished goods and work-in-progress	23	**5,442.38**	(18,243.98)
Employee benefits expense	24	**6,544.46**	7,235.42
Finance costs	25	**9,502.36**	6,662.48
Depreciation and amortisation expenses	26	**12,195.37**	10,515.53
Power and fuel expense	27	**13,802.14**	14,713.05
Other expenses	28	**19,485.74**	22,612.16
TOTAL EXPENSES (II)		**1,60,170.07**	1,56,816.81
Profit before tax		**13,197.68**	3,127.12
Tax expenses:			
Current tax		**3,080.18**	333.81
Deferred tax		**329.01**	545.82
Tax expense		**3,409.19**	879.63
Profit for the year (III)		**9,788.49**	2,247.49
Other comprehensive income			
Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans		**15.81**	63.46
Income tax related to items that will not be reclassified to profit or loss		**(4.08)**	(17.85)
Total other comprehensive income for the year (IV)		**11.73**	45.61
Total comprehensive income for the year (III + IV)		**9,800.22**	2,293.10
Earnings per equity share: nominal value of share Rs.10/- each			
Basic and diluted (Rs.)	36	**25.06**	5.75
Notes to the standalone financial statements	3 to 43		
Material accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Bubani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Ltd. Navi Mumbai

Privi Speciality Chemicals Limited

Standalone Statement of Cash Flows

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2024	Year ended March 31, 2023
A	**Cash flow from operating activities**		
	Profit before tax	13,197.68	3,127.12
	Adjustment for:		
	Depreciation and amortisation	11,635.31	9,986.50
	Amortisation of right of use assets	560.06	529.03
	Gain on write-back of financial liabilities measured at amortised cost (refer note 21)	-	(2.57)
	Sundry balances written off	0.78	-
	Unrealised foreign exchange loss (net)	(680.84)	936.28
	Interest income	(29.38)	(26.15)
	Finance cost	9,502.36	6,662.48
	Loss on sale of property, plant and equipment (net)	25.60	59.44
	(Gain) on sale of investments (net)	(8.70)	(8.88)
	Operating cash flow before working capital changes	34,202.87	21,263.25
	Movements in working capital		
	(Increase) in trade receivables	(4,659.48)	(2,702.91)
	Decrease / (Increase) in inventories	14,213.69	(18,375.47)
	Decrease in other assets	2,620.41	2,349.49
	(Decrease) in trade payable	(1,435.87)	(1,013.88)
	(Decrease) / Increase in other current liabilities and provisions	(6,113.46)	5,231.32
		4,625.29	(14,511.45)
	Cash generated from operations	38,828.16	6,751.80
	Income taxes paid	(2,649.71)	(1,282.64)
	Net cash generated from operating activities [A]	36,178.45	5,469.16
B	**Cash flow from investing activities**		
	Purchase of property, plant and equipment	(10,261.43)	(14,212.51)
	Proceeds from sales of property, plant & equipment	2.65	7.67
	Purchase of investment in subsidiaries	(1,020.00)	-
	Investment in structure entity	(499.50)	-
	Fixed deposit placed	(32.83)	(23.53)
	Proceeds on maturity of Fixed deposit	7.30	122.61
	Interest received	29.38	25.04
	Net cash (used in) investing activities [B]	(11,774.43)	(14,080.30)
C	**Cash flow from financing activities**		
	Proceeds from Non-current borrowings	17,400.00	12,500.00
	Repayment of Non-current borrowings	(15,987.10)	(6,065.15)
	Current borrowings (net)	(15,530.33)	8,290.90
	Payment of lease liabilities	(560.40)	(489.11)
	Dividend paid	-	(781.25)
	Interest paid	(9,178.38)	(6,460.70)
	Net cash (used in) / generated from financing activities [C]	(23,854.21)	6,994.49
	Net increase / (decrease) in cash and cash equivalents (A+B+C)	549.81	(1,616.65)
	Cash and cash equivalents at the beginning of the year	1,025.27	2,636.96
	Exchange differences on translation of foreign currency cash and cash equivalents	-	4.96
	Cash and cash equivalents at end of the year (refer note 10)	1,575.08	1,025.27

B S R & Co. LLP
14th Floor, Central B Wing and North C Wing, Nirlon Knowledge Park, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

Privi Speciality Chemicals Ltd
Navi Mumbai

Standalone Statement of Cash Flows *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Note B : Purchase of Property, Plant and Equipment includes movements in capital work-in-progress (including capital advances) during the year.

Note C : Reconciliation of net debts

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2023	**1,354.99**	**40,370.49**	**62,560.05**
Loan/ lease taken during the current year	**276.59**	**17,400.00**	-
Repayment during the current year	-	**(5,809.30)**	**(25,708.13)**
Foreign exchange gain or loss	-	**115.18**	**(198.34)**
Current maturities of long term debt (refer note 13 a)	-	**(13,726.17)**	**13,726.17**
Interest accrued but not due on borrowings	-	-	**83.16**
Interest on lease liabilities	**120.72**	-	-
Payment against lease liabilities	**(558.40)**	-	-
Closing balance as on March 31, 2024	**1,193.90**	**38,350.20**	**50,462.91**

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2022	1,715.21	38,060.00	49,904.67
Loan/ lease taken during the current year	-	12,500.00	8,290.90
Repayment during the current year	-	-	(6,065.15)
Foreign exchange gain or loss	-	103.47	(40.49)
Current maturities of long term debt (refer note 13 a)	-	(10,292.98)	10,292.98
Interest accrued but not due on borrowings	-	-	177.14
Interest on lease liabilities	129.09	-	-
Payment against lease liabilities	(489.31)	-	-
Closing balance as on March 31, 2023	1,354.99	40,370.49	62,560.05

Note D : For Corporate social responsibility related spends, refer note 42

Material accounting policies **2**
The accompanying notes forms an integral part of the standalone financial statements **3 to 43**

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051762

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Standalone Statement of Changes in Equity

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	March 31, 2024	March 31, 2023
Balance at the beginning of the current reporting year	**3,906.27**	3,906.27
Changes in Equity Share Capital due to prior year errors		
Restated balance at the beginning of the current reporting year	**3,906.27**	**3,906.27**
Changes in equity share capital during the current year		
Balance at the end of the current reporting year	**3,906.27**	3,906.27

B. Other equity

	Reserves and Surplus			
	General reserve	Retained earnings*	Capital Reserve (refer note 12(b))	Total
Balance as at April 01, 2022	35,573.76	41,254.78	1.00	76,829.54
Profit for the year	-	2,247.49	-	2,247.49
Other comprehensive income / (loss) (net of tax)	-	45.61	-	45.61
Total comprehensive income for the year	35,573.76	43,547.88	1.00	79,122.64
Contribution and distribution to the owners				
Dividend of Rs 2.00 per share for the year ended March 31, 2022 (refer note 38)	-	(781.25)	-	(781.25)
Balance as at March 31, 2023	35,573.76	42,766.63	1.00	78,341.39
Profit for the year	-	**9,788.49**	-	**9,788.49**
Other comprehensive income / (loss) (net of tax)	-	**11.73**	-	**11.73**
Total comprehensive income for the year	-	**9,800.22**	-	**9,800.22**
Contribution and distribution to the owners				
	-	-	-	-
Balance as at March 31, 2024	**35,573.76**	**52,566.85**	**1.00**	**88,141.61**
* The Balance arising out of remeasurement of defined plans is adjusted against the available retained earnings.				

Notes to the standalone financial statements 3 to 43
Material accounting policies 2

The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached
For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 02, 2024

Privi Speciality Chemicals Limited

Notes to the Standalone Financial Statements

for the-year ended March 31,2024

(Currency: Indian Rupees in Lakhs)

1 General Information

Privi Speciality Chemicals Limited ('PSCL or 'the Company') incorporated on 25 May 1985 under the provisions of the Companies Act, 1956 is a public company domiciled in India. The Company is having register office at A-71, Privi House, Thane Belapur road, TTC, Navi Mumbai-400710, Maharashtra, India. The Company is primarily engaged in the manufacture and export of aroma chemicals and in trading of chemicals. The Company's manufacturing units are located at Mahad and Jhagadia. The equity shares of the Company are listed on Bombay Stock Exchange Limited and National Stock Exchange of India Ltd.

2 Material accounting policies

This note provides a list of the material accounting policies adopted by the Company in the preparation of standalone financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of Compliance

These Standalone Financial Statements of the Company comprising the Balance Sheet as at March 31, 2024, Statement of Profit and Loss (including other comprehensive income), Statement of Changes in Equity, and Cash Flow Statement for the year ended March 31, 2024, and a summary of material accounting policies and other explanatory information have been prepared by the Company in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the 'Act'), other relevant provisions of the Act and guidelines issued by the Securities and Exchange Board of India.

The standalone financial statements were authorised for issue by the Company's Board of Directors at their meetings held on May ,02 2024.

i. Basis of preparation and Presentation

Basis of Preparation

The financial statements have been prepared on a historical cost basis, except for the following assets and liabilities:

(i) Derivative Financial Instruments measured at fair value.

(ii) Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments)

(iii) Employee's Defined Benefit Plan as per actuarial valuation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

i. Basis of preparation and Presentation (Continued)

Functional and Presentation Currency

The standalone financial statements are presented in Indian Rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates. All values are rounded to the nearest lakh, unless otherwise stated.

ii. Use of estimates, judgements, and assumptions

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of income, expenses, assets and liabilities, Actual results may differ from these estimates and assumptions.

Estimate and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised prospectively.

The Company has identified the following areas where significant judgements, estimates and assumptions are required. Further information on each of these areas and how they impact the various accounting policies are described below and in the relevant notes to the financial statements.

Financial reporting results rely on the estimate of the effect of certain matters that are inherently uncertain. Future events rarely develop exactly as forecast and the best estimates require adjustments, as actual results may differ from these estimates under different assumptions or conditions. Estimates and Judgments are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. The Management believes that the estimates used in preparation of these financial statements are prudent and reasonable. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. "revisions to accounting estimates are accounted for prospectively.

Judgements:

In the process of applying the Company's accounting policies, management has made the following judgements, which have the most significant effect on the amounts recognized in the financial statements.

a. Lease term, whether the Company is reasonably certain to exercise extension options – (Note 4 a)

Assumptions and estimation uncertainties

Information about judgements in applying accounting policies, as well as estimates and assumptions that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are included in the following notes:

(a) Measurement of defined benefit obligations for key actuarial assumptions - Note 31

(b) Recognition of deferred tax assets – Note 16

Privi Speciality Chemicals Ltd. Navi Mumbai

BSR & Co. LLP Chartered Accountants

2. Material accounting policies *(continued)*

iii. Current and non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is expected to be realised within 12 months after the balance sheet date; or

(d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the balance sheet date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is due to be settled within 12 months after the balance sheet date; or

(d) the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Terms of a liability that could, at the option of the counter party, result in its settlement by issue of equity instruments do not affect its classification. Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is twelve months from the time between the acquisition of assets for processing and their realization in cash or cash equivalents.

iv. Property, Plant and Equipment ("PPE") and depreciation

I Recognition and Measurement

Items of Property, Plant and equipment are measured at cost including nonrefundable taxed and import duties, which also includes capitalized borrowing costs less accumulated depreciation and any accumulated impairment losses. The Company's date of transition to the standards was determined with the reference to its fair value at the date.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of Property, Plant and equipment Any Gain or loss on disposal of an item of Property, Plant and equipment is recognized in profit or loss.

PSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

iv. *Property, Plant and Equipment ("PPE") and depreciation (continued)*

II Subsequent Expenditure

Subsequent Expenditure is capitalized only if it is probable that the future economic benefits flow to the associated with the Expenditure will flow to the entity.

Depreciation and amortization

Depreciation is calculated using the straight-line method to allocate cost of property plant and equipment, net of residual values, over their estimated useful lives as per the useful life prescribed in schedule II of the Companies Act, 2013 except in case of the following class of assets where the useful life is based on technical evaluation of the management:

Fixtures in leasehold premises are amortized over the primary period of the lease or useful life of the fixtures, whichever is lower.

Asset Class	Estimated useful life (in Years)	
	Useful life considered by the Company as per Schedule II / Technical Evaluation	Schedule II of the Companies Act, 2013
Building	33	30
Plant and Machinery	10	15
Electrical installation	10	10
Laboratory equipment's	10	10
Furniture & Fixtures	16	10
Office Equipment	10	5
Leasehold Improvement	15	15
Vehicle	10	8
Computer	6	6

Depreciation on additions / deletions during the year is provided from the date in which the asset is ready to use to the date in which the asset is disposed of.

The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets required under finance leases are depreciated over the shorter of the lease term and their useful lives (not being greater than the useful life envisaged in Schedule II of Companies Act, 2013) unless it is reasonably certain that Company will obtain ownership by the end of lease term, in which case the depreciation rates applicable for similar assets owned by the Company are applied.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss within other gains/(losses).

2. Material accounting policies *(continued)*

v. Intangible assets and amortisation

Intangible assets with finite useful life are stated at cost of acquisition, less accumulated depreciation/ amortisation and impairment loss, if any. Cost includes taxes, duties and other incidental expenses related to acquisition and other incidental expenses.

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

Asset Class	Estimated useful life (in Years)
Computers Soft wares	3 to 6 Years
Rights of Sale of Products	5 Years
Development Rights	5 Years

About internally generated intangible assets:

Expenditure on research activities, undertaken with the prospect of development of new products or gaining new technical knowledge and understanding, is recognised in profit or loss as incurred.

Capital expenditure on research and development is capitalized and depreciated as per accounting policy mentioned above. Revenue expenditure is charged off in the year in which it is incurred.

Development activities involve a plan or design for the production of new or substantially improved products or processes. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of tangible fixed assets). Other development expenditure is recognised in profit or loss as incurred.

Intangible assets are amortised in profit or loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the asset.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

vi. Impairment of Non-financial assets

At each reporting date, the Company reviews the carrying amounts of its non-financial assets (other than biological assets. investment property, inventories, contract assets and deferred tax assets to determine whether there is any indication of impairment nt. If any such indication exists, then the asset's referable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or group of CGUs that are expected to benefit from the synergies of the combination.

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Pvt. Ltd. Navi Mumbai

2. Material accounting policies *(continued)*

vi. Impairment of Non-financial assets (continued)

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value Jess costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its Recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset's carrying a mount does not exceed the carrying amount that would have been determined, net of depreciation or amortization. if no impairment loss had been recognized.

vii. Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing. Borrowing costs include interest costs measured at EIR amortization of discounts, hedge related cost incurred in connection with foreign currency borrowings, ancillary costs incurred in connection with borrowing of funds and exchange differences arising from foreign currency borrowings (other than long term foreign currency borrowings) to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognised as an expense in the period which they are incurred.

viii. *Foreign currency transactions*

Transactions denominated in foreign currency are recorded at the exchange rate prevailing on the date of transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of profit and loss of the year.

Monetary assets and liabilities in foreign currency, which are outstanding as at the balance sheet date are translated at the year-end at the closing exchange rate and the resultant exchange differences are recognized in the statement of profit and loss.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

viii. *Foreign currency transactions (continued)*

Foreign exchange differences regarded as an adjustment to borrowing costs are presented in the statement of profit and loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit and loss on a net basis within other incomes/expenses.

ix. *Financial Instruments*

a. Financial assets

Initial Recognition and Measurement

All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset, However, trade receivables that do not contain a significant financing component are measured at transaction price.

Revenue Recognition

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold, and services rendered is net of variable consideration on account of various discounts and schemes offered by the Company as part of the contract

Classification and subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortised cost

A financial asset is classified as subsequently measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through Other Comprehensive Income ("FVTOCI")

A financial asset is classified as subsequently measured at fair value through Other Comprehensive Income if both the following conditions are met:

- The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

ix. ***Financial Instruments (continued)***

a. Financial assets *(continued)*

Financial assets included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in other comprehensive income (OCI). However, the Company recognizes interest income,

impairment losses & reversals and foreign exchange gain or loss in the P&L. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from equity to P&L. The Company did not have any financial assets at FVTOCI during the current year as well as previous year.

Financial assets at fair value through Profit and loss ("FVTPL")

Financial assets at FVTPL are a residual category for financial assets. Any financial assets which do not meet the criteria of categorizing it at amortised cost or at FVTOCI is classified as at FVTPL.

Financial assets included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.
- When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

  Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

2. Material accounting policies *(continued)*

ix. Financial Instruments (continued)

a. Financial assets *(continued)*

Impairment of Financial Assets

In view of its past experience of having insignificant impairment bad debts / write-offs and based on management's estimate considering its portfolio of customers, this trend would continue for the foreseeable future, the Company has determined that significant impairment of Financial assets is not required to be recognised based on Expected Credit Loss model.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at amortised cost and financial liabilities at FVTPL. Derivative liabilities are classified as FVTPL. All financial liabilities are recognised initially at fair value. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognised in the profit or loss. Except derivative instruments, the Company has not designated any financial liability as at FVTPL.

Financial liabilities at amortised cost

All financial liabilities except for derivatives are classified as measured at amortised cost. This category includes bank and other borrowings, trade payables and other financial liabilities.

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

2. Material accounting policies *(continued)*

ix. Financial Instruments (continued)

c. Offsetting of Financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Business Model Assessment

Financial assets -Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed, and information is provided to management. The information considered includes:

the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities, or expected cash outflows or realizing cash flows through the sale of the assets.

- how the performance of the portfolio is evaluated and reported to the Company's management.
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed.
- how managers of the business are compensated- e.g., whether compensation is based on the fair value of the assets managed, or the contractual cash flows collected, and the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial Assets that are held for trading or are managed and whose performance I evaluated on a fair value basis are measured at FVTPL.

d. Derivatives

Initial recognition and subsequent measurement The Company uses derivative financial instruments, such as forward currency contracts, interest rate swaps and currency SWAPS, to hedge its foreign currency risks, interest rate risks and its long term loans, respectively. Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative. The purchase contracts that meet the definition of a derivative under Ind-AS 109 are recognised in the Statement of Profit and Loss.

RSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

x. ***Segment Reporting***

The Chief Operational Decision Maker (CODM) monitors the operating results of its business Segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on

profit and loss and is measured consistently with profit or loss in the standalone financial statements. Operating segments have been identified on the basis of nature of

products / services. The Accounting Policies adopted for segment reporting are in line with the Accounting Policies of the Company. Segment assets include all operating assets used by the business segments and consist principally of fixed assets, trade receivables and inventories. Segment liabilities include the operating liabilities that result from the operating activities of the business. Segment assets and liabilities that cannot be allocated between the segments are shown as part of unallocated corporate assets and liabilities respectively. Income / Expenses relating to the enterprise as a whole and not allocable on a reasonable basis to business segments are reflected as unallocated corporate income / expenses.

xi. ***Cash flows***

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flow. The cash flows from operating, investing and financing activities of the Company are segregated based on available information.

xii. ***Cash and Cash equivalents***

Cash and cash equivalent in the balance sheet and for the statement cash flow comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

xiii. ***Investment in subsidiaries and joint ventures***

Investment in subsidiary companies and joint venture companies are carried at cost less accumulated impairment losses, if any. Where an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiary companies and joint venture companies, the difference between net disposal proceeds and the carrying amount are recognised in the statement of Profit and Loss.

xiv. ***Leases***

The Company has adopted Ind AS 116 effectives from April 01 2019 using modified retrospective approach. For the purpose of preparation of Standalone Financial statement, management has evaluated the impact of change in accounting policies required due to adoption of Ind AS 116 in first year of applicability.

2. Material accounting policies *(continued)*

xiv. ***Leases (continued)***

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Company assesses whether: (i) the contact involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

As a lessee, the Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In

addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method.

The Company has used number of practical expedients when applying Ind AS 116: - Short-term leases, leases of low-value assets and single discount rate.

The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company applied a single discount rate to a portfolio of leases of similar assets in similar economic environment with a similar end date.

The Company's leases primarily comprise land and buildings and Plant and equipment. The Company leases land and buildings for warehouse facilities.

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

xv. Inventories

Inventories include raw materials, packing materials, fuel, consumable stores and spares and manufactured inventory. Inventory is valued at the lower of cost and net realisable value.

Cost comprises the purchase price, costs of conversion and other related costs incurred in bringing the inventories to their present location and condition. Cost of raw materials, packing materials, fuel, consumable, stores and spares are determined on the basis of Periodic moving weighted average method. Cost of finished goods and work in progress are determined using the absorption costing principle. Cost includes the cost of material consumed, labour and appropriate proportion of costs of conversion which include variable and fixed overheads.

Obsolete, defective, and unserviceable inventories are duly provided for. The comparison of cost and net realisable value is made on an item-to-item basis. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

xvi. Revenue Recognition

Revenue recognition Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer i.e., when the customer is able to direct the use of the transferred goods or rendering of services and obtains substantially.

all of the remaining benefits at an amount that reflects the consideration entitled in exchange for those goods or services. The policy of recognizing the revenue is determined according to Ind AS 115 "Revenue from contracts with customers".

Sale of Goods: Revenue is recognised upon transfer of control of promised goods to customers for an amount that reflects the consideration which the Company expects to receive in exchange for those goods. Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer which is usually on dispatch/ delivery of goods, based on contracts with the customers. Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, price concessions, incentives, and returns, if any, as specified in the contracts with the customers. Revenue excludes taxes collected from customers on behalf of the government. Accruals for discounts/incentives and returns are estimated (using the most likely method) based on accumulated experience and underlying schemes and agreements with customers. Due to the short nature of credit period given to customers, there is no financing component in the contract.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortised cost.

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

xvi. ***Revenue Recognition (continued)***

Export incentive

An export incentive is recognised in the statement of profit and loss when the right to receive credit as per the terms of the scheme is established in respect of export made, and there is no uncertainty as to its receipt.

xvii. ***Employee Benefits***

Short Term Employee Benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus, ex-gratia etc. These are recognised as an expense at an undiscounted amount in the Statement of Profit and Loss of the year in which the related service is rendered.

Post-employment Benefits

(i) Provident Fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's.

contribution is recognised as an expense in the statement of profit and loss during the period in which the employee renders the related service.

(ii) Gratuity

The Company's gratuity benefit scheme is a defined benefit plan. The Company`s net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary usingthe projected unit credit method. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the assets ceiling (if any, excluding interest), are recognised in OCI. All expenses related to defined benefit plan are recognised in employee benefits expense in the Statement of Profit and Loss.

(iii) Compensated Absences

The Company provides for encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/ availment. The Company makes provision for compensated absences based on an independent external actuarial valuation carried out at the end of the year.

2. Material accounting policies *(continued)*

xviii. Taxation

Income tax expense comprises current tax and deferred tax charge or credit.

Current Income Tax

Provision for current tax is determined as the amount of tax payable in respect of taxable income for the year in accordance with the provisions of the Income Tax Act, 1961.Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the enacted or substantively enacted tax rates and tax laws. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

"Current tax is recognised in statement of profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current tax is also recognised in other comprehensive income or directly in equity respectively. "

"Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate."

On March 30, 2019, MCA has issued amendment regarding the income tax Uncertainty over Income Tax Treatments. The notification clarifies the recognition and measurement requirements when there is uncertainty over income tax treatments. In assessing the uncertainty, an entity shall consider whether it is probable that a taxation authority will accept the uncertain tax treatment. This notification is effective for annual reporting periods beginning on or after April 1, 2019. As per the Company's assessment, there are no material income tax uncertainties over income tax treatments.

Current tax assets and current tax liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.

Current Tax is recognised in profit or loss except to the extent that it relates to a business combination or to an item recognised directly in equity or in other comprehensive income.

Deferred Tax

Deferred tax is recognized in respect of temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Material accounting policies *(continued)*

xviii. Taxation (continued)

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised either in other comprehensive income or in equity. Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

xix. Earnings per share

Basic earnings per share are calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share are the net profit for the year attributable to equity shareholders.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares, except where the results would be anti-dilutive.

xx. Provisions and contingent liabilities

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

2. Material accounting policies *(continued)*

xx. Provisions and contingent liabilities (continued)

Provision in respect of loss contingencies relating to claims litigation, assessment, fines, penalties etc. are recognized when it is probable that a liability has been incurred, and the amount can be estimated reliably.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, probably will not, require an outflow of resources embodying economic benefits, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the standalone financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic resources embodying economic benefits will arise, related income are recognized in the year in which the change occurs.

xxi. Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement

date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

xxii. Recent accounting pronouncements: -

Ministry of Corporate Affairs ("MCA") notifies new standards or amendments to the existing standards under Companies (Indian Accounting Standards) Rules as issued from time to time.

For the year ended March 31, 2024, MCA has not notified any new standards or amendments to the existing standards applicable to the Company.

S S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

3 Property, plant and equipment

Description	Gross carrying amount				Accumulated Depreciation				Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2024	As at April 01, 2023	Depreciation for the year	Disposal / #Transfer during the year	As at March 31, 2024	As at March 31, 2024
At cost :									
Building	25,075.20	2,921.88	-	27,997.08	2,915.63	868.26	-	3,783.89	24,213.19
Leasehold Improvement	565.20	35.22	-	600.42	516.34	3.44	-	519.78	80.64
Plant and equipment	1,05,877.67	9,153.23	-	1,15,030.90	41,986.35	9,287.96	-	51,274.31	63,756.59
Electrical installation	7,558.29	864.06	-	8,422.35	2,417.80	709.66	-	3,127.46	5,294.89
Furniture and fittings	267.92	-	-	267.92	68.57	15.01	-	83.58	184.34
Office equipment	466.58	4.57	-	471.15	208.24	35.12	-	243.36	227.79
Computers	1,185.51	11.57	-	1,197.08	665.79	146.15	-	811.94	385.14
Laboratory equipments	1,870.60	67.31	-	1,937.91	830.36	144.97	-	975.33	962.58
Vehicles	496.95	-	47.22	449.73	197.85	41.29	18.97	220.17	229.56
	1,43,363.92	13,057.84	47.22	1,56,374.54	49,806.93	11,251.86	18.97	61,039.82	95,334.72
Capital work -in- progress	8,821.37	5,895.05	13,057.84	1,658.58	-	-	-	-	1,658.58
	1,52,185.29	18,952.89	13,105.06	1,58,033.12	49,806.93	11,251.86	18.97	61,039.82	96,993.30

During the year completed capital projects Rs. 13,057.84 lakhs transferrd from Capital work-in-progress to Property, plant and equipment

a) The net carrying amount of property, plant and equipment amounting to Rs. 95,334.72 lakhs (March 31, 2023 : Rs 93,556.99 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans. (refer note 13a and 14)

b) The Plant and equipment, Building and Electrical Installation includes an amount of Rs.443.38 lakhs, Rs. 67.18 lakhs and Rs. 14.65 lakhs respectively (March 31, 2023 : Rs.1,004.41 lakhs, Rs. 269.29 lakhs and Rs. 99.75 lakhs) that represent other incidental cost (i.e borrowing cost, power and fuel, salary etc) capitalised

c) The Company has not recognised any impairment loss during the current year (March 31, 2023 : Nil).

d) The title deeds of immovable properties as disclose above are held in name of the Company.

Ageing for capital work-in-progress as at March 31, 2024 is as follows :

Description	Amount in Capital work-in-progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress #	959.24	699.34	-	-	1,658.58
Projects temporarily suspended	-	-	-	-	-
	959.24	699.34	-	-	1,658.58

CWIP projects in progress consists Common Infrastructure and Sustained Capex at Mahad plant, Amber Extreme 2TPM In MPP Plant, etc. For CWIP, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-24.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

3 Property, plant and equipment *(Continued)*

Description	Gross carrying amount				Accumulated Depreciation			Net carrying amount	
	As at April 01, 2022	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2023	As at April 01, 2022	Depreciation for the year	Disposal / #Transfer during the year	As at March 31, 2023	As at March 31, 2023
At cost :									
Building	17,714.20	7,361.00	-	25,075.20	2,205.13	710.50	-	2,915.63	22,159.57
Leasehold Improvement	547.20	18.00	-	565.20	514.91	1.43	-	516.34	48.86
Plant and equipment	76,467.75	29,409.92	-	1,05,877.67	33,935.32	8,051.03	-	41,986.35	63,891.32
Electrical installation	4,071.23	3,487.06	-	7,558.29	1,893.43	524.37	-	2,417.80	5,140.49
Furniture and fixtures	123.08	144.84	-	267.92	56.53	12.04	-	68.57	199.35
Office equipment	400.54	66.04	-	466.58	175.99	32.25	-	208.24	258.34
Computers	1,149.81	35.70	-	1,185.51	521.54	144.25	-	665.79	519.72
Laboratory equipments	1,778.72	91.88	-	1,870.60	688.78	141.58	-	830.36	1,040.24
Vehicles	596.38	20.10	119.53	496.95	197.40	52.87	52.42	197.85	299.10
	1,02,848.91	40,634.54	119.53	1,43,363.92	40,189.03	9,670.32	52.42	49,806.93	93,556.99
Capital work -in- progress	36,118.43	13,337.48	40,634.54	8,821.37	-	-	-	-	8,821.37
	1,38,967.34	53,972.02	40,754.07	1,52,185.29	40,189.03	9,670.32	52.42	49,806.93	1,02,378.36

During the year completed capital projects Rs. 40,634.54 lakhs transferrd from Capital work-in-progress to Property, plant and equipment

a) The net carrying amount of property, plant and equipment amounting to Rs. 93,556.99 lakhs (March 31, 2022 : Rs 62,659.88 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans.

b) The Plant and equipment, Building and Electrical Installation includes an amount of Rs.1,004.41 lakhs, Rs. 269.29 lakhs and Rs. 99.75 lakhs respectively (March 31, 2022 : Rs.381.30 lakhs, Rs. 87.84 lakhs and Rs. 20.81 lakhs) that represent borrowing cost capitalized @ 6.75% to 9.50% during the year.(March 31, 2022 : 6.75%).

c) The Company has not recognised any impairment loss during the current year (March 31, 2022 : Nil).

d) The title deeds of immovable properties as disclose above are held in name of the Company.

Ageing for capital work-in-progress as at March 31, 2023 is as follows:

Description	Amount in Capital-work-in progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	8,495.24	326.13	-	-	8,821.37
Projects temporarily suspended	-	-	-	-	-
	8,495.24	326.13	-	-	8,821.37

CWIP projects in progress consists Galameran & Galaxkone, Hydrogen Generation Plant, Zero Liquid Discharge, 400 Kw Roof Top Solar Plant etc. For CWIP, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-23, except as disclosed below

Ageing for capital-work-in progress, whose completion is overdue as at March 31, 2023 is as follows :

Description	Amount in Capital-work-in progress to be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Hydrogen Generation	1,636.30		-	-	1,636.30
	1,636.30	-	-	-	1,636.30

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

4 a Right of use assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal during the year	As at March 31, 2024	As at April 01, 2023	Amortisation for the year	Disposal during the year	As at March 31, 2024	As at March 31, 2024
Land	3,990.41	730.69	-	4,721.10	927.69	330.04	-	1,257.73	3,463.37
Building	1,006.13	-	371.84	634.29	465.53	230.02	371.84	323.71	310.58
Plant and Machinery #	67.00	-	-	67.00	63.64	-	-	63.64	3.36
Total right of use assets	5,063.54	730.69	371.84	5,422.39	1,456.86	560.06	371.84	1,645.08	3,777.31

Company has hired few machinery on rental basis and basis that arrangement the underlying machinery will get transferred to the Company. This assets will be capitalising under property plant and equipment.
The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.
The Company has not recognised any impairment loss during the current year (March 31, 2023 - Nil).

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2022	Addition during the year	Disposal during the year	As at March 31, 2023	As at April 01, 2022	Amortisation for the year	Disposal during the year	As at March 31, 2023	As at March 31, 2023
Land	3,272.97	802.62	85.18	3,990.41	626.77	308.58	7.66	927.69	3,062.72
Building	1,006.13	-	-	1,006.13	245.08	220.45	-	465.53	540.60
Plant and Machinery #	67.00	-	-	67.00	63.64	-	-	63.64	3.36
Total right of use assets	4,346.10	802.62	85.18	5,063.54	935.49	529.03	7.66	1,456.86	3,606.68

Company has hired few machinery on rental basis and basis that arrangement the underlying machinery will get transferred to the Company. This assets will be capitalising under property plant and equipment.
The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.
The Company has not recognised any impairment loss during the current year (March 31, 2023 - Nil).

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

4 a Right of use assets (Continued)

i) The Company has taken land on lease for a non-cancellable period ranging 3 to 99 years, Building on lease for a tenure ranging from 3-5 years and plant and machinery for 10 years.
ii) The Company leases with contract term of less than 1 year. These leases are short term leases. The company has elected not to recognise right of use assets and lease liabilities of these assets.
iii) Maturity analysis of lease liabilities– contractual undiscounted cash flows:

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Less than one year	**463.26**	461.80
One to five years	**890.97**	1,341.04
More than five years	**-**	-
Total undiscounted lease liabilities	**1,354.23**	1,802.84
Discounted lease liabilities included in the statement of financial position	**1,193.90**	1,354.99
Current lease labilities	**373.86**	360.22
Non-current lease labilities	**820.04**	994.77

iv) The weighted average incremental borrowing rate of 6.25% to 9.40% (March 31, 2023 : 6.25% p.a.) has been applied for measuring the lease liability.
v) The total cash outflow for leases for year ended March 31, 2024 is Rs. 558.40 lakhs (March 31, 2023 : Rs. 489.31 lakhs.)
vi) Income from sub leasing of Right to use assets is Rs. 43.23 lakh. (March 31, 2023 : Rs. 38.80 lakh) to related parties

Notes to the Standalone Financial Statements ***(Continued)***
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

4 b Other Intangible assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2024	As at April 01, 2023	Amortisation for the year	Disposal / #Transfer during the year	As at March 31, 2024	As at March 31, 2024
Computer softwares	1,259.20	41.45	-	1,300.65	586.73	266.45	-	853.18	447.47
Rights of sale of products	1,387.24	159.33	-	1,546.57	1,058.64	114.13	-	1,172.77	373.80
Development rights	265.65	-	-	265.65	249.44	2.87	-	252.31	13.34
Total intangible assets	2,912.09	200.78	-	3,112.87	1,894.81	383.45	-	2,278.26	834.61
Intangible assets under development	487.07	722.27	200.78	1,008.56	-	-	-	-	1,008.56
	3,399.16	923.05	200.78	4,121.43	1,894.81	383.45	-	2,278.26	1,843.17

During the year completed capital projects Rs. 200.78 lakhs transferrd from Intangible assets under development to Other Intangible assets

Ageing for intangible assets under development as at March 31, 2024 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress #	626.06	382.50	-	-	1,008.56
Projects temporarily suspended	-	-	-	-	-
	626.06	382.50	-	-	1,008.56

Intangible assets under development in progress consists development of Menthol, Floravone and Indomarone etc. For Intangible assets under development, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-24.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

4 b Other Intangible assets *(Continued)*

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2022	Addition during the year	Disposal / #Transfer during the year	As at March 31, 2023	As at April 01, 2022	Amortisation for the year	Disposal / #Transfer during the year	As at March 31, 2023	As at March 31, 2023
Computer softwares	480.69	778.51	-	1,259.20	455.63	131.10	-	586.73	672.47
Rights of sale of products	1,318.14	69.10	-	1,387.24	389.80	168.84	-	1,058.64	328.60
Development rights	265.65	-	-	265.65	233.20	16.24	-	249.44	16.21
Total intangible assets	2,064.48	847.61	-	2,912.09	1,578.63	316.18	-	1,894.81	1,017.28
Intangible assets under development	855.54	479.14	847.61	487.07	-	-	-	-	487.07
	2,920.02	1,326.75	847.61	3,399.16	1,578.63	316.18	-	1,894.81	1,504.35

During the year completed capital projects Rs. 847.61 lakhs transferrd from Intangible assets under development to Other Intangible assets

Ageing for intangible assets under development as at March 31, 2023 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	479.14	7.93	-	-	487.07
Projects temporarily suspended	-	-	-	-	-
	479.14	7.93	-	-	487.07

Intangible assets under development in progress consists development of Menthol, Floravone and Indomarone etc. For Intangible assets under development, there are no such projects whose completion is over due or exceeds its cost compared to its original plan as at 31-Mar-23.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

5 Investments

Unquoted

	As at March 31, 2024		As at March 31, 2023	
	Number of shares	**Amount**	Number of shares	Amount
Investments measured at Cost:				
Equity Instruments:				
Subsidiaries:				
Face value of Rs. 10 each fully paid:				
Privi Biotechnologies Private Limited	**3,62,74,728**	**4,271.70**	3,62,74,728	4,271.70
Face value of USD 1 each fully paid:				
Privi Speciality Chemicals USA Corporation	**51,000**	**30.61**	51,000	30.61
Face value of Rs. 10 each fully paid:				
Prigiv Specialties Private Limited	**1,78,50,000**	**1,785.00**	76,50,000	765.00
Face value of Rs. 10 each fully paid:				
Total		**6,087.31**		5,067.31
Structured entity				
Radiance MH Sunrise Ten Private Limited	**49,95,000**	**75.83**		-
Face value of Rs. 10 each fully paid:		**75.83**		-
Aggregate amount of unquoted investments		**6,163.14**		5,067.31

During the current year, the company has subscribed to the shares of Radiance Sunrise Ten Private Limited (Structured entity), for 49,95,000 equity shares of Rs. 10 each amounting to Rs. 499.50 lakhs. Investment in Structured entity initially recognised as at its fair value as per INDAS 109, subsequently it will be carried at amortised cost. The excess of the nominal value of investment over the fair value on initial recognition is recognise as prepaid expense and amortised overt the term of contractual agreement (20 years) (refer note. 40)

Aggregate amount of impairment in value of investments	-

6 Other financial assets

	Non-current		Current	
	As at March 31, 2024	As at March 31, 2023	**As at March 31, 2024**	As at March 31, 2023
Security deposits *	**1,656.56**	1,496.78	-	-
Investments in term deposits (with remaining maturity of more than twelve months) **	-	0.57	-	-
Insurance claim receivable			-	9.84
	1,656.56	1,497.35	-	9.84

* An amount of Rs. 376 lakhs (March 31, 2023 : Rs. 376 lakhs) receivable from related parties. These receivable are pertaining to security deposit given for lease hold premises. (refer note 30 and below table).

Particulars	**As at March 31, 2024**	**As at March 31, 2023**
Privi Biotechnologies Private Limited	**25.00**	25.00
Money Mart Securities Private Limited	**300.00**	300.00
MM Infra & Leasing Private Limited	**51.00**	51.00
Total	**376.00**	376.00

** Note : Term deposits with no lien amounting to Rs.Nil lakhs (March 31, 2023: Rs 0.57 lakhs) against which bank guarantee given to statutory authorities and vendors

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

7 Other non-current assets

	Non-current		Current	
	As at March 31, 2024	As at March 31, 2023	As at March 31, 2024	As at March 31, 2023
Capital advances*				
Considered good	**181.60**	647.78	-	-
Considered doubtful	**36.15**	36.15	-	-
Less: Allowance for doubtful advances	**(36.15)**	(36.15)	-	-
	181.60	647.78	-	-
Advances other than capital advances				
Deposits with custom authorities	**6.00**	6.00	-	-
Prepaid expenses #	**771.15**	48.85	**670.45**	1,092.05
GST Receivable	**390.67**	2,390.67	**2,703.02**	5,262.10
Advances to employees	-	-	**21.06**	12.82
Advance for supply of goods and services*	-	-	**3,099.43**	1,195.40
Less: Allowance for doubtful advances	-	-	**(160.00)**	(160.00)
	1,349.42	3,093.30	**6,333.96**	7,402.37

*An amount of Rs.929.20 lakhs (March 31, 2023 : Rs. 136.38 lakhs) receivable from related parties. These receivable are pertaining to advance for supply of goods and services given for lease hold premises. (refer note 30 and below table)

Prepaid expenses include investment in structured entity amounting to Rs.428.42 Lakhs (refer note 5)

Particulars	Nature of transaction	As at March 31, 2024	As at March 31, 2023
Privi Speciality Chemicals USA Corporation	Advance for supply of goods and services	**916.99**	136.38
Privi Biotechnologies Private Limited	Advance for supply of goods and services	**12.21**	-
Total		**929.20**	136.38

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

	As at March 31, 2024	As at March 31, 2023
8 Inventories		
(valued at lower of cost and net realisable value)		
Raw materials including goods in transit Rs.4,462.40 lakhs (March 31,2023 : Rs. 7,764.63 lakhs)	**11,118.67**	19,655.08
Finished goods including goods in transit Rs. 11,843.84 lakhs (March 31, 2023 : Rs. 9,997.30 lakhs)	**22,033.85**	25,948.48
Work-in-progress	**26,224.34**	27,752.09
Stores and spares	**744.72**	680.55
Packing material	**73.61**	119.71
Fuel	**87.37**	340.34
	60,282.56	74,496.25

i) During the year ended March 31, 2024 : Rs. 39.65 lakhs (March 31, 2023: Rs. 270.89 lakhs) was recognised as an expense for inventories carried at net realisable value.
ii) The mode of valuation of inventories has been stated in note 2 xv of significant accouting policies.
iii) Bank overdrafts, cash credit and short-term loan from bank facility are secured by first paripassu charge on inventories (including raw material, finished goods and work-in-progress) and book debts (refer note 9 and 14).

9 Trade receivables		
Trade receivables considered good- Secured		
Dues from related parties (refer note 30)	**9,843.37**	8,621.50
Dues from others (Other than related party)	**26,264.90**	22,827.29
Trade receivables credit impaired (Other than related party)	**27.84**	27.84
Less: Allowance for expected credit loss and credit impairment	**(27.84)**	(27.84)
	36,108.27	31,448.79

Refer note 33 for information about credit risk and market risk of trade receivables.

The movement in allowance for expected credit loss and credit impariment of receivable is as follows:		
Balance as at beginning of the year	**27.84**	27.84
Allowance for expected credit loss and credit impariment	-	-
Allowance for expected credit loss written off during the year	-	-
Balance as at the end of the year	**27.84**	27.84

Trade receivables ageing as at March 31, 2024 based on due date

Particulars	Not Due	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered go	26,906.87	8,910.50	210.41	80.49	-	-	36,108.27
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undispured trade receivables-credit impai	-	-	-	-	-	22.45	22.45
(iv) Disputed trade receivables-considered goc	-	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables-credit	-	-	-	-	-	5.39	5.39
	26,906.87	8,910.50	210.41	80.49	-	27.84	36,136.11
Less:-							
Allowance for doubtful trade receivables	-	-	-	-	-	27.84	27.84
	26,906.87	8,910.50	210.41	80.49	-	-	36,108.27

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

9 Trade receivables (continued)

Trade receivables ageing as at March 31, 2023 based on due date

Particulars	Not due	Less than 6 months	6 months- 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered gc	24,038.04	7,136.99	250.93	22.83	-	-	31,448.79
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(iii) Undisputed trade receivables-credit impair	-	-	-	-	22.45	-	22.45
(iv) Disputed trade receivables-considered goc	-	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-	-
(vi) Disputed trade receivables-credit	-	-	-	-	-	5.39	5.39
	24,038.04	7,136.99	250.93	22.83	22.45	5.39	31,476.63
Less:-							
Allowance for doubtful trade receivable		-	-	-	22.45	5.39	27.84
	24,038.04	7,136.99	250.93	22.83	-	-	31,448.79

	As at March 31, 2024	As at March 31, 2023
10 Cash and cash equivalents		
Balances with banks:-		
In current accounts	**1,531.25**	963.91
In Earner exchange foreign currency account	**26.71**	45.30
Term deposits (with original maturity of less than three months)	**8.87**	7.80
Cash on hand	**8.25**	8.26
	1,575.08	1,025.27
Current accounts include dividend accounts balance Rs.9.78 lakhs (March 31, 2023: Rs 12.25lakhs)		
11 Bank balances other than cash and cash equivalents		
Margin money deposits (with original maturity of more than three months but less than twelve months)	**444.78**	418.68
	444.78	418.68

Note : Margin money deposit amounting to Rs.36.49 lakhs (March 31, 2023: Rs 116.36 lakhs) are pledged with banks for non cash limits and term deposit Rs.152.24 lakhs (March 31, 2023: Rs.194.29 lakhs) are pledged as cash security with banks for the loans taken by the Company and Rs. 256.05 lakhs (March 31, 2023 Rs.108.03 lakhs) other deposits with no lien.

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

	As at March 31, 2024	As at March 31, 2023
12 a Share capital		
Authorised Share Capital		
50,010,000 (March 31 2023: 50,010,000) equity shares of Rs. 10 each	**5,001.00**	5,001.00
5,000,000 (March 31, 2023 5,000,000) preference shares of Rs. 10 each	**500.00**	500.00
	5,501.00	**5,501.00**
Issued, subscribed and fully paid up:		
39,062,706 equity shares of Rs. 10 each (March 31 2023 : 39,062,706 equity shares of Rs.10 each)	**3,906.27**	3,906.27
	3,906.27	3,906.27

A Reconciliation of the number of equity shares

Description	As at March 31, 2024		As at March 31, 2023	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**3,90,62,706**	**3,906.27**	3,90,62,706	3,906.27
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	3,90,62,706	3,906.27	3,90,62,706	3,906.27

B Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid. Failure to pay any amount called up on shares may lead to forfeiture of the shares. On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

C Details of shareholders holding more than 5% of shares

Name of the Share holders	As at March 31, 2024		As at March 31, 2023	
	Number	%	Number	%
Vivira Investment and Trading Pvt Ltd	**1,54,95,188**	**39.67%**	1,54,95,188	39.67%
Moneymart Securities Pvt Ltd	**34,12,502**	**8.74%**	34,12,502	8.74%
Mr. Mahesh P Babani	**25,86,348**	**6.62%**	25,86,348	6.62%
Banbridge Limited	**23,83,958**	**6.10%**	23,83,958	6.10%

D Aggregate number of shares allotted as fully paid up by way of following (during 5 years immediately preceding March 31, 2024) :
(a) Aggregate number and class of shares allotted as fully paid up pursuant to contract(s) without payment being received in cash. Nil (March 31, 2023 - Nil)
(b) Aggregate number and class of shares allotted as fully paid up by way of bonus shares. Nil (March 31, 2023 - Nil)
(c) Aggregate number and class of shares bought back Nil (March 31, 2023 - Nil)

BSR & Co. Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

12 a Share capital (continued)

E Shares held by promoters as at the March 31, 2024

Sr.	Promoter name	As at March 31, 2024		As at March 31, 2023		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,54,95,188	39.67%	-
2	Moneymart Securities Pvt Ltd	34,12,502	8.74%	34,12,502	8.74%	-
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	15,48,202	3.96%	15,48,202	3.96%	-
6	Vinaykumar Doppalapudi	8,91,068	2.28%	8,91,068	2.28%	-
7	Vijaykumar Doppalapudi	8,55,006	2.19%	8,55,006	2.19%	-
8	Jyoti Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
9	Seema Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
10	Snehal Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
11	Premaleela Doppalapudi	5,24,522	1.34%	5,24,522	1.34%	-
12	Sharon Doppalapudi Rao	2,45,656	0.63%	2,45,656	0.63%	-
13	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	2,32,185	0.59%	-
14	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	93,446	0.24%	-
15	MM Infra & Leasing Private Limited *	79,758	0.20%	79,758	0.20%	-

Shares held by promoters as at March 31, 2023

Sr.	Promoter name	As at March 31, 2023		As at March 31, 2022		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,54,95,188	39.67%	-
2	Moneymart Securities Pvt Ltd	34,12,502	8.74%	34,12,502	8.74%	-
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	15,48,202	3.96%	11,20,346	2.87%	1.09%
6	Vinaykumar Doppalapudi	8,91,068	2.28%	7,41,068	1.90%	0.38%
7	Vijaykumar Doppalapudi	8,55,006	2.19%	7,05,006	1.80%	0.39%
8	Rajkumar Doppalapudi Rao	-	-	6,90,782	1.77%	-1.77%
9	Jyoti Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
10	Seema Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
11	Snehal Mahesh Babani	3,90,000	1.00%	3,90,000	1%	-
12	Prasanna Doppalapudi Rao	-	-	2,87,074	0.73%	-0.73%
13	Premaleela Doppalapudi	5,24,522	1.34%	2,74,522	0.70%	0.64%
14	Sharon Doppalapudi Rao	2,45,656	0.63%	2,45,656	0.63%	-
15	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	2,32,185	0.59%	-
16	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	93,446	0.24%	-
17	MM Infra & Leasing Private Limited *	79,758	0.20%	79,758	0.20%	-

Note: * Vivira Chemicals Private Limited (VCPL) amalgamated into MM Infra & Leasing Private Limited as per NCLT order dated October 13, 2021 and hence Shares held by VCPL in the Company also got transferred to MM Infra on May 04, 2022. The same is intimated to Stock Exchanges on May 05, 2022

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024

(Currency: Indian Rupees in lakhs)

	As at March 31, 2024	As at March 31, 2023
12 b Other equity		
General reserve	**35,573.76**	35,573.76
Capital reserve	**1.00**	1.00
Retained earnings	**52,566.85**	42,766.63
Total other equity	**88,141.61**	78,341.39

The description of the nature and purpose of each reserve within equity is as follows:

A **General reserve**
As per the approved scheme of arrangement (Demerger) between the Privi Organics India Limited , Privi Specialities Chemicals Limited and Privi Organics Limited during the period ended 31 March 2017, the excess of book value of assets over liabilities is treated as general reserve.

B **Retained earnings**
Retained earnings represent the amount of undistributed accumulated earnings at each Balance Sheet date of the Company.

C **Capital reserve**
As per the approved Scheme of Arrangement and Amalgamation amongst Fairchem Speciality Limited (Demerged / Transferee Company) and Privi Organics India Limited (Transferor Company). vide NCLT Mumbai order dated June 30 , 2020, all the assets , liabilities and reserve pursuant to the scheme, have been transferred at carrying amount and the difference if any being the excess is treated as capital reserve.

D The Capital management objective of the Company is to (a) maximize shareholder value and provide benefits to other stakeholders and (b) maintain an optimal capital structure to reduce the cost of capital.

For the purposes of the Company's capital management, capital includes issued equity share capital, share premium and all other equity. The Company monitors capital using debt-equity ratio, which is total debt less liquid investments and bank deposits divided by total equity.

The Company's debt equity ratio as at March 31, 2024 was as follows:

Particulars	As at March 31, 2024	As at March 31, 2023
Total Debt	**88,813.11**	1,02,930.54
Less: Cash and cash equivalents and term deposits	**2,019.86**	1,443.95
Net Liabilities (A)	**86,793.25**	1,01,486.59
Total Equity (B)	**92,047.88**	82,247.66
Debt - Equity Ratio	**0.94**	1.23

In addition, the Company has complied all the financial covenants (as at March 31, 2024) relating to the borrowing facilities that it has taken from the lenders like interest coverage service ratio, Debt to EBITDA, etc.

RSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd. Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2024
(Currency: Indian Rupees in lakhs)

13 a Non-current borrowings

	Non-current		Current maturity of long term debt (*)	
	As at March 31, 2024	As at March 31, 2023	As at March 31, 2024	As at March 31, 2023
Secured:				
Term loans from banks (refer note (i))				
Term loan in Indian currency (refer note (iii) below)	30,272.86	39,021.18	13,045.24	9,616.67
Term loans in foreign currency (refer note (ii) & (iii) below)	676.64	1,344.17	676.63	672.06
Term loans from financial institutions				
Vehicle loan (hypothecated with the lender) (refer note iii belov	0.70	5.14	4.30	4.25
Unsecured:				
Intercorporate Loan (refer note (vi))	900.00	-	-	-
Loan from Directors (refer note (vii))	6,500.00	-	-	-
	38,350.20	40,370.49	13,726.17	10,292.98

(*) Amount disclosed under the head ' current borrowings (secured) ' refer note 14

i) Term loan are secured by a first mortgage on the Company's immovable properties both present and future ranking paripassu interest and a first charge by way of hypothecation of all the company's assets (save and except book debts and inventories) including movable machinery (save and except spares tools and accessories) both present and future subject to charges created in favour of the Company's bankers for inventories, book debts and other specified movable assets for securing the borrowings of working capital .

ii) Currency swap on IDFC Rupee loan of Rs.4,000 lakhs and ICICI bank Rupee loan of Rs.4,000 lakhs are taken @ 64.42 per USD and @ 68.13 per USD respectively and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76.78 per USD and @ 75.85 per USD respectively, the currency swap represents derivative instruments which has been restated at the closing rate of exchange.

iii) **Terms and repayment schedule**

Terms and conditions of outstanding borrowings are as follows:

Name of the Bank / Financial Inst	Currency	Interest Rate	Year of Maturity	Installment	Carrying amount as at March 31, 2024	Carrying amount as at March 31, 2023
Foreign Currency (External Commercial borrowing (ECB))						
Ratnakar Bank	EUR	2.75%	2026	The term loan is repayable in 24 quarterly installments of EURO 187,500.00 each starting from Apr 2020.	1,353.27	2,016.23
Foreign Currency-Total (A)					1,353.27	2,016.23
Indian Currency						
Kotak Mahindra Bank	INR	8.43%	2027	The term loan is repayble in 20 quarterly installments of Rs.250 lakhs starting from Mar 2023 .	5,236.80	6,629.42
CITI Bank	INR	9.00%	2025	The term loan is repayable in 12 quarterly installments of Rs 750 lakhs starting from Mar 2023 .	6,411.16	10,071.31
ICICI Bank	INR	7.90% - 8.60%	2025	The term loan is repayble in 20 quarterly installments of Rs.200 lakhs starting from Sep 2020 .	999.52	1,798.60
ICICI Bank	INR	7.14% - 9.75%	2028	The term loan is repayable in 15 quarterly installments of Rs.125 lakhs starting from Jun 2024 and increase by Rs.125 lakh after every	4,864.09	-
IDFC Bank	INR	8.60%	2024	The term loan is repayable in 20 quarterly installments of Rs.200 lakhs starting from Mar 2020 .	-	1,400.00
IDFC Bank	INR	9.05%-9.30%	2024		-	4,989.14
IDFC Bank	INR	8.80% -9.50%	2026	The term loan is repayable in 20 quarterly installments of Rs.280 lakhs starting from Apr 2021 .	2,235.89	3,350.91
HDFC Bank	INR	7.48% - 8.38%	2027	The term loan is repayble in 20 quarterly installments of Rs.370 lakhs starting from Jun 2022 .	4,440.00	5,920.00
HDFC Bank	INR	8.60%	2028	The term loan is repayable in 20 quarterly installments of Rs.350 lakhs starting from Jan 2024 .	6,650.00	7,000.00
HDFC Bank	INR	7.50%	2029	The term loan is repayable in 20 quarterly installments of Rs.375 lakhs starting from Sep 2024 .	7,487.02	7,478.17
RBL Bank	INR	7.14% - 9.75%	2028	The term loan is repayble in 14 quarterly installments of Rs.357.14 lakhs starting from May 2024 .	4,993.30	-
Yes Bank (Vehicle loan)	INR	8.97%	2024	The term loan is repayable in 65 monthly installments of Rs.0.41 lakh starting from Jan-2020	5.02	9.39
Indian Currency total -B					43,323.10	48,647.24
Total Term Loan (A+B)					44,676.37	50,663.47

iv) Term loans availed have been utilized for the purpose for which the funds have been borrowed.

v) Previous financial year 2022-23, the Company has not complied on certain financial covenants with respect to term loans availed from banks. However, based on the review of periodic filings made by the Company to the Banks, the Banks have continued with the facilities, (have not placed any demand on the loans and the facility). Accordingly, the Company continues to classify these loans as current and non-current based on the original maturity.
In current year Company has complied all the financial covenants with respective term loan availed from bank

vi) During the year Company has taken Inter corporate loan from Privi Biotechnologies Private Limited with interest rate of 7.25% p.a. Company is not expecting any demand of intercorporate loan in next 12 months

vii) During the year Company has taken unsecured loan from Directors with interest rate of 8.75% p.a. Company is not expecting any demand of unsecured loan in

13 b Lease liabilities

	Non-Current		Current	
	As at March 31, 2024	As at March 31, 2023	As at March 31, 2024	As at March 31, 2023
Lease liabilities	820.04	994.77	373.86	360.22
	820.04	994.77	373.86	360.22

	As at March 31, 2024	As at March 31, 2023
14 Current borrowings		
From Banks:		
Cash credit (refer note e)	-	76.77
Working capital demand loan (refer note b & c)	28,584.42	34,950.00
Packing credit from bank (refer note d)	7,791.96	14,391.95
Buyers credit (refer note f)	-	1,404.83
Interest accrued but not due on borrowings	360.98	448.32
Current maturities of long term debt (refer note 13 a)	13,726.17	10,292.98
Total	50,462.91	62,560.05

a) All the above loans except Current maturities of long term debt. are Rs 31,000 (March 2023 Rs 31,000) Lakhs fund base secured by first pari passu charge on all current assets of the Company both present and future. Balance loan of Rs. 3,736.74lakh (March 2023 Rs.11,267 lakh) is unsecured.

b) Working capital demand loans from banks are secured by way of hypothecation of inventories both on hand and in transit and book debts and other receivables both present and future and also secured by way of second charge on fixed assets. Working capital loans carry interest rate @ 7.63% to 9.00%.

c) **Quarterly statements of current assets filed by the company with the banks are in agreement with the books of accounts except below (FY 2023-24)**

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Amount of difference	Reason for material discrepancies
Jun-23	refer note-i	Trade receivables and Inventories	1,00,585.56	1,00,969.00	-383.44	refer note-ii
Sep-23	refer note-i	Trade receivables and Inventories	98,401.60	97,349.00	1,052.60	refer note-ii
Dec-23	refer note-i	Trade receivables and Inventories	1,00,517.77	1,00,464.00	53.77	refer note-ii
Mar-24	refer note-i	Trade receivables and Inventories	96,390.83	96,925.00	-534.17	refer note-ii

i) The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd., IDFC bank, ICICI Bank Ltd, Standard Chartered Bank

ii) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory, the related amounts are mentioned below:

Jun-23 unrealised gain of Rs. 161.32 lakhs, stores and spares inventory of Rs. 726.03 lakhs and Goods in transit of Rs. (1,270.79) lakhs not included in quarterly statement submitted to bank.

Sep-23 unrealised gain Rs. 281.16 lakhs, stores and spares inventory Rs. 755.33 lakhs and GIT Rs. 16.11 lakhs not included in quarterly statement submitted to bank.

Dec-23 unrealised gain Rs. 209.10 lakhs, stores and spares inventory Rs. 777.25 lakhs and GIT Rs. (933.68) lakhs not included in quarterly statement submitted to bank.

Mar-24 unrealised gain Rs. 270.21 lakhs. Stores and spares inventory Rs.744.72 lakhs and GIT Rs. (1,549.10) lakhs not included in quarterly statement submitted to bank.

Quarterly statements of current assets filed by the company with the banks are in agreement with the books of accounts except below (FY 2022-23)

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Amount of difference	Reason for material discrepancies
Jun-22	refer note-i	Trade receivables and Inventories	1,01,280.58	96,290.40	4,990.18	refer note-ii
Sep-22	refer note-i	Trade receivables and Inventories	1,11,592.04	1,11,688.59	-96.55	refer note-ii
Dec-22	refer note-i	Trade receivables and Inventories	1,10,032.65	1,09,117.06	915.59	refer note-ii
Mar-23	refer note-i	Trade receivables and Inventories	1,05,945.04	1,05,812.86	132.18	refer note-ii

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2024

(Currency: Indian Rupees in lakhs)

14 **Current borrowings (secured) (Continued)**

i) The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd., IDFC bank, ICICI Bank Ltd. Standard Chartered Bank

ii) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory, the related amounts are mentioned below :

Jun-22 unrealised gain of Rs. 945.27 lakhs, advance from customers of Rs. 284.32 lakhs, stores and spares inventory of Rs. 714.87 lakhs and Goods in transit of Rs. 3,045.72 lakhs not included in quarterly statement submitted to bank.

Sep-22 unrealised gain Rs. 1,060.08 lakhs, advance from customers Rs.560.32 lakhs, stores and spares inventory Rs. 712.39 lakhs and GIT Rs. (2,429.34) lakhs not included in quarterly statement submitted to bank.

Dec-22 unrealised gain Rs. 788.13 lakhs, advance from customers Rs. 587.13 lakhs stores and spares inventory Rs. 713.94 lakhs and GIT Rs. (1,173.61) lakhs not included in quarterly statement submitted to bank.

Mar-23 unrealised gain Rs. 149.32 lakhs, Stores and spares inventory Rs.(680.55) lakhs and GIT Rs. 663.51 lakhs not included in quarterly statement

d) Packing credit in rupees carry interest rate @ 8.00% to 9.00% p.a.

e) Cash credit loan from bank carry interest rate @ 8.10% to 9.50%.

f) Buyers credit carry interest rate @ SOFR +1.41% to SOFR + 2.79% and due for payment within 180 days

15 Provisions

	Non-Current		Current	
	As at March 31, 2024	As at March 31, 2023	As at March 31, 2024	As at March 31, 2023
Provisions for employee benefits				
Compensated absences (refer note 31)	371.63	431.12	62.91	75.27
Gratuity (refer note 31)	1,407.33	1,319.05	136.01	137.29
	1,778.96	1,750.17	198.92	212.56

16 Income tax

	As at March 31, 2024	As at March 31, 2023
Amounts recognised in profit or loss		
The major components of income tax expense for the years ended March 31, 2024 and March 31, 2023 are:		
Current income tax:		
Current income tax expenses	3,080.18	333.81
Deferred		
Relating to origination and reversal of temporary differences	329.01	545.82
Income tax expense reported in the statement of profit or loss	3,409.19	879.63
Income tax recognised in other comprehensive income (OCI)		
Tax expense related to items recognised in OCI during the year:		
Remeasurements of defined benefit	4.98	17.85
Income tax related to OCI	4.98	17.85

Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for March 31, 2024 and March 31, 2023:

Accounting profit before income tax	13,197.68	3,127.12
At India's statutory income tax rate of 25.17% (March 31, 2023 : 25.17%)	3,321.86	787.10
Non-deductible expenses for tax purposes (CSR expenses)	58.40	83.82
Others (Interest on delay payment of income tax etc)	28.93	8.71
	3,409.19	879.63
	3,409.19	879.63

16 Income Tax *(Continued)*

Income tax expense reported in the statement of profit and loss

Impact of tax rate change: During FY 2019-20, the Company elected to exercise the option permitted under Section 115BAA of the Income-tax Act, 1961 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company re-measured its Net Deferred Tax Assets basis the rate prescribed in the said section. The full impact of this change was recognised in the standalone statement of profit and loss for that year.

Deferred Tax movement

	As at 1 April 2023	(Credit) / Charge in the statement of profit and Loss	(Credit) / Charge in other comprehensive income	As at March 31, 2024
Deferred tax (assets)/liabilities				
Difference between WDV as per books and income tax for Property plant and eq	2,954.74	353.64	-	3,308.38
Deferred asset on Right of use assets and lease liabilities (net)	(24.30)	(34.28)	-	(58.58)
Provision for doubtful debts and advances	(54.79)	-	-	(54.79)
Expenses allowable for tax purposes when paid (Gratuity, Leave encashment and	(422.88)	13.91	4.98	(404.86)
Forex loss unrealised impact (Derivative instrument)	(430.83)	(2.29)	-	(433.12)
	2,021.94	329.01	4.98	2,355.03

	As at 1 April 2022	(Credit) / Charge in the statement of profit and Loss	(Credit) / Charge in other comprehensive income	As at March 31, 2023
Deferred tax (assets)/liabilities				
Difference between WDV as per books and income tax for Property plant and eq	2,408.92	545.82	-	2,954.74
Deferred asset on Right of use assets and lease liabilities (net)	(24.30)	-	-	(24.30)
Provision for doubtful debts and advances	(54.79)	-	-	(54.79)
Expenses allowable for tax purposes when paid (Gratuity, Leave encashment and	(440.73)	-	17.85	(422.88)
Forex loss unrealised impact (Derivative instrument)	(430.83)	-	-	(430.83)
	1,458.27	545.82	17.85	2,021.94

a) In respect of Deferred taxes, all items are attributable to origination and reversal of temporary differences.

b) Deferred tax benefits are generally recognized for all deductible temporary differences to the extent it is probable that taxable profits will be available against which, those deductible temporary differences can be realised.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2024

(Currency: Indian Rupees in lakhs)

		As at March 31, 2024	As at March 31, 2023
17	**Trade payables**		
a)	Total outstanding dues of micro and small enterprises	1,275.87	927.53
b)	Total outstanding dues of creditors other than micro and small enterprises		
	i) Payable to related parties : (refer note no: 36)	2,629.21	2,665.59
	ii) Payable to others	24,431.34	26,179.17
		28,336.42	29,772.29

The Company's exposure to credit and currency and liquidity risk related to trade payables are disclosed in Note 32

Information as per the requirement of Section 23 of The Micro, Small and Medium Enterprises Development Act, 2006

a)	(i) The principal amount remaining unpaid to any supplier at the end of accounting year included in trade payables	1,275.87	927.53
	(ii) The principal amount remaining unpaid to any supplier at the end of accounting year included in Payable for capital expenditure (refer note 18)	345.28	
	(iii) The interest due on above	-	-
	The total of (i) & (ii)	1,621.15	927.53
b)	The amount of interest paid by the buyer in terms of section 16 of the Act, The amount of the payment made to the	-	-
c)	The amounts of interest accrued and remaining unpaid at the end of financial year	-	-
d)	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the due date during the year) but without adding the interest specified under this Act.	-	-
e)	the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006.	-	-

The above information has been determined to the extent such parties have been identified on the basis of information available with the Company.

Trade payables ageing as on 31-Mar-2024

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	1,172.60	103.27	-	-	-	1,275.87
(ii) Others	7,274.20	5,261.05	128.16	-	2.04	12,665.45
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
(v) Unbilled dues (Provision for expenses, Vendor Finance, Goods-in transit etc)	-	-	-	-	-	14,395.10
	8,446.80	5,364.32	128.16	-	2.04	28,336.42

Trade payables ageing as on 31-Mar-2023

Particulars	Not Due	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	927.53	-	-	-	-	927.53
(ii) Others	7,345.15	6,173.03	21.23	-	2.04	13,541.45
(iii) Disputed dues - MSME	-	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-	-
(v) Unbilled dues (Provision for expenses, Vendor Finance, Goods-in transit etc)	-	-	-	-	-	15,003.31
	8,272.68	6,173.03	21.23	-	2.04	29,772.29

		As at March 31, 2024	As at March 31, 2023
18	**Other financial liabilities**		
	Payable for capital expenditure #	1,051.21	5,114.03
	Deposits	102.25	1.00
	Salaries, wages and bonus payable	675.43	994.50
	Derivative Instruments (forward exchange contracts and interest rate swaps (Refer note 33 a))	433.51	1,174.85
	Interest on delayed payment of income tax	77.34	-
		2,339.34	7,284.18

Payable for capital expenditure includes MSME amounting to Rs. 345.28 lakh

The Company's exposure to credit and currency and liquidity risk related to the above financial liabilities are disclosed in note 33

19	**Other current liabilities**		
	Statutory liabilities	267.24	242.68
	Contract Liabilities (Advance from customer) (refer note 37)	391.52	5,607.18
		658.76	5,849.86

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nirlon Knowledge Park, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2024	Year ended March 31, 2023
20 Revenue from operations		
Revenue from contracts with customers		
a) Sale of products- Manufactured Goods (refer note 29 and 37)	**1,71,148.96**	1,57,541.82
	1,71,148.96	1,57,541.82
b) Other operating revenues - Scrap Sales	**57.16**	242.50
	57.16	242.50
Total	**1,71,206.12**	**1,57,784.32**
21 Other income		
Interest income from fixed deposits carried at amortised cost	**29.38**	26.15
Gain on write-back of Financial liabilities measured at amortised cost	**-**	2.57
Profit on disposal of property, plant and equipment	**-**	5.04
Gain on sales of investment (net)	**8.70**	8.88
Net Gain on Foreign currency transactions	**1,882.65**	1,820.78
Miscellaneous income	**240.90**	296.19
	2,161.63	2,159.61
22 Cost of materials consumed		
Raw material consumed		
Opening Stock	19,655.08	19,639.62
Add: Purchases	**82,078.42**	1,11,101.61
Less: Closing stock	**11,118.67**	19,655.08
Consumption	**90,614.83**	1,11,086.15
Packing material consumed		
Opening Stock	119.71	105.26
Add: Purchases	**2,536.69**	2,250.45
Less: Closing Stock	73.61	119.71
Consumption	**2,582.79**	2,236.00
Total	**93,197.62**	**1,13,322.15**

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

	Year ended March 31, 2024	Year ended March 31, 2023
23 Changes in inventories of finished goods and work in progress		
Closing stock:		
Finished goods	**22,033.85**	25,948.48
Work in progress	**26,224.34**	27,752.09
	48,258.19	53,700.57
Opening stock:		
Finished goods	**25,948.48**	17,283.55
Work in progress	**27,752.09**	18,173.04
	53,700.57	35,456.59
Decrease / (Increase) in inventories	**5,442.38**	(18,243.98)
24 Employee benefits expense		
Salaries, wages and bonus	**5,689.73**	6,327.32
Contribution to provident and other funds	**327.78**	333.29
Staff welfare expenses	**526.95**	574.81
	6,544.46	7,235.42
25 Finance cost		
Interest on term loans using effective interest rate measured at amortised cost	**4,011.01**	3,387.35
Less: Interest capitalised (refer note 3)	**-**	(1,049.11)
Net interest on term loans	**4,011.01**	2,338.24
Interest on working capital loans using effective interest rate measured at amortised	**4,775.83**	4,163.91
Interest on vehicle loans using effective interest rate measured at amortised cost	**0.50**	1.66
Loan arrangement fees amortised using effective rate of interest basis	**42.76**	29.58
Interest on unsecured Loans	**474.20**	-
Interest on delayed payment of income tax	**77.34**	-
Interest cost lease liability using effective interest rate measured at amortised cost	**120.72**	129.09
	9,502.36	6,662.48

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

	Year ended March 31, 2024	Year ended March 31, 2023
26 Depreciation and amortisation expenses		
Depreciation on property, plant and equipment	11,251.86	9,670.32
Amortisation of intangible assets	383.45	316.18
Amortisation of right of use assets	560.06	529.03
	12,195.37	10,515.53
27 Power and fuel expenses		
Fuel	7,950.90	9,234.49
Power	5,633.82	5,242.29
Water Charges	217.42	236.27
	13,802.14	14,713.05

28 Other expenses

	Year ended March 31, 2024	Year ended March 31, 2023
Consumption of stores and spares	1,437.86	1,655.82
Job work charges	2,087.60	1,919.77
Repairs and maintenance of:		
Buildings	244.37	453.01
Plant and machinery	1,043.01	1,329.73
Others	32.55	143.78
Contract labour charges	1,196.72	846.42
Research and development expense	202.52	537.11
Pollution control expenses	964.40	1,018.12
Other factory expenses	1,068.06	961.84
Insurance	899.01	1,356.61
Postage and telephone expense	80.61	74.03
Rates and taxes	143.49	54.66
Training expenses	6.10	4.98
Auditors remuneration:		
'For audit	48.00	43.00
'For limited review	27.00	27.00
'Other services	1.20	0.25
Out of pocket expenses	1.20	2.08
Brokerage and commission	160.92	166.78
Printing and stationery	42.81	45.57
Freight outward	5,924.60	7,771.36
Selling and distribution	1,078.73	948.60
Legal and professional fees	1,048.92	1,312.93
Travelling and conveyance	823.42	857.30
Bank charges	157.07	153.39
CSR expenses (refer note 42)	232.01	333.00
Sundry balances written off	0.78	-
Loss on Sale of property, plant and equipment	25.60	64.48
Miscellaneous expenses	507.18	530.54
	19,485.74	22,612.16

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

29 Segment information

A. Factors used to identify the entity's reportable segments, including the basis of organisation

The Company has determined its reportable segment as "Aromatic chemicals" since the chief operating decision maker (CODM) evaluates the Company's performance as a single segment.

B. Information about reportable segments

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
Revenue from sale of products (Manufactured goods)	1,71,148.96	1,57,541.82
	1,71,148.96	1,57,541.82

C. Geographic information

The geographic information analyses the Company's revenue and non-current assets by the Company's country of domicile and other countries. In presenting the geographical information, segment revenue has been based on the geographic location of customers and segments assets were based on the geographic location of the respective non-current assets.

The product offerings which are part of the speciality chemicals portfolio of the Company are managed on a worldwide basis from India. (refer note 37)

The amount of the Company's revenue from sale of products is shown in the table below.

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
India	49,401.92	35,765.81
Outside India #	1,21,747.04	1,21,776.01
Total	1,71,148.96	1,57,541.82

Includes deemed exports of Rs.4,008.20 lakhs for the year (March 31, 2023 : Rs.3,856.43 lakhs)

All the non-current assets of Company are located within India.

D. Information about Major Customers

No single customer contributed more than 10% to the Company's revenue in FY 2023-24 and FY 2022-23.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

30 Related party disclosures

Details of transactions between the Company and other related party are disclosed below.

a) **List of Related Parties**

Promoter Group

Vivira Investment and Trading Private Limited (w.e.f. April 29, 2021)

Subsidiary Companies

Privi Biotechnologies Private Limited
Privi Speciality Chemicals USA Corporation
Prigiv Specialties Private Limited (w.e.f. September 01, 2021)

Enterprises owned by key management personnel or their relatives

Vivira Chemical Industries
Privi Life Science Private Limited
Privi Fine Sciences Private Limited
Money Mart Securities Private Limited
Satellite Technologies Private Limited
Vivira Investment and Trading Private Limited
Prasad Organics Pvt Ltd
MM Infra & Leasing Private Limited
Babani Bros. LLP
Privi Organics Limited (Amalgameted with Privi Fine Sciences Private Limited w.e.f 01.04.2023)

Key Management Personnel (KMP)

Mr. Mahesh P. Babani	Chairman & Managing Director
Mr. D. B. Rao	Executive Director
Mr. Rajesh Budhrani	Independent Director upto March 31, 2024
Mr. P.R. Barpande	Independent Director upto March 31, 2024
Mr. Anurag Surana	Independent Director
Mrs. Anuradha Thakur	Independent Director
Mr. Hemang Gandhi	Independent Director from November 07, 2023
Mr. Dwarko Topandas Khilnani	Independent Director

Relatives of Key Management Personnel

Mahesh Purshottam Babani HUF
Mrs. Seema Mahesh Babani
Ms. Snehal Mahesh Babani
Ms. Jyoti Mahesh Babani
Mr. Vijaykumar Doppalapudi Rao
Mr. Vinaykumar Doppalapudi Rao
Mrs. Grace Vinaykumar Doppalapudi Rao
Mrs. Sharon Doppalapudi Rao
Mrs.Premaleela Doppalapudi Rao
Mr. Rajkumar Doppalapudi Rao
Mrs. Prasanna Raj Doppalapudi Rao
Mr. Rameshbabu Gokameswararao Gudmu

BSR & Co. Chartered Accountants

Privi Speciality Chemicals Pvt. Ltd. Navi Mumbai

Notes to the Standalone Financial Statements ***(Continued)***
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

30 Related party disclosures ***(Continued)***

b) During the year, following transactions were carried out with the related parties :

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
Transactions						
Purchase of raw materials						
Privi Life Science Private Limited	-	-	**0.80**	33.60	-	-
Privi Speciality Chemicals USA Corporation	9,948.75	12,068.21	-	-	-	-
Prasad Organics Private Limited	-	-	**2,831.22**	1,068.79	-	-
Privi Organics Limited (Amalgameted with Privi Fine Sciences Pvt. Ltd. w.e.f 01.04.2023)				63.07		
Privi Fine Sciences Private Limited	-	-	**35.62**	-	-	-
Job work charges paid						
Privi Fine Sciences Private Limited	-	-	**80.13**	-	-	-
Sale of finished goods						
Privi Speciality Chemicals USA Corporation	32,949.49	26,864.30	-	-	-	-
Prasad Organics Private Limited	-	-	**1,498.94**	987.32	-	-
Lease expense						
MM Infra & Leasing Private Limited	-	-	**85.68**	78.10	-	-
Money Mart Securities Private Limited	-	-	**205.71**	195.92	-	-
Privi Biotechnologies Private Limited	**90.00**	105.00	-	-	-	-
Technical Fees						
Privi Biotechnologies Private Limited	**555.00**	622.50	-	-	-	-
Lease income						
Privi Life Science Private Limited	-	-	**39.87**	37.26	-	-
Money Mart Securities Private Limited			**1.26**	1.22		
Privi Organics Limited (Amalgameted with Privi Fine Sciences Pvt. Ltd. w.e.f 01.04.2023)				0.32		
Privi Fine Sciences Private Limited			**0.90**	-		
Vivira Investment & Trading Pvt. Ltd	-	-	**0.60**	-	-	-
Privi Biotechnologies Pvt. Ltd	**0.60**	-	-	-	-	-
Unsecured loan taken						
Mr. Mahesh P Babani	**6,500.00**	-	-	-	-	-
Privi Biotechnologies Pvt Ltd	**900.00**	-	-	-	-	-
Interest on unsecured loan taken						
Mr. Mahesh P Babani	**438.84**					
Privi Biotechnologies Pvt Ltd	**35.36**					
Reimbursement of expense received						
Prigiv Specialties Private Limited	**233.75**	220.54	-	-	-	-
Privi Speciality Chemicals USA Corporation	**53.07**	52.92	-	-	-	-
Commission and reimbursement other expenses paid						
Privi Speciality Chemicals USA Corporation	-	29.17	-	-	-	-
Loans and advances						
Privi Speciality Chemicals USA Corporation	**916.99**	136.38	-	-	-	-
Investment in shares						
Prigiv Specialties Private Limited	**1,020.00**	765.00	-	-	-	-

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

b) During the year, following transactions were carried out with the related parties : *(Continued)*

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
Managerial renumeration						
Mr. D.B.Rao	-	-	-	-		
Short Term Employee Benefits	-	-	-	-	32.67	50.00
Post Employment Benefits	-	-	-	-	-	-
Other Long Term Benefits	-	-	-	-	-	-
Mr. Mahesh P Babani						
Short Term Employee Benefits	-	-	-	-	480.00	600.00
Post Employment Benefits	-	-	-	-	-	-
Other Long Term Benefits	-	-	-	-	-	-
Mr.Vinaykumar Doppalapudi Rao						
Short Term Employee Benefits (Salary paid)	-	-	-	-	26.98	25.04
Post Employment Benefits	-	-	-	-	15.77	13.90
Other Long Term Benefits	-	-	-	-	-	-
Dividend Paid						
Mr. Mahesh P Babani	-	-	-	-	-	51.73
Mahesh Purshottam Babani Huf	-	-	-	-	-	35.83
Mr. D.B.Rao	-	-	-	-	-	22.41
Money Mart Securities Private Limited	-	-	-	68.25	-	-
Vivira Investment and Trading Private Limited	-	-	-	309.90	-	-
Mm Infra & Leasing Private Limited	-	-	-	1.60	-	-
Mrs. Seema Mahesh Babani	-	-	-	-	-	7.80
Ms. Jyoti Mahesh Babani	-	-	-	-	-	7.80
Ms. Snehal Mahesh Babani	-	-	-	-	-	7.80
Mrs. Premaleela Doppalapudi Rao	-	-	-	-	-	5.49
Mr. Vinaykumar Doppalapudi Rao	-	-	-	-	-	14.82
Mrs. Grace Vinaykumar Doppalapudi Rao	-	-	-	-	-	4.64
Mr.Vijaykumar Doppalapudi Rao	-	-	-	-		14.10
Mrs. Sharon Doppalapudi Rao	-	-	-	-	-	4.91
Mr. Rajkumar Doppalapudi Rao	-	-	-	-	-	13.82
Mrs. Prasanna Raj Doppalapudi Rao	-	-	-	-	-	5.74
Mr. Rameshbabu Gokarneswararao Guduru	-	-	-	-	-	1.87
Sitting fees						
Mr. Anurag Surana	-	-	-	-	5.00	3.00
Mrs. Anuradha Thakur	-	-	-	-	5.00	4.00
Mr. Rajesh Budhrani	-	-	-	-	5.00	4.00
Mr. P.R. Barpande	-	-	-	-	5.00	4.00
Mr. Hemang Gandhi					1.00	-
Mr. Dwarko Topandas Khilnani	-	-	-	-	4.00	4.00

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

c) Outstanding balances

Particulars	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
Receivables /Other assets						
Privi Speciality Chemicals USA Corporation	9,939.01	7,769.86	-	-	-	-
MM Infra & Leasing Private Limited	-	-	51.00	51.00	-	-
Privi Life Science Private Limited	-	-	85.67	38.63	-	-
Money Mart Securities Private Limited	-	-	300.00	300.00	-	-
Prasad Organics Private Limited	-	-	704.58	904.00	-	-
Privi Biotechnologies Private Limited	37.21	25.00	-	-	-	-
Prigiv Specialties Private Limited	31.09	45.39				
Investments						
Privi Speciality Chemicals USA Corporation	30.61	30.61	-	-	-	-
Privi Biotechnologies Private Limited	4,271.70	4,271.70	-	-	-	-
Prigiv Specialties Private Limited	1,785.00	765.00	-	-	-	-
Trade Payables / Other Labilities						
Privi Biotechnologies Private Limited	-	279.77	-	-	-	-
Privi Life Science Private Limited	-	-	0.25	39.86	-	-
MM Infra & Leasing Private Limited	-	-	129.25	36.72	-	-
Money Mart Securities Private Limited	-	-	314.24	90.19	-	-
Prasad Organics Private Limited	-	-	531.81	464.74	-	-
Privi Organics Limited (Amalgameted with Privi Fine Sciences Pvt. Ltd. w.e.f 01.04.2023)	-	-		57.61	-	-
Privi Fine Sciences Private Limited			39.06			
Privi Speciality Chemicals USA Corporation	1,614.60	1,696.70	-	-	-	-
Payable to Key Management Personal						
Mr. Mahesh P Babani (*)	-	-	-	-	13.69	9.70
Mr. D.B.Rao (*)	-	-	-	-	1.55	2.94
Relatives of Key Management Personnel						
Mr.Vinaykumar Doppalapudi Rao (*)	-	-	-	-	1.33	1.33
Company has provided Corporate Bank Guarantee to CITI Bank against a working capital Loan sanction to Privi Speciality Chemicals USA Corporation (formally known as Privi Organics USA Corporation) (refer note d below)	3,334.96	3,288.80	-	-		

* Remuneration Net of Tax Deducted at Source and includes short term benefit and post employment benefit

d) Disclosure required under Sec 186(4) of the Companies Act, 2013

Provided the guarantee on behalf of wholly owned subsidiary Privi Speciality Chemicals USA Corporation (Formerly known as Privi Organics USA Corporation) to Citi Bank USA which are disclosed below as required by Sec 186(4) of the Companies Act, 2013

Name of the lonnee	Rate of Interest	Due date	Secured/ unsecured	31 March 2024	31 March 2023
Privi Speciality Chemicals USA Corporation	Not applicable	Not applicable	Working capital	3,334.96	3,288.80
				3,334.96	3,288.80

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

31 Employee benefits - post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the note 24 under "Contribution to provident & other funds":

	Year ended March 31, 2024	Year ended March 31, 2023
Contribution to employees provident fund	**327.06**	331.64
Contribution to labour welfare fund	**0.16**	0.32
Contribution to ESI	**0.56**	1.33

b) Defined benefit plans

The Company operates one post-employment defined benefit plan that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

Amount recognised in the balance sheet in respect of Gratuity		
Present value of the defined benefit obligation at the end of the year	**1,543.34**	1,456.35
Fair value of the plan assets	**-**	-
Net liability	**1,543.34**	1,456.35

	As at March 31, 2024	As at March 31, 2023
Movement in present value of defined benefit obligation		
Opening Liability	**1,456.35**	1,371.47
Current service cost	**112.61**	115.37
Interest cost	**108.35**	98.06
Actuarial loss	**(15.81)**	(63.46)
Benefits paid	**(118.16)**	(65.09)
Closing defined benefit obligation	**1,543.34**	1,456.35
Expense recognised in statement of profit and loss		
Current service cost	**112.61**	115.37
Interest on defined benefit obligations	**108.35**	98.06
Total	**220.96**	213.43
Remeasurements recognised in Other comprehensive income		
Change in financial assumptions	**28.01**	(32.24)
Change in Demographic Assumptions	**-**	-
Experience adjustments	**(43.82)**	(31.22)
Total	**(15.81)**	(63.46)
Total expense recognised	**205.15**	149.97

B.K. & Co. Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

31 Employee benefits - Post-employment benefit plans *(Continued)*

b) Defined benefit plans *(Continued)*

	As at March 31, 2024	As at March 31, 2023
Principal actuarial assumptions at the balance sheet date		
Discount rate (p.a)	7.44%	7.44%
Expected rate of salary increase (p.a.)	8.25%	8.25%
Attrition rate	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.
Mortality tables	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)

At March 31, 2024 the weighted average duration of the defined benefit obligation was 9 years (March 31, 2023 : 9 years)

The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
	March 31, 2024	March 31, 2023	March 31, 2024	March 31, 2023
Impact on defined benefit obligation due to:				
a. 1% increase	**(106.77)**	(101.99)	**119.48**	114.70
b. 1% decrease	**121.94**	116.77	**(106.71)**	(102.16)

The sensitivity analysis above has been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment for last five years

	March 31, 2024	March 31, 2023	March 31, 2022	March 31, 2021	March 31, 2020
Defined benefit obligation	1,543.34	1,456.35	1,371.47	1,167.16	1,016.53
Surplus/(deficit)	(1,543.34)	(1,456.35)	(1,371.47)	(1,167.16)	(1,016.53)
Experience adjustment on plan liabilities	(43.32)	(31.22)	90.57	11.38	43.72

Compensatory absences

The Company provides for the encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits, for future encashment. The liability is provided based on the number of days of unutilized leave at each balance sheet date on the basis of an independent actuarial valuation. Amount of Rs. 15.01 lakhs (31 March, 2023 : Rs 82.13 lakhs) has been recognised in the Standalone Statement of profit and loss of provision for long-term employment benefit.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

32 Financial instruments

a. Accounting classification and fair values

The Company is exposed to the risks of changes in fair value of its financial assets and liabilities. The following table summarises the fair values and carrying amounts of financial instruments.

		Carrying value			Fair value measurement using		
As on 31 March 2024	**Note**	**Amortised cost**	**Financial assets/liabilities at FVTPL**	**Financial assets/liabilities at FVOCI**	**Total carrying amount**	**Level 1**	**Level 2**	**Level 3**
Financial assets:								
Investment in equity instruments (unquoted)	5	6,163.14	-	-	6,163.14	-	-	-
Trade receivables	9	36,108.27	-	-	36,108.27	-	-	-
Cash and cash equivalents	10	1,575.08	-	-	1,575.08	-	-	-
Bank balances other than cash and cash equivalents	11	444.78	-	-	444.78	-	-	-
Other financial assets	6	1,656.56	-	-	1,656.56	-	-	-
Financial liabilities:								
Non Current borrowings	13 a	38,350.20	-	-	38,350.20	-	-	38,350.20
Current borrowings	14	50,462.91	-	-	50,462.91	-	-	50,462.91
Trade payables	17	28,336.42	-	-	28,336.42	-	-	-
Derivatives	18	-	433.51	-	433.51	-	433.51	
Lease liabilities	13 b	1,193.90	-	-	1,193.90	-	-	1,193.90
Other financial liabilities (other than lease liabilities)	18	1,905.83	-	-	1,905.83	-	-	

		Carrying value			Fair value measurement using		
As on 31 March 2023	Note	Amortised cost	Financial assets/liabilities at FVTPL	Financial assets/liabilities at FVOCI	Total carrying amount	Level 1	Level 2	Level 3
Financial assets:								
Investment in equity instruments (unquoted)	5	5,067.31	-	-	5,067.31	-	-	-
Trade receivables	9	31,448.79	-	-	31,448.79	-	-	-
Cash and cash equivalents	10	1,025.27		-	1,025.27	-	-	-
Bank balances other than cash and cash equivalents	11	418.68			418.68	-	-	-
Other financial assets	6	1,507.19		-	1,507.19	-	-	-
Financial liabilities:								
Non Current borrowings	13 a	40,370.49	-	-	40,370.49	-	-	40,370.49
Current borrowings	14	62,560.05	-	-	62,560.05	-	-	62,560.05
Trade payables	17	29,772.29	-		29,772.29			
Derivatives	18	-	1,174.85	-	1,174.85	-	1,174.85	
Lease liabilities	13 b	1,354.99	-	-	1,354.99	-	-	1,354.99
Other financial liabilities (other than lease liabilities)	18	6,109.33	-	-	6,109.33		-	

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

32 Financial instruments *(Continued)*

b. The fair value of financial instruments as referred to in note (a) above have been classified into a three categories depending on the inputs used in the valuation technique.

The categories used are as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

c. **Calculation of fair values**

The fair values of the financial assets and liabilities are defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Methods and assumptions used to estimate the fair values are consistent with those used for the year ended March 31, 2024.

(i) The fair values of the derivative financial instruments has been determined using valuation techniques with market observable inputs. The models incorporate various inputs including the credit quality of counter-parties and foreign exchange forward rates. In case the forwards are taken from banks and financial institutions, the fair value is determined using quoted forward exchange rates at the reporting date and present value calculations based on high credit quality yield curves in the respective currencies by the bankers.

(ii) The fair values of investments in mutual fund units is based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at Balance Sheet date. NAV represents the price at which the issuer will issue further units of mutual fund and the price at which issuers will redeem such units from the investors.

(iii) Loans, lease liabilities and borrowings have fair values that approximate to their carrying amounts as it is based on the net present value of the anticipated future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities.

(iv) Cash and cash equivalents, trade receivables, investments in term deposits, other financial assets (except derivative financial instruments), trade payables, and other financial liabilities (except derivative financial instruments) have fair values that approximate to their carrying amounts due to their short-term nature.

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

33 Financial risk management

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.The Board of Directors has established the risk management committee, which is responsible for developing and monitoring the company's risk management policies. The committee reports regularly to the board of Directors on its activities.
The Company's risk management are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits.Risk management policies and systems are reviewed regularly to reflect changes in market conditions and activities.
The Audit committee oversees how management monitors compliance with the company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Audit committee is assisted in its oversight role by internal audit by external party.

The Company has exposure to the following risks arising from the financial instruments:

a. **Credit Risk**

Credit risk is the risk of financial loss to the Company if a customer or counter-party fails to meet its contractual obligations and arises principally from the Company's receivables from customers.The carrying amount of financial assets represent the maximum credit exposure.
The Company's exposure to credit risk is influenced mainly by the individual characterisitc of each customer.However, management also consider the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which company operates
The Company analyses credit worthiness of each new customer individually before standard payment and delivery terms are offered.The Company is monitoring economic environment in countires where it operates and is taking actions to limit its exposure to customers in those countries experiencing particular economic volatility.

Impairment of Trade receivables

At March 31, 2024 the ageing of trade and other receivables that were not impaired was as follows.

	Carrying amount	
	March 31, 2024	March 31, 2023
Neither past due nor impaired	26,906.87	24,038.04
Past due 0-90 days	8,715.43	6,405.38
Past due 90-180 days	194.02	731.61
Past due 180-270 days	113.16	162.82
Past due 270-365 days	97.25	88.11
More than 365 days	80.49	22.83
	36,108.27	31,448.79

Movement in Loss allowance measured at amount equal to life time expected credit losses for trade receivables.

	Amount
Balance as at April 01, 2022	27.84
Impairment loss recognised	-
Amount written off	
Balance as at March 31, 2023	27.84
Impairment loss recognised	-
Amounts written off	-
Balance as at March 31, 2024	27.84

The Company uses an allowance matrix to measure the expected credit loss of trade receivables.Based on the industry practices and the business environment in which the entity operates, Management considers that the trade receivables are in default (credit impaired) if the payments are more than 365 days past due.

Management believes that the unimpaired amounts that are past due by more than 30 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk and the current provision for the bad debts represents the impacted credit loss it foresees in its receivables.

Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

a. Credit Risk *(Continued)*

Financial assets other than trade receivables are not impaired and further, there are no amounts that are past due. Management believes that the amounts are collectible in full, based on historical payment behavior.

b. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company maintains the level of its cash and cash equivalents at an amount in excess of expected cash outflow on financial liabilities.The Company also monitors the level of expected cash inflows on trade and other receivables together with expected cash inflows on trade and other payables

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

March 31, 2024	Carrying amount	Total	Contractual cash flows 1 year or less	1-2 years	2-5 years	More than 5 years
Non-derivative financial liabilities						
Term loans from banks	52,076.37	52,076.37	13,726.17	10,292.98	21,353.23	6,769.37
Other borrowings	36,736.74	36,736.74	36,736.74	-	-	-
Trade payables	28,336.42	28,336.42	28,336.42	-	-	-
Other financial liabilities	1,905.83	1,905.83	1,905.83	-	-	-
Lease liability	1,193.90	1,193.90	373.86	463.26	517.11	-
Derivative financial linbilities						
Interest rate swaps	433.51	433.51	433.51	-	-	-
	1,20,682.77	1,20,682.77	81,512.53	10,756.24	21,870.34	6,769.37

March 31, 2023	Carrying		Contractual cash flows 1 year or less	1-2 years	2-5 years	More than 5
Non-derivative financial liabilities						
Term loans from banks	50,663.47	50,663.47	10,292.98	21,353.23	19,017.26	-
Other borrowings	52,267.07	52,267.07	52,267.07	-	-	-
Trade payables	29,772.29	29,772.29	29,772.29	-	-	-
Other financial liabilities	5,749.11	5,749.11	5,749.11	-	-	-
Lease liabilities	1,354.99	1,354.99	360.22	994.77	-	-
Derivative financial liabilities						
Interest rate swaps	1,174.85	1,174.85	1,174.85	-	-	-
	1,40,981.78	1,40,981.78	99,616.52	22,348.00	19,017.26	-

The gross inflows/(outflows) disclosed in the above table represent the contractual undiscounted cash flows relating to derivative financial liabilities held for risk management purposes and which are not usually closed out before contractual maturity. The disclosure shows net cash flow amounts for derivatives that are net cash-settled and gross cash inflow and outflow amounts for derivatives that have simultaneous gross cash settlement.

c. Currency Risk

The Company is exposed to currency risk on account of its borrowings and other payables in foreign currency. The functional currency of the Company is Indian Rupee. The Company uses forward exchange contracts to hedge its currency risk, most with a maturity of less than one year from

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at March 31, 2024 and March 31, 2023 are as below:

	March 31, 2024 USD in lakh	March 31, 2024 EURO in lakh	March 31, 2023 USD in lakh	March 31, 2023 EURO in lakh
Financial assets				
Cash and cash equivalents	0.16	0.02	1.03	0.02
Trade Receivables	277.58	14.79	236.84	17.74
	277.74	14.81	237.87	17.76
Financial liabilities				
Borrowings	-	15.00	-	22.50
Buyers Credit	-	-	29.99	-
Packing credit in foreign currency	51.61	-	-	-
Working capital demand Loan	39.20	-	10.06	-
Trade payables and other financial liabilities	89.85	0.66	129.44	2.42
Other Current financial liabilities - Derivative Instruments Interest rate sw	9.39	0.05	15.29	0.92
	190.14	15.71	193.08	25.84
Net exposure	87.60	(0.90)	44.79	(8.08)

* **The exposure disclosed here is net of currency swap taken by the Company**

Currency exposure for borrowings is exclusive of Currency swap on IDFC Rupee loan of Rs.4,000 lakhs and ICICI bank Rupee loan of Rs.4,000 lakhs are taken @64.42 per USD and @68.13 per USD respectively and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76.78 per USD and @ 75.83 per USD respectively which are classified as Indian currency loan.

The Company's corporate treasury function provides services to the business, co-ordinates access to domestic financial markets, monitors and manages the financial risk relating to the operation of the Company through internal risk reports which analyse exposures by degree and magnitude of risks. These risks include market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The use of financial derivatives is governed by the Company's policies approved by the board of directors, which provide written principles on foreign exchange risk, interest rate risk, credit risk, etc.

The Corporate treasury function reports quarterly to the Company's risk management committee, an independent body that monitors risks and policies implemented to mitigate risk exposures.

d. **Sensitivity analysis**

A reasonably possible strengthening (weakening) of the foreign currencies against INR at March 31, 2024 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases

Effect in Indian Rupees in lakhs	Profit before tax Strengthening	Profit before tax Weakening	Equity, net of tax Strengthening	Equity, net of tax Weakening
March 31, 2024				
USD (3 % movement)	219.11	(219.11)	165.96	(143.23)
EUR (3 % movement)	(2.44)	2.44	(1.83)	1.60
	216.67	(216.67)	162.13	(141.68)

Effect in Indian Rupees in lakhs	Profit before tax Strengthening	Profit before tax Weakening	Equity, net of tax Strengthening	Equity, net of tax Weakening
March 31, 2023				
USD (3 % movement)	110.48	(110.48)	82.67	(72.25)
EUR (3 % movement)	(21.72)	21.72	(16.25)	14.20
	88.76	(88.76)	66.42	(58.05)

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

e. Interest risk

The company is exposed primarily to fluctuation in USD LIBOR rates. Interest rate risk on financial debt is managed through interest rate swaps.

The interest rate profile of the Company's interest-bearing financial instruments is as

	March 31, 2024	March 31, 2023
Fixed-rate instruments	88,813.11	1,02,930.54
Variable-rate instruments	-	-
Total borrowings	88,813.11	1,02,930.54

*Effect of interest rate swaps is disclosed in Note 13 a .

Financial assets classified at amortized cost have fixed interest rate. Hence, the Company is not subject to interest rate risk on such financial assets.

Cash flow sensitivity analysis for variable-rate instruments

A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

	Profit or loss		Equity, net of tax	
	100 bp increase	100 bp decrease	100 bp increase	100 bp
March 31, 2024				
Variable-rate instruments	-	-	-	-
March 31, 2023				
Variable-rate instruments	-	-	-	-

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements (Continued)

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

34 Contingent liabilities:

Claims against the Company not acknowledged as debts are below

	As at March 31, 2024	As at March 31, 2023
Income tax authorities	932.16	932.16
Custom Duty *	106.06	106.06

* Demand of Rs. 15.52 lakhs (out of which Rs. 6.00 lakhs paid) raised by Customs, Excise and Service Tax Appellate Tribunal West Zonal Bench, Mumbai for clearance of imported goods under DEPB scheme. (Contravention of the provisions of Section 111 (o) of the Customs Act, 1962). Further the demand of Rs. 101.53 lakh was raised by Customs authority out of which Rs. 10.98 lakh is paid under protest, balance Rs. 90.54 lakhs are unpaid as on March 31, 2024.

The claims against the Company comprise of pending litigations / proceedings pertaining to demands raised by Excise, Custom, Sales / VAT tax and other authorities / bodies. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial statements.

It is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above pending resolution of the respective proceedings as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

The Company does not expect any reimbursements in respect of the above contingent liabilities

35 Commitments

	As at March 31, 2024	As at March 31, 2023
Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of advances of Rs.181.60 lakhs, (March 31, 2023 : Rs. 647.78 lakhs)	1,699.50	2,104.47
Bank Guarantee	514.56	-
Bank Guarantee to wholly own subsidiary (refer note 30 d)	3,334.96	3,288.80
LC's issued in favour of suppliers, but the material not dispatched	911.91	754.57
Other Investment	-	1,600.00

36 Earnings per share

	As at March 31, 2024	As at March 31, 2023
Profit after tax attributable to equity shareholders [A]	9,788.49	2,247.49
Number of equity shares at the beginning of the year [B]	3,90,62,706	3,90,62,706
Number of equity shares outstanding at the end of the year [C]	3,90,62,706	3,90,62,706
Weighted average number of equity shares outstanding during the year [D]	3,90,62,706	3,90,62,706
Basic and diluted earnings per share of face value Rs. 10 [A]/[D]	25.06	5.75

Notes to the Standalone Financial Statements (Continued)

for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

37 Revenue from Contracts with Customers

(A) The Company is primarily in the business of manufacture and sale of Aroma chemicals. All sales are made at a point in time and revenue recognised upon satisfaction of the performance obligations which is typically upon dispatch/ delivery. The Company has a credit evaluation policy based on which the credit limits for the trade receivables are established, the Company does not give significant credit period resulting in no significant financing component.

(B) **Reconciliation of revenue recognised from Contract liability:**

Particulars	As at March 31, 2024	As at March 31, 2023
Opening Contract liability	5607.18	264.01
Less: Recognised as revenue during the year	8,642.17	2,697.06
Add: Addition to contract liability during the year	3,336.91	8,040.23
Closing Contract liability	301.92	5607.18

Contract liability primarily relates to advance consideration received from customers for sale of products in case of few contracts based on terms agreed. The contract liability is expected to be recognised within 12 months.

There is no contract asset as at 31 March 2024(31 March 2023 : Nil)

(C) **Reconciliation of revenue as per contract price and as recognised in statement of standalone profit and loss:**

Particulars	As at March 31, 2024	As at March 31, 2023
Revenue from contract with customer as per Contract price	1,71,148.96	1,57,570.03
Less: Discounts and other adjustments	-	28.21
Revenue from contract with customer as per statement of standalone profit and loss	1,71,148.96	1,57,541.82

(D) **Disaggregation of revenue from contract with customers**

Particulars	Revenue from contracts with customers March 31, 2024	Revenue from contracts with customers March 31, 2023
India	53,410.11	40,270.01
Europe(excluding UK)	41,163.66	37,776.94
North America	46,425.26	41,703.11
Asia (Excluding India)	12,994.32	18,564.10
Middle East	6,400.41	7,443.05
United Kingdom	6,403.70	5,170.08
South America	2,464.29	3,872.38
Africa	1,860.75	2,658.01
Australia and New Zealand	26.46	84.14
	1,71,148.96	1,57,541.82

(E) **Unsatisfied Performance Obligations**

The Company applies the practical expedient in Paragraph 121 of Ind AS 115 and does not disclose information about remaining performance obligations.

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements (Continued)
for the year ended March 31, 2024

(Currency: Indian Rupees in lakhs)

38 Dividend on equity shares

	As at March 31, 2024	As at March 31, 2023
Dividend on equity shares declared and paid during the		
Final dividend for the year ended March 31, 2023 -Rs. 0.00 (March 31, 2022 Rs.: 2.00) per fully paid up share	-	781.21
	-	781.21
Dividends not recognized at the end of reporting period		
Dividends declared by the Company are based on the profit available for distribution. On May 02, 2024, the Board of Directors of the Company have proposed a final dividend of Rs. 2.00 per share in respect of the year ended March 31, 2024 subject to the approval of shareholders at the Annual General Meeting, and if approved, would result in a cash outflow of approximately Rs.781.21 lakh.		
	-	-

39 Transfer Pricing

Transactions with related parties are governed by transfer pricing regulations of the Indian Income-tax Act, 1961. The Company's international and domestic transactions with related parties are at arm's length as per the independent accountants report for the year ended March 31, 2023. Management believes that the Company's international and domestic transactions with related parties post March 2023 continue to be at arm's length and that the transfer pricing legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.

40 Investment in shares of Radiance Sunrise Ten Private Limited

The Company has been supplementing its incremental energy requirements by sourcing power from renewable sources. To this end, the Company has executed a Share Subscription and Shareholder's Agreement dated December 28, 2022 to acquire 26% stake in Radiances MH Sunrise Ten Private Limited for supply of 10 MW electricity generated through Solar Power Plant ("Solar plant") at a concessional rate with a minimum entitlement of 51% of power generated from the Solar Plant. As per the agreement , the company has subscribed 49,95,000 equity shares of ₹ 10 each of Radiances MH Sunrise Ten Private Limited during the current year. The benefit by way of reduction in Electricity expenses started from February, 2024 amounting to Rs.126.85 lakh considered in the accounts net of expenses.

Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

41 Other Statutory Information

a) Other informations

(i) As on March 31, 2024 there is no untilised amounts in respect of any issue of securities and long term borrowings from banks and financial institutions. The borrowed funds have been utilised for the specific purpose for which the funds were raised.

(ii) The Company do not have any transactions with struck off companies.

(iii) The Company do not have any charges or satisfaction, which is yet to be registered with Registrar of Companies beyond the statutory period.

(iv) The Company is in compliance with the number of layers prescribed under clause (87) of section 2 of the Companies Act read with the Companies (Restriction on number of Layers) Rules, 2017.

(v) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property.

(vi) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year.

(vii) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(viii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

(ix) The Company have not entered in any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

b) Changes in accounting policy : The Company has changed its accounting policy in respect of valuation of inventory - Indian Accounting Standard (Ind AS) 2 – Inventories

The change in accounting policy for valuation of inventory is from First in First out to Periodic Weighted Average Method retrospectively, to the earliest period reported on voluntary basis. The change is owing to more reliable, relevant information being available through newly migrated accounting system, SAP and resulting in better presentation.

Inventories include Raw Material, Packing Material, Fuel, consumable stores and spares are valued and determined basis of Periodic Unit Price Moving Weighted Average Method as against First in first out adopted until 31 March 2022. The Company has implemented SAP S4 Hana integrated ERP system from current financial year as against the earlier oracle R12.1.1 ERP system. SAP ERP system is more robust and conducive to the manufacturing operations. It provides real time data across modules. Inventory valuation now automated from SAP system and gives granular details and valuations of items at various stage of its operations. The Company thought it prudent to move from the legacy FIFO basis of valuation to the Periodic Moving Weighted Average Method of the SAP ERP system. This is also in line with the global practices followed in the industry. The voluntary change in method of valuation of Inventory is in the nature of Change in Accounting Policy and requires retrospective application as per Ind AS 8. As per the detailed assessment and re-computation performed by the Management, the impact thereof is not to be material and hence the financial statements are not re-stated to the earliest reported period.

This change has resulted in inventories being higher than Rs 19.02 lakhs and corresponding effect in the retained earnings as at 31 March 2023. There is no significant impact on the opening equity as a result of the change. The impact on basic and diluted EPS is not material.

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2024

42 Corporate social responsibility

As per section 135 of the Companies Act, 2013 a corporate social responsibility (CSR) committee has been formed by the Company. The areas for CSR activities are Education, Environment Sustainability, Health and hygiene and Disaster Management. Amount spent during the year on activities which are specified in Schedule VII of the Companies Act 2013 are as mentioned below:

Particulars	Year ended March 31, 2024	Year ended March 31, 2023
a) Amount required to be spent by the Company during the year	232.01	333.00
b) Amount approved by the Board to be spent during the year	232.01	333.00
c) Amount spent during the year		
Paid		
(i) construction / acquisition of any asset	-	-
(ii) on purpose other than (i) above	232.01	333.00
Total	232.01	333.00
d) Details of related party transactions	-	-
e) Details of unspent obligations	Nil	Nil

Details of other than ongoing project

In case of Section 135(5) of the Companies Act, 2013 (Other than ongoing project)				
Opening Balance as at April 01, 2023	Amount deposited in specified fund of Schedule VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance as at March 31, 2024
-	-	232.01	232.01	-

In case of Section 135(5) of the Companies Act, 2013 (Other than ongoing project)				
Opening Balance as at 1 April 2022	Amount deposited in specified fund of Schedule VII within 6 months	Amount required to be spent during the year	Amount spent during the year	Closing balance as at 31 March 2023
-	-	333.00	333.00	-

Note: There are no ongoing projects as at March 31, 2024 and March 31, 2023

43 Additional Regulatory Information

Ratio	Numerator	Denominator	Year ended March 31, 2024	Year ended March 31, 2023	% Variance	Reason for Variance greater than 25%
Current Ratio (in times)	Total current assets	Total current liabilities	1.25	1.07	16.82%	
Debt - Equity ratio (in times) (net)	Debt consists of borrowings Less Cash and cash equivalents and short term investments	Total equity	0.94	1.23	-23.58%	
Debt service coverage ratio (in times)	Net profit before tax + Depreciation + Interest (EBITDA)	Debt service = Interest + Principal repayments	1.37	1.59	-13.84%	
Return on equity ratio (in %)	Net profit after tax for the year	Average Total Equity	11.23%	2.76%	306.88%	Increase due to increase in profitability during the current year.
net capital turnover ratio (in times)	Revenue from operations Average	Average working capital (i.e. Total current assets less Total current liabilities)	11.76	17.5	-32.80%	Decrease due to increase in Revenue from operations Average
net profit ratio (in %)	Net profit after tax for the year	Revenue from operations	5.72%	1.42%	302.82%	Increase due to increase in profitability during the current year and Increase due to increase in revenue from operation along with reduction in raw material cost during the current year
return on capital employed (in %)	Profit before tax and finance costs	Total equity + Borrowings +Deferred tax liabilities (net)	12.39%	5.23%	136.90%	Increase due to increase in profitability during the current year
Inventory turnover ratio	Revenue from operations	Average Inventory	2.54	2.42	4.96%	
Trade receivable turnover ratio	Revenue from operations	Average Trade receivable	5.07	5.27	-3.80%	
Trade payables turnover ratio	Purchases	Average Trade payables	3.03	3.80	-20.26%	

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 02, 2024

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Kothari
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S
Chief Financial Officer
Membership No: 105520

Srishti Shah
Company Secretary
Membership No:A-58578

Mumbai
Date : May 02, 2024

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing,
Nesco IT Park 4, Nesco Center,
Western Express Highway,
Goregaon (East), Mumbai – 400063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Independent Auditor's Report

To the Members of Privi Speciality Chemicals Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Speciality Chemicals Limited (the "Company") which comprise the standalone balance sheet as at 31 March 2023, and the standalone statement of profit and loss (including other comprehensive income), standalone statement of changes in equity and standalone statement of cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ("Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31 March 2023, and its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the* Standalone *Financial Statements* section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the standalone financial statements.

Key Audit Matter

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone financial statements of the current period. These matters were addressed in the context of our audit of the standalone financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Revenue recognition	
See Note 20 and 37 to standalone financial statements	
The key audit matter	**How the matter was addressed in our audit**

258

The Company's revenue is derived primarily from sale of products. The principal products of the Company comprise of aroma chemicals. Revenue from sale of goods is recognized on transfer of the products to the customer. The Company uses a variety of shipment terms across its operating markets and this has an impact on the timing of revenue recognition. The performance obligations in the contracts may be fulfilled at the time of dispatch, delivery or upon formal customer acceptance depending on contract terms. There is a risk that revenue could be recognised at a time which is different from transfer of control especially for sales transactions occurring on and around the reporting period. Also, there is a risk of recognizing fictitious revenue throughout the year. In view of this and since revenue is a key performance indicator of the Company, we have identified timing of the revenue recognition as a key audit matter.	• In view of the significance of the matter we applied the following audit procedures in this area, among others to obtain sufficient appropriate audit evidence:- • Assessed the appropriateness of Company's accounting policies relating to revenue recognition as per the applicable accounting standard. • Obtained an understanding of the Company's sales process and evaluated the design and implementation of key internal controls in relation to the timing of revenue recognition. We also tested the operating effectiveness of such controls for a sample of transactions with special reference to controls over revenue recognised on and around the year end. • For a sample of sale transactions selected using statistical sampling, performed detailed testing and in particular examined whether these are recognised in the period in which control is transferred. This included examination of the terms and conditions as per customer orders, such as shipping terms, transporter documents and customer acceptances. • Tested on a sample basis, specific revenue transactions recorded around the year end date to check whether revenue has been recognised in the correct reporting period by examining the underlying documents. • Tested sample journal entries for revenue recognised during the year, selected based on specified risk-based criteria, to identify unusual transactions.

Other Information

The Company's Management and Board of Directors are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements and auditor's report thereon. The annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

Management's and Board of Directors Responsibilities for the Standalone Financial Statements

The Company's Management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/ loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, the Management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's

report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

2 A. As required by Section 143(3) of the Act, we report that:

a. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c. The standalone balance sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone statement of cash flows dealt with by this Report are in agreement with the books of account.

d. In our opinion, the aforesaid standalone financial statements comply with the Ind AS specified under Section 133 of the Act.

e. On the basis of the written representations received from the directors as on 31 March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164(2) of the Act.

f. With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".

B. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

a. The Company has disclosed the impact of pending litigations as at 31 March 2023 on its financial position in its standalone financial statements - Refer Note 34 to the standalone financial statements.

b. The Company has made provision, as required under the applicable law or accounting standards, for material foreseeable losses, if any, on long-term contracts including derivative contracts –

Refer Note 18 to the standalone financial statements.

c. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

d (i) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 42 to the standalone financial statements, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(ii) The management has represented that, to the best of its knowledge and belief, as disclosed in the Note 42 to the standalone financial statements, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Parties ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(iii) Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (i) and (ii) above, contain any material misstatement.

e. The final dividend paid by the Company during the year, in respect of the same declared for the previous year, is in accordance with Section 123 of the Act to the extent it applies to payment of dividend. The Company has not declared any dividend during the year.

f. As proviso to rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable for the Company only with effect from 1 April 2023, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 is not applicable.

C. With respect to the matter to be included in the Auditor's Report under Section 197(16) of the Act:

In our opinion and according to the information and explanations given to us, the remuneration paid by the Company to its directors during the current year is in accordance with the provisions of Section 197 of the Act. The remuneration paid to any director is not in excess of the limit laid down under Section 197 of the Act. The Ministry of Corporate Affairs has not prescribed other details under Section 197(16) of the Act which are required to be commented upon by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar

Partner

Membership No.: 113959

ICAI UDIN:23113959BGXKTF1922

Place: Mumbai

Date: 29 May 2023

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023

(Referred to in paragraph 1 under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

(i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(i) (b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has a regular programme of physical verification of its Property, Plant and Equipment by which all property, plant and equipment are verified once in two years. In accordance with this programme, no property, plant and equipment were verified during the year. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets. No discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) The inventory, except goods-in-transit and stocks lying with third parties, has been physically verified by the management during the year.For stocks lying with third parties at the year-end, written confirmations have been obtained and for goods-in-transit subsequent evidence of receipts has been linked with inventory records. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has been sanctioned working capital limits in excess of five crore rupees, in aggregate, from banks or financial institutions on the basis of security of current assets. In our opinion, the quarterly returns or statements filed by the Company with such banks or financial institutions are in agreement with the books of account of the Company except as follows:

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

Quarter	Name of bank	Particulars	Amount as per books of account (Rs in lakhs)	Amount as reported in the quarterly return/ statement (Rs in lakhs)	Amount of difference (Rs in lakhs)	Whether return/statement subsequently rectified
Jun-22	Kotak Mahindra Bank and others	Trade Receivables and Inventories	101,281	96,290	4,990	No
Sep-22	Kotak Mahindra Bank and others	Trade Receivables and Inventories	111,592	111,689	-97	No
Dec-22	Kotak Mahindra Bank and others	Trade Receivables and Inventories	110,033	109,117	916	No
Mar-23	Kotak Mahindra Bank and others	Trade Receivables and Inventories	105,945	105,813	132	No

Refer note 14 of the standalone financial statements.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any investments in companies, firms, limited liability partnership or any other parties. The Company has provided guarantee and security to Companies during the year in respect of which the requisite information is as below. The Company has not granted loans and advances in the nature of loans to Companies during the year in respect of which the requisite information is as below. The Company has not provided any guarantee or security, granted any loans or advances in the nature of loans, secured or unsecured, to limited liability partnership or any other parties during the year.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

Particulars	Guarantees (Rs in lakhs)	Security	Loans	Advances in nature of loans
Aggregate amount during the year				
Subsidiaries*	256	-	-	-
Joint ventures*	-	-	-	-
Associates*	-	-	-	-
Others	-	-	-	-
Balance outstanding as at balance sheet date				
Subsidiaries*	3,288	-	-	-
Joint ventures*	-	-	-	-
Associates*	-	-	-	-
Others*	-	-	-	-

**As per the Companies Act, 2013*

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, in our opinion the investments made, guarantees provided, security given during the year and the terms and conditions of the grant of loans and advances in the nature of loans and guarantees provided during the year are, prima facie, not prejudicial to the interest of the Company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loans are given during the year Further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loans given. Further, the Company has not given any advances in the nature of loans to any party during the year. Accordingly, clause 3(iii) (d) of the Order is not applicable.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted. Accordingly, clause 3(iii) (e) of the Order is not applicable

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans. Accordingly, clause 3(iii) (f) of the Order is not applicable

(iv) According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and loans, guarantees and security given by the Company, in our opinion the provisions of Section 185 and 186 of the Companies Act, 2013 ("the Act") have been complied with.

(v) The Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) We have broadly reviewed the books of accounts maintained by the Company pursuant to the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Act in respect of its manufactured goods and are of the opinion that prima facie, the prescribed accounts and records have been made and maintained. However, we have not carried out a detailed examination of the records with a view to determine whether these are

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

accurate or complete.

(vii) (a) The Company does not have liability in respect of Service tax, Duty of excise, Sales tax and Value added tax during the year since effective 1 July 2017, these statutory dues has been subsumed into GST.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, in our opinion amounts deducted / accrued in the books of account in respect of undisputed statutory dues including Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues have been regularly deposited by the Company with the appropriate authorities.

According to the information and explanations given to us and on the basis of our examination of the records of the Company, no undisputed amounts payable in respect of Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues were in arrears as at 31 March 2023 for a period of more than six months from the date they became payable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, statutory dues relating to Goods and Service Tax, Provident Fund, Employees State Insurance, Income-Tax, Duty of Customs or Cess or other statutory dues which have not been deposited on account of any dispute are as follows:

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
The Income Tax Act, 1961	Income Tax	3.33	2005-06	CIT Appeals	Not Yet Paid
The Income Tax Act, 1961	Income Tax	316.13	2014-15	Commissioner (Appeals)	Not Yet Paid
The Income Tax Act, 1961	Income Tax	31.21	2015-16	CIT Appeals	Not Yet Paid
The Income Tax Act, 1961	Income Tax	317.00	2017-18	ITAT	Not Yet Paid
The Income Tax Act, 1961	Income Tax	1,119.00	2017-18	ITAT	Not Yet Paid
The Income Tax Act, 1961	Income Tax	268.79	2018-19	Commissioner (Appeals)	Not Yet Paid
The Customs	Custom Duty	9.52	1998-99	CESTAT	Not Yet Paid

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

Name of the statute	Nature of the dues	Amount (Rs. in lakhs)	Period to which the amount relates	Forum where dispute is pending	Remarks, if any
Act, 1962					
The Customs Act, 1962	Custom Duty	90.54	2013-14	CESTAT	Not Yet Paid

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to any lender.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the standalone financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Act.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under the Act).

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments). Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Act has been filed by the auditors in Form ADT-4 as prescribed under Rule 13 of the Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

(xii) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Act, where applicable, and the details of the related party transactions have been disclosed in the standalone financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Act are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group (as per the provisions of the Core Investment Companies (Reserve Bank) Directions, 2016 as amended). Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that the Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.

Also refer to the Other Information paragraph of our main audit report which explains that the other information comprising the information included in annual report is expected to be made available to us after the date of this auditor's report.

(xx) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of Section 135 of the Act pursuant to any project. Accordingly,

Annexure A to the Independent Auditor's Report on the Standalone Financial Statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
ICAI UDIN:23113959BGXKTF1922

Place: Mumbai
Date: 29 May 2023

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023

Report on the internal financial controls with reference to the aforesaid standalone financial statements under Clause (i) of Sub-section 3 of Section 143 of the Act

(Referred to in paragraph 2(A) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Speciality Chemicals Limited ("the Company") as of 31 March 2023 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls with reference to financial statements and such internal financial controls were operating effectively as at 31 March 2023, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the "Guidance Note").

Management's and Board of Directors' Responsibilities for Internal Financial Controls

The Company's Management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor's Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of internal financial controls with reference to financial statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Annexure B to the Independent Auditor's Report on the standalone financial statements of Privi Speciality Chemicals Limited for the year ended 31 March 2023 *(Continued)*

Meaning of Internal Financial Controls with Reference to Financial Statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of standalone financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of standalone financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the standalone financial statements.

Inherent Limitations of Internal Financial Controls with Reference to Financial Statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
ICAI UDIN.23113959BGXKTF1922

Place: Mumbai
Date: 29 May 2023

Privi Speciality Chemicals Limited

Standalone Balance Sheet

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

	Note	As at March 31, 2023	As at March 31, 2022
Assets			
Non-current assets			
Property, plant and equipment	3	93,556.99	62,659.88
Capital work-in-progress	3	8,821.37	36,118.43
Right of use assets	4 a	3,606.68	3,410.61
Other Intangible assets	4 b	1,017.28	485.85
Intangible assets under development	4 b	487.07	855.54
Financial assets			
Investments	5	5,067.31	5,067.31
Other financial assets	6	1,497.35	1,389.77
Income tax assets (net)		2,343.19	1,394.36
Other non-current assets	7	3,093.30	1,696.26
Total non-current assets		1,19,490.54	1,13,078.01
Current assets			
Inventories	8	74,496.25	56,120.78
Financial assets			
Trade receivables	9	31,448.79	28,421.72
Cash and cash equivalents	10	1,025.27	2,636.96
Bank balances other than cash and cash equivalents	11	418.68	452.29
Other financial assets	6	9.84	1,320.51
Other current assets	7	7,402.37	10,808.22
Total current assets		1,14,801.20	99,760.48
TOTAL ASSETS		2,34,291.74	2,12,838.49
EQUITY AND LIABILITIES			
EQUITY			
Equity share capital	12 a	3,906.27	3,906.27
Other equity	12 b	78,341.39	76,829.54
Total equity		82,247.66	80,735.81
LIABILITIES			
Non-current liabilities			
Financial liabilities			
Borrowings	13 a	40,370.49	38,060.00
Lease liabilities	13 b	994.77	1,290.41
Provisions	15	1,750.17	1,675.45
Deferred tax liabilities (net)	16	2,021.94	1,458.27
Total non-current liabilities		45,137.37	42,484.13
Current liabilities			
Financial liabilities			
Borrowings	14	62,560.05	49,904.67
Lease liabilities	13 b	360.22	424.80
Trade payables			
a) Total outstanding dues of micro enterprises and small enterprises	17	927.53	-
b) Total outstanding dues of creditors other than micro enterprises and small	17	28,844.76	30,822.69
Other financial liabilities	18	7,284.18	6,916.09
Other current liabilities	19	5,849.86	487.77
Provisions	15	212.56	194.98
Current tax liabilities (net)		867.55	867.55
Total current liabilities		1,06,906.71	89,618.55
Total liabilities		1,52,044.08	1,32,102.68
TOTAL EQUITY AND LIABILITIES		2,34,291.74	2,12,838.49
Notes to the standalone financial statements	3 to 44		
Significant accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date May 29, 2023

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 29, 2023

Privi Speciality Chemicals Limited

Standalone Statement of Profit and Loss

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2023	Year ended March 31, 2022
INCOME			
Revenue from operations	20	1,57,784.32	1,39,146.57
Other income	21	2,159.61	3,259.92
TOTAL INCOME (I)		1,59,943.93	1,42,406.49
EXPENSES			
Cost of materials consumed	22	1,13,322.15	97,682.64
Changes in inventories of finished goods and work-in-progress	23	(18,243.98)	(14,726.56)
Employee benefits expense	24	7,235.42	6,778.94
Finance costs	25	6,662.48	2,377.64
Depreciation and amortisation expenses	26	10,515.53	7,304.39
Power and fuel expense	27	14,713.05	9,902.17
Other expenses	28	22,612.16	19,950.80
TOTAL EXPENSES (II)		1,56,816.81	1,29,270.02
Profit before exceptional items and tax expense (I) - (II)		3,127.12	13,136.47
Exceptional items			
Exceptional income/(loss) (refer note 40)		-	529.24
Profit before tax expense		3,127.12	13,665.71
Tax expenses:			
Current tax		333.81	3,395.97
Deferred tax		545.82	103.26
Tax expense		879.63	3,499.23
Profit for the year (III)		2,247.49	10,166.48
Other comprehensive income			
Items that will not be reclassified to profit or loss Remeasurements of the net defined benefit plans		63.46	(58.67)
Income tax related to items that will not be reclassified to profit or loss		(17.85)	15.02
Total other comprehensive income / (loss) for the year net of taxes (IV)		45.61	(43.65)
Total comprehensive income for the year (III + IV)		2,293.10	10,122.83
Earnings per equity share: nominal value of share Rs.10/- each Basic and diluted (Rs.)	36	5.75	26.03
Notes to the standalone financial statements	3 to 44		
Significant accounting policies	2		

The accompanying notes forms an integral part of the standalone financial statements.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 29, 2023

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 29, 2023

Privi Speciality Chemicals Ltd. Navi Mumbai

Privi Speciality Chemicals Limited

Standalone Statement of Cash Flows

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2023	Year ended March 31, 2022
A	**Cash flow from operating activities**		
	Profit before tax after exceptional items	**3,127.12**	13,665.71
	Adjustment for:		
	Depreciation and amortisation	**9,986.50**	6,900.17
	Amortisation of right of use assets	**529.03**	404.22
	Gain on write-back of financial liabilities measured at amortised cost (refer note 21)	**(2.57)**	(158.67)
	Sundry balances written off	**-**	53.21
	Unrealised foreign exchange loss (net)	**936.28**	104.07
	Interest income	**(26.15)**	(26.53)
	Finance cost	**6,662.48**	2,377.64
	Loss / (Profit) on tangible assets sold (net)	**59.44**	(0.69)
	Profit on sales of investment (net)	**(8.88)**	(0.27)
	Allowance for expected credit loss and credit impariment	**-**	20.92
	Operating cash flow before working capital changes	**21,263.25**	23,339.78
	Movements in working capital		
	(Increase) in trade receivables	**(2,702.91)**	(4,440.36)
	(Increase) in inventories	**(18,375.47)**	(24,623.26)
	Decrease / (Increase) in other assets	**2,349.49**	(1,884.38)
	(Decrease) / Increase in trade payable	**(1,013.88)**	12,799.35
	Increase / (Decrease) in other current liabilities and provisions	**5,231.32**	(558.25)
		(14,511.45)	(18,706.90)
	Cash generated from operations	**6,751.80**	4,632.88
	Income taxes paid	**(1,282.64)**	(3,158.38)
	Net cash generated from operating activities [A]	**5,469.16**	1,474.50
B	**Cash flow from investing activities**		
	Purchase of property, plant and equipment	**(14,212.51)**	(31,636.21)
	Proceeds from sales of property, plant & equipment	**7.67**	13.57
	Purchase of investment in subsidiaries	**-**	(765.00)
	Investment in fixed deposits	**(23.53)**	(29.99)
	Realisation from fixed deposits	**122.61**	0.35
	Interest received	**25.46**	27.59
	Net cash (used in) investing activities [B]	**(14,080.30)**	(32,389.69)
C	**Cash flow from financing activities**		
	Proceeds from Non-current borrowings	**12,500.00**	10,985.17
	Repayment of Non-current borrowings	**(6,065.15)**	(3,370.02)
	Current borrowings (net)	**8,290.90**	29,326.00
	Payment of lease liabilities	**(489.31)**	(323.15)
	Dividend paid	**(781.25)**	(781.21)
	Interest paid	**(6,460.70)**	(3,407.77)
	Net cash generated from financing activities [C]	**6,994.49**	32,429.02
	Net (decrease) / increase in cash and cash equivalents (A+B+C)	**(1,616.65)**	1,513.83
	Cash and cash equivalents at the beginning of the year	**2,636.96**	1,136.42
	Exchange differences on translation of foreign currency cash and cash equivalents	**4.96**	(13.29)
	Cash and cash equivalents at end of the year (refer note 10)	**1,025.27**	2,636.96

Privi Speciality Chemicals Ltd. Navi Mumbai

Standalone Statement of Cash Flows *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

Note B : Purchase of Property, Plant and Equipment includes movements in capital work-in-progress (including capital advances) during the year.

Note C : Reconciliation of net debts

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2022	1,715.21	38,060.00	49,904.67
Loan/ lease taken during the current year	-	12,500.00	8,290.90
Repayment during the current year	-	-	(6,065.15)
Foreign exchange gain or loss	-	103.47	(40.49)
Current maturities of long term debt (refer note 13 a)	-	(10,292.98)	10,292.98
Interest accrued but not due on borrowings	-	-	177.14
Interest on lease liabilities	129.09	-	-
Payment against lease liabilities	(489.31)	-	-
Closing balance as on March 31, 2023	1,354.99	40,370.49	62,560.05

Particulars	Lease liabilities	Non current borrowings	Current borrowings
Balance as on 1 April 2021	739 56	36,621 67	14,228 16
Loan/ lease taken during the current year	1200 59	10,985 17	29,326 00
Repayment during the current year	-	(3,370 02)	-
Foreign exchange gain or loss	-	(71 18)	(21 51)
Current maturities of long term debt (refer note 13 a)	-	(6,105 64)	6,105 64
Interest accrued but not due on borrowings	-	-	266 38
Interest on lease liabilities	98.21	-	-
Payment against lease liabilities	(323 15)	-	-
Closing balance as on March 31, 2022	1,715 21	38,060 00	49,904 67

Note D : For Corporate social responsibility related spends, refer note 42

Significant accounting policies	**2**
The accompanying notes forms an integral part of the standalone financial statemer	**3 to 44**

As per our report of even date attached

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 29, 2023

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 29, 2023

Privi Speciality Chemicals Ltd. Navi Mumbai

Privi Speciality Chemicals Limited

Standalone Statement of Changes in Equity

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	As at March 31, 2023	As at March 31, 2022
Balance at the beginning of the year	3,906.27	3,906.27
Changes in equity share capital during the year	-	-
Balance at the end of the year	3,906.27	3,906.27

B. Other equity

	Reserves and Surplus			
	General reserve	Retained earnings*	Capital Reserve (refer note 12(b))	Total
Balance as at April 01, 2021	35,573.76	31,913.16	1.00	67,487.92
Profit for the year	-	10,166.48	-	10,166.48
Other comprehensive income / (loss) (net of tax)	-	(43.65)	-	(43.65)
Total comprehensive income for the year	35,573.76	42,035.99	1.00	77,610.75
Contribution and distribution to the owners				
Dividend of Rs 2.00 per share for the year ended March 31, 2021 (including dividend distribution tax) (refer note 38)	-	(781.21)	-	(781.21)
Balance as at March 31, 2022	35,573.76	41,254.78	1.00	76,829.54
Profit for the year	-	2,247.49	-	2,247.49
Other comprehensive income / (loss) (net of tax)	-	45.61	-	45.61
Total comprehensive income for the year	-	2,293.10	-	2,293.10
Contribution and distribution to the owners				
Dividend of Rs 2.00 per share for the year ended March 31, 2022 (including dividend distribution tax) (refer note 38)	-	(781.25)	-	(781.25)
Balance as at March 31, 2023	35,573.76	42,766.63	1.00	78,341.39

* The Balance arising out of remeasurement of defined plans is adjusted against the available retained earnings

Notes to the standalone financial statements 3 to 44
Significant accounting policies 2
The accompanying notes forms an integral part of the standalone financial statements.

As per our report of even date attached
For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 29, 2023

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Balani
Chairman & Managing Director
DIN: 00051162

D. B. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date : May 29, 2023

Privi Speciality Chemicals Ltd. Navi Mumbai

Privi Speciality Chemicals Limited

Notes to the Standalone Financial Statements

for the year ended March 31,2023

(Currency: Indian Rupees in Lakhs)

1 Corporate Information

Privi Speciality Chemicals Limited ('PSCL or 'the Company') incorporated on 25 May 1985 under the provisions of the Companies Act, 1956 is a public company domiciled in India. The Company was incorporated as H. K. Agro Oil Ltd. and later changed its name and style to Adi Finechem Limited. The Company is primarily engaged in the manufacture and export of aroma chemicals and in trading of chemicals. The Company's manufacturing units are located at Mahad and Jhagadia. The equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Ltd.

2 Significant accounting policies

This note provides a list of the significant accounting policies adopted by the Company in the preparation of these financial statements. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of Compliance

These Financial Statements of the Company comprising the Balance Sheet as at March 31, 2023, Statement of Profit and Loss (including other comprehensive income), Statement of Changes in Equity, and Cash Flow Statement for the year ended March 31, 2023, and a summary of significant accounting policies and other explanatory information have been prepared by the Company in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 (the 'Act'), The Audit report of statutory auditor on these standalone financial statements of the company will be addressed to the Shareholders. The standalone financial statements were authorised for issue by the Company's Board of Directors at their meetings held on May ,29 2023.

i. Basis of preparation and Presentation

Basis of Preparation

The financial statements have been prepared on a historical cost basis, except for the following assets and liabilities:

(i) Derivative Financial Instruments measured at fair value.

(ii) Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments)

(iii) Employee's Defined Benefit Plan as per actuarial valuation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

i. Basis of preparation and Presentation (Continued)

Functional and Presentation Currency

The standalone financial statements are presented in Indian Rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates. All values are rounded to the nearest lakh, unless otherwise stated.

ii. Use of estimates, judgements, and assumptions

In preparing these financial statements, management has made judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of income, expenses, assets and liabilities, Actual results may differ from these estimates and assumptions.

Estimate and underlying assumptions are reviewed on an ongoing basis. Revision to accounting estimates are recognised prospectively.

The Company has identified the following areas where significant judgements, estimates and assumptions are required. Further information on each of these areas and how they impact the various accounting policies are described below and in the relevant notes to the financial statements.

Financial reporting results rely on the estimate of the effect of certain matters that are inherently uncertain. Future events rarely develop exactly as forecast and the best estimates require adjustments, as actual results may differ from these estimates under different assumptions or conditions. Estimates and Judgments are continually evaluated and are based on historical experience and other factors, including expectation of future events that are believed to be reasonable under the circumstances. The Management believes that the estimates used in preparation of these financial statements are prudent and reasonable. Existing circumstances and assumptions about future developments, however, may change due to market changes or circumstances arising that are beyond the control of the Company. "revisions to accounting estimates are accounted for prospectively.

Judgements:

In the process of applying the Company's accounting policies, management has made the following judgements, which have the most significant effect on the amounts recognized in the financial statements.

a. Lease term, whether the Company is reasonably certain to exercise extension options – (Note 4 a)

Assumptions and estimation uncertainties

Information about judgements in applying accounting policies, as well as estimates and assumptions that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are included in the following notes:

(a) Measurement of defined benefit obligations for key actuarial assumptions - Note 31

(b) Recognition of deferred tax assets – Note 16

2. Significant accounting policies *(continued)*

iii. Current and non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is expected to be realised within 12 months after the balance sheet date; or

(d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the balance sheet date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in, the Company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is due to be settled within 12 months after the balance sheet date; or

(d) the Company does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Terms of a liability that could, at the option of the counter party, result in its settlement by issue of equity instruments do not affect its classification. Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is twelve months from the time between the acquisition of assets for processing and their realization in cash or cash equivalents.

iv. *Property, Plant and Equipment ("PPE") and depreciation*

I Recognition and Measurement

Items of Property, Plant and equipment are measured at cost including nonrefundable taxed and import duties, which also includes capitalized borrowing costs less accumulated depreciation and any accumulated impairment losses. The cost of property, plant and equipment certain items of the property, plant, and equipment as of 1st January 2005. The Company's date of transition to the standards was determined with the reference to its fair value at the date.

If significant parts of an item of property, plant and equipment have different useful lives, then they are accounted for as separate items (major components) of Property, Plant and equipment Any Gain or loss on disposal of an item of Property, Plant and equipment is recognized in profit or loss.

2. Significant accounting policies *(continued)*

iv. ***Property, Plant and Equipment ("PPE") and depreciation (continued)***

II Subsequent Expenditure

Subsequent Expenditure is capitalized only if it is probable that the future economic benefits flow to the associated with the Expenditure will flow to the entity.

Depreciation and amortization

Depreciation is calculated using the straight-line method to allocate cost of property plant and equipment, net of residual values, over their estimated useful lives as per the useful life prescribed in schedule II of the Companies Act, 2013 except in case of the following class of assets where the useful life is based on technical evaluation of the management:

Fixtures in leasehold premises are amortized over the primary period of the lease or useful life of the fixtures, whichever is lower.

Asset Class	Estimated useful life (in Years)
Building	33
Plant and Machinery	10
Electrical installation	10
Laboratory equipment's	10
Furniture & Fixtures	16
Office Equipment	10
Leasehold Improvement	15
Vehicle	10
Computer	6

Depreciation on additions / deletions during the year is provided from the date in which the asset is ready to use to the date in which the asset is disposed of.

The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets required under finance leases are depreciated over the shorter of the lease term and their useful lives (not being greater than the useful life envisaged in Schedule II of Companies Act, 2013) unless it is reasonably certain that Company will obtain ownership by the end of lease term, in which case the depreciation rates applicable for similar assets owned by the Company are applied.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amount. These are included in profit or loss within other gains/(losses).

v. ***Intangible assets and amortisation***

Intangible assets with finite useful life are stated at cost of acquisition, less accumulated depreciation/ amortisation and impairment loss, if any. Cost includes taxes, duties and other incidental expenses related to acquisition and other incidental expenses.

2. Significant accounting policies *(continued)*

v. Intangible assets and amortization (continued)

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

Asset Class	Estimated useful life (in Years)
Computers Soft wares	3 to 6 Years
Rights of Sale of Products	5 Years
Development Rights	5 Years

About internally generated intangible assets:

Expenditure on research activities, undertaken with the prospect of development of new products or gaining new technical knowledge and understanding, is recognised in profit or loss as incurred.

Capital expenditure on research and development is capitalized and depreciated as per accounting policy mentioned above. Revenue expenditure is charged off in the year in which it is incurred.

Development activities involve a plan or design for the production of new or substantially improved products or processes. Development expenditure is capitalised only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalised includes the cost of materials, direct labour, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of tangible fixed assets). Other development expenditure is recognised in profit or loss as incurred.

Intangible assets are amortised in profit or loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the asset.

Gains or losses arising from derecognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit or loss when the asset is derecognised.

vi. Impairment of Non-financial assets

At each reporting date, the Company reviews the carrying amounts of its non-financial assets (other than biological assets. investment property, inventories, contract assets and deferred tax assets to determine whether there is any indication of impairment nt. If any such indication exists, then the asset's referable amount is estimated. Goodwill is tested annually for impairment.

For impairment testing, assets are grouped together into the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows of other assets or CGUs. Goodwill arising from a business combination is allocated to CGUs or group of CGUs that are expected to benefit from the synergies of the combination.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd. Navi Mumbai

2. Significant accounting policies *(continued)*

vi. Impairment of Non-financial assets (continued)

The recoverable amount of an asset or CGU is the greater of its value in use and its fair value Jess costs to sell. Value in use is based on the estimated future cash flows, discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU.

An impairment loss is recognized if the carrying amount of an asset or CGU exceeds its Recoverable amount.

Impairment losses are recognized in profit or loss. They are allocated first to reduce the carrying amount of any goodwill allocated to the CGU, and then to reduce the carrying amounts of the other assets in the CGU on a pro rata basis.

An impairment loss in respect of goodwill is not reversed. For other assets, an impairment loss is reversed only to the extent that the asset's carrying a mount does not exceed the carrying amount that would have been determined, net of depreciation or amortization. if no impairment loss had been recognized.

vii. Borrowing costs

Borrowing costs are interest and other costs that the Company incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing. Borrowing costs include interest costs measured at EIR amortization of discounts, hedge related cost incurred in connection with foreign currency borrowings, ancillary costs incurred in connection with borrowing of funds and exchange differences arising from foreign currency borrowings (other than long term foreign currency borrowings) to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction / development of the qualifying asset up to the date of capitalisation of such asset are added to the cost of the assets. Capitalisation of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognised as an expense in the period which they are incurred.

viii. *Foreign currency transactions*

Transactions denominated in foreign currency are recorded at the exchange rate prevailing on the date of transactions. Exchange differences arising on foreign exchange transactions settled during the year are recognized in the Statement of profit and loss of the year.

Monetary assets and liabilities in foreign currency, which are outstanding as at the balance sheet date are translated at the year-end at the closing exchange rate and the resultant exchange differences are recognized in the statement of profit and loss.

2. Significant accounting policies *(continued)*

viii. *Foreign currency transactions*

Foreign exchange differences regarded as an adjustment to borrowing costs are presented in the statement of profit and loss, within finance costs. All other foreign exchange gains and losses are presented in the statement of profit and loss on a net basis within other incomes/expenses.

ix. Financial Instruments

a. Financial assets

Initial Recognition and Measurement

All financial assets are recognized initially at fair value, plus in the case of financial assets not recorded at fair value through profit or loss (FVTPL), transaction costs that are attributable to the acquisition of the financial asset, However, trade receivables that do not contain a significant financing component are measured at transaction price.

Revenue Recognition

Revenue towards satisfaction of a performance obligation is measured at the amount of transaction price (net of variable consideration) allocated to that performance obligation. The transaction price of goods sold, and services rendered is net of variable consideration on account of various discounts and schemes offered by the Company as part of the contract

Classification and subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortised cost

A financial asset is classified as subsequently measured at the amortised cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

The losses arising from impairment are recognised in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through Other Comprehensive Income ("FVTOCI")

A financial asset is classified as subsequently measured at fair value through Other Comprehensive Income if both the following conditions are met:

- The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

2. Significant accounting policies *(continued)*

ix. ***Financial Instruments (continued)***

a. Financial assets *(continued)*

Financial assets included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in other comprehensive income (OCI). However, the Company recognizes interest income,

impairment losses & reversals and foreign exchange gain or loss in the P&L. On derecognition of the asset, cumulative gain or loss previously recognised in OCI is reclassified from equity to P&L. The Company did not have any financial assets at FVTOCI during the current year as well as previous year.

Financial assets at fair value through Profit and loss ("FVTPL")

Financial assets at FVTPL are a residual category for financial assets. Any financial assets which do not meet the criteria of categorizing it at amortised cost or at FVTOCI is classified as at FVTPL.

Financial assets included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a Company of similar financial assets) is primarily derecognised (i.e., removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.
- When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset, the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

  Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

BSR & Co. Chartered Accountants

Privi Speciality Chemicals Ltd. Navi Mumbai

2. Significant accounting policies *(continued)*

ix. Financial Instruments (continued)

a. Financial assets *(continued)*

Impairment of Financial Assets

In view of its past experience of having insignificant impairment bad debts / write-offs and based on management's estimate considering its portfolio of customers, this trend would continue for the foreseeable future, the Company has determined that significant impairment of Financial assets is not required to be recognised based on Expected Credit Loss model.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at amortised cost and financial liabilities at FVTPL. Derivative liabilities are classified as FVTPL. All financial liabilities are recognised initially at fair value. The Company's financial liabilities include trade and other payables, loans and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes derivative financial instruments entered by the Company that are not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognised in the profit or loss. Except derivative instruments, the Company has not designated any financial liability as at FVTPL.

Financial liabilities at amortised cost

All financial liabilities except for derivatives are classified as measured at amortised cost. This category includes bank and other borrowings, trade payables and other financial liabilities.

De-recognition

A financial liability is derecognised when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the derecognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognised in the statement of profit or loss.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

ix. Financial Instruments (continued)

c. Offsetting of Financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognised amounts and there is an intention to settle on a net basis, to realise the assets and settle the liabilities simultaneously.

Business Model Assessment

Financial assets -Business model assessment

The Company makes an assessment of the objective of the business model in which a financial asset is held at a portfolio level because this best reflects the way the business is managed, and information is provided to management. The information considered includes:

the stated policies and objectives for the portfolio and the operation of those policies in practice. These include whether management's strategy focuses on earning contractual interest income, maintaining a particular interest rate profile, matching the duration of the financial assets to the duration of any related liabilities, or expected cash outflows or realizing cash flows through the sale of the assets.

- how the performance of the portfolio is evaluated and reported to the Company's management.
- the risks that affect the performance of the business model (and the financial assets held within that business model) and how those risks are managed.
- how managers of the business are compensated- e.g., whether compensation is based on the fair value of the assets managed, or the contractual cash flows collected, and the frequency, volume and timing of sales of financial assets in prior periods, the reasons for such sales and expectations about future sales activity.

Transfers of financial assets to third parties in transactions that do not qualify for derecognition are not considered sales for this purpose, consistent with the Company's continuing recognition of the assets.

Financial Assets that are held for trading or are managed and whose performance I evaluated on a fair value basis are measured at FVTPL.

d. Derivatives

Initial recognition and subsequent measurement The Company uses derivative financial instruments, such as forward currency contracts, interest rate swaps and currency SWAPS, to hedge its foreign currency risks, interest rate risks and its long term loans, respectively.Such derivative financial instruments are initially recognised at fair value on the date on which a derivative contract is entered into and are subsequently re-measured at fair value. Derivatives are carried as financial assets when the fair value is positive and as financial liabilities when the fair value is negative.The purchase contracts that meet the definition of a derivative under Ind-AS 109 are recognised in the Statement of Profit and Loss.

2. Significant accounting policies *(continued)*

x. Segment Reporting

The Chief Operational Decision Maker (CODM) monitors the operating results of its business Segments separately for the purpose of making decisions about resource allocation and performance assessment. Segment performance is evaluated based on

profit and loss and is measured consistently with profit or loss in the consolidated financial statements. Operating segments have been identified on the basis of nature of

products / services. The Accounting Policies adopted for segment reporting are in line with the Accounting Policies of the Company. Segment assets include all operating assets used by the business segments and consist principally of fixed assets, trade receivables and inventories. Segment liabilities include the operating liabilities that result from the operating activities of the business. Segment assets and liabilities that cannot be allocated between the segments are shown as part of unallocated corporate assets and liabilities respectively. Income / Expenses relating to the enterprise as a whole and not allocable on a reasonable basis to business segments are reflected as unallocated corporate income / expenses.

xi. Cash flows

Cash flows are reported using the indirect method, whereby profit / (loss) before extraordinary items and tax is adjusted for the effects of transactions of non-cash nature and any deferrals or accruals of past or future cash receipts or payments and item of income or expenses associated with investing or financing cash flow. The cash flows from operating, investing and financing activities of the Company are segregated based on available information.

xii. Cash and Cash equivalents

Cash and cash equivalent in the balance sheet and for the statement cash flow comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

xiii. Investment in subsidiaries and joint ventures

Investment in subsidiary companies and joint venture companies are carried at cost less accumulated impairment losses, if any. Whare an indication of impairment exists, the carrying amount of the investment is assessed and written down immediately to its recoverable amount. On disposal of investments in subsidiary companies and joint venture companies, the difference between net disposal proceeds and the carrying amount are recognised in the statement of Profit and Loss.

xiv. Leases

The Company has adopted Ind AS 116 effective from April 01 2019 using modified retrospective approach. For the purpose of preparation of Standalone Financial Information, management has evaluated the impact of change in accounting policies required due to adoption of Ind AS 116 for year ended March 31, 2023.

BSR & Co. Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xiv. Leases (continued)

The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified assets, the Company assesses whether: (i) the contact involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

As a lessee, the Company recognises a right-of-use asset and a lease liability at the lease commencement date. The right of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. The estimated useful lives of right-of-use assets are determined on the same basis as those of property and equipment. In

addition, the right-of-use asset is periodically reduced by impairment losses, if any, and adjusted for certain remeasurements of the lease liability.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. Generally, the Company uses its incremental borrowing rate as the discount rate.

Lease payments included in the measurement of the lease liability comprise the fixed payments, including in-substance fixed payments.

The lease liability is measured at amortised cost using the effective interest method.

The Company has used number of practical expedients when applying Ind AS 116: - Short-term leases, leases of low-value assets and single discount rate.

The Company has elected not to recognise right-of-use assets and lease liabilities for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Company recognises the lease payments associated with these leases as an expense on a straight-line basis over the lease term. The Company applied a single discount rate to a portfolio of leases of similar assets in similar economic environment with a similar end date.

The Company's leases primarily comprise land and buildings and Plant and equipment. The Company leases land and buildings for warehouse facilities.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd. Navi Mumbai

2. Significant accounting policies *(continued)*

xv. Inventories

Inventories include raw materials, packing materials, fuel, consumable stores and spares and manufactured inventory. Inventory is valued at the lower of cost and net realisable value.

Cost comprises the purchase price, costs of conversion and other related costs incurred in bringing the inventories to their present location and condition. Cost of raw materials, packing materials, fuel, consumable, stores and spares are determined on the basis of Periodic moving weighted average method. Cost of finished goods and work in progress are determined using the absorption costing principle. Cost includes the cost of material consumed, labour and appropriate proportion of costs of conversion which include variable and fixed overheads.

Obsolete, defective, and unserviceable inventories are duly provided for. The comparison of cost and net realisable value is made on an item-to-item basis. Net realisable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

xvi. Revenue Recognition

Revenue recognition Revenue from contracts with customers is recognised when control of the goods or services are transferred to the customer i.e., when the customer is able to direct the use of the transferred goods or rendering of services and obtains substantially.

all of the remaining benefits at an amount that reflects the consideration entitled in exchange for those goods or services. The policy of recognizing the revenue is determined according to Ind AS 115 "Revenue from contracts with customers".

Sale of Goods: Revenue is recognised upon transfer of control of promised goods to customers for an amount that reflects the consideration which the Company expects to receive in exchange for those goods. Revenue from the sale of goods is recognised at the point in time when control is transferred to the customer which is usually on dispatch/ delivery of goods, based on contracts with the customers. Revenue is measured based on the transaction price, which is the consideration, adjusted for volume discounts, price concessions, incentives, and returns, if any, as specified in the contracts with the customers. Revenue excludes taxes collected from customers on behalf of the government. Accruals for discounts/incentives and returns are estimated (using the most likely method) based on accumulated experience and underlying schemes and agreements with customers. Due to the short nature of credit period given to customers, there is no financing component in the contract.

Insurance

Income in respect of Insurance and other claim is recognized only on reasonable certainty of ultimate collection. as per the requirement of the accounting standards.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortised cost.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xvi. Revenue Recognition (continued)

Dividend Income

Dividend income is recognised when the right to receive payment is established.

Export incentive

An export incentive is recognised in the statement of profit and loss when the right to receive credit as per the terms of the scheme is established in respect of export made, and there is no uncertainty as to its receipt.

xvii. Employee Benefits

Short Term Employee Benefits

Employee benefits payable wholly within twelve months of receiving employee services are classified as short-term employee benefits. These benefits include salaries and wages, bonus, ex-gratia etc. These are recognised as an expense at an undiscounted amount in the Statement of Profit and Loss of the year in which the related service is rendered.

Post-employment Benefits

(i) Provident Fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's.

contribution is recognised as an expense in the statement of profit and loss during the period in which the employee renders the related service.

(ii) Gratuity

The Company's gratuity benefit scheme is a defined benefit plan. The Company`s net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary usingthe projected unit credit method. Remeasurements of the net defined benefit liability, which comprise actuarial gains and losses, the return on plan assets (excluding interest) and the effect of the assets ceiling (if any, excluding interest), are recognised in OCI. All expenses related to defined benefit plan are recognised in employee benefits expense in the Statement of Profit and Loss.

(iii) Compensated Absences

The Company provides for encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/ availment. The Company makes provision for compensated absences based on an independent external actuarial valuation carried out at the end of the year.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xviii. Taxation

Income tax expense comprises current tax and deferred tax charge or credit.

Current Income Tax

Provision for current tax is determined as the amount of tax payable in respect of taxable income for the year in accordance with the provisions of the Income Tax Act, 1961.Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the enacted or substantively enacted tax rates and tax laws. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

"Current tax is recognised in statement of profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current tax is also recognised in other comprehensive income or directly in equity respectively. "

"Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate."

On March 30, 2019, MCA has issued amendment regarding the income tax Uncertainty over Income Tax Treatments. The notification clarifies the recognition and measurement requirements when there is uncertainty over income tax treatments. In assessing the uncertainty, an entity shall consider whether it is probable that a taxation authority will accept the uncertain tax treatment. This notification is effective for annual reporting periods beginning on or after April 1, 2019. As per the Company's assessment, there are no material income tax uncertainties over income tax treatments.

Current tax assets and current tax liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to income taxes levied by the same tax authority, but they intend to settle current tax liabilities and assets on a net basis, or their tax assets and liabilities will be realized simultaneously.

Current Tax is recognised in profit or loss except to the extent that it relates to a business combination or to an item recognised directly in equity or in other comprehensive income.

Deferred Tax

Deferred tax is recognized in respect of temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognised for all taxable temporary differences.

Deferred tax assets are recognised for all deductible temporary differences, the carry forward of unused tax credits and any unused tax losses. Deferred tax assets are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences, and the carry forward of unused tax credits and unused tax losses can be utilized.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xviii. Taxation (continued)

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilised. unrecognised deferred tax assets are re-assessed at each reporting date and are recognised to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realised or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognised outside profit or loss is recognised either in other comprehensive income or in equity. Deferred tax items are recognised in correlation to the underlying transaction either in OCI or directly in equity.

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum Alternative tax ('MAT') under the provisions of the Income tax Act, 1961 is recognized as current tax in the Statement of Profit and loss. The credit available under the Act in respect of MAT paid is recognized as an asset only when and to the extent it is probable that the Company will pay normal income tax during the year for which the MAT credit can be carried forward for set-off against the normal tax liability. MAT credit recognized as an asset is reviewed at each balance sheet date and written down to the extent the aforesaid convincing evidence no longer exists.

xix. Earnings per share

Basic earnings per share are calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share are the net profit for the year attributable to equity shareholders.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares, except where the results would be anti-dilutive.

xx. Provisions and contingent liabilities

Provisions are recognised when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognised as a finance cost.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xx. Provisions and contingent liabilities (continued)

Provision in respect of loss contingencies relating to claims litigation, assessment, fines, penalties etc. are recognized when it is probable that a liability has been incurred, and the amount can be estimated reliably.

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, probably will not, require an outflow of resources embodying economic benefits, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the standalone financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic resources embodying economic benefits will arise, related income are recognized in the year in which the change occurs.

xxi. Fair value measurement

The Company measures financial instruments, such as, derivatives at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement

date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

xxii. Estimation of uncertainties relating to the global health pandemic from COVID-19:

The Global pandemic Covid-19 continues. The business of the Company was not affected for the year ended March 31,2023 and impact is insignificant.

Having reviewed the underlying data and based on current estimates the Company expects the carrying amount of assets will be recovered and there is no significant impact on liabilities accrued. The impact of COVID-19 on the Company's standalone financial statements may differ from that estimated as at the date of approval of these standalone financial statements and the Company will continue to closely monitor any material changes to future economic conditions.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

2. Significant accounting policies *(continued)*

xxii. Recent accounting pronouncements: -

Ministry of Corporate Affairs (MCA), on 31 March 2023, through the Companies (Indian Accounting Standards (Ind AS)) Amendment Rules, 2023 amended certain existing Ind ASs on miscellaneous issues with effect from 1 April 2023. Following are few key amendments relevant to the Company:

i. Ind AS 1 – Presentation of Financial Statements & Ind AS 34 – Interim Financial Reporting – Material accounting policy information (including focus on how an entity applied the requirements of Ind AS) shall be disclosed instead of significant accounting policies as part of financial statements.
ii. Ind AS 107 – Financial Instruments: Disclosures – Information about the measurement basis for financial instruments shall be disclosed as part of material accounting policy information.
iii. Ind AS 8 – Accounting policies, changes in accounting estimate and errors- Clarification on what constitutes an accounting estimate provided.
iv. Ind AS 12 – Income Taxes – This amendment has narrowed the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offsetting temporary differences.
The Company does not expect the effect of this on the financial statements to be material, based on preliminary evaluation.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2023

(Currency: Indian Rupees in lakhs)

3 Property, plant and equipment

Description	Gross carrying amount				Accumulated Depreciation				Net carrying amount
	As at April 01, 2022	Addition during the year	Disposal during the year	As at March 31, 2023	As at April 01, 2022	Depreciation for the year	Disposal during the year	As at March 31, 2023	As at March 31, 2023
At cost :									
Building	17,714.20	7,361.00	-	25,075.20	2,205.13	710.50	-	2,915.63	22,159.57
Leasehold Improvement	547.20	18.00	-	565.20	514.91	1.43	-	516.34	48.86
Plant and equipment	76,467.75	29,409.92	-	1,05,877.67	33,935.32	8,051.03	-	41,986.35	63,891.32
Electrical installation	4,071.23	3,487.06	-	7,558.29	1,893.43	524.37	-	2,417.80	5,140.49
Furniture and fittings	123.08	144.84	-	267.92	56.53	12.04	-	68.57	199.35
Office equipment	400.54	66.04	-	466.58	175.99	32.25	-	208.24	258.34
Computers	1,149.81	35.70	-	1,185.51	521.54	144.25	-	665.79	519.72
Laboratory equipments	1,778.72	91.88	-	1,870.60	688.78	141.58	-	830.36	1,040.24
Vehicles	596.38	20.10	119.53	496.95	197.40	52.87	52.42	197.85	299.10
	1,02,848.91	40,634.54	119.53	1,43,363.92	40,189.03	9,670.32	52.42	-9,806.93	93,555.99
Capital work -in- progress	36,118.43	13,337.48	40,634.54	8,821.37	-	-	-	-	8,821.37
	1,38,967.34	53,972.02	40,754.07	1,52,185.29	40,189.03	9,670.32	52.42	-9,806.93	1,02,377.36

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2023

(Currency: Indian Rupees in lakhs)

a) The net carrying amount of property, plant and equipment amounting to Rs. 93,556.99 lakhs (March 31, 2022 : Rs 62,659.88 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans.

b) The Plant and equipment, Building and Electrical Installation includes an amount of Rs 1,004.41 lakhs, Rs. 269.29 lakhs and Rs. 99.75 lakhs respectively (March 31, 2022 : Rs 381.30 lakhs, Rs. 87.84 lakhs and Rs 20.81 lakhs) that represent borrowing cost capitalized @ 6.75% to 9.50% during the year.(March 31, 2022 : 6.75%).

c) The Company has not recognised any impairment loss during the current year (March 31, 2022 : Nil).

d) The title deeds of property plant and equiments are held in name of the Company.

Ageing for capital work-in-progress as at March 31, 2023 is as follows :

Description	Amount in Capital work-in-progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	8,495.24	326.13	-	-	8,821.37
Projects temporarily suspended	-	-	-	-	-
	8,495.24	326.13	-	-	8,821.37

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan.

Ageing for capital-work-in progress, whose completion is overdue as at March 31, 2023 is as follows:

Description	Amount in Capital-work-in progress to be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Hydrogen Generation	1,636.30	-	-	-	1,636.30
	1,636.30	-	-	-	1,636.30

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2023

(Currency: Indian Rupees in lakhs)

3 Property, plant and equipment *(Continued)*

Description	Gross carrying amount				Accumulated Depreciation				Net carrying amount
	As at April 01, 2021	Addition during the year	Disposal during the year	As at March 31, 2022	As at April 01, 2021	Depreciation for the year	Disposal during the year	As at March 31, 2022	As at March 31, 2022
At cost :									
Building	15,047.70	2,666.50	-	17,714.20	1,689.37	515.76	-	2,205.13	15,509.07
Leasehold Improvement	547.20	-	-	547.20	501.74	13.17	-	514.91	32.29
Plant and equipment	65,155.69	11,328.28	16.22	76,467.75	28,405.04	5,533.62	3.34	33,935.32	42,532.43
Electrical installation	3,488.98	582.25	-	4,071.23	1,595.78	297.65	-	893.43	2,177.80
Furniture and fixtures	111.51	11.57	-	123.08	51.47	5.06	-	56.53	66.55
Office equipment	388.12	12.42	-	400.54	144.71	31.28	-	175.99	224.55
Computers	960.66	243.84	54.69	1,149.81	403.51	126.90	8.87	521.54	628.27
Laboratory equipments	1,188.56	590.16	-	1,778.72	599.58	89.20	-	688.78	1,089.94
Vehicles	596.38	-	-	596.38	143.74	53.66	-	197.40	398.98
	87,484.80	15,435.02	70.91	1,02,848.91	33,534.94	6,666.30	12.21	40,189.03	62,659.88
Capital work -in- progress	17,444.95	34,108.50	15,435.02	36,118.43	-	-	-	-	36,118.43
	1,04,929.75	49,543.52	15,505.93	1,38,967.34	33,534.94	6,666.30	12.21	40,189.03	98,778.31

a) The net carrying amount of property, plant and equipment, amounting to Rs. 62,659.88 lakhs (March 31, 2021: Rs 53,949.86 lakhs) are pledged as first charge security to banks providing term loans and second charge to banks providing working capital loans.

b) The Plant and machinery, Building and electrical installation includes an amount of Rs.381.30 lakhs, Rs. 87.84 lakhs and Rs. 20.81 lakhs respectively (March 31, 2021 : Rs.53.21 lakhs, Rs. 21.58 lakhs and Rs. 2.54 lakhs) that represent borrowing cost capitalized @ 6.75% during the year.(March 31, 2021 : 6.75%)

c) The Company has not recognised any impairment loss during the current year (March 31, 2021 : Nil).

d) The title deeds of property plant and equiments are held in name of the Company

Ageing for capital work-in-progress as at March 31, 2022 is as follows:

Description	Amount in Capital-work-in progress for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	34,498.25	1,620.18	-	-	36,118.43
Projects temporarily suspended	-	-	-	-	-
	34,498.25	1,620.18	-	-	36,118.43

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan

Ageing for capital-work-in progress, whose completion is overdue as at March 31, 2022 is as follows :

Description	Amount in Capital-work-in progress to be completed in				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Capital Warehousing	1,262.03		-	-	1,262.03
GalaxMusk	14,715.09				14,715.09
Camphor	11,203.08				11,203.08
	27,180.20	-	-	-	**27,180.20**

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

4 a Right of use assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2022	Addition during the year	Disposal during the year	As at March 31, 2023	As at April 01, 2022	Amortisation for the year	Disposal during the year	As at March 31, 2023	As at March 31, 2023
Land	3,272.97	802.62	85.18	3,990.41	626.77	308.58	7.66	927.69	3,062.72
Building	1,006.13	-	-	1,006.13	245.08	220.45	-	465.53	540.60
Plant and Machinery	67.00		-	67.00	63.64	-	-	63.64	3.36
Total right of use assets	4,346.10	802.62	85.18	5,063.54	935.49	529.03	7.66	1,456.86	3,606.68

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.

The Company has not recognised any impairment loss during the current year (March 31, 2022 - Nil).

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2021	Addition during the year	Disposal during the year	As at March 31, 2022	As at April 01, 2021	Amortisation for the year	Disposal during the year	As at March 31, 2022	As at March 31, 2022
Land	2,150.46	1,167.37	44.86	3,272.97	451.73	219.90	44.86	626.77	2,646.20
Building	419.01	767.50	180.38	1,006.13	244.74	180.72	180.38	245.08	761.05
Plant and Machinery	67.00		-	67.00	60.04	3.60	-	63.64	3.36
Total right of use assets	2,636.47	1,934.87	225.24	4,346.10	756.51	404.22	225.24	935.49	3,410.61

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.

The Company has not recognised any impairment loss during the current year (March 31, 2021 - Nil).

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

i) The Company has taken land on lease for a non-cancellable period ranging 3 to 99 years, Building on lease for a tenure ranging from 3-5 years and plant and machinery for 10 years.
The Company leases with contract term of less than 1 year. These leases are short term and/or leases of low value items. The company has elected not to recognise right of use assets and lease liabilities of these assets.

ii) Lease expenses recognized in statement of profit and loss not included in the measurement of lease liabilities:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Variable lease payments	-	-
Expenses relating to short-term leases	-	-
Interest cost lease labilities	129.09	98.21
Expenses relating to leases of low-value assets, excluding short-term leases of low value assets	-	-

iii) Maturity analysis of lease liabilities– contractual undiscounted cash flows:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Less than one year	461.80	492.90
One to five years	1,341.04	1,688.83
More than five years	-	-
Total undiscounted lease liabilities	1,802.84	2,181.73
Discounted lease linbilities included in the statement of financial position	1,354.99	1,715.21
Current lease labilities	360.22	424.80
Non-current lease labilities	994.77	1,290.41

iv) The weighted average incremental borrowing rate of 6.25% (March 31, 2022 : 6.25% p.a.) has been applied for measuring the lease liability.

v) The total cash outflow for leases for year ended March 31, 2023 is Rs. 489.31 lakhs (March 31, 2022 : Rs. 323.15 lakhs.)

vi) Income from sub leasing of Right to use assets is Rs. NIL. (March 31, 2022 : Rs. NIL)

BSR & Co. LLP

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

4 b Other Intangible assets

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2022	Addition during the year	Disposal during the year	As at March 31, 2023	As at April 01, 2022	Amortisation for the year	Disposal during the year	As at March 31, 2023	As at March 31, 2023
Computer softwares	480.69	778.51	-	1,259.20	455.63	131.10	-	586.73	672.47
Rights of sale of products	1,318.14	69.10	-	1,387.24	889.80	168.84	-	1,058.64	328.60
Development rights	265.65	-	-	265.65	233.20	16.24	-	249.44	16.21
Total intangible assets	2,064.48	847.61	-	2,912.09	1,578.63	316.18	-	1,894.81	1,017.28
Intangible assets under development	855.54	479.14	847.61	487.07	-	-	-	-	487.07
	2,920.02	1,326.75	847.61	3,399.16	1,578.63	316.18	-	1,894.81	1,504.35

Ageing for intangible assets under development as at March 31, 2023 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	479.14	7.93	-	-	487.07
Projects temporarily suspended	-	-	-	-	-
	479.14	7.93	-	-	487.07

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

4 b Other Intangible assets *(Continued)*

Description	Gross carrying amount				Accumulated Amortisation				Net carrying amount
	As at April 01, 2021	Addition during the year	Disposal during the year	As at March 31, 2022	As at April 01, 2021	Amortisation for the year	Disposal during the year	As at March 31, 2022	As at March 31, 2022
Computer softwares	480.69	-	-	480.69	448.09	7.54	-	455.63	25.06
Rights of sale of products	1,240.42	77.72	-	1,318.14	679.71	210.09	-	889.80	428.34
Development rights	265.65	-	-	265.65	216.96	16.24	-	233.20	32.45
Total intangible assets	1,986.76	77.72	-	2,064.48	1,344.76	233.87	-	1,578.63	485.85
Intangible assets under development	63.89	933.26	141.61	855.54	63.89	-	63.89	-	855.54
	2,050.65	1,010.98	141.61	2,920.02	1,408.65	233.87	63.89	1,578.63	1,341.39

Ageing for intangible assets under development as at March 31, 2022 is as follows :

Description	Amount in intangible assets under development for the period of				Total
	Less than 1 year	1-2 years	2-3 years	More than 3 years	
Projects in progress	855.54	-	-	-	855.54
Projects temporarily suspended	-	-	-	-	-
	855.54	-	-	-	**855.54**

Project execution plans are modulated basis capacity requirement assessment on an annual basis and all the projects are executed as per rolling annual plan.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

5 Investments

Unquoted

	As at March 31, 2023		As at March 31, 2022	
	Number of shares	Amount	Number of shares	Amount
Investments measured at Cost:				
Equity Instruments:				
Subsidiaries:				
Face value of Rs. 10 each fully paid:				
Privi Biotechnologies Private Limited	36,274,728	4,271.70	36,274,728	4,271.70
Face value of USD 1 each fully paid:				
Privi Speciality Chemicals USA Corporation	50,100	30.61	50,100	30.61
Face value of Rs. 10 each fully paid:				
Prigiv Specialties Private Limited	7,650,000	765.00	7,650,000	765.00
Face value of Rs. 10 each fully paid:				
Total		5,067.31		5,067.31
Aggregate amount of unquoted investments		5,067.31		5,067.31
Aggregate amount of impairment in value of investments		-		-

6 Other financial assets

	Non-current portion		Current portion	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Security deposits *	1,496.78	1,323.73	-	-
Investments in term deposits (with remaining maturity of more than twelve months) **	0.57	66.04	-	-
Insurance claim receivable			9.84	1,320.51
	1,497.35	1,389.77	9.84	1,320.51

* An amount of Rs. 376 lakhs (March 31, 2022 : Rs. 376 lakhs) due from director, other officer of the Company or firms in which any director is a partner or private companies in which any director is a director or member at anytime during the reporting period (refer note 30 and below table)

Particulars	As at March 31, 2023	As at March 31, 2022
Privi Biotechnologies Private Limited	25.00	25.00
Money Mart Securities Private Limited	300.00	300.00
MM Infra & Leasing Private Limited	51.00	51.00
Total	376.00	376.00

** Note : Term deposits with no lien amounting to Rs.0.57 lakhs (March 31, 2022: Rs 66.04 lakhs) against which bank guarantee given to statutory authorities and vendors.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

7 Other non-current assets

	Non-current portion		Current portion	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Capital advances*				
Considered good	647.78	1,510.19	-	-
Considered doubtful	36.15	36.15	-	-
Less: Allowance for doubtful advances	(36.15)	(36.15)	-	-
	647.78	1,510.19	-	-
Advances other than capital advances				
Deposits with custom authorities	6.00	6.00	-	-
Prepaid expenses	48.85	73.83	1,092.05	1,280.40
Receivable from government authorities	2,390.67	106.24	5,262.10	7,274.58
Advances to employees	-	-	12.82	12.48
Advance for supply of goods and services*	-	-	1,195.40	2,400.76
Less: Allowance for doubtful advances	-	-	(160.00)	(160.00)
	3,093.30	1,696.26	7,402.37	10,808.22

*An amount of Rs.136.37 lakhs (March 31, 2022 : Rs. 897.50 lakhs) due from director, other officer of the Company or firms in which any director is a partner or private companies in which any director is a director or member at anytime during the reporting period . (refer note 30 and below table)

Particulars	Nature of transaction	As at March 31, 2023	As at March 31, 2022
Privi Speciality Chemicals USA Corporation	Advance for supply of goods and services	136.38	166.50
MM Infra & Leasing Private Limited *	Capital advances	-	731.00
Total		136.38	897.50

* Consequent to the scheme of merger passed by NCLT vide their order dated October 13, 2021, Mina Organics Private Limited and Vivita Chemicals Private Limited are merged with MM Infra & Leasing Private Limited. Accordingly, the related capital advances of Rs. 225 lakhs and Rs. 175 lakhs respectively has been transferred to MM Infra & Leasing Private Limited.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

	As at March 31, 2023	As at March 31, 2022
8 Inventories		
(valued at lower of cost and net realisable value)		
Raw materials including goods in transit Rs.7,764.63 lakhs (March 31,2022 : Rs. 9,741.49 lakhs)	19,655.08	19,639.62
Finished goods including goods in transit Rs. 9,997.30 lakhs (March 31, 2022 : Rs. 10,206.11 lakhs)	25,948.48	17,283.55
Work-in-progress	27,752.09	18,173.04
Stores and spares	680.55	597.15
Packing material	119.71	105.26
Fuel	340.34	322.16
	74,496.25	56,120.78

i) During the year ended March 31, 2023 : Rs. 270.89 lakhs (March 31, 2022: Rs. 33.19 lakhs) was recognised as an expense for inventories carried at net realisable value.

ii) The mode of valuation of inventories has been stated in note 2 xv of significant accouting policies.
iii) Bank overdrafts, cash credit and short-term loan from bank facility are secured by first paripassu charge on inventories (including raw material, finished goods and work-in-progress) and book debts (refer note 9 and 14).

9 Trade receivables		
Trade receivables considered good- Secured		
Dues from related parties (refer note 30)	8,621.50	6,737.56
Dues from others (Other than related party)	22,827.29	21,684.16
Trade receivables credit impaired (Other than related party)	27.84	27.84
Less: Allowance for expected credit loss and credit impariment	(27.84)	(27.84)
	31,448.79	28,421.72

Refer note 33 for information about credit risk and market risk of trade receivables.

The movement in allowance for expected credit loss and credit impariment of receivable is as follows:

Balance as at beginning of the year	27.84	10.86
Allowance for expected credit loss and credit impariment	-	20.92
Allowance for expected credit loss written off during the year	-	(3.94)
Balance as at the end of the year	27.84	27.84

Trade receivables ageing as at March 31, 2023 based on due date

Particulars	Less than 6 months	6 months - 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered good	31,175.03	250.93	22.83	-	-	31,448.79
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed trade receivables-credit impaired	-	-	-	22.45	-	22.45
(iv) Disputed trade receivables-considered good	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed trade receivables-credit impaired	-	-	-	-	5.39	5.39
	31,175.03	250.93	22.83	22.45	5.39	31,476.63
Less:-						
Allowance for doubtful trade receivables	-	-	-	22.45	5.39	27.84
	31,175.03	250.93	22.83	-	-	31,448.79

Notes to the Standalone Financial Statements *(Continued)*
as at March 31, 2023

(Currency: Indian Rupees in lakhs)

9 Trade receivables (continued)

Trade receivables ageing as at March 31, 2022 based on due date

Particulars	Less than 6	6 months- 1 year	1-2 years	2-3 years	More than 3 years	Total
(i) Undisputed trade receivables-considered good	28,036.24	333.33	52.15	-		28,421.72
(ii) Undisputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-
(iii) Undisputed trade receivables-credit impaired	-	-	-	20.92	-	20.92
(iv) Disputed trade receivables-considered good	-	-	-	-	-	-
(v) Disputed trade receivables-which have significant increase in credit risk	-	-	-	-	-	-
(vi) Disputed trade receivables-credit impaired	-	-	-		6.92	6.92
	28,036.24	333.33	52.15	20.92	6.92	28,449.56
Less:-						
Allowance for doubtful trade receivable	-	-	-	20.92	6.92	27.84
	28,036.24	333.33	52.15	-	-	28,421.72

10 Cash and cash equivalents

Balances with banks:-		
In current accounts	**963.91**	1,566.29
In Earner exchange foreign currency account	**45.30**	1,054.44
Term deposits (with original maturity of less than three months)	**7.80**	7.45
Cash on hand	**8.26**	8.78
	1,025.27	2,636.96

Current accounts include dividend accounts balance Rs.12.25 lakhs (March 31, 2022: Rs 1.76 lakhs)

11 Bank balances other than cash and cash equivalents

Margin money deposits (with original maturity of more than three months but less than twelve months)	**418.68**	452.29
	418.68	452.29

Note : Margin money deposit amounting to Rs.116.36 lakhs (March 31, 2022: Rs 85.82 lakhs) are pledged with banks for non cash limits and term deposit Rs.194.29 lakhs (March 31, 2022: Rs.204.95 lakhs) are pledged as cash security with banks for the loans taken by the Company and Rs. 108.03 lakhs (March 31, 2022 Rs.161.52 lakhs) other deposits with no lien.

SR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency Indian Rupees in lakhs)

	As at March 31, 2023	As at March 31, 2022
12 a Share capital		
Authorised Share Capital		
50,010,000 (March 31 2022: 50,010,000) equity shares of Rs. 10 each	5,001.00	5,001.00
5,000,000 (March 31, 2022 5,000,000) preference shares of Rs. 10 each	500.00	500.00
	5,501.00	5,501.00
Issued, subscribed and fully paid up:		
39,062,706 equity shares of Rs. 10 each (March 31 2022 : 39,062,706 equity shares of Rs 10 each)	3,906.27	3,906.27
	3,906.27	3,906.27

A Reconciliation of the number of equity shares

Description	As at March 31, 2023		As at March 31, 2022	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,90,62,706	3,906.27	3,90,62,706	3,906.27
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	3,90,62,706	3,906.27	3,90,62,706	3,906.27

B Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid. Failure to pay any amount called up on shares may lead to forfeiture of the shares. On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

C Details of shareholders holding more than 5% of shares

Name of the Share holders	As at March 31, 2023		As at March 31, 2022	
	Number	%	Number	%
Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,54,95,188	39.67%
Moneymart Securities Pvt Ltd	34,12,502	8.74%	34,12,502	8.74%
Mr. Mahesh P Bahani	25,86,348	6.62%	25,86,348	6.62%
Banbridge Limited	23,83,958	6.10%	24,61,914	6.30%

In the previous year, the Company was informed by promoters about the inter-se transaction between the Promoter/ Promoter Group on April 29, 2021, April 30, 2021, May 04, 2021, whereby entire holding of FIH Mauritius Investments Ltd , Mr. Utkarsh Shah, M/s. Jariwala Trade Link LLP and M/s.Nahoosh Trade Link LLP (collectively called as "Sellers") were acquired by Mr. Mahesh Babani, Mr.D.B. Rao and Promoter group (collectively called as "Acquirers"). FIH Private Investments Ltd Promoter Group Company sold its entire holding of 3,250 equity shares in the market on February 16, 2022. The necessary compliances as required under SEBI (Prohibition of insider Trading) Regulations, 2015 and SEBI (Substantial Acquisition of Shares and Takeovers) Regulations,2011 has been complied with by the Acquirers, Sellers and Company.

D Aggregate number of shares allotted as fully paid up by way of bonus shares (during 5 years immediately preceding March 31, 2023) :

Equity shares allotted as fully paid up Bonus shares - Nil (March 31, 2022 - Nil)

E Shares allotted as fully paid up pursuant to scheme of arrangement without payment being received in cash (during 5 years immediately preceding March 31, 2023)

During Financial year ended March 31, 2017 -Equity shares of Rs. 10/each - 12,634,353 shares

F Statement of changes in equity as at March 31, 2023

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting period
3,906.27	-	-	-	3,906.27

Statement of changes in equity as at March 31, 2022

Balance at the beginning of the current reporting period	Changes in Equity Share Capital due to prior period errors	Restated balance at the beginning of the current reporting period	Changes in equity share capital during the current year	Balance at the end of the current reporting
3,906.27	-	-	-	3,906.27

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

12 a Share capital (continued)

G Shares held by promoters as at the March 31, 2023

Sr.	Promoter name	As at March 31, 2023		As at March 31, 2022		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,54,95,188	39.67%	-
2	Moneymart Securities Pvt Ltd	34,12,502	8.74%	34,12,502	8.74%	-
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	15,48,202	3.96%	11,20,346	2.87%	1.09%
6	Vinaykumar Doppalapudi	8,91,068	2.28%	7,41,068	1.90%	0.38%
7	Vijaykumar Doppalapudi	8,55,006	2.19%	7,05,006	1.80%	0.39%
8	Rajkumar Doppalapudi Rao	-		6,90,782	1.77%	-1.77%
9	Jyoti Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
10	Seema Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
11	Snehal Mahesh Babani	3,90,000	1.00%	3,90,000	1.00%	-
12	Prasanna Doppalapudi Rao	-	-	2,87,074	0.73%	-0.73%
13	Premaleela Doppalapudi	5,24,522	1.34%	2,74,522	0.70%	0.64%
14	Sharon Doppalapudi Rao	2,45,656	0.63%	2,45,656	0.63%	-
15	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	2,32,185	0.59%	-
16	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	93,446	0.24%	-
17	MM Infra & Leasing Private Limited *	79,758	0.20%	79,758	0.20%	-

Shares held by promoters as at March 31, 2022

Sr.	Promoter name	As at March 31, 2022		As at March 31, 2021		% Change during the year
		No. of shares	% of total shares	No. of shares	% of total shares	
1	Vivira Investment and Trading Pvt Ltd	1,54,95,188	39.67%	1,89,918	0.49%	39.18%
2	Moneymart Securities Pvt Ltd	34,12,502	8.74%	2,06,712	0.53%	8.21%
3	Mahesh P Babani	25,86,348	6.62%	25,86,348	6.62%	-
4	Mahesh Purshottam Babani HUF	17,91,720	4.59%	17,91,720	4.59%	-
5	Doppalapudi Bhaktavatsala Rao	11,20,346	2.87%	7,23,060	1.85%	1.02%
6	Vinaykumar Doppalapudi	7,41,068	1.90%	4,78,278	1.22%	0.68%
7	Vijaykumar Doppalapudi	7,05,006	1.80%	4,55,004	1.16%	0.64%
8	Rajkumar Doppalapudi Rao	6,90,782	1.77%	4,45,824	1.14%	0.63%
9	Jyoti Mahesh Babani	3,90,000	1%	3,90,000	1%	-
10	Seema Mahesh Babani	3,90,000	1%	3,90,000	1%	-
11	Snehal Mahesh Babani	3,90,000	1%	3,90,000	1%	-
12	Prasanna Doppalapudi Rao	2,87,074	0.73%	1,85,274	0.47%	0.26%
13	Premaleela Doppalapudi	2,74,522	0.70%	1,77,174	0.45%	0.25%
14	Sharon Doppalapudi Rao	2,45,656	0.63%	1,58,544	0.41%	0.22%
15	Grace Vinay Kumar Doppalapudi Rao	2,32,185	0.59%	1,49,850	0.38%	0.21%
16	Rameshbabu Gokarneswararao Guduru	93,446	0.24%	60,309	0.15%	0.09%
17	Vivira Chemicals Private Limited *	79,758	0.20%	79,758	0.20%	-
18	Utkarsh Bhikhoobhai Shah	-	-	25,000	0.06%	-0.06%
19	Nahoosh Tradelink Llp	-	-	6,63,019	1.70%	-1.70%
20	Janwala Tradelink Llp	-	-	3,36,981	0.86%	-0.86%
21	FIH Mauritius Investments Ltd	-	-	1,90,42,828	48.75%	-48.75%
22	FIH Private Investments Ltd	-	-	3,250	0.01%	-0.01%

Note * Vivira Chemicals Private Limited (VCPL) amalgamated into MM Infra & Leasing Private Limited as per NCLT order dated October 13, 2021 and hence Shares held by VCPL in the Company also get transferred to MM Infra on May 04, 2022. The same is intimated to Stock Exchanges on May 05, 2022

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

	As at March 31, 2023	As at March 31, 2022
12 b Other equity		
General reserve	**35,573.76**	35,573 76
Capital reserve	**1.00**	1 00
Retained earnings	**42,766.63**	41,254 78
Total other equity	**78,341.39**	76,829 54

The description of the nature and purpose of each reserve within equity is as follows

A General reserve

As per the approved scheme of arrangement (Demerger) between the Privi Organics India Limited , Privi Specialities Chemicals Limited and Privi Organics Limited during the period ended 31 March 2017, the excess of book value of assets over liabilities is treated as general reserve

B Retained earnings

Retained earnings represent the amount of accumulated earnings/ (losses) at each Balance Sheet date of the Company, prepared in accordance with the basis of preparation section

C Capital reserve

As per the approved Scheme of Arrangement and Amalgamation amongst Fairchem Speciality Limited (Demerged / Transferee Company) and Privi Organics India Limited (Transferor Company) vide NCLT Mumbai order dated June 30 , 2020, all the assets , liabilities and reserve pursuant to the scheme, have been transferred at carrying amount and the difference if any being the excess is treated as capital reserve

D The Capital management objective of the Company is to (a) maximize shareholder value and provide benefits to other stakeholders and (b) maintain an optimal capital structure to reduce the cost of capital

For the purposes of the Company's capital management, capital includes issued equity share capital, share premium and all other equity
The Company monitors capital using debt-equity ratio, which is total debt less liquid investments and bank deposits divided by total equity

The Company's debt equity ratio as at March 31, 2023 was as follows:

Particulars	As at March 31, 2023	As at March 31, 2022
Total Debt	1,02,930.54	87,964 67
Less: Cash and cash equivalents and short term investments	1,443.95	3,089.25
Net Liabilities (A)	1,01,486.59	84,875 42
Total Equity (B)	82,247.66	80,735 81
Debt - Equity Ratio	1.23	1.05

In addition, the Company has financial covenants relating to the borrowing facilities that it has taken from the lenders like interest coverage service ratio, Debt to EBITDA, etc

B S R & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency Indian Rupees in lakhs)

13 a Non-current borrowings

	Non-current portion		Current portion (*)	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Secured:				
Term loans from banks (refer note (i))				
Term loan in Indian currency (refer note (iii) below)	39,021.18	36,145.76	9,616.67	3,466.67
Term loans in foreign currency (refer note (ii) & (iii) below)	1,344.17	1,904.85	672.06	634.95
Term loans from financial institutions				
Vehicle loan (hypothecated with the lender) (refer note in below)	5.14	9.39	4.25	4.03
	40,370.49	38,060.00	10,292.98	4,105.64

(*) Amount disclosed under the head ' current borrowings (secured) ' refer note 14

i) Term loan are secured by a first mortgage on the Company's immovable properties both present and future ranking paripassu interest and a first charge by way of hypothecation of all the company's assets (save and except book debts and inventories) including movable machinery (save and except spares tools and accessories) both present and future subject to charges created in favour of the Company's bankers for inventories, book debts and other specified movable assets for securing the borrowings of working capital

ii) Currency swap on IDFC Rupee loan of Rs 4,000 lakhs and ICICI bank Rupee loan of Rs 4,000 lakhs are taken @ 64 42 per USD and @ 68 13 per USD respectively and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76 78 per USD and @ 75 83 per USD respectively, the currency swap represents derivative instruments which has been restated at the closing rate of exchange

iii) **Terms and repayment schedule**

Terms and conditions of outstanding borrowings are as follows:

Name of the Bank / Financial Institutions	Currency	Interest Rate	Year of Maturity	Installment	Carrying amount as at March 31, 2023	Carrying amount as at March 31, 2022
Foreign Currency						
Kotakbar Bank - ECB	EUR	2.75%	2026	The term loan is repayable in 24 quarterly installments of EURO 187,500.00 each starting from Apr 2020	2,016.23	2,539.80
Foreign Currency-Total (A)					2,016.23	2,539.80
Indian Currency						
Kotak Mahindra Bank	INR	8.43%	2027	The term loan is repayable in 20 quarterly installments of Rs 250 lakhs starting from Mar 2023	6,629.42	6,971.27
CITI Bank	INR	9.00%	2025	The term loan is repayable in 12 quarterly installments of Rs 750 lakhs starting from Mar 2023	10,071.30	10,979.69
ICICI Bank	INR	7.90% - 8.60%	2025	The term loan is repayable in 20 quarterly installments of Rs 200 lakhs starting from Sep 2020	1,798.60	2,597.24
HDFC Bank	INR	8.60%	2024	The term loan is repayable in 20 quarterly installments of Rs 200 lakhs starting from Mar 2020	1,400.00	2,200.00
HDFC Bank	INR	9.05%-9.30%	2029	The term loan is repayable in 20 quarterly installments of Rs 250 lakhs starting from Oct 2024	4,989.14	-
HDFC Bank	INR	8.80% -9.50%	2026	The term loan is repayable in 20 quarterly installments of Rs 280 lakhs starting from Apr 2021	3,350.91	4,464.23
HDFC Bank	INR	7.48% - 8.38%	2027	The term loan is repayable in 20 quarterly installments of Rs 370 lakhs starting from Jun 2022	5,920.00	7,400.00
HDFC Bank	INR	8.60%	2028	The term loan is repayable in 20 quarterly installments of Rs 350 lakhs starting from Jan 2024	7,000.00	7,000.00
HDFC Bank	INR	7.50%	2029	The term loan is repayable in 20 quarterly installments of Rs 375 lakhs starting from Sep 2024	7,478.47	-
Yes Bank (Vehicle loan)	INR	8.97%	2024	The term loan is repayable in 65 monthly installments of Rs 0.41 lakh starting from Jun-2020	9.40	13.41
Indian Currency total - B					48,647.24	44,625.84
Total Term Loan (A+B)					50,663.47	44,165.64

iv) Term loans availed have been utilized for the purpose for which the funds have been borrowed

v) During the year, the Company has not complied on certain financial covenants with respect to term loans availed from banks However, based on the review of periodic filings made by the Company to the Banks, the Banks have continued with the facilities (have not placed any demand on the loans and the facility) Accordingly, the Company continues to classify these loans as current and non-current based on the original maturity

13 b Lease liabilities

	Non-Current		Current	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
	994.77	1,290.41	360.22	424.80
	994.77	1,290.41	360.22	424.80

BSR & Co. LLP Chartered Accountants
Privi Speciality Chemicals Ltd Navi Mumbai

	As at March 31, 2023	As at March 31, 2022
14 Current borrowings		
From Banks:		
Cash credit (refer note e)	76.77	-
Working capital demand loan (refer note b & c)	34,950.00	29,500.00
Packing credit from bank (refer note d)	14,391.95	12,790.36
Buyers credit (refer note f)	2,404.83	1,242.29
Interest accrued but not due on borrowings	443.52	266.38
Current maturities of long term debt (refer note 13 a)	10,292.98	6,105.64
Total	62,560.05	49,904.67

a) All the above loans are Rs 31,000 Lakhs fund base secured by first pari passu charge on all current assets of the Company both present and future. Balance Rs 21,267 Unsecured

b) Working capital demand loans from banks are secured by way of hypothecation of inventories both on hand and in transit and book debts and other receivables both present and future and also secured by way of second charge on fixed assets. Working capital loans carry interest rate @ 7.63% to 9.00%

c) Quarterly statements of current assets filed by the company with the banks are in agreement with the books of accounts

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/ statement	Amount of difference	Reason for material discrepancies
Jun-22	refer note-i	Trade receivables and Inventories	1,01,280.58	96,290.40	4,990.18	refer note-ii
Sep-22	refer note-i	Trade receivables and Inventories	1,11,592.04	1,11,688.59	-96.55	refer note-ii
Dec-22	refer note-i	Trade receivables and Inventories	1,10,032.65	1,09,117.06	915.59	refer note-ii
Mar-23	refer note-i	Trade receivables and Inventories	1,05,945.04	1,05,812.86	132.18	refer note-ii

i) The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd , IDFC bank, ICICI Bank Ltd, Standard Chartered Bank

ii) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory. the related amounts are mentioned below :

Jun-22 unrealised gain of Rs. 945.27 lakhs, advance from customers of Rs. 284.32 lakhs, stores and spares inventory of Rs. 714.87 lakhs and Goods in transit of Rs. 3045.72 lakhs not included in quarterly statement submitted to bank

Sep-22 unrealised gain Rs. 1060.08 lakhs, advance from customers Rs. 560.32 lakhs, stores and spares inventory Rs. 712.39 lakhs and GIT Rs. (2429.34) lakhs not included in quarterly statement submitted to bank

Dec-22 unrealised gain Rs. 788.13 lakhs, advance from customers Rs. 587.13 lakhs stores and spares inventory Rs. 713.94 lakhs and GIT Rs. (1173.61) lakhs not included in quarterly statement submitted to bank.

Mar-23 unrealised gain Rs. 149.22 lakhs. Stores and spares inventory Rs.(680.55) lakhs and GIT Rs. 663.51 lakhs not included in quarterly statement submitted to bank.

Quarter	Name of bank	Particulars of Securities Provided	Amount as per books of account	Amount as reported in the quarterly return/	Amount of difference	Reason for material
Jun-21	refer note-i	Trade receivables and Inventories	59,480.62	57,625.27	1,855.35	refer note-ii
Sep-21	refer note-i	Trade receivables and Inventories	60,709.21	59,551.09	1,158.12	refer note-ii
Dec-21	refer note-i	Trade receivables and Inventories	70,221.18	69,368.49	852.69	refer note-ii
Mar-22	refer note-i	Trade receivables and Inventories	84,542.50	83,680.57	861.93	refer note-ii

i) The bank includes Kotak Mahindra Bank, HDFC Bank Ltd, CITI bank, RBL Ltd , IDFC bank, ICICI Bank Ltd, Standard Chartered Bank

ii) The returns are based on unaudited financial information in the interim period and are extracted from the books and records of the Company, as adjusted for certain quarterly closing entries, like adjustments in relation to unrealised gain/ (loss) on trade receivables and further adjusted by advances received from customers, exclusion of stores and spares and goods in transit from inventory. the related amounts are mentioned below :

Jun-21 unrealised gain of Rs. (238.35) lakhs, advance from customers of Rs. (338.00) lakhs, stores and spares inventory of Rs. 612.00 lakhs and Goods in transit of Rs. 1819.70 lakhs not included in quarterly statement submitted to bank

Sep-21 unrealised gain Rs. (146.03) lakhs, advance from customers Rs (1,016.18) lakhs, stores and spares inventory Rs. 681.70 lakhs and GIT Rs. 1,638.63 lakhs not included in quarterly statement submitted to bank

Dec-21 unrealised gain Rs. (108.98) lakhs, advance from customers Rs. (320.45) lakhs stores and spares inventory Rs. 783.40 lakhs and GIT Rs. 498.72 lakhs not included in quarterly statement submitted to bank

Mar-22 unrealised gain Rs. (373.23) lakhs, advance from customers Rs. (264.56) lakhs, stores and spares inventory Rs. 597.15 lakhs and GIT Rs. 902.57 lakhs not included in quarterly statement submitted to bank

d) Packing credit in rupees carry interest rate @ 8.00% to 9.00% p.a.

e) Cash credit loan from bank carry interest rate @ 8.10% to 9.50%

f) Buyers credit carry interest rate @ SOFR +1.41% to SOFR + 2.79% and due for payment within 180 days

15 Provisions

	Non-Current		Current	
	As at March 31, 2023	As at March 31, 2022	As at March 31, 2023	As at March 31, 2022
Provisions for employee benefits				
Compensated absences (refer note 31)	431.12	427.00	75.27	71.97
Gratuity (refer note 31)	1,319.05	1,248.45	137.29	123.01
	1,750.17	1,675.45	212.56	194.98

16 Income tax

	As at March 31, 2023	As at March 31, 2022
Amounts recognised in profit or loss		
The major components of income tax expense for the years ended March 31, 2023 and March 31, 2022 are:		
Current income tax:		
Current income tax expenses	333.81	3,395.97
Recognition of MAT credit entitlement	-	-
Tax Adjustment of earlier years	-	-
Deferred		
Relating to origination and reversal of temporary differences	545.82	103.26
Income tax expense reported in the statement of profit or loss	879.63	3,499.23
Income tax recognised in other comprehensive income		
Tax expense related to items recognised in OCI during the year:		
Remeasurements of defined benefit (asset)	17.85	(15.02)
Income tax charged to OCI	17.85	(15.02)
Reconciliation of tax expense and the accounting profit multiplied by India's domestic tax rate for March 31, 2023 and March 31, 2022:		
Accounting profit before income tax	3,127.12	13,665.71
At India's statutory income tax rate of 25.17% (March 31, 2022: 25.17%)	787.10	3,439.66
Non-deductible expenses for tax purposes	83.82	58.01
Others	8.71	1.56
	879.63	3,499.23
	879.63	3,499.23

Income tax expense reported in the statement of profit and loss

The Company has chosen to exercise the option of lower tax rate of 25.17% (inclusive of surcharge and cess) under section 115BAA of the Income tax act,1961 as introduced by the Taxation laws (Amendment) Ordinance 2019. The impact of this change has been recognised in tax expenses for the year ended March 31, 2023 and March 31, 2022 respectively at the effective tax rate.

	As at 1 April 2022	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	As at March 31, 2023
Deferred tax (assets)/liabilities				
Provision for post retirement benefits and other employee benefits				-
Tax depreciation	2,408.92	545.82	-	2,954.74
Deferred asset on ROU impact	(24.30)	-	-	(24.30)
Provision for doubtful debts and advances	(54.79)		-	(54.79)
Expenses allowable for tax purposes when paid	(440.73)	-	17.85	(422.88)
Forex loss unrealised Impact (Derivative instrument)	(430.83)	-	-	(430.83)
	1,458.27	545.82	17.85	2,021.94

	As at 1 April 2021	Credit/(charge) in the Statement of Profit and Loss	Credit/(charge) in Other Comprehensive Income	As at March 31, 2022
Deferred tax (assets)/liabilities				
Tax Depreciation	2,305.66	103.26	-	2,408.92
Deferred asset on ROU impact	(24.30)	-	-	(24.30)
Provision for doubtful debts and advances	(54.79)	-	-	(54.79)
Expenses allowable for tax purposes when paid	(425.71)	-	(15.02)	(440.73)
Forex loss unrealised Impact (Derivative instrument)	(430.83)	-	-	(430.83)
	1,370.03	103.26	(15.02)	1,458.27

a) In respect of Deferred taxes, all items are attributable to origination and reversal of temporary differences

b) Deferred tax benefits are generally recognized for all deductible temporary differences to the extent it is probable that taxable profits will be available against which those deductible temporary differences can be realised.

Notes to the Standalone Financial Statements *(Continued)*

as at March 31, 2023

(Currency: Indian Rupees in lakhs)

		As at March 31, 2023	As at March 31, 2022
17	**Trade payables**		
a)	Total outstanding dues of micro and small enterprises	927.53	-
b)	Total outstanding dues of creditors other than micro and small enterprises		
	i) Payable to related parties : (refer note no 30)	2,665.59	2,266.67
	ii) Payable to others	26,179.17	28,556.02
		29,772.29	30,822.69

The Company's exposure to credit and currency and liquidity risk related to trade payables are disclosed in Note 32

Information as per the requirement of Section 22 of The Micro, Small and Medium Enterprises Development Act, 2006

a)	(i) The principal amount remaining unpaid to any supplier at the end of accounting year included in trade payables	927.53	-
	(ii) The interest due on above	-	-
	The total of (i) & (ii)	927.53	-
b)	The amount of interest paid by the buyer in terms of section 16 of the Act	-	-
c)	The amount of the payment made to the supplier beyond the appointed day during the accounting year	-	-
d)	The amounts of interest accrued and remaining unpaid at the end of financial year	-	-
e)	The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the due date during the year) but without adding the interest specified under this Act	-	-
f)	the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise, for the purpose of disallowance of a deductible expenditure under section 23 of the Micro, Small and Medium Enterprises Development Act, 2006	-	-

The above information has been determined to the extent such parties have been identified on the basis of information available with the group company and the same has been relied upon by the auditors

Trade payables ageing as on 31-Mar-2023

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	927.53	-	-	-	927.53
ii) Others	28,821.49	21.23		2.04	28,844.76
iii) Disputed dues - MSME	-	-	-	-	-
iv) Disputed dues-Others	-	-	-	-	-
	29,749.02	21.23	-	2.04	29,772.29

Trade payables ageing as on 31-Mar-2022

Particulars	Less than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	-	-	-	-	-
ii) Others	30,748.85	60.75	0.98	12.11	30,822.69
iii) Disputed dues - MSME	-	-	-	-	-
iv) Disputed dues-Others	-	-	-	-	-
	30,748.85	60.75	0.98	12.11	30,822.69

18	**Other financial liabilities**		
	Payable for capital expenditure	5,114.03	5,657.31
	Deposits	1.00	0.75
	Salaries, wages and bonus payable	994.30	791.18
	Derivative instruments (forward exchange contracts and interest rate swaps (Refer note 13 a))	1,174.85	466.70
	Book overdrafts	-	0.15
		7,284.18	6,916.09

The Company's exposure to credit and currency and liquidity risk related to the above financial liabilities are disclosed in note 33

19	**Other current liabilities**		
	Statutory liabilities	242.68	223.76
	Advance from customers (refer note 37)	5,607.18	264.01
		5,849.86	487.77

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2023	Year ended March 31, 2022
20 Revenue from operations		
Revenue from contracts with customers disaggregated based on nature of product or services		
Sale of products (refer note 29 and 37)	1,57,541.82	1,39,012.53
	1,57,541.82	1,39,012.53
Other operating revenues		
a) Scrap Sales	242.50	127.70
b) Job work	-	6.34
	242.50	134.04
Total Income	1,57,784.32	1,39,146.57
21 Other income		
Interest income from fixed deposits carried at amortised cost	26.15	26.53
Gain on write-back of Financial liabilities measured at amortised cost	2.57	158.67
Profit on disposal of property, plant and equipment	5.04	0.69
Profit on sales of investment (net)	8.88	0.27
Net Gain on Foreign currency transactions and translation	1,820.78	2,949.98
Miscellaneous income	296.19	123.78
	2,159.61	3,259.92
22 Cost of materials consumed		
Raw material consumed		
Opening Stock	19,639.62	9,591.30
Add: Purchases	1,11,101.61	1,05,491.02
Less: Stock lost on Flood	-	171.93
Less: Closing stock	19,655.08	19,639.62
Consumption	1,11,086.15	95,270.77
Packing material consumed		
Opening Stock	105.26	86.91
Add: Purchases	2,250.45	2,442.07
Less: Stock lost on Flood	-	11.85
Less: Closing Stock	119.71	105.26
Consumption	2,236.00	2,411.87
	1,13,322.15	97,682.64

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2023	Year ended March 31, 2022
23 Changes in inventories of finished goods and work in progress		
Closing stock:		
Finished goods	25,948.48	17,283.55
Work in progress	27,752.09	18,173.04
	53,700.57	35,456.59
Stock lost by flood		222.07
	53,700.57	35,678.66
Opening stock:		
Finished goods	17,283.55	11,645.11
Work in progress	18,173.04	9,306.99
	35,456.59	20,952.10
(Increase)/ decrease in inventories	(18,243.98)	(14,726.56)
24 Employee benefits expense		
Salaries, wages and bonus	6,327.32	5,892.13
Contribution to provident and other funds	333.29	323.23
Staff welfare expenses	574.81	563.58
	7,235.42	6,778.94
25 Finance cost		
Interest on term loans using effective interest rate measured at amortised cost	3,387.35	2,010.60
Less: Interest capitalised (refer note 3)	(1,049.11)	(1,428.03)
Net interest on term loans	2,338.24	582.57
Interest on working capital loans using effective interest rate measured at amortised cost	4,163.91	1,666.59
Interest on vehicle loans using effective interest rate measured at amortised cost	1.66	4.83
Loan arrangement fees amortised using effective rate of interest basis	29.58	25.44
Interest cost lease liability using effective interest rate measured at amortised cost	129.09	98.21
	6,662.48	2,377.64

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

	Year ended March 31, 2023	Year ended March 31, 2022
26 Depreciation and amortisation		
Depreciation on property, plant and equipment	9,670.32	6,666.30
Amortisation of intangible assets	316.18	233.87
Amortisation of right of use assets	529.03	404.22
	10,515.53	7,304.39
27 Power and fuel consumed		
Fuel	9,234.49	6,338.51
Power	5,242.29	3,372.41
Water Charges	236.27	191.25
	14,713.05	9,902.17
28 Other expenses		
Consumption of stores and spares	1,655.82	987.27
Excise duty related to (decrease) / increase in inventory of finished goods	-	-
Job work charges	1,919.77	2,281.43
Repairs and maintenance of:		
Buildings	453.01	327.84
Plant and machinery	1,329.73	1,007.07
Others	143.78	50.81
Contract labour charges	846.42	952.43
Research and development expense	537.11	651.70
Pollution control expenses	1,018.12	439.29
Other factory expenses	961.84	665.23
Insurance	1,356.61	1,104.70
Postage and telephone expense	74.03	43.27
Rates and taxes	54.66	57.92
Training expenses	4.98	5.32
Auditors remuneration:		
'For audit	43.00	38.00
'For limited review	27.00	27.00
'Other services	0.25	4.69
Out of pocket expenses	2.08	1.98
Brokerage and commission	166.78	124.47
Printing and stationery	45.57	64.46
Freight outward	7,771.36	7,126.78
Selling and distribution	948.60	854.82
Legal and professional fees	1,312.93	1,433.44
Travelling and conveyance	857.30	589.21
Bank charges	153.39	112.46
CSR expenses (refer note 43)	333.00	255.53
Sundry balances w/off	-	53.21
Allowance for expected credit loss and credit impairment	-	20.92
Loss on Sale of property, plant and equipment	64.48	-
Miscellaneous expenses (net)	530.54	669.55
	22,612.16	19,950.80

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

29 Segment information

A. Factors used to identify the entity's reportable segments, including the basis of organisation

For management purpose, the Company has determined its reportable segment as "Aromatic chemicals" since the chief operating decision maker (CODM) evaluates the Company's performance as a single segment.

B. Information about reportable segments

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
Revenue sale of products	1,57,541.82	1,39,012.53
	1,57,541.82	1,39,012.53

C. Geographic information

The geographic information analyses the Company's revenue and non-current assets by the Company's country of domicile and other countries. In presenting the geographical information, segment revenue has been based on the geographic location of customers and segments assets were based on the geographic location of the respective non-current assets.
The product offerings which are part of the speciality chemicals portfolio of the Company are managed on a worldwide basis from India (refer note 37)

The amount of the group's revenue from sale of products is shown in the table below.

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
India	35,765.81	35,220.65
Outside India #	1,21,776.01	1,03,791.88
Total	1,57,541.82	1,39,012.53

Includes deemed exports of Rs.3,856.43 lakhs for the year (March 31, 2022 : Rs.4,233.03 lakhs)
All the non-current assets of Company are located within India.

D. Information about Major Customers
Revenue from one major customer represented approximately Rs.26,864.29 lakhs (March 31, 2022 : Rs.22,202.94 lakhs)

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

30 Related party disclosures

Details of transactions between the Company and other related party are disclosed below.

a) **List of Related Parties**

Promoter Group

Vivira Investment and Trading Private Limited (w.e.f. April 29, 2021)

FIH Mauritius Investments Limited , Republic of Mauritius (FMIL) upto April 29, 2021

FIH Private Investments Limited, Mauritius upto April 29, 2021 upto April 29, 2021

(FMIL is wholly owned and controlled by Fairfax India Holdings Corporation, Canada)

Subsidiary Companies

Privi Biotechnologies Private Limited

Privi Speciality Chemicals USA Corporation

Prigiv Specialties Private Limited (w.e.f. September 01, 2021)

Enterprises owned by key management personnel or their relatives

Vivira Chemical Industries

Minar Organics Private Limited, merged with MM Infra & Leasing Private Limited (w.e.f. dated October 13, 2021)

Vivira Chemicals Private Limited, merged with MM Infra & Leasing Private Limited dated (w.e.f. October 13, 2021)

Privi Life Science Private Limited

Privi Fine Sciences Limited

Money Mart Securities Private Limited

Babani Investment and Trading Private Limited

Satellite Technologies Private Limited

Vivira Investment and Trading Private Limited

Prasad Organics Pvt Ltd

MM Infra & Leasing Private Limited

Babani Bros. LLP

Fairchem Organics Limited upto April 29, 2021

Privi Organics Ltd

Jariwala Tradelink LLP upto April 29, 2021

Nahoosh Tradelink LLP upto April 29, 2021

Key Management Personnel (KMP)

Mr. Mahesh P. Babani	Chairman & Managing Director
Mr. D. B. Rao	Executive Director
Mr. Sumit Maheshwari	Nominee Director upto April 29, 2021
Mr. Rajesh Budhrani	Independent Director
Mr. P.R. Barpande	Independent Director
Mr. Anurag Surana	Independent Director
Mrs. Anuradha Thakur	Independent Director
Mr. Dwarko Topandas Khilnani	Independent Director

Relatives of Key Management Personnel

Mahesh Purshottam Babani HUF

Mrs. Seema Mahesh Babani

Ms. Snehal Mahesh Babani

Ms. Jyoti Mahesh Babani

Mr. Vijaykumar Doppalapudi Rao

Mr. Vinaykumar Doppalapudi Rao

Mrs. Grace Vinaykumar Doppalapudi Rao

Mrs. Sharon Doppalapudi Rao

Mrs Premaleela Doppalapudi Rao

Mr. Rajkumar Doppalapudi Rao

Mrs. Prasanna Raj Doppalapudi Rao

Mr. Rameshbabu Gokameswararao Guduru

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

b) During the year, following transactions were carried out with the related parties :

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Transactions						
Purchase of raw materials						
Privi Life Science Private Limited	-	-	33.60	18.00	-	-
Privi Speciality Chemicals USA Corporation	12,068.21	9,115.54	-	-	-	-
Prasad Organics Private Limited	-	-	1,068.79	2,052.42	-	-
Privi Organics Limited	-	-	63.07	2.39	-	-
Purchase of machinery						
Privi Life Science Private Limited	-	-	-	26.11	-	-
Sale of finished goods						
Privi Speciality Chemicals USA Corporation	26,864.30	22,202.95	-	-	-	-
Privi Life Science Private Limited	-	-	-	6.34	-	-
Prasad Organics Private Limited	-	-	987.32	919.81	-	-
Privi Biotechnologies Private Limited	-	5.09	-	-	-	-
Privi Organics Limited	-	-	-	13.98	-	-
Sale of Property plant & equipment						
Privi Organics Limited	-	-	-	13.57	-	-
Lease expense						
MM Infra & Leasing Private Limited	-	-	78.10	171.00	-	-
Money Mart Securities Private Limited	-	-	195.92	48.38	-	-
Privi Biotechnologies Private Limited	105.00	90.00	-	-	-	-
Technical Fees						
Privi Biotechnologies Private Limited	622.50	510.00	-	-	-	-
Lease Income						
Minar Organics Private Limited merged with MM Infra & Leasing Private Limited dated October, 13 2021	-	-	-	0.18	-	-
Privi Life Science Private Limited	-	-	37.26	24.00	-	-
Money Mart Securities Private Limited			1.22	0.70		
Privi Organics Limited			0.32	-		
Vivita Chemicals Private Limited merged with MM Infra & Leasing Private Limited dated October, 13 2021	-	-	-	0.18	-	-
Security deposit						
Money Mart Securities Private Limited	-	-	-	300.00	-	-
MM Infra & Leasing Private Limited	-	-	-	51.00	-	-
Reimbursement of expense received						
Prigiv Specialties Private Limited	220.54	-	-	-	-	-
Privi Speciality Chemicals USA Corporation	52.92	37.50	-	-	-	-
Commission and reimbursement other expenses paid						
Privi Speciality Chemicals USA Corporation	29.17	42.90	-	-	-	-
Loans and advances						
Privi Speciality Chemicals USA Corporation	136.38	166.50	-	-	-	-
MM Infra & Leasing Private Limited	-	-	-	331.00	-	-
Investment in shares						
Prigiv Specialties Private Limited	-	-	-	-	-	-

B SR & Co. 14th Floor, Central Wing and North Wing, Nesco IT Park, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*
for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

b) During the year, following transactions were carried out with the related parties : *(Continued)*

	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Managerial remuneration						
Mr D B Rao (*)	-	-	-	-	50.00	56.00
Mr Mahesh P Babani (*)	-	-	-	-	600.00	600.00
Salary paid						
Mr Vinaykumar Doppalapudi Rao	-	-	-	-	26.22	23 47
Dividend Paid						
Mr Mahesh P Babani	-	-	-	-	51.73	51 73
Mahesh Purshottam Babani Huf	-	-	-	-	35.83	35 83
Mr D B Rao	-	-	-	-	22.41	22 41
Money Mart Securities Private Limited	-	-	68.25	68 25	-	-
Visira Investment and Trading Private Limited	-	-	309.90	309 90	-	-
Mm Infra & Leasing Private Limited	-	-	1.60	1 60	-	-
Mrs Seema Mahesh Babani	-	-	-	-	7.80	7 80
Ms Jyoti Mahesh Babani	-	-	-	-	7.80	7 80
Ms Snehal Mahesh Babani	-	-	-	-	7.80	7 80
Mrs Premaleela Doppalapudi Rao	-	-	-	-	5.49	5 49
Mr Vinaykumar Doppalapudi Rao	-	-	-	-	14.82	14 82
Mrs Grace Vinaykumar Doppalapudi Rao	-	-	-	-	4.64	4 64
Mr Vijaykumar Doppalapudi Rao	-	-	-	-	14.10	12 49
Mrs Sharon Doppalapudi Rao	-	-	-	-	4.91	4 91
Mr Rajkumar Doppalapudi Rao	-	-	-	-	13.82	14 00
Mrs Prasanna Raj Doppalapudi Rao	-	-	-	-	5.74	5,74
Mr Rameshbabu Gokameswararao Guduru	-	-	-	-	1.87	1 87
Sitting fees						
Mr Anurag Surana	-	-	-	-	3.00	5 00
Mrs Anuradha Thakur	-	-	-	-	4.00	5 00
Mr Rajesh Budhrani	-	-	-	-	4.00	4,00
Mr P R Barpande	-	-	-	-	4.00	5,00
Mr Dwarko Topandas Khilnani	-	-	-	-	4.00	5 00

*Remuneration does not include charge for gratuity and leave encashment as employee-wise break up is not available

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

30 Related party disclosures *(Continued)*

c) **Outstanding balances**

Particulars	Subsidiaries		Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Receivables /Other assets						
Privi Speciality Chemicals USA Corporation	7,769.86	6,685 36	-	-	-	-
MM Infra & Leasing Private Limited	-	-	51.00	782 00	-	-
Privi Life Science Private Limited	-	-	38.63	15 90	-	-
Money Mart Securities Private Limited	-	-	300.00	300 00	-	-
Prasad Organics Private Limited	-	-	904.00	201 91	-	-
Privi Biotechnologies Private Limited	25.00	25 00	-	-	-	-
Prigiv Specialties Private Limited	45.39	-				
Privi Organics Limited	-	-	-	0 89	-	-
Investments						
Privi Speciality Chemicals USA Corporation	30.61	30 61	-	-	-	-
Privi Biotechnologies Private Limited	4,271.70	4,271 70	-	-	-	-
Prigiv Specialties Private Limited	765.00	765 00	-	-	-	-
Trade Payables / Other Liabilities						
Privi Biotechnologies Private Limited	279.77	105 01	-	-	-	-
Privi Life Science Private Limited	-	-	39.86	18 25	-	-
MM Infra & Leasing Private Limited	-	-	36.72	-	-	-
Money Mart Securities Private Limited	-	-	90.19	0 75	-	-
Prasad Organics Private Limited	-	-	464.74	265 36	-	-
Privi Organics Limited	-	-	57.61	2 82	-	-
Privi Speciality Chemicals USA Corporation	1,696 70	1,877 23	-	-	-	-
Payable to Key Management Personal						
Mr. Mahesh P Babani (*)	-	-	-	-	9.70	28 41
Mr. D.B.Rao (*)	-	-	-	-	2.94	2 57
Relatives of Key Management Personnel						
Mr.Vinaykumar Doppalapudi Rao (*)	-	-	-	-	1.33	1.42
Company has provided Corporate Bank Guarantee to CITI Bank against a working capital Loan sanction to Privi Speciality Chemicals USA Corporation (formally known as Privi Organics USA Corporation) (refer note d below)	-	-	-	-	3,288.80	3,032 28

* Remuneration Net of Tax Deducted at Source and includes short term benefit and post employment benefit

d) **Disclosure required under Sec 186(4) of the Companies Act, 2013**

Provided the guarantee on behalf of wholly owned subsidiary Privi Speciality Chemicals USA Corporation (Formerly known as Privi Organics USA Corporation) to Citi Bank USA which are disclosed below as required by Sec 186(4) of the Companies Act, 2013

Name of the loanee	Rate of Interest	Due date	Secured/ unsecured	31 March 2023	31 March 2022
Privi Speciality Chemicals USA Corporation	Not applicable	Not applicable	Working capital	3,288.80	3,032.28
				3,288.80	3,032.28

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

31 Employee benefits - post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the note 24 under "Contribution to provident & other funds":

	Year ended March 31, 2023	Year ended March 31, 2022
Contribution to employees provident fund	331.64	320.86
Contribution to ESI	1.33	1.97

b) Defined benefit plans

The Company operates one post-employment defined benefit plan that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

Amount recognised in the balance sheet in respect of Gratuity		
Present value of the defined benefit obligation at the end of the year	1,456.34	1,371.47
Fair value of the plan assets	-	-
Net liability	1,456.34	1,371.47

	As at March 31, 2023	As at March 31, 2022
Movement in present value of defined benefit obligation		
Opening Liability	1,371.47	1,167.16
Current service cost	115.37	106.69
Interest cost	98.06	80.07
Actuarial /loss	(63.47)	58.67
Benefits paid	(65.09)	(41.12)
Closing defined benefit obligation	1,456.34	1,371.47
Expense recognised in statement of profit and loss		
Current service cost	115.37	106.69
Interest on defined benefit obligations	98.06	80.07
Total	213.43	186.76
Remeasurements recognised in Other comprehensive income		
Change in financial assumptions	(32.24)	(32.30)
Change in Demographic Assumptions	-	0.40
Experience adjustments	(31.23)	90.57
Total	(63.47)	58.67
Total expense recognised	149.96	245.43

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

31 Employee benefits - Post-employment benefit plans *(Continued)*

b) Defined benefit plans *(Continued)*

	As at March 31, 2023	As at March 31, 2022
Principal actuarial assumptions at the balance sheet date		
Discount rate (p.a.)	7.44%	7.15%
Expected rate of salary increase (p.a.)	8.25%	8.25%
Attrition rate	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.	For service 2 years and below 20.00% p.a. For service 3 years to 4 years 10.00% p.a. For service 5 years and above 5.00% p.a.
Mortality tables	Indian Assured Lives Mortality 2012-14 (Urban)	Indian Assured Lives Mortality 2012-14 (Urban)

At March 31, 2023 the weighted average duration of the defined benefit obligation was 9 years (March 31, 2022 : 10 years)
The estimates of future salary increase, considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
	March 31, 2023	March 31, 2022	March 31, 2023	March 31, 2022
Impact on defined benefit obligation due to:				
a. 1% increase	(101.99)	(101.88)	114.70	114.87
b. 1% decrease	116.77	117.28	(102.16)	(101.79)

The sensitivity analysis above has been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment for last five years

	March 31, 2023	March 31, 2022	March 31, 2021	March 31, 2020	March 31, 2019
Defined benefit obligation	1,456.34	1,371.47	1,167.16	1,016.53	789.99
Surplus/(deficit)	(1,456.34)	(1,371.47)	(1,167.16)	(1,016.53)	(789.99)
Experience adjustment on plan liabilities	(31.23)	90.57	11.38	43.72	54.61

Compensatory absences

The Company provides for the encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits, for future encashment. The liability is provided based on the number of days of unutilized leave at each balance sheet date on the basis of an independent actuarial valuation. Amount of Rs. 82.13 lakhs (31 March, 2022 : Rs 145.46 lakhs) has been recognised in the Standalone Statement of profit and loss of provision for long-term employment benefit.

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

32 Financial instruments

a. Accounting classification and fair values

The Company is exposed to the risks of changes in fair value of its financial assets and liabilities. The following table summarises the fair values and carrying amounts of financial instruments.

As on 31 March 2023	Note	Carrying value				Fair value measurement using		
		Amortised cost	Financial assets/liabilities at FVTPL	Financial assets/liabilities at FVOCI	Total carrying amount	Level 1	Level 2	Level 3
Financial assets:								
Investment in equity instruments (unquoted)	5	5,067.31	-	-	5,067.31	-	-	-
Trade receivables	9	31,448.79	-	-	31,448.79	-	-	-
Cash and cash equivalents	10	1,025.27	-	-	1,025.27	-	-	-
Bank balances other than cash and cash equivalents	11	418.68	-	-	418.68	-	-	-
Other financial assets	6	1,507.19	-	-	1,507.19	-	-	-
		-						
Financial liabilities:		-						
Non Current borrowings	13 a	40,370.49	-	-	40,370.49	-	-	40,370.49
Current borrowings	14	62,560.05	-	-	62,560.05	-	-	-
Trade payables	17	29,772.29	-	-	29,772.29	-	-	-
Derivatives	18	-	1,174.85	-	1,174.85	-	1,174.85	
Lease liabilities	13 b	1,354.99	-	-	1,354.99	-	-	1,354.99
Other financial liabilities (other than lease liabilities)	18	6,109.33	-	-	6,109.33	-	-	

As on 31 March 2022	Note	Carrying value				Fair value measurement using		
		Amortised cost	Financial assets/liabilities at FVTPL	Financial assets/liabilities at FVOCI	Total carrying amount	Level 1	Level 2	Level 3
Financial assets:								
Investment in equity instruments (unquoted)	5	5,067.31	-	-	5,067.31	-	-	-
Trade receivables	9	28,421.72	-	-	28,421.72	-	-	-
Cash and cash equivalents	10	2,636.96	-	-	2,636.96	-	-	-
Bank balances other than cash and cash equivalents	11	452.29	-	-	452.29	-	-	-
Other financial assets	6	2,710.28	-	-	2,710.28	-	-	-
		-						
Financial liabilities:		-						
Non Current borrowings	13 a	38,060.00	-	-	38,060.00	-	-	38,060.00
Current borrowings	14	49,904.67	-	-	49,904.67	-	-	-
Trade payables	17	30,822.69	-	-	30,822.69	-	-	-
Derivatives	18	-	466.70	-	466.70	-	466.70	
Lease liabilities	13 b	1,715.21	-	-	1,715.21	-	-	1,715.21
Other financial liabilities (other than lease liabilities)	18	6,449.39	-	-	6,449.39		-	

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

32 Financial instruments *(Continued)*

b. The fair value of financial instruments as referred to in note (a) above have been classified into a three categories depending on the inputs used in the valuation technique.

The categories used are as follows:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2 – Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

Level 3 - Inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

c. **Calculation of fair values**

The fair values of the financial assets and liabilities are defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Methods and assumptions used to estimate the fair values are consistent with those used for the year ended March 31, 2023.

(i) The fair values of the derivative financial instruments has been determined using valuation techniques with market observable inputs. The models incorporate various inputs including the credit quality of counter-parties and foreign exchange forward rates. In case the forwards are taken from banks and financial institutions, the fair value is determined using quoted forward exchange rates at the reporting date and present value calculations based on high credit quality yield curves in the respective currencies by the bankers.

(ii) The fair values of investments in mutual fund units is based on the net asset value ('NAV') as stated by the issuers of these mutual fund units in the published statements as at Balance Sheet date. NAV represents the price at which the issuer will issue further units of mutual fund and the price at which issuers will redeem such units from the investors.

(iii) Loans, lease liabilities and borrowings have fair values that approximate to their carrying amounts as it is based on the net present value of the anticipated future cash flows using rates currently available for debt on similar terms, credit risk and remaining maturities.

(iv) Cash and cash equivalents, trade receivables, investments in term deposits, other financial assets (except derivative financial instruments), trade payables, and other financial liabilities (except derivative financial instruments) have fair values that approximate to their carrying amounts due to their short-term nature.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

33 Financial risk management

The Company's Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework.The Board of Directors has established the risk management committee, which is responsible for developing and monitoring the company's risk management policies. The committee reports regularly to the board of Directors on its activities.
The Company's risk management are established to identify and analyse the risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adherence to limits.Risk management policies and systems are reviewed regularly to reflect changes in market conditions and activities.
The Audit committee oversees how management monitors compliance with the company's risk management policies and procedures and reviews the adequacy of the risk management framework in relation to the risks faced by the Company. The Audit committee is assisted in its oversight role by internal audit by external party.

The Company has exposure to the following risks arising from the financial instruments:

a. Credit Risk

Credit risk is the risk of financial loss to the Company if a customer or counter-party fails to meet its contractual obligations and arises principally from the Company's receivables from customers.The carrying amount of financial assets represent the maximum credit exposure.
The Company's exposure to credit risk is influenced mainly by the individual characterisitc of each customer.However, management also consider the factors that may influence the credit risk of its customer base, including the default risk associated with the industry and country in which company operates.
The Company analyses credit worthiness of each new customer individually before standard payment and delivery terms are offered.The Company is monitoring economic environment in countires where it operates and is taking actions to limit its exposure to customers in those countries experiencing particular economic volatility.

Impairment of Trade receivables

At March 31, 2023 the ageing of trade and other receivables that were not impaired was as follows.

	Carrying amount	
	March 31, 2023	March 31, 2022
Neither past due nor impaired	24,038.04	22,801.87
Past due 0-90 days	6,405.38	4,919.50
Past due 90-180 days	731.61	314.87
Past due 180-270 days	162.82	154.63
Past due 270-365 days	88.11	178.70
More than 365 days	22.83	52.15
	31,448.79	28,421.72

Movement in Loss allowance measured at amount equal to life time expected credit losses for trade receivables.

	Amount
Balance as at April 01, 2021	10.86
Impairment loss recognised	20.92
Amounts written off	3.94
Balance as at March 31, 2022	27.84
Impairment loss recognised	-
Amounts written off	-
Balance as at March 31, 2023	**27.84**

The Company uses an allowance matrix to measure the expected credit loss of trade receivables.Based on the industry practices and the business environment in which the entity operates, Management considers that the trade receivables are in default (credit impaired) if the payments are more than 365 days past due.

Management believes that the unimpaired amounts that are past due by more than 30 days are still collectible in full, based on historical payment behaviour and extensive analysis of customer credit risk and the current provision for the bad debts represents the impacted credit loss it foresees in its receivables.

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

a. Credit Risk *(Continued)*

Financial assets other than trade receivables are not impaired and further, there are no amounts that are past due. Management believes that the amounts are collectible in full, based on historical payment behavior.

b. Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company maintains the level of its cash and cash equivalents at an amount in excess of expected cash outflow on financial liabilities.The Company also monitors the level of expected cash inflows on trade and other receivables together with expected cash inflows on trade and other payables

Exposure to liquidity risk:

The following are the remaining contractual maturities of financial liabilities at the reporting date. The amounts are gross and undiscounted, and include estimated interest payments and exclude the impact of netting agreements.

March 31, 2023	Carrying amount	Contractual cash flows				
		Total	1 year or less	1-2 years	2-5 years	More than 5 years
Non-derivative financial liabilities						
Term loans from banks	50,663.47	50,663.47	10,292.98	21,353.23	19,017.26	-
Other borrowings	52,267.07	52,267.07	52,267.07	-	-	-
Trade payables	29,772.29	29,772.29	29,772.29	-	-	-
Other financial liabilities	5,749.11	5,749.11	5,749.11	-	-	-
Lease liability	1,354.99	1,354.99	360.22	994.77	-	-
Derivative financial liabilities						
Interest rate swaps	1,174.85	1,174.85	1,174.85	-	-	-
	1,40,981.78	**1,40,981.78**	**99,616.52**	**22,348.00**	**19,017.26**	**-**

March 31, 2022	Carrying amount	Contractual cash flows				
		Total	1 year or less	1-2 years	2-5 years	More than 5 years
Non-derivative financial liabilities						
Term loans from banks	44,165.64	44,165.64	6,105.64	21,353.23	16,706.77	-
Other borrowings	43,799.03	43,799.03	43,799.03	-	-	-
Trade payables	30,822.69	30,822.69	30,822.69	-	-	-
Other financial liabilities	6,024.59	6,024.59	6,024.59	-	-	-
Lease liabilities	1,715.21	1,715.21	424.80	1,290.41	-	
Derivative financial liabilities						
Interest rate swaps	466.70	466.70	466.70	-	-	-
	1,26,993.86	1,26,993.86	87,643.45	22,643.64	16,706.77	-

The gross inflows/(outflows) disclosed in the above table represent the contractual undiscounted cash flows relating to derivative financial liabilities held for risk management purposes and which are not usually closed out before contractual maturity. The disclosure shows net cash flow amounts for derivatives that are net cash-settled and gross cash inflow and outflow amounts for derivatives that have simultaneous gross cash settlement.

c. Currency Risk

The Company is exposed to currency risk on account of its borrowings and other payables in foreign currency. The functional currency of the Company is Indian Rupee. The Company uses forward exchange contracts to hedge its currency risk, most with a maturity of less than one year

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency. Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

Exposure to currency risk

The currency profile of financial assets and financial liabilities as at March 31, 2023 and March 31, 2022 are as below:

	March 31, 2023	March 31, 2023	March 31, 2022	March 31, 2022
	USD	EURO	USD	EURO
Financial assets				
Cash and cash equivalents	1.03	0.02	8.54	0.10
Trade Receivables	236.84	17.74	255.66	8.87
	237.87	17.76	264.20	8.97
Financial liabilities				
Borrowings	-	22.50	-	30.00
Buyers Credit	29.99	-	16.47	-
Packing credit in foreign currency	-	-	50.00	
Working capital demand Loan	18.36	-	-	-
Trade payables and other financial liabilities	129.44	2.42	180.15	0.56
Other Current financial liabilities - Derivative Instruments Interest rate swap	15.29	0.92	6.11	0.04
	193.08	25.84	252.73	30.60
Net exposure	44.79	(8.08)	11.47	(21.63)

*** The exposure disclosed here is net of currency swap taken by the Company**

Currency exposure for borrowings is exclusive of Currency swap on IDFC Rupee loan of Rs.4,000 lakhs and ICICI bank Rupee loan of Rs.4,000 lakhs are taken @64.42 per USD and @68.13 per USD respectively and other currency swap on HDFC Bank Rupee loan of Rs 5,600 lakhs and Rs 7,400 lakhs are taken @ 76.78 per USD and @ 75.83 per USD respectively which are classified as Indian currency loan.

The Company's corporate treasury function provides services to the business, co-ordinates access to domestic financial markets, monitors and manages the financial risk relating to the operation of the Company through internal risk reports which analyse exposures by degree and magnitude of risks. These risks include market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The use of financial derivatives is governed by the Company's policies approved by the board of directors, which provide written principles on foreign exchange risk, interest rate risk, credit risk. the

The Corporate treasury function reports quarterly to the Company's risk management committee, an independent body that monitors risks and policies implemented to mitigate risk exposures.

d. Sensitivity analysis

A reasonably possible strengthening (weakening) of the foreign currencies against INR at March 31, 2023 would have affected the measurement of financial instruments denominated in US dollars and affected equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases.

	Profit before tax		Equity, net of tax	
Effect in INR	Strengthening	Weakening	Strengthening	Weakening
March 31, 2023				
USD (3 % movement)	110.48	(110.48)	82.67	(72.25)
EUR (3 % movement)	(21.72)	21.72	(16.25)	14.20
	88.76	(88.76)	66.42	(58.05)

	Profit before tax		Equity, net of tax	
Effect in INR	Strengthening	Weakening	Strengthening	Weakening
March 31, 2022				
USD (3 % movement)	26.09	(26.09)	19.52	(17.06)
EUR (3 % movement)	(54.94)	54.94	(41.11)	35.93
	(28.85)	28.85	(21.59)	18.87

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

33 Financial risk management *(Continued)*

e. Interest risk

The company is exposed primarily to fluctuation in USD LIBOR rates. Interest rate risk on financial debt is managed through interest rate

The interest rate profile of the Company's interest-bearing financial instruments is as

	March 31, 2023	March 31, 2022
Fixed-rate instruments	1,02,930.54	87,964.67
Variable-rate instruments	-	-
Total borrowings	1,02,930.54	87,964.67

*Effect of interest rate swaps is disclosed in Note 13 a .

Financial assets classified at amortized cost have fixed interest rate. Hence, the group is not subject to interest rate risk on such financial assets.

Cash flow sensitivity analysis for variable-rate instruments

A reasonably possible change of 100 basis points in interest rates at the reporting date would have increased (decreased) equity and profit or loss by the amounts shown below. This analysis assumes that all other variables, in particular foreign currency exchange rates, remain constant.

	Profit or loss		Equity, net of tax	
	100 bp increase	100 bp decrease	100 bp increase	100 bp decrease
March 31, 2023				
Variable-rate instruments	-	-	-	-
March 31, 2022				
Variable-rate instruments	-	-	-	-

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements (Continued)

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

34 Contingent liabilities:

Claims against the Company not acknowledged as debts are below

	As at 'March 31, 2023	As at 'March 31, 2022
Income tax authorities	932.16	1,787.34
Custom Duty *	106.06	106.06

* Demand of Rs. 15.52 lakhs (out of which Rs. 6.00 lakhs paid) raised by Customs, Excise and Service Tax Appellate Tribunal West Zonal Bench, Mumbai for clearance of imported goods under DEPB scheme. (Contravention of the provisions of Section 111 (o) of the Customs Act, 1962) Further the demand of Rs. 101.53 lakh was raised by Customs authority out of which Rs. 10.98 lakh is paid under protest, balance Rs. 90.54 lakhs are unpaid as on March 31, 2023.

The claims against the Company comprise of pending litigations / proceedings pertaining to demands raised by Excise, Custom, Sales / VAT tax and other authorities / bodies. The Company has reviewed all its pending litigations and proceedings and has adequately provided for where provisions are required and disclosed as contingent liabilities where applicable, in its financial statements. The Company does not expect the outcome of these proceedings to have a materially adverse effect on its financial statements.

It is not practicable for the Company to estimate the timings of cash outflows, if any, in respect of the above pending resolution of the respective proceedings as it is determinable only on receipt of judgements/decisions pending with various forums/authorities.

The Company does not expect any reimbursements in respect of the above contingent liabilities.

35 Commitments

	As at 'March 31, 2023	As at 'March 31, 2022
Estimated amount of contracts remaining to be executed on capital account and not provided for (Net of advances of Rs 647.78 lakhs, (March 31, 2022 : Rs. 1,510.19 lakhs)	2,104.47	3,703.87
LC's issued in favour of suppliers, but the material not dispatched	754.57	1,319.00
Other Investment	1,600.00	-

36 Earnings per share

	As at 'March 31, 2023	As at 'March 31, 2022
Profit after tax attributable to equity shareholders [A]	2,247.49	10,166.48
Number of equity shares at the beginning of the year [B]	3,90,62,706	3,90,62,706
Number of equity shares outstanding at the end of the year [C]	3,90,62,706	3,90,62,706
Weighted average number of equity shares outstanding during the year [D]	3,90,62,706	3,90,62,706
Basic and diluted earnings per share of face value Rs. 10 [A]/[D]	5.75	26.03

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements (Continued)

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

37 Revenue from Contracts with Customers

(A) The Company is primarily in the business of manufacture and sale of Aroma chemicals. All sales are made at a point in time and revenue recognised upon satisfaction of the performance obligations which is typically upon dispatch/ delivery. The Company has a credit evaluation policy based on which the credit limits for the trade receivables are established, the Company does not give significant credit period resulting in no significant financing component.

(B) Reconciliation of revenue recognised from Contract liability:

Particulars	As at March 31, 2023	As at March 31, 2022
Opening Contract liability	264.01	116.67
Less Recognised as revenue during the year	2,697.06	1,324.79
Add: Addition to contract liability during the year	8,040.23	1,472.13
Closing Contract liability	5607.18	264.01

Contract liability primarily relates to advance consideration received from customers for sale of products in case of few contracts based on terms agreed. The contract liability is expected to be recognised within 12 months.

There is no contract asset as at 31 March 2023(31 March 2022 : Nil)

(C) Reconciliation of revenue as per contract price and as recognised in statement of standalone profit and loss:

Particulars	As at March 31, 2023	As at March 31, 2022
Revenue from contract with customer as per Contract price	1,57,570.03	1,39,117.94
Less Discounts and other adjustments	28.21	105.41
Revenue from contract with customer as per statement of standalone profit and loss	1,57,541.82	1,39,012.53

(D) Disaggregation of revenue from contract with customers

Particulars	Revenue from contracts with customers March 31, 2023	Revenue from contracts with customers March 31, 2022
India	40,270.01	39,453.68
Europe(excluding UK)	37,776.94	33,198.47
North America	41,703.11	32,334.13
Asia (Excluding India)	18,564.10	15,776.38
Middle East	7,448.09	7,930.81
United Kingdom	5,170.08	5,819.30
South America	3,872.38	3,048.67
Africa	2,658.01	1,772.44
Australia and New Zealand	84.14	68.63
	1,57,541.82	1,39,012.53

(E) Unsatisfied Performance Obligations

The Company applies the practical expedient in Paragraph 121 of Ind AS 115 and does not disclose information about remaining performance obligations.

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements (Continued)

for the year ended March 31, 2023

(Currency: Indian Rupees in lakhs)

38 Dividend on equity shares

	As at March 31, 2023	As at March 31, 2022
Dividend on equity shares declared and paid during the		
Final dividend for the year ended March 31, 2022 -Rs. 2.00 (March 31, 2021 Rs. 2.00) per fully paid up share	781.21	781.21
(Amount of Cash-out flow of dividend is inclusive of dividend distribution tax.)		
	781.21	781.21
Dividends not recognized at the end of reporting period		
Final dividend of Rs. 0.00 per fully paid up equity shares (March 31, 2022 Rs. 2.00 per fully paid up share). This proposed dividend is subject to the approval of share holders in the ensuing annual general meeting	-	781.21
	-	781.21

39 Transfer Pricing

Transactions with related parties are governed by transfer pricing regulations of the Indian Income-tax Act, 1961. The Company's international and domestic transactions with related parties are at arm's length as per the independent accountants report for the year ended March 31, 2022. Management believes that the Company's international and domestic transactions with related parties post March 2022 continue to be at arm's length and that the transfer pricing legislation will not have any impact on the financial statements, particularly on the amount of tax expense and that of provision for taxation.

40 Exceptional items

a) Flood claim settlement (Net) :- Unprecedented rainfall on July 22 and 23, 2021 in Raigad district of Maharashtra including Mahad and consequent overflow of Savitri river caused flooding and major power outage in and around Mahad. The factory operations at the units were temporarily suspended. The necessary steps were taken to resume the operations in phased manner from August 12, 2021 after taking into consideration the safety norms. There has been loss to assets comprising of Inventories, Plant & Machineries and Other fixed assets, etc. The profitability has also been impacted due to loss of sales. All the said losses are adequately insured including coverage towards loss of profit and replacement cost of fixed assets.

As per Management's best estimate, the book value of the assets lost due to flood including other expenses for the year ended March 31, 2022 is Rs. 1,791.28 lakhs which is debited to the statement of profit and loss and is disclosed as an exceptional item and netted off with final insurance claim settlement aggregating to Rs. 2,320.51 lakhs for which a settlement letter is also issued by insurance company resulting in an exceptional gain(net) of Rs. 529.24 lakhs for the year ended March 31, 2022. The Company has received partial insurance claim of Rs. 1,000 lakhs from the insurance company which is recognised in the quarter ended September 30, 2021. The balance amount of Rs.1,320.51 lakhs (of which Rs. 300 lakhs is received subsequent to the balance sheet date) is shown as receivable from insurance company in balance sheet as at March 31, 2022. The entire insurance claim settlement amount is being recognised in the statement of profit and loss as per the requirement of Accounting Standards.

41 Estimation of uncertainties related to global health pandemic from COVID-19

Government of India announced a Nationwide Lockdown due to Covid-19 Global Pandemic due to which the Compnay shutdown few of its plants at Mahad & Jhagadia factories (except those involved in manufacture of chemicals used in essential goods) from March 24,2020 which continued till April 7, 2020. Although sales were partially affected during the period of shutdown, however, impact is not significant. The Company had not seen any significant impact on net realisable value of its current assets.

The Global pandemic Covid-19 continued in the year 2021-22 as well. The business of the Compnay was not affected during the year. However, the completion of major capex project were delayed by 4 to 5 months due to second wave of Covid-19 during the period March 2021 to July 2021, on account of non-availability of labour, transport facilities, industrial oxygen, etc. Further, given the uncertainty due to Covid-19, the Company would continue to monitor any material changes to future economic conditions and the consequential impact on the standalone financial statements.

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

42 Other Statutory Information

a) Other informations

(i) As on March 31, 2023 there is no untilised amounts in respect of any issue of securities and long term borrowings from banks and financial institutions. The borrowed funds have been utilised for the specific purpose for

which the funds were raised

(ii) The Company do not have any transactions with struck off companies

(iii) The Company do not have any charges or satisfaction which is yet to be registered with Registrar of Companies beyond the statutory period

(iv) The Company is in compliance with the number of layers prescribed under clause (87) of section 2 of the Companies Act read with the Companies (Restriction on number of Layers) Rules, 2017

(v) The Company do not have any Benami property, where any proceeding has been initiated or pending against the Company for holding any Benami property

(vi) The Company have not traded or invested in Crypto currency or Virtual Currency during the financial year

(vii) The Company have not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries

(viii) The Company have not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (Ultimate Beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries

(ix) The Company have not entered in any such transaction which is not recorded in the books of accounts that has been surrendered or disclosed as income during the year in the tax assessments under the Income Tax Act, 1961 (such as, search or survey or any other relevant provisions of the Income Tax Act, 1961

b) Changes in accounting policy : The Company has changed its accounting policy in respect of valuation of inventory - Indian Accounting Standard (Ind AS) 2 – Inventories

The change in accounting policy for valuation of inventory is from First in First out to Periodic Weighted Average Method, retrospectively, to the earliest period reported on voluntary basis. The change is owing to more reliable, relevant information being available through newly migrated accounting system, SAP and resulting in better presentation

Inventories include Raw Material, Packing Material, Fuel, consumable stores and spares are valued and determined basis of Periodic Unit Price Moving Weighted Average Method as against First in first out adopted until 31 March 2022. The Company has implemented SAP S4 Hana integrated ERP system from current financial year as against the earlier oracle R12.1.1 ERP system. SAP ERP system is more robust and conducive to the manufacturing operations. It provides real time data across modules. Inventory valuation now automated from SAP system and gives granular details and valuations of items at various stage of its operations. The Company thought it prudent to move from the legacy FIFO basis of valuation to the Periodic Moving Weighted Average Method of the SAP ERP system. This is also in line with the global practices followed in the industry. The voluntary change in method of valuation of Inventory is in the nature of Change in Accounting Policy and requires retrospective application as per Ind AS 8. As per the detailed assessment and re-computation performed by the Management, the impact thereof is not to be material and hence the financial statements are not re-stated to the earliest reported period.

This change has resulted in inventories being higher than Rs 19 02 lakhs and corresponding effect in the retained earnings as at 31 March 2023. There is no significant impact on the opening equity as a result of the change. The impact on basic and diluted EPS is not material.

43 Corporate social responsibility

As per section 135 of the Companies Act, 2013 a corporate social responsibility (CSR) committee has been formed by the Company. The areas for CSR activities are Education, Environment Sustainability, Health and hygiene and Disaster Management. Amount spent during the year on activities which are specified in Schedule VII of the Companies Act 2013 are as mentioned below:

Particulars	Year ended March 31, 2023	Year ended March 31, 2022
a) amount required to be spend by the company / amount approved by the board for the year	333.00	250 68
b) amount of expenditure till date:		
Paid		
(i) construction / acquisition of any asset		
(ii) on purpose other than (i) above	333.00	255 53
Yet to be paid		
(i) construction / acquisition of any asset	-	-
(ii) on purpose other than (i) above	-	-
Total	333.00	255 53
c) shortfall at the end of the year	-	-
d) reason for shortfall	NA	NA
e) total of pervious year shortfall	NA	NA
f) nature of CSR activities	Education, Environment Sustainability, Health and hygiene and Disaster Management	Education, Environment Sustainability, Health and hygiene and Disaster Management

BSR & Co. LLP Chartered Accountants

Privi Speciality Chemicals Ltd Navi Mumbai

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31, 2023

44 **Additional Regulatory Information**

Ratio	Numerator	Denominator	Year ended March 31, 2023	Year ended March 31, 2022	% Variance
Current Ratio (in times)	Total current assets	Total current liabilities	1.07	1.11	-3.60%
Debt - Equity ratio (in times) (net)	Debt consists of borrowings Less Cash and cash equivalents and short term investments	Total equity	1.23	1.05	17.14%
Debt service coverage ratio (in times)	Net profit before tax + Depreciation + Interest (EBITDA)	Debt service = Interest + Principal repayments	1.59	4.01	-60.35%
Return on equity ratio (in %)	Net profit after tax for the	Equity share capital	2.76%	17.00%	-83.76%
net capital turnover ratio (in times)	Revenue from operationsAverage	Average working capital (i e Total current assets less Total current liabilities)	17.5	8.39	108.58%
net profit ratio (in %)	Net profit after tax for the	Revenue from operations	1.42%	10.00%	-85.80%
return on capital employed (in %)	Profit before tax and finance costs	Total equity + Borrowings +Deferred tax liabilities (net)	5.23%	20.00%	-73.85%
Inventory turnover ratio	Average Inventory	Revenue from operations	0.41	0.40	2.50%
Trade receivable turnover ratio	Average Trade receivable	Revenue from operations	0.19	0.20	-5.00%
Trade payables turnover ratio	Average Trade payables	Purchases	0.26	0.22	18.18%

For B S R & Co. LLP
Chartered Accountants
Firm's Registration No: 101248W/W-100022

Jayesh T Thakkar
Partner
Membership No: 113959

Mumbai
Date : May 29, 2023

For and on behalf of the Board of Directors of
Privi Speciality Chemicals Limited

Mahesh Dubani
Chairman & Managing Director
DIN: 00051162

D. D. Rao
Executive Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No:A-58378

Mumbai
Date : May 29, 2023

Privi Speciality Chemicals Ltd Navi Mumbai

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

AUDITOR'S REPORT

To the Members of PRIVI FINE SCIENCES PRIVATE LIMITED

Report on the Financial Statements

We have audited the accompanying financial statements of **PRIVI FINE SCIENCES PRIVATE LIMITED** ("the Company"), which comprise the standalone balance sheet as at 31st March 2025, and the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as 'standalone financial statements')..

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2025, and its loss and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Emphasis of Matter

With reference to note no.29 of Financial Statement which specifies the basis of Scheme of merger of M/s Privi Organics Ltd and Privi Fine Science Pvt. Ltd from retrospective date 1st April 2023 as approved by the National Company Law Tribunal (NCLT) Mumbai bench. As per the requirement of Appendix C to Ind AS-103 the merger has been given effect to as if it has occurred from the beginning of the year i.e.1st April 2023 in the financial statement.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. **As required by section 143 (3) of the Act, we report that:**

   a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

   b. In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books [and proper returns adequate for the purposes of our audit have been received from branches not visited by us];

   c. The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account;

   d. In our opinion, the Balance Sheet and Statement of Profit and loss comply with the Accounting Standards referred to in Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014

   e. On the basis of the written representations received from the Directors as on 31 March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2025 from being appointed as a director in terms of Section 164 (2) of the Act; and.

   f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".

FOR E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS

ESMAIL SITABKHAN
PROPRIETOR
M. No. O-30721
Firm Reg. No.110300W
UDIN: 25030721BMJACT9840

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Place: Mumbai
Date: 5th June 2025

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

PRIVI FINE SCIENCES PRIVATE LIMITED

"Annexure A" to the Independent Auditors' Report – 31 March 2025

(Referred to in our report of even date)

(i) **(a)** (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment items purchased but not pending for installation.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) All fixed assets are physically verified by the management in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. The physical verification of fixed assets was done in financial year 2024-25 and No material discrepancies were noticed on such verification.

(c) According to the Information and explanations given to us and on the basis of our verification of records of the Company, the title deed of Lease hold land Plot no. C-39, C-39(Part) ,MIDC lote , Tq.- Khed, Dist. Ratnagiri held in the name of M/s Privi Organics Limited (the Transferor Company) prior to merger. The merger scheme of M/s Privi Organics Ltd. (the Transferor Company) and M/s Privi Fine Sciences Pvt. Ltd. (the Transferee Company) duly approved by NCLT Mumbai Bench. Subsequently the transferee company has applied for change of name to MIDC authority at Ratnagiri for transfer of title deed of leasehold land in the name of transferee company and the matter is pending with the authority and order for transfer is awaited.

As regards Factory building and other assets held in the name of the M/s Privi Organic Limited, the reason for not being in the name of Company is that the matter is pending for adjudication and after the payment of duties amount the assets will be transferred in the name of transferee Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) As explained to me, the inventories are physically verified during the year by the Management at reasonable intervals and no material discrepancies are noticed on such physical verification.

(b)(1) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has sanctioned working capital facility from banks or financial institutions.

(2) The quarterly returns or statements filed by the company with such banks or financial institutions are in agreement with the books of account of the Company.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(iii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company has not made Investment during the
(b) The terms and conditions of investments made are not prejudicial to the interest of the company.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any security as specified under section 185 and 186 of the Companies Act, 2013. In respect of investment made by the Company the Provision of sec 186 of the Act has been complied with.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) In our opinion the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013 is not applicable to Company.

(vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues have been generally regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.

(b) The company has not declared willful defaulter by any bank or financial institution or other lender.

(c) The company has obtained term loan and its being used for the purpose it was obtained;

(d)According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures; hence this clause is not applicable;

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(f) The company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies; hence this clause is not applicable.

(x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) (a) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has no internal audit system commensurate with the size and nature of its business.

(b) Since there is no internal audit system, the question of considering the internal audit report of the company does not arise.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has incurred a cash loss during the year amounting to Rs.2217 Lakhs.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

FOR E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS

ESMAIL SITABKHAN
PROPRIETOR
M. No. O-30721
Firm Reg. No.110300W
UDIN: 25030721BMJACT9840

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Place: Mumbai
Date: 5th June 2025

Privi FINE SCIENCES PVT. Ltd.

Registered / Corporate Office : A-71, MIDC, TTC, THANE BELAPUR ROAD< NAVI MUMBAI - 400 709.

BALANCE SHEET &

PROFIT & LOSS ACCOUNT

(ALONGWITH NOTES)

31-03-2025

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U241110MH2021PTC358857

BALANCE SHEET AS AT 31st March 2025

(Currency: Indian Rupees in Lakhs)

Particulars	Refer to Note No.	As at 31st March 2025	As at 31st March 2024
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	3	**23,382.92**	20,489.35
(b) Reserves and Surplus	4	**(2,525.48)**	(227.81)
(2) Non-Current Liabilities			
(a) Long-Term Borrowings	5	**4,387.93**	5,926.00
(b) Deferred Tax Liabilities (Net)	6	**388.69**	330.15
(3) Current Liabilities			
(a) Short-Term Borrowings	7a	**241.54**	-
(b) Trade Payables	7b	**1,647.27**	1,545.00
(c) Other Current Liabilities	8	**1,134.42**	724.29
Total Equity & Liabilities		**28,657.29**	28,786.98
II.ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	**12,030.80**	13,230.42
(ii) Intangible Assets	9	**6,301.43**	6,301.43
(iii) Capital Work-in-Progress	9	**4,662.31**	2,974.18
(2) Current Assets			
(a) Current Investments	10	**-**	1,369.63
(b) Inventories	11	**1,262.00**	770.99
(c) Trade Receivables	12	**1,502.87**	767.90
(d) Cash and Cash Equivalents	13	**54.13**	342.61
(e) Short-Term Loans and Advances	14	**234.00**	750.27
(f) Other Current Assets	15	**2,609.75**	2,279.50
Total Assets		**28,657.29**	28,786.98
Significant Accounting Policies	2		
Notes Forming Integral Part of the Financial Statement	3 - 31		

This is the Balance Sheet referred to in our Report of even date.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of
Privi Fine Sciences Pvt. Ltd.
CIN:U241110MH2021PTC358857

Snehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Rathuria
Company Secretary

Arun Newalkar
Chief Financial Officer

Place : Mumbai
Date : 5th June, 2025

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U241110MH2021PTC358857

PROFIT & LOSS STATEMENT FOR THE PERIOD ENDED ON 31st March, 2025

(Currency: Indian Rupees in Lakhs)

Sr. No	Particulars	Refer to Note No.	Year Ended 31st March 2025	Year Ended 31st March 2024
I	Revenue from operations	16	**4,825.16**	472.54
I	Other Income	17	**389.82**	334.77
III	**III. Total Revenue (I +II)**		**5,214.98**	807.31
IV	**Expenses:**			
	Cost of materials consumed	18	**3,947.76**	449.86
	Changes in inventories	19	**(285.67)**	-
	Employee Benefit Expense	20	**835.72**	103.14
	Financial Costs	21	**356.57**	40.68
	Depreciation and Amortization Expense	22	**1,228.61**	96.66
	Other Expenses	23	**2,528.55**	91.13
	Total Expenses (IV)		**8,611.54**	781.47
			-	
			-	
V	Profit/(Loss) before exceptional and extraordinary items and tax	(III - IV)	**(3,396.56)**	25.84
VI	Exceptional Item		-	-
VII	Profit/(Loss) before extraordinary items and tax (V - VI)		**(3,396.56)**	25.84
VIII	Extraordinary Items		-	-
IX	Profit/(Loss) before tax (VII - VIII)		**(3,396.56)**	25.84
X	**Tax expense:**			
	(1) Current Tax		-	-
	(2) Deferred Tax		**58.54**	249.65
XI	Profit /(Loss) from the perid from continuing operations	(IX-X)	**(3,455.10)**	(223.81)
XII	Profit/(Loss) from discontinuing operations		-	-
XIII	Tax expense of discounting operations		-	-
XIV	Profit/(Loss) from Discontinuing operations (XII - XIII)		-	-
XV	Profit/(Loss) for the period (XI + XIV)		**(3,455.10)**	(223.81)
XVI	Earning per equity share:			
	(1) Basic		**(1.48)**	(0.11)
	(2) Diluted		**(1.48)**	(0.11)
	Significant Accounting Policies	2		
	Notes Forming Integral Part of the Financial Statement	3-31		
	This is the statement of Profit & Loss referred to in our Report of even date.			

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Place : Mumbai
Date : 5th June, 2025

For and on behalf of the Board of
Privi Fine Sciences Private Limited
CIN:U241110MH2021PTC358857

Snehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary

Arun Newalkar
Chief Financial Officer

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U241110MH2021PTC358857

CASH FLOW STATEMENT FOR THE YEAR ENDED 31st March 2025

(Currency: Indian Rupees in Lakhs)

	Particulars	As At 31st March 2025	As At 31 March 2024
A	**Cash flows from operating activities**		
	Net profit or (Loss) before tax	(3,396.56)	25.84
	Adjustments for :		
	Depreciation and amortisation	1,228.61	96.66
	Interest Received	(58.27)	(66.87)
	Interest Expenses	356.57	40.68
	Gain on sale of Investment	(19.39)	(179.85)
	Operating profit before working capital changes	(1,889.04)	(83.54)
	Operating cash flow before working capital changes		
	(Increase)/ Decrease in trade receivables	(734.97)	(606.61)
	(Increase)/ Decrease in Inventories	(491.01)	(595.00)
	Decrease / (Increase) in loans and advances	516.27	(512.16)
	(Increase) / decrease in other assets	(330.25)	(670.21)
	Increase/(Decrease) in Other Current Liabilities	410.13	(193.14)
	Increase/(Decrease) in Trade Payables	102.27	(40.25)
	Cash generated from operations	(527.56)	(2,617.37)
	Income taxes paid	(2,416.60)	(2,700.91)
	Net cash generated from operating activities (A)	(2,416.60)	(2,700.91)
B	**Cash flows from investing activities**		
	Purchase of Property , Plant & Equipment	(1,717.11)	(4,463.71)
	Sale/(Purchase) of current investment	1,369.63	1,889.32
	Profit on Sale of Investment	19.39	179.86
	Interest Paid	-	(40.68)
	Interest received	58.27	66.87
	Net cash (used in) investing activities (B)	(269.82)	(2,368.34)
C	**Cash flows from financing activities**		
	Issue of Share Capital	2,893.57	11,384.91
	Security premium	1,157.43	-
	Increase/(Decrease) in Long Term Borrowing	3,450.51	3,488.50
	Increase/(Decrease) in Short Term Borrowing	241.54	(4,500.00)
	Repayment of long term Borrowings	(4,988.58)	(5,045.10)
	Interest Paid	(356.57)	-
	Net cash (used in) / generated from financing activities (C)	2,397.90	5,328.30
	Net (decrease) / increase in cash and cash equivalents (A+B+C)	(288.52)	259.11
	Cash and cash equivalents at beginning of the year	342.61	83.50
	Cash and cash equivalents at end of the year	54.13	342.61
		(288.52)	259.11

ii) The cash flow statement has been prepared under the indirect method as set out in Accounting Standard-3 (AS-3) on cash flow statement issued by Companies (Accounting Standards) Rules,2006.

The notes referred to above form an integral part of the Provisional financial statements.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 5th June, 2025

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of
M/s.Privi Fine Sciences Private Limited
CIN:U241110MH2021PTC358857

Snehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary

Arun Newalkar
Cheif Financial Officer

Privi Fine Sciences Private Limited

Notes to the financial statements *(Continued)*

for the period from 01 April 2024 to 31 March 2025

(Currency: Indian Rupees in Lakhs)

1 Company overview

Privi Fine Sciences Pvt. Ltd. ("Privi" or "the Company") is a manufacturer, exporter, and trader in Specialty chemicals and other chemical products having presence in Maharahtra & Gujarat State. The unit located at Lote Parshuram MIDC, Dist.- Ratnagiri in Maharashtra commenced it's manufacturing operations from 30th September, 2023 at factory located at Plot No. C-39 & C-39 (Part), MIDC Lote, Tq.-Khed, Dist.- Ratnagiri.

The unit located at Jhagadia, Dist.Bharuch in the state of Gujarat has acquired land during the year 2022-23 for the purpose of manufacturing the products, is in the process of acquiring various statutory permissions from regulatory authorities to start the construction of the project for manufacture of the products using the green technology. The Company intends to manufacture Furfural, Furfuryl Alcohol, Cyclopentanone, Ethanol ,Vanillin, Maltol, Ethyl Maltol etc. from natural renewable materials.

2 Significant accounting policies

The accounting policies set out below have been applied consistently to the periods presented in these financial statements.

2.1 Basis of preparation of financial statements

The financial statements have been prepared and presented under the historical cost convention on an accrual basis of accounting and in accordance with the accounting principles generally accepted in India and comply with the accounting standards referred in the Companies (Accounting Standards) Rules, 2006 which continue to apply under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Account) Rules, 2014 and other relevant provision of the Companies Act, 1956 to the extent applicable. The financial statements are prepared on the Historical Cost basis and on the principles of a going concern.

2.2 Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in India requires management to make estimates and assumptions that affect the reported amount of assets, liabilities, and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

2.3 Current and non-current classification

Schedule III to the Companies Act, 2013 requires assets and liabilities to be classified as either Current or Non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is expected to be realised within 12 months after the reporting date; or

(d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is due to be settled within 12 months after the reporting date; or

(d) the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include the current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents and is 12 months for the Company.

2.4 Inventories

Inventories which comprise Raw material, packing material, stock-in-trade, stores and spares, and work-in-process are carried at a lower of cost and net realizable value. Costs include purchase price (net of refundable taxes and levies) and other costs incurred in bringing the inventories to their present location and condition. The closing stock of finished goods is valued at cost or net realizable value, whichever is lower.

2.5 Revenue Recognition

Revenue from the sale of goods in the course of ordinary activities is recognized when property in the goods or all significant risks and rewards of their ownership is transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection.

E.E. SITABKHAN & CO. MUMBAI Charter

2.6 Fixed Asset

Tangible assets are stated at cost less accumulated depreciation and net of impairment if any. The cost of an asset comprises its purchase price (net of taxes if any) and the directly attributable cost of bringing an asset to working condition for its intended use.

Leasehold land is amortized at a rate, which will reduce the lease amount to "Nil" at the expiry of the remaining period of the lease.

Depreciation is provided on the Straight line method at the rate specified in Schedule II and provisions made therein, of the Companies Act, 2013 on the Original Cost of the assets. The rate of depreciation is charged per triple shift of work. Asset costs individually depreciated up to 95% of the cost of each Individual asset only.

2.7 (i) Depreciation and Amortization

Depreciation is calculated using the straight-line method to calculate the cost of Property Plant and equipment net of residual values, over their estimated useful lives as per the useful lives prescribed in Schedule II of the Companies Act, 2013 except in the case of the following class of assets where useful life is based on technical evaluation of the management:

Asset Class	Useful life Considered
Factory Building	30 Years
Plant & Machinery	10 Years
Furniture & Fixtures	16 Years
Office Equipment	10 Years
Computers	6 Years
Vehicle	10 Years

Depreciation on additions/ deletions during the year is provided from the month in which the asset is capitalized up to the month in which the asset is disposed off.

The estimated useful lives, residual values, and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

(ii) Intangible assets & Amortization

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

2.8 Retirement Benefits

Provident Fund: Provident Fund contributions are made to the Government Provident Fund Authority

Gratuity: The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary using the projected unit credit method. All expenses related to the defined benefit plan are recognized in employee benefits expense in the Statement of Profit and Loss.

Compensated Absences: The Company provides for encashment of leave or leaves with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/ availment. The Company makes

F. E. SITABKHAN & CO. MUMBAI Chartered Accountants

provision for compensated absences based on an Independent external actuarial valuation carried out at the end of the year.

2.9 Provisions and contingent liabilities

A provision is recognized if, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognized at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an undiscounted basis.

A contingent liability exists when there is a possible but not probable obligation or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of an outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

2.10 Taxes on Income

Current Tax:- Provision for Income Tax is determined in accordance with the provision of the Income Tax Act 1961.

Deferred Taxation: Income tax expense comprised current tax and deferred tax charge or release. The deferred tax charge or credit is recognized using current tax rates. Deferred tax assets are recognized only if there is virtual certainty of realization of such amounts.

2.11 Earnings per share ('EPS')

Basic EPS is computed using the weighted average number of equity shares outstanding during the year. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the year except where the results would be anti-dilutive.

2.12 Cash and cash equivalent

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN:U241110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement:

(Currency: Indian Rupees in Lakhs)

3 Share Capital

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	AUTHORIZED CAPITAL 24,00,00,000 Equity shares of Rs. 10 each (PY 20,50,00,000 Equity Shares of Rs.10 each	**24,000.00**	20,500.00
		24,000.00	20,500.00
	ISSUED , SUBSCRIBED & PAID UP CAPITAL 23,38,29,210 Equity Shares of Rs.10/- each fully paid up (PY 20,48,93,496 Equity Shares of Rs. 10/- each fully paid up)	**23,382.92**	20,489.35
	Total	**23,382.92**	20,489.35

Pursuant to the Scheme of Merger of Privi Organics Limited (POL) with Privi Fine Sciences Pvt Limited (PFSPL), the National Company Law Tribunal (NCLT) issued an order of Merger in the month of 19th December 2023 and a revised order was issued on 13th March, 2024. The Company, then accordingly, had filed an NCLT order in form INC-28 with MCA.

The Authorised Share capital of POL was Rs. 5000 lakhs and Paid-up Capital was Rs. 4699.66 lakhs. The authorised Capital of PFSPL was Rs. 5500 lakhs and the paid-up Capital was Rs. 5215.46 lakhs. Post-merger the Authorized Capital of both the companies would have been Rs. 10500 lakhs.

The combined authorised share capital of the company post-merger was reflected on 29th May 2024 on the MCA portal. Now, the company is in the process of filing the necessary forms with MCA to increase its authorized share capital from 10500 lakhs to 20500 lakhs and allotment of shares.

As per the Scheme of Merger, the shareholders of POL were entitled for 3.25 shares of PFSPL per one Equity share of POL. In order to allot shares of PFSPL, the company has increased its Authorised Capital from Rs.10500 lakhs to Rs. 20500 lakhs at its Board Meeting held on 29th March , 2024, and member's approval was obtained at EGM held on 30th March , 2024. The company then has allotted shares on 31 March, 2024 accordingly.

3(A) Reconciliation of no. of Shares outstanding

Particulars	Equity Shares		Equity Shares	
	As At 31st March 2025		As At 31st March 2024	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**20,48,93,496**	**20,489.35**	10,000	1.00
Shares Issued during the period	**2,89,35,714**	**2,893.57**	20,48,83,496	20,488.35
Share Premium	-	-	-	-
Shares bought back during the period	-	-	-	-
Shares outstanding at the end of the period	**23,38,29,210**	**23,382.92**	20,48,93,496	20,489.35

3(B) Details of shareholders holding of more than 5% shares

Sr. No.	Name of Shareholder	As At 31st March 2025		As At 31st March 2024	
		No. of Shares held	% of Holding	No. of Shares held	% of Holding
	Vivira Investments & Trading Private Limited	**13,09,05,950**	**55.98%**	13,09,05,950	63.89%
	Mahesh P Babani	**4,64,10,544**	**19.84%**	4,64,10,543	22.65%
	Karma Fine Sciences PTE Ltd.	**2,89,35,714**	**12.37%**	-	-
	Money Mart Secutrities Pvt. Ltd.	**1,36,43,187**	**5.83%**	1,36,43,187	6.66%
		21,98,95,395	94.02%	19,09,59,680	93.20%

4 Reserve & Surplus:

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	Surplus (Profit & Loss Account)		
	Balance brought forward from previous year	**(227.81)**	(4.00)
	Add: Profit / (Loss) for the period	**(3,455.10)**	(223.81)
	Less: Utilised during the period	-	-
	Less: Transfer to reserve	-	-
	Closing Balance	**(3,682.91)**	(227.81)
	Share Premium		
	Balance brought forward from previous year	-	-
	Add: Addition during the period	**1,157.43**	-
	Less: Utilised during the period	-	-
	Closing Balance	1,157.43	-
		1,157.43	-
	Total	**(2,525.48)**	(227.81)

5 Long-Term Borrowings

Sr. No	Particulars	Non-Current Portion		Current Portion	
		As At 31st March 2025	As At 31st March 2024	As At 31st March 2025	As At 31st March 2024
	Secured				
	Term Loan from banks (refer note (I))	**937.42**	1875.00	**750.00**	562.50
	TermLoan in Indian Currency				
	Unsecured				
	ECB loan (refer note (II))	-	4051.00	-	-
	Other loans	**3450.51**		-	-
		4,387.93	5,926.00	**750.00**	562.50

i)	Term loans are secured by a first mortgage on the Company's immovable properties both present and future and a first charge by way of all the company's assets except book debts and inventories including movable machinery (and expect spare tools and accessories) both present and future subject to charges created favour of the company's bankers for inventories, book debts, and other specified movable assets for securing the borrowings of working capital.
ii)	During the year pursuant to the ECB loan agreement, On 31st December, 2024 company has converted the outstanding loan amount of Rs. 4051 lakhs into 2,89,35,714 equity shares of Rs. 10 Each, at a premium of Rs.4 per Share. The necessary compliance related to MCA have been duly completed & RBI compliances are in progress.

Notes Forming Integral Part of the Financial Statement:

(Currency: Indian Rupees in Lakhs)

III) **Terms and repayment schedule of Term Loan**
Terms and conditions of outstanding borrowings are as follows:

Name of the bank	Installment	Interest rate	Year of Maturity	Carrying amount As At 31st March 2025	Carrying amount As At 31st March 2024
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.28,75,000 each starting from August 2023.	8.25%	2027	258.75	373.75
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.32,81,250 each starting from August 2023.	8.50%	2027	295.31	426.56
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.14,06,250 each starting from August 2023.	9.05%	2027	126.56	182.81
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.13,43,750 each starting from August 2023.	9.05%	2027	134.37	174.69
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.6,81,250 each starting from August 2023.	9.20%	2027	47.87	88.56
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.91,62,500 each starting from August 2023.	9.20%	2027	824.57	1191.13
				1,687.42	2,437.50

6 Deferred Tax Liability (Net):

Sr. No	Partiulars	As At 31st March 2025	As At 31st March 2024
	Deferred Tax Liability		
	- Related to Fixed Assets	388.69	330.15
	Deferred Tax Assets		
	- Related to Fixed Assets	-	-
	Deferred Tax Liabilities (Net)	388.69	330.15

7a Short Term Borrowings:

Sr. No	Particulars	As At 31st March, 2025	As At 31st March 2024
	HDFC Bank	21.96	-
	ICICI Bank	219.58	-
	Total	241.54	-

Note: Secured against hypothecation of stocks and sundry debtors

7b Trade Payable:

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	Sundry Creditors For Goods	1,647.27	1,545.00
	Total (A + B)	1,647.27	1,545.00

The Company has not received any intimation from the "Supplier" regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence the disclosure relating to amount unpaid as at the end of the year together with interest paid / payable as required under the said Act has not been furnished and provision for interest, if any, on delayed payments, is not ascertainable at this stage.

8 Other Current Liabilities:

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	Other liabilities- expenses	288.34	116.09
	Statutory liabilities	48.03	10.50
	Current maturities of long term borrowing (refer note 5)	750.00	562.50
	Provision for Gratuity and leave encashment	68.05	35.20
	Total	1,134.42	724.29

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN:U241110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement as at 31st March,2025

9 Fixed Assets

(Currency: Indian Rupees in Lakhs)

Sr. No	Particulars	Gross Block				Depreciaton				Net Block As on	
		As on 01.04.2024	Total Additions	Deduction	As on 31.03.2025	As on 01.04.2024	For the period	Deductions	As on 31.03.2025	As on 31.03.2025	As on 31.03.2024
I	Intangible Assets										
	Goodwill	6,301.43	-	-	6,301.43	-	-	-	-	6,301.43	6,301.43
	Total	6,301.43	-	-	6,301.43					6,301.43	6,301.43
II	Tangible Assets										
1	Leasehold Land (U1)	156.50	1.65	-	158.15	8.47	2.18	-	10.65	147.50	148.03
2	Leasehold land (U2)	1,777.42	-	-	1,777.42	26.69	21.35	-	48.04	1,729.38	1,750.73
3	Building	714.26	-	-	714.26	26.93	23.86	-	50.79	663.47	687.33
4	Plant & Machinery	10,588.89	-	-	10,588.89	675.91	1,094.89	-	1,770.80	8,818.09	9,912.98
5	Electrical Installation	482.02	-	-	482.02	24.19	49.84	-	74.03	407.99	457.83
6	Furniture & Fixtures	8.67	5.39	-	14.06	1.22	0.69	-	1.91	12.15	7.45
7	OfficeE Equipments	13.48	4.25	-	17.73	1.55	1.59	-	3.14	14.59	11.93
8	Computers	18.98	17.69	-	36.67	6.11	4.87	-	10.98	25.69	12.87
9	Vehicle	308.79	-		308.79	67.52	29.34	-	96.86	211.93	241.27
	Total	14,069.01	28.98	-	14,098.00	838.59	1,228.61	-	2,067.20	12,030.80	13,230.42
	Capital Work in Progress	2,974.18	1,688.13	-	4,662.31	-	-	-	-	4,662.31	2,974.18
		-	-	-	-	-	-	-	-	-	-
	Total	17,043.19	1,717.11	-	18,760.30	838.59	1,228.61	-	2,067.20	16,693.10	16,204.60

During the year Capital work in progress includes Rs.NIL - towards Trial run expenses (PY: 2024 Rs.1668.75-lakhs) (Refer Note: 29) and preoperative expenses incurred Rs. NIL lakhs (PY- Rs. 781.36 Lakhs).

Notes Forming Integral Part of the Financials as at 31st March, 2024

(Amounts in Rupees)

Sr. No	Particulars	Gross Block				Depreciaton				Net Block As on	
		As on 01.04.2023	Total Additions	Deduction	As on 31.03.2024	As on 01.04.2023	For the period	Deductions	As on 31.03.2024	As on 31.03.2024	As on 31.03.2023
	Intangible Assets										
	Goodwill	-	6,301.43	-	6,301.43	-	-	-	-	6,301.43	-
	Total	-	6,301.43	-	6,301.43	-	-	-	-	6,301.43	-
II	Tangible Assets										
1	Land- (U1)	156.50	-	-	156.50	6.29	2.18	-	8.47	148.03	-
2	Leasehold land (U2)	1,777.42	-	-	1,777.42	5.34	21.35	-	26.69	1,750.73	1,772.08
3	Building	98.70	615.56	-	714.26	12.41	14.52	-	26.93	687.33	-
4	Plant & Machinery	1,238.39	9,350.50	-	10,588.89	112.48	563.43	-	675.91	9,912.98	-
5	Electrical Installation	-	482.02	-	482.02	-	24.19	-	24.19	457.83	-
6	Furniture & Fixtures	4.15	4.52	-	8.67	0.19	1.03	-	1.22	7.45	-
7	OfficeE Equipments	5.02	8.46	-	13.48	0.57	0.98	-	1.55	11.93	-
8	Computers	16.36	2.62	-	18.98	3.12	2.99	-	6.11	12.87	-
9	Vehicle	307.53	1.26		308.79	38.10	29.42	-	67.52	241.27	-
	Total	3,604.07	10,464.94	-	14,069.01	178.50	660.09	-	838.59	13,230.42	1,772.08
	Capital Work in Progress	8,397.99	5,024.27	10,448.08	2,974.18	-	-	-	-	2,974.18	414.23
										-	
	Total	12,002.06	15,489.21	10,448.08	17,043.19	178.50	660.09	-	838.59	16,204.60	2,186.31

During the year Capital work in progress includes Rs.1668.75 lakhs - towards Trial run expenses (PY: 2023 Rs.NIL-lakhs) (Refer Note: 29) and preoperative expenses incurred Rs. 781.36 lakhs (PY- Rs. 710.28 Lakhs).

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U241110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement: (Currency: Indian Rupees in Lakhs)

10 Current Investment

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	Mutual Fund: Quoted		
	Investment In Mutual Fund	-	1,369.63
	Total in	-	1,369.63

11 Inventories
(Valued at lower of Cost and Net Realisable Value)

Sr No.	Particulars	As At 31st March 2025	As At 31st March 2024
	Raw Materials	339.20	136.58
	Finished Goods	111.17	99.70
	Packing Material	9.62	4.62
	W I P	776.75	502.55
	Fuel	7.74	7.67
	Stores and spares	17.52	19.87
	Total	1,262.00	770.99

12 Trade Recivables

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
1	**Outstanding for more than six months**		
	Secured, Considered Good	-	-
	Unsecured, Considered Good	-	-
	Doubtful	-	-
2	**Others**		
	Secured, Considered Good	-	-
	Unsecured, Considered Good	1,502.87	767.90
	Doubtful	-	
	Total	1,502.87	767.90

13 Cash & Cash Equivalent

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
1	**Cash-in-Hand**		
	Cash Balance	2.18	0.78
	Sub Total (A)	2.18	0.78
2	**Bank Balance**		
	With Banks	4.56	262.36
	Fixed Deposit	47.39	79.48
	Sub Total (B)	51.95	341.83
	Total [A + B]	54.13	342.61

14 Short Term Loans & Advances

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	Advance against purchase of Fixed Assets	225.00	225.00
	short term advance	9.00	525.27
	Total	234.00	750.27

15 Other Current Assets

Sr. No	Particulars	As At 31st March 2025	As At 31st March 2024
	TDS Receivable	14.79	9.13
	Input Tax Credit (Indirect Taxes)	2,435.24	2,165.65
	Prepaid Insurance	26.01	29.47
	Prepaid Expenses	23.85	6.72
	Security Deposit	109.86	67.64
	Employee advance	-	0.89
	Total	2,609.75	2,279.50

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN:U241110MH2021PTC358857

Notes Forming Part of the Profit & Loss Accounts for the year ended 31st March ,2025

(Currency: Indian Rupees in Lakhs)

16 Revenue from Operations

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Sales	4,825.16	472.54
	Total	4,825.16	472.54

16.1 Break-up of revenue from sale of products

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Manufactured goods		
	Chemicals	4,825.16	472.54
	Total	4,825.16	472.54

17 Other Income

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Interest Received	58.27	68.87
	Misc income	8.47	4.01
	Jobwork charges received	294.41	80.13
	Exchange rate gain loss	9.28	3.91
	Gain on Investment (MF)	19.39	179.85
	Total	389.82	334.77

18 Cost of Material Consumed

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
a)	Opening Stock		
	-Raw materials	136.58	67.64
	-Packing materials	4.62	1.44
	Transferred :- Trial Run Expenses		
	-Raw materials	-	(67.64)
	-Packing materials	-	(1.44)
	Sub-total (a)	141.20	(0.00)
b)	**Add: Purchase of materials**		
	Raw Materials	4,016.66	436.80
	Packing Materials	138.72	13.06
	Sub-total (b)	4,155.38	449.86
c)	**Less: Closing Stock of Materials**		
	-Rawmaterials	339.20	136.58
	-Packingmaterials	9.62	4.62
	Transferred to Trial Run Expenses		
	-Raw materials	-	(136.58)
	-Packing materials	-	(4.62)
	Sub-total (c)	348.82	-
d)	**Cost of Material Consumed** **Sub-total(a+b-c)**	3,947.76	449.86
	Total	3,947.76	449.86

Note 1: The Opening Stock of Raw Material and Packing Material related to "Privi Organics Limited" merged into "Privi Fine Sciences Private Limited" vide NCLT order dt. 19th December, 2023, effective from 01st April, 2023.

Note 2: The Total Purchases of Raw Material and Packing Material amounting to Rs 2,108.41 lakhs out of which Rs. 1,658.55 lakhs transferred to Trial Run expenses.

19 Changes in Inventories

Sr No.	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
1	**Closing Stock:**		
	Finished Goods	111.17	99.70
	Work in Process	776.75	502.55
	Transferred to Trial run expense:-		
	Finished Goods	-	(99.70)
	Work in Process	-	(502.55)
		887.92	-
2	**Opening Stock:**		
	Finished Goods	99.70	25.46
	Work in Process	502.55	71.98
	Transferred to Trial run expense:-		
	Finished Goods	-	(25.46)
	Work in Process	-	(71.98)
		602.25	-
		(285.67)	-

Note: The Opening stock of Finished Goods and Work In Process of "Privi Organics Limited" merged into "Privi Fine Sciences Private Limited" vide NCLT order dt. 19 December, 2023 effective from 1st April, 2023

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN:U241110MH2021PTC358857

Notes Forming Part of the Profit & Loss Accounts for the year ended 31st March ,2025

20 Employee Benefits Expenses

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Salary,wages and bonus	727.48	91.01
	Contribution to Provident and other funds	39.08	4.00
	Staff Welfare expenses	69.16	8.12
	Total	835.72	103.14

21 Financial Cost

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Interest on Loan	356.57	40.68
	Total	356.57	40.68

22 Depreciation & Amortised Cost

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Depreciation on Tangible Assets	1,228.61	96.66
	Total	1,228.61	96.66

23 Other Expenses

Sr. No	Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
	Consumption of Stores and Spares	151.82	2.80
	Power,Fuel & water	1,407.67	14.22
	Jobwork charges	51.63	1.80
	Repairs & Maintenance- Machinery	126.64	0.48
	Repairs & Maintenance Others	16.95	1.20
	Contract Labour Charges	156.46	0.48
	Lab Expenses	16.76	2.56
	Other Factory Expenses	114.51	11.93
	Insurance	43.68	9.19
	Postage and Telephone Expenses	1.80	0.23
	Rates and Taxes	9.46	1.21
	Auditor Remuneration	1.30	0.68
	Selling & Distribution expenses	136.70	10.10
	Printing & Stationery	6.39	0.77
	Legal and Professional Fees	133.67	25.11
	Travelling and Conveyance	81.85	0.46
	Bank Charges	10.09	2.70
	Office & admin Exp	58.97	4.21
	Total	2,628.55	91.13

Notes to the financial statements (Continued)

(Currency: Indian Rupees In Lakhs)

24 Earnings per share

Particulars	Year Ended 31st March 2025	Year Ended 31st March 2024
Basic and diluted earnings per share		
Net profit after tax attributable to equity shareholders (A)	**(3,455.10)**	(223.81)
Number of equity shares outstanding at the end of the year	**23,38,29,210**	20,48,93,496
The weighted average number of equity shares outstanding during the year (B)'	**23,38,29,210**	20,48,93,496
Earnings per share		
Basic earnings per share (face value of Rs. 10 per share) (2024: Rs 0.11 per share)	**(1.48)**	(0.11)
Diluted earnings per share (face value of Rs. 10 per share) (2024: Rs 0.11 per share)	**(1.48)**	(0.11)

25 Related party disclosure

1 List of related parties

a) Enterprises owned or significantly influenced
Privi Speciality Chemicals Limited
Privi Life Sciences Private Limited
Privi Biotechnologies Private Limited
Priqiv Specialties Private Limited
Moneymart Securities Private Limited
Vivira Investment And Trading Private Limited
MM infra & Leasing Pvt. Ltd
Satellite Technologies Private Limited
Snejyo Agro LLP
SNEJYO Ventures Pvt. Ltd.
Prasad Organics Pvt.Ltd.
Babani Brothers LLP

b) Key Management Personnel (KMP)

Ms. Snehal Mahesh Babani (Managing Director)
Mr. Mahesh P. Babani (Director)
Mr. Arun Newalkar (Chief Financial Officer)
Mr. Ramesh Kathuria (Company Secretary)

c) Relatives of Key Management Personnel
Mrs. Seema Mahesh Babani
Mahesh Purshottam Babani (HUF)
Ms. Jyoti Mahesh Babani (Director)

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U241110MH2021PTC358857

Notes to the financial statements (Continued)

(Currency: Indian Rupees in Lakhs)

2 During the year, following transactions were carried out with the related parties :

	Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	31st March 2025	31st March 2024	**31st March 2025**	31st March 2024
Purchase of Assets/Chemicals/Fuel				
Privi Life Sciences Pvt.Ltd.	-	2.61	-	-
Prasad Organics Pvt.Ltd.	**138.01**	12.75	-	-
Privi Speciality Chemicals Ltd	-	-	-	-
Rent Paid				
Privi Speciality Chemicals Ltd	**0.60**	0.90	-	-
Sale of Chemicals				
Privi Speciality Chemicals Ltd.	-	33.17	-	-
Privi Speciality Chemicals Ltd. USA	**381.91**	383.34	-	-
Prigiv Specialities Pvt.Ltd.	**19.55**	-	-	-
Salary Paid				
Snehal Babani	-	-	**7.20**	6.00
Job Work Chgs. Received				
Privi Speciality Chemicals Ltd.	**307.23**	80.13	-	-
Interest Paid:-				
Vivira Investment and Trading Pvt. Ltd.	**157.69**	25.77	-	-
Moneymart Securities Pvt.Ltd.	-	1.64	-	-
Equity shares Issued				
Vivira Investment and Trading Pvt. Ltd.	-	6,710.95	-	-
Moneymart Securities Pvt.Ltd.	-	266.42	-	-
Deposit For Rent				
Privi Speciality Chemicals Ltd.	-	0.50	-	-
Loan taken				
Vivira Investment and Trading Pvt. Ltd.	**3,450.00**	2,025.00	-	-
Loan Repaid				
Vivira Investment and Trading Pvt. Ltd.	**10.00**	11,570.00	-	-
Receivables /Other assets				
Privi Speciality Chemicals Ltd.	**53.39**	40.08	-	-
Privi Speciality Chemicals Ltd. USA	**111.78**	215.64	-	-
Payables / Other Labilities				
Privi Speciality Chemicals Ltd.	**5.05**	-	-	-
Snehal Babani	-	-	**0.50**	0.50

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Notes to the Standalone Financial Statements *(Continued)*
for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

26 Employee benefits - Post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund, Super annuation fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the Note 20 under "Contribution to provident & other funds":

	Year ended March 31, 2025	Year ended March 31, 2024
Contribution to employees provident fund	34.51	10.41
Contribution to ESI	4.42	2.18

b) Defined benefit plans

The Company operates one post-employment defined benefit plan (funded plan) that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

	As at March 31, 2025	As at March 31, 2024
Amount recognised in the Balance Sheet in respect of Gratuity		
Present value of the funded defined benefit obligation at the end of the year	30.44	21.25
Net liability/(asset)	30.44	21.25
Movement in present value of defined benefit obligation		
Opening Defined Benefit Obligations	21.25	16.42
Current service cost	6.54	3.79
Interest cost	1.53	1.22
Actuarial (gain)/loss	3.71	(0.18)
Benefits paid	(2.59)	-
Closing defined benefit obligation	30.44	21.25

Expense recognised in statement of profit and loss

	As at March 31, 2025	As at March 31, 2024
Current service cost	6.54	3.79
Interest on defined benefit obligations	1.53	1.22
Total	8.07	5.01
Remeasurements recognised in Other comprehensive income		
Change in Demographic Assumption	-	-
Change in Financial Assumption	1.44	-
Experience adjustments	2.26	(0.18)
Total	3.70	(0.18)
Total expense recognised	9.18	4.83

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Notes to the financial statements (Continued)

(Currency: Indian Rupees In Lakhs)

27 Segmental Reporting

a) Primary Business Segment

In accordance with the requirements of Accounting Standard 17 'Segment Reporting' ('AS17'), the Company has determined its business segment as "Aromatic chemicals/Industrial chemicals" since the entire business of the Company is from Aromatic chemicals. As the Company is engaged only in one business segment, the segment revenue, segment result, total carrying amount of segment assets, total carrying amount of segment liabilities, the total cost incurred to acquire segment assets, the total amount of charge for depreciation and amortization during the year are as reflected in the financial statements for the year ended 31 March 2025

b) Secondary Geographical Segment

In respect of secondary segment information, the company has identified its geographical segments as Domestic and Overseas. The Secondary Segment information has been disclosed accordingly.

	Year	Domestic	Overseas	Total
Revenue	**31st March 2025**	1,104.27	469.97	1,574.24
	31st March 2024	1,045.20	529.04	1,574.24
Carrying amount of segment asset*	**31st March 2025**	12,030.80		12,030.80
	31st March 2024	13,230.42	-	13,230.42
Capital expenditure during the year	**31st March 2025**	1,688.13		1,688.13
	31st March 2024	5,024.27	-	5,024.27

28 CSR activities

As per Section 135 of the Companies Act, 2013, the Company has constituted a Corporate Social Responsibility (CSR) Committee. The total amount spent by the Company on CSR activities during the year is Rs. Nil (FY 2023-24: NIL), as the company incurred, a loss during the year.

29 Trial run expenses capitalized.

During the year 2023-24 the company started the manufacturing of the product wef 30th September, 2023. However the company could not achieve its production capacity intended for. As a result, the cost of operations net of sales revenue during the period, treated as the trial run expenses & has been included in Capital WIP. Given below are the details of expenses during the year.

	For the Period Ended 31st March 2025	Year Ended 31st March 2024
Revenue:-		
Sales of Privial/Lilial	-	1,101.70
Total (A)	-	1,101.70
Expenses		
Consumption of Material	-	1,081.62
Other expenses	-	1,688.83
Total (B)	-	2,770.45
Pre-operative expenses (Trial Run expenses) included in CWIP- Total(C) = (B-A)	-	1,668.75

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

(Currency: Indian Rupees in Lakhs)

30 During the year 2023-24, "Privi Organics Ltd." a company manufacturer, exporter, and trader in Specialty chemicals (aroma chemicals) and other Chemicals products, vide the NCLT order dt. 19th December,2023 amalgmated & merged with "Privi Fine Sciences Pvt. Ltd." wef 01st April, 2023, under section 230 to 232 read with section 66 & other applicable provisions of the Company's Act, 2013. The Company commenced it's manufacturing from 30th Septemeber,2023 in factory located at Plot No. C-39 & C-39 (Part), MIDC Lote, Tq.-Khed, Dist.- Ratnagiri. Further the purchase consideration was settled by way of issue of shares in the ratio of 3.25 shares of "Privi Fine Sciences Pvt. Ltd." for every share of "Privi Organics Ltd." held on 31.3.2024. As a result the Goodwill of Rs. 6301.43 lakhs was generated in the process of merger.

31 Prior year comparative

Figures for the previous year have been reclassified and regrouped wherever considered necessary to conform to the current year's presentation

As per our report of even date attached

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 5th June, 2025

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of
Privi Fine Sciences Pvt. Ltd.
CIN:U241110MH2021PTC358857

Snehal Babani	**Mahesh Babani**
DIN: 07672706	**DIN: 00051162**
Managing Director	**Director**
Ramesh Kochuria	**Arun Newalkar**
Company Secretary	**Chief Financial Officer**

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

AUDITOR'S REPORT

To the Members of PRIVI FINE SCIENCES PRIVATE LIMITED

Report on the Financial Statements

We have audited the accompanying financial statements of **PRIVI FINE SCIENCES PRIVATE LIMITED** ("the Company"), which comprise the standalone balance sheet as at 31st March 2024, and the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as 'standalone financial statements')..

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India of the state of affairs of the Company as at 31st March 2024, and its profit and other comprehensive income, changes in equity and its cash flows for the year ended on that date.

Emphasis of Matter

With reference to note no.29 of Financial Statement which specifies the basis of Scheme of merger of M/s Privi Organics Ltd and Privi Fine Science Pvt. Ltd from retrospective date 1st April 2023 as approved by the National Company Law Tribunal (NCLT) Mumbai bench. As per the requirement of Appendix C to Ind As-103 the merger has been given effect to as if it has occurred from the beginning of the year i.e.1st April 2023 in the financial statement.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditors' Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. **As required by section 143 (3) of the Act, we report that:**

   a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

   b. In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books [and proper returns adequate for the purposes of our audit have been received from branches not visited by us];

   c. The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account;

   d. In our opinion, the Balance Sheet and Statement of Profit and comply with the Accounting Standards referred to in Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014

   e. On the basis of the written representations received from the Directors as on 31 March 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2024 from being appointed as a director in terms of Section 164 (2) of the Act; and.

   f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B".

FOR E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS

ESMAIL SITABKHAN
PROPRIETOR
M. No. O-30721
Firm Reg. No.110300W
UDIN:24030721BKAOZY5561

Place: Mumbai
Date: 20th June 2024

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

PRIVI FINE SCIENCES PRIVATE LIMITED

"Annexure A" to the Independent Auditors' Report – 31 March 2024

(Referred to in our report of even date)

(i) **(a)** (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment items purchased but not pending for installation.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) All fixed assets are physically verified by the management in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. The physical verification of fixed assets was done in financial year 2023-24 and No material discrepancies were noticed on such verification.

(c) According to the Information and explanations given to us and on the basis of our verification of records of the Company, the title deed of Lease hold land Plot no. C-39, C-39(Part) ,MIDC lote , Tq.- Khed, Dist. Ratnagiri held in the name of M/s Privi Organics Limited (the Transferor Company) prior to merger. The merger scheme of M/s Privi Organics Ltd. (the Transferor Company) and M/s Privi Fine Sciences Pvt. Ltd. (the Transferee Company) duly approved by NCLT Mumbai Bench. Subsequently the transferee company has applied for change of name to MIDC authority at Ratnagiri for transfer of title deed of leasehold land in the name of transferee company and the matter is pending with the authority and order for transfer is awaited.

As regards Factory building and other assets held in the name of the M/s Privi Organic Limited, the reason for not being in the name of Company is that the matter is pending for adjudication and after the payment of duties amount the assets will be transferred in the name of transferee Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a) As explained to me, the inventories are physically verified during the year by the Management at reasonable intervals and no material discrepancies are noticed on such physical verification.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has no sanctioned working capital facility from banks or financial institutions.

E. E. SITABKHAN & CO. * MUMBAI * Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(iii) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company has made Investment during the year as specified below:

Nature	Closing Balance as on 31st March 2024
Mutual Fund	1369.63 lakhs

(b) The terms and conditions of investments made are not prejudicial to the interest of the company.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any security as specified under section 185 and 186 of the Companies Act, 2013. In respect of investment made by the Company the Provision of sec 186 of the Act has been complied with.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) In our opinion the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013 is not applicable to Company.

(vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues have been generally regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2024 for a period of more than six months from the date they became payable.

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) The Company has not defaulted in repayment of loans or other borrowings or in the payment of interest thereon to any lender.

(b) The company has not declared willful defaulter by any bank or financial institution or other lender.

(c) The company has obtained term loan and its being used for the purpose it was obtained;

(d)According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

E. E. SITABKHAN & CO. * MUMBAI * Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures; hence this clause is not applicable;

(f) The company has not raised loans during the year on the pledge of securities held in its subsidiaries, joint ventures or associate companies; hence this clause is not applicable.

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) (a) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has no internal audit system commensurate with the size and nature of its business.

(b) Since there is no internal audit system, the question of considering the internal audit report of the company does not arise.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash loss during the year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

FOR E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS

ESMAIL SITABKHAN
PROPRIETOR
M. No. O-30721
Firm Reg. No.110300W

Place: Mumbai
Date: 20th June 2024

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Fine Sciences Private Limited

Annexure B to the Independent Auditors' report - 31 March 2024

(Referred to in paragraph A (f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Fine Sciences Private Limited ("the Company") as of 31 March 2024 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls system with reference to financial statements and such internal financial controls were operating effectively as at 31 March, 2024, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the 'Guidance Note').

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as 'the Act').

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Fine Sciences Private Limited

Annexure B to the Independent Auditors' Report (Continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial controls with Reference to financial statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : JUNE 20,2024

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

BALANCE SHEET AS AT 31ST MARCH 2024

(Currency: Indian Rupees In Lakhs)

Particulars	Refer to Note No.	As at 31st March, 2024	As at 31st March 2023
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	3	20,489.35	1.00
(b) Reserves and Surplus	4	(227.81)	(4.00)
(2) Share Application money pending allotment		-	-
(2) Non-Current Liabilities			
(a) Long-Term Borrowings	5	5,926.00	5,045.10
(b) Deferred Tax Liabilities (Net)	6	330.15	-
(3) Current Liabilities			
(a) Trade Payables	7	1,545.00	49.50
(b) Other Current Liabilities	8	724.29	178.37
Total Equity & Liabilities		28,786.98	5,269.97
II.ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	9	13,230.42	1,772.08
(ii) Intangible Assets	9	6,301.43	-
(iii) Capital Work-in-Progress	9	2,974.18	414.23
(2) Current Assets			
(a) Current Investments	10	1,369.63	2,854.59
(b) Inventories	11	770.99	-
(c) Trade Receivables	12	767.95	-
(d) Cash and Cash Equivalents	13	342.61	4.01
(e) Short-Term Loans and Advances	14	750.27	225.00
(f) Other Current Assets	15	2,279.50	0.06
Total Assets		28,786.98	5,269.97
Significant Accounting Policies	2		
Notes Forming Integral Part of the Financial Statement	3 - 31		

This is the Balance Sheet referred to in our Report of even date.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 20th June, 2024

For and on behalf of the Board of
Privi Fine Sciences Private Limited
CIN:U24110MH2021PTC358857

Shehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary
A-11214

Arun Newalkar
Chief Financial Officer

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

E.E.SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

PROFIT & LOSS STATEMENT FOR THE PERIOD ENDED ON 31ST MARCH 2024

(Currency: Indian Rupees in Lakhs)

Sr. No	Particulars	Refer to Note No.	Year Ended 31st March 2024	Year Ended 31st March 2023
I	Revenue from operations	16	472.54	-
I	Other Income	17	334.77	61.76
III	**III. Total Revenue (I +II)**		807.31	61.76
IV	**Expenses:**			
	Cost of materials consumed	18	449.86	-
	Changes in inventories	19	-	-
	Employee Benefit Expense	20	103.14	0.17
	Financial Costs	21	40.68	58.69
	Depreciation and Amortization Expense	22	96.66	5.34
	Other Expenses	23	91.13	1.57
	Total Expenses (IV)		781.47	65.76
V	Profit/(Loss) before exceptional and extraordinary items and tax	(III - IV)	25.84	(4.00)
VI	Exceptional Item		-	-
VII	Profit/(Loss) before extraordinary items and tax (V - VI)		25.84	(4.00)
VIII	Extraordinary Items		-	-
IX	Profit/(Loss) before tax (VII - VIII)		25.84	(4.00)
X	**Tax expense:**			
	(1) Current Tax		-	-
	(2) Deferred Tax		249.65	-
XI	Profit(Loss) from the perid from continuing operations	(IX-X)	(223.81)	(4.00)
XII	Profit/(Loss) from discontinuing operations		-	-
XIII	Tax expense of discounting operations		-	-
XIV	Profit/(Loss) from Discontinuing operations (XII - XIII)		-	-
XV	Profit/(Loss) for the period (XIII + XIV)		(223.81)	(4.00)
XVI	Earning per equity share:	24		
	(1) Basic		(0.11)	(39.99)
	(2) Diluted		(0.11)	(39.99)
	Significant Accounting Policies	2		
	Notes Forming Integral Part of the Financial Statement	3-31		
	This is the statement of Profit & Loss referred to in our Report of even date attached.			

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 20th June, 2024

For and on behalf of the Board of
Privi Fine Sciences Private Limited
CIN:U241110MH2021PTC358857

Snehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary
A-11214

Arun Newalkar
Chief Financial Officer

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

CASH FLOW STATEMENT FOR THE YEAR ENDED 31ST MARCH 2024

(Currency: Indian Rupees in Lakhs)

	Particulars	As At 31st March 2024	As At 31 March 2023
A	**Cash flows from operating activities**		
	Net profit or (Loss) before tax	25.85	(4.00)
	Adjustments for :		
	Depreciation and amortisation	96.66	5.34
	Interest Received	(66.87)	-
	Interest Expenses	40.68	-
	Gain on sale of Investment	(179.86)	-
	Operating profit before working capital changes	(83.53)	1.34
	Operating cash flow before working capital changes		
	(Increase)/ Decrease in trade receivables	(606.61)	-
	(Increase)/ Decrease in Inventories	(595.00)	-
	(Increase) / decrease in loans and advances	(512.16)	364.94
	(Increase) / decrease in Other Current Assets	(670.21)	-
	Increase/(Decrease) in Other Current Liabilities	(193.14)	165.46
	Increase/(Decrease) in Trade Payables	(40.25)	49.50
		(2,617.37)	579.90
	Cash generated from operations	(2,700.90)	581.24
	Income taxes paid	-	-
	Net cash generated from operating activities (A)	(2,700.90)	581.24
B	**Cash flows from investing activities**		
	Purchase of Property , Plant & Equipment	(4,463.71)	(2,178.38)
	Sale/(Purchase) of current investment	1,889.32	(2,849.59)
	Gain on Sale of Investment	179.86	-
	Interest Paid	(40.68)	-
	Interest received	66.87	-
	Net cash (used in) investing activities (B)	(2,368.34)	(5,027.97)
C	**Cash flows from financing activities**		
	Issue of Share Warrants		-
	Issue of Share Capital	11,384.91	-
	Increase/(Decrease) in Long Term Borrowing	3,488.50	4,445.10
	Increase/(Decrease) in Short Term Borrowing	(4,500.00)	-
	Repayment of long term Borrowings	(5,045.10)	-
	Net cash (used in) / generated from financing activities (C)	5,328.30	4,445.10
	Net (decrease) / increase in cash and cash equivalents (A+B+	259.08	(1.62)
*	**Cash and cash equivalents at beginning of the year**	83.50	5.63
	Cash and cash equivalents at end of the year	342.58	4.01
		259.08	(1.62)

* The Opening Balance of Cash and Cash equivalents consists Rs 79.49 lakhs related to "Privi Organics Limited" merged with "Privi Fine Sciences Private Limited. Vide NCLT order dt. 19th December, 2023 "wef 01st April, 2023

The cash flow statement has been prepared under the indirect method as set out in Accounting Standard-3 (AS-3) on cash flow statement issued by Companies (Accounting Standards) Rules,2006.

The notes referred to above form an integral part of the financial statements.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 20th June, 2024

For and on behalf of the Board of
Privi Fine Sciences Private Limited
CIN:U24110MH2021PTC358857

Snehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary
A-11214

Arun Newalkar
Chief Financial Officer

1 Company overview

Privi Fine Sciences Pvt. Limited ('Privi',or 'the Company') is manufacturer of chemicals & other products. The company has acquired land during the year 2022-23 for the purpose of manufacturing the chemicals at Jhagadia, dist.- Bharuch, in state of Gujarat & started land levelling & other related activities. The Company intends to manufacture Furfural, Furfuryl Alcohol, Cyclopentanone, Ethanol ,Vanillin, Maltol, Ethyl Maltol etc. from natural renewable materials. The necessary statutory permissions are sought to start the construction of project for manufacture of above products using the green technology.

Privi Organics Ltd. is a manufacturer, exporter, and trader in Specialty chemicals (aroma chemicals) and other chemical products, which vide the scheme of amalgamation approved by NCLT order dt. 19th December, 2023 merged with Privi Fine Sciences Pvt. Ltd. with effect from 01st April, 2023. The Company commenced it's manufacturing from 30th September, 2023 at factory located at Plot No. C-39 & C-39 (Part), MIDC Lote, Tq.-Khed, Dist.- Ratnagiri in Maharashtra state.

2 Significant accounting policies

The accounting policies set out below have been applied consistently to the periods presented in these financial statements.

2.1 Basis of preparation of financial statements

The financial statements have been prepared and presented under the historical cost convention on an accrual basis of accounting and in accordance with the accounting principles generally accepted in India and comply with the accounting standards referred in the Companies (Accounting Standards) Rules, 2006 which continue to apply under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Account) Rules, 2014 and other relevant provision of the Companies Act, 1956 to the extent applicable. The financial statements are prepared on the Historical Cost basis and on the principles of a going concern.

2.2 Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in India requires management to make estimates and assumptions that affect the reported amount of assets, liabilities, and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognized prospectively in current and future periods.

2.3 Current and non-current classification

Schedule III to the Companies Act, 2013 requires assets and liabilities to be classified as either Current or Non-current.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is expected to be realised within 12 months after the reporting date; or

(d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is due to be settled within 12 months after the reporting date; or

(d) the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include the current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents and is 12 months for the Company.

2.4 Inventories

Inventories which comprise Raw material, packing material, stock-in-trade, stores and spares, and work-in-process are carried at a lower of cost and net realizable value. Costs are determined on a FIFO basis. Costs include purchase price (net of refundable taxes and levies) and other costs incurred in bringing the inventories to their present location and condition. The closing stock of finished goods is valued at cost or net realizable value, whichever is lower.

2.5 Revenue Recognition

Revenue from the sale of goods in the course of ordinary activities is recognized when property in the goods or all significant risks and rewards of their ownership is transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

2.6 Fixed Asset

Tangible assets are stated at cost less accumulated depreciation and net of impairment if any. The cost of an asset comprises its purchase price (net of taxes if any) and the directly attributable cost of bringing an asset to working condition for its intended use.

Leasehold land is amortized at a rate, which will reduce the lease amount to "Nil" at the expiry of the remaining period of the lease.

Depreciation is provided on the Straight line method at the rate specified in Schedule II and provisions made therein, of the Companies Act, 2013 on the Original Cost of the assets. The rate of depreciation is charged per triple shift of work. Asset costs individually deprecated up to 95% of the cost of each individual asset only.

2.7 (i) Depreciation and Amortization

Depreciation is calculated using the straight-line method to collocate the cost of Property Plant and equipment net of residual values, over their estimated useful lives as per the useful lives prescribed in Schedule II of the Companies Act, 2013 except in the case of the following class of assets where useful life is based on technical evaluation of the management:

Asset Class	Useful life Considered
Factory Building	30 Years
Plant & Machinery	10 Years
Furniture & Fixtures	16 Years
Office Equipment	10 Years
Computers	6 Years
Vehicle	11 Years

Depreciation on additions/ deletions during the year is provided from the month in which the asset is capitalized up to the month in which the asset is disposed off.

The estimated useful lives, residual values, and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

(ii) Intangible assets & Amortization

Amortisation is recognised in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

2.8 Retirement Benefits

Provident Fund: Provident Fund contributions are made to the Government Provident Fund Authority

Gratuity: The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary using the projected unit credit method. All expenses related to the

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

defined benefit plan are recognized in employee benefits expense in the Statement of Profit and Loss.

Compensated Absences: The Company provides for encashment of leave or leaves with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/ availment. The Company makes provision for compensated absences based on an independent external actuarial valuation carried out at the end of the year.

2.9 *Provisions and contingent liabilities*

A provision is recognized if, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognized at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an undiscounted basis.

A contingent liability exists when there is a possible but not probable obligation or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of an outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognized in the period in which the change occurs.

2.10 *Taxes on Income*

Current Tax:- Provision for Income Tax is determined in accordance with the provision of the Income Tax Act 1961.

Deferred Taxation: Income tax expense comprised current tax and deferred tax charge or release. The deferred tax charge or credit is recognized using current tax rates. Deferred tax assets arising from unabsorbed depreciation or carry forward losses are recognized only if there is virtual certainty of realization of such amounts. Other deferred tax assets are recognized only to the extent there is reasonable certainty of realization in the future.

2.11 *Earnings per share ('EPS')*

Basic EPS is computed using the weighted average number of equity shares outstanding during the year. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the year except where the results would be anti-dilutive.

2.12 *Cash and cash equivalent*

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short-term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PROVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement:

3 Share Capital (Currency: Indian Rupees in Lakhs)

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	AUTHORIZED CAPITAL 20,50,000,000 equity shares of Rs. 10/- each (PY 10,000 equity shares of Rs. 10/- each)	**20,500.00**	1.00
		20,500.00	1.00
	ISSUED , SUBSCRIBED & PAID UP CAPITAL 20,48,93,496 Equity Shares of Rs.10/- each fully paid up (PY 10,000 equity shares of Rs. 10/- each fully paid up)	**20,489.35**	1.00
	Total	**20,489.35**	1.00

Pursuant to the Scheme of Merger of Privi Organics Limited (POL) with Privi Fine Sciences Pvt Limited (PFSPL), the National Company Law Tribunal (NCLT) issued an order of Merger in the month of 19th December 2023 and a revised order was issued on 13th March, 2024. The Company, then accordingly, had filed an NCLT order in form INC-28 with MCA.
The Authorised Share capital of POL was Rs. 5000 lakhs and Paid up Capital was Rs. 4699.66 lakhs. The authorised Capital of PFSPL was Rs. 5500 lakhs and the paid-up Capital was Rs. 5215.46 lakhs. Post-merger the Authorized Capital of both the companies would have been Rs. 10500 lakhs.
The combined authorised share capital of the company post-merger was reflected on 29th May 2024 on the MCA portal. Now, the company is in the process of filing the necessary forms with MCA to increase its authorized share capital from 10500 lakhs to 20500 lakhs and allotment of shares.
As per the Scheme of Merger, the shareholders of POL were entitled for 3.25 shares of PFSPL per one Equity share of POL. In order to allot shares of PFSPL, the company has increased its Authorised Capital from Rs.10500 lakhs to Rs. 20500 lakhs at its Board Meeting held on 29th March , 2024, and member's approval was obtained at EGM held on 30th March , 2024. The company then has allotted shares on 31 March, 2024 accordingly.

3(A) Reconciliation of no. of Shares outstanding

Particulars	Equity Shares As At 31st March 2024		Equity Shares As At 31st March 2023	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**10,000**	**1.00**	10,000	1.00
Shares Issued during the period	**20,48,83,496**	**20,488.35**	-	-
Share Premium	-	-	-	-
Shares bought back during the period	-	-	-	-
Shares outstanding at the end of the period	**20,48,93,496**	**20,489.35**	10,000	1.00

3(B) Details of shareholders holding of more than 5% shares

Sr. No.	Name of Shareholder	As At 31st March 2024		As At 31st March 2023	
		No. of Shares	% of Holding	No. of Shares held	% of Holding
	Vivira Investments & Trading Private Limited	**13,09,05,950**	**63.89%**	-	
	Mahesh P Babani	**4,64,10,543**	**22.65%**	2,500	25.00%
	Money Mart Secutrities Pvt. Ltd.	**1,36,43,187**	**6.66%**	-	0.00%
		19,09,59,680	**93.20%**	2,500	25.00%

4 Reserve & Surplus:

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Surplus (Profit & Loss Account)		
	Balance brought forward from previous year	**(4.00)**	-
	Add: Profit / (Loss) for the period	**(223.81)**	(4.00)
	Less: Utilised during the period	-	-
	Less: Transfer to reserve	-	-
	Closing Balance	**(227.81)**	(4.00)
	Total	**(227.81)**	(4.00)

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement:

5 Long-Term Borrowings

Sr. No	Particulars	Non-Current Portion		Current Portion	
		As At 31st March 2024	As At 31st March 2023	**As At 31st March 2024**	As At 31st March 2023
	Secured				
	Term Loan from banks (refer note (I)	**1,875.00**	5,045.10	**562.50**	-
	TermLoan in Indian Currency				
	Unsecured				
	ECB loan (refer note (II)	**4,051.00**	-	-	-
	Other loans	-	-	-	-
		5,926.00	5,045.10	**562.50**	-

I) Term loans are secured by a first mortgage on the Company's immovable properties both present and future and a first charge by way of all the company's assets except book debts and inventories including movable machinery (and expect spare tools and accessories) both present and future subject to charges created favour of the company's bankers for inventories, book debts, and other specified movable assets for securing the borrowings of working capital.

II) The Company has availed an ECB Loan of Rs. 4051 lakhs from Karma Fine Sciences PTE Ltd. which is unsecured in nature and the tenure of loan is ten years. The lender have an option to cause the Borrower to convert the Outstanding Loan Amount into Equity Shares post completion of one year from the 1st disbursement date.

III) **Terms and repayment schedule of Term Loan**

Terms and conditions of outstanding borrowings are as follows:

Name of the bank	Installment	Interest rate	Year of Maturity	Carrying amount	
				As At 31st March 2024	As At 31st March 2023
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.28,75,000 each starting from August 2023.	8.25%	2027	**373.75**	-
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.32,81,250 each starting from August 2023.	8.50%	2027	**426.56**	-
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.14,06,250 each starting from August 2023.	9.05%	2027	**182.81**	-
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.13,43,750 each starting from August 2023.	9.05%	2027	**174.69**	-
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.6,81,250 each starting from August 2023.	9.20%	2027	**88.56**	-
HDFC bank INR	The term loan is repayable in 16 quarterly installments of Rs.91,62,500 each starting from August 2023.	9.20%	2027	**1,191.13**	-
				2,437.50	-

6 Deferred Tax Liability (Net):

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Deferred Tax Liability		
	- Related to Fixed Assets	**330.15**	-
	Deferred Tax Assets	-	-
	- Related to Fixed Assets	-	-
	Deferred Tax Liabilities (Net)	**330.15**	-

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement:

7 #Trade Payable:

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Sundry Creditors For Goods	**1,545.00**	-
	Sundry Creditors- Others	**-**	49.50
	Total (A + B)	**1,545.00**	49.50
	# The Company has not received any intimation from the "Supplier" regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence the disclosure relating to amount unpaid as at the end of the year together with interest paid / payable as required under the said Act has not been furnished and provision for interest, if any, on delayed payments, is not ascertainable at this stage.		

8 Other Current Liabilities:

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Other liabilities- expenses	**116.09**	158.69
	Statutory liabilities	**10.50**	19.68
	Provision for Gratuity and leave encashement	**35.20**	-
	Current maturities of long term borrowing (refer note 5)	**562.50**	-
	Total	**724.29**	178.37

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement as at 31st March,2024

9 Fixed Assets

(Currency: Indian Rupees in Lakhs)

Sr. No	Particulars	Gross Block				Depreciaton				Net Block As on	
		As on 01.04.2023	Total Additions	Deduction	As on 31.03.2024	As on 01.04.2023	For the period	Deductions	As on 31.03.2024	As on 31.03.2024	As on 31.03.2023
I	**Intangible Assets**										
	Goodwill	-	6,301.43	-	6,301.43	-	-	-	-	6,301.43	-
	Total	-	6,301.43	-	6,301.43	-	-	-	-	6,301.43	-
II	**Tangible Assets**										
1	Land- Unit 1	156.50	-	-	156.50	6.29	2.18	-	8.47	148.03	-
2	Leasehold land (U2)	1,777.42	-	-	1,777.42	5.34	21.35	-	26.69	1,750.73	1,772.08
3	Building	98.70	615.56	-	714.26	12.41	14.52	-	26.93	687.33	-
4	Plant & Machinery	1,238.39	9,350.50	-	10,588.89	112.48	563.43	-	675.91	9,912.98	-
5	Electrical Installation	-	482.02	-	482.02	-	24.19	-	24.19	457.83	-
6	Lab Equipments	-	-	-	-	-	-	-	-	-	-
7	Furniture & Fixtures	4.15	4.52	-	8.67	0.19	1.03	-	1.22	7.45	-
8	OfficeE Equipments	5.02	8.46	-	13.48	0.57	0.98	-	1.55	11.93	-
9	Computers	16.36	2.62	-	18.98	3.12	2.99	-	6.11	12.87	-
10	Vehicle	307.53	1.26		308.79	38.10	29.42	-	67.52	241.27	-
11	Leasehold land (U2)	-	-	-	-	-	-	-	-	-	-
	Total	3,604.07	10,464.94	-	14,069.01	178.50	660.09	-	838.59	13,230.42	1,772.08
	Capital Work in Progress	8,397.99	5,024.27	10,448.08	2,974.18	-	-	-	-	2,974.18	414.23
										-	
	Total	8,397.99	5,024.27	10,448.08	2,974.18	178.50	660.09	-	838.59	2,974.18	414.23
	Previous year	13.27	2,178.39	-	2,191.65	-	5.34	-	5.34	2,186.31	13.27

** During the year Capital work in progress includes Rs.1668.75 lakhs - towards Trial run expenses (PY: 2023 Rs.NIL-lakhs) (Refer Note: 28) and preoperative expenses incurred Rs. 781.36 lakhs (PY- Rs. 710.28 Lakhs).

E.E. SITABKHAN & CO. Chartered Accountants MUMBAI

319

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement as at 31st March,2024

Notes to the Financial Statement as at March 31,2023

(Amounts in lakhs)

Note : 9 Fixed Asset

Sr. No	Particulars	Gross Block				Depreciaton				Net Block	
		April 01,2022	Addition/ Revaluation during the year	Deduction during the year	March 31,2023	April 01,2022	Addition during the year	Deduction during the year	March 31,2023	WDV as on March 31,2023	WDV as on March 31,2022
I	Tangible Assets										
1	Leasehold land	-	1,777.42	-	1,777.42	-	5.34	-	5.34	1,772.08	
2	Building	-	-		-	-	-	-	-	-	
3	Furniture and fixtures	-	-	-	-	-	-	-	-	-	
	Total Tangible Assets I	-	1,777.42	-	1,777.42	-	5.34	-	5.34	1,772.08	-
II	CAPITAL WORKING PROGRESS										
1	CWIP(Building)	13.27	142.96	-	156.23	-	-	-	-	156.23	13.27
2	CWIP(Plant & Machinery)	-	258.00	-	258.00	-	-	-	-	258.00	-
	Total Capital Working Progress II	13.27	400.96	-	414.23	-	-	-	-	414.23	13.27
	Grand Total I+II	13.27	2,178.39		2,191.65	-	5.34	-	5.34	2,186.31	13.27
	Fixed Assets-Year 2021-2022	-	-	-	-	-	-	-	-	-	-
	CWIP- Year 2021-2022	-	13.27	-	13.27	-	-	-	-	-	13.27

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Integral Part of the Financial Statement: (Currency: Indian Rupees In Lakhs)

10 Current Investment

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Mutual Fund: Quoted		
	Investment in Mutual Fund	1,369.63	2,854.59
	Total	1,369.63	2,854.59

11 Inventories

(Valued at lower of Cost and Net Realisable Value)

Sr No.	Particulars	As At 31st March 2024	As At 31st March 2023
	Raw Materials	136.58	-
	Finished Goods	99.70	-
	Packing Material	4.62	-
	W I P	502.55	-
	Fuel	7.67	-
	Stores and spares	19.87	-
	Total	770.99	-

12 Trade Receivables

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
1	**Outstanding for more than six months**		
	Secured, Considered Good	-	-
	Unsecured, Considered Good	-	-
	Doubtful	-	-
2	**Others**		
	Secured, Considered Good	-	-
	Unsecured, Considered Good	767.96	-
	Doubtful	-	-
	Total	767.96	-

13 Cash & Cash Equivalent

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
1	**Cash-in-Hand**		
	Cash Balance	0.78	-
	Sub Total (A)	0.78	-
2	**Bank Balance**		
	With Banks	262.35	4.01
	Fixed Deposit	79.48	-
	Sub Total (B)	341.83	4.01
	Total [A + B]	342.61	4.01

Note : 13(A) - Disclosure regarding pursant to circular no. G.S.R. 308(E) dated March 30, 2017.

14 Short Term Loans & Advances

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	Advance for land levelling work	225.00	225.00
	Loans & Advances	525.27	-
	Total	750.27	225.00

15 Other Current Assets

Sr. No	Particulars	As At 31st March 2024	As At 31st March 2023
	TDS Receivable	9.13	-
	Input Tax Credit (Indirect Taxes)	2,165.65	0.06
	Prepaid Insurance	29.47	-
	Prepaid Expenses	6.72	-
	Security Deposit	67.64	-
	Employee advance	0.89	-
	Total	2,279.50	0.06

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED

CIN:U24110MH2021PTC358857

Notes Forming Part of the Profit & Loss Accounts for the year ended 31st March ,2024

(Currency: Indian Rupees In Lakhs)

16 Revenue from Operations

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Sales	472.54	-
	Total	472.54	-

16.1 Break-up of revenue from sale of products

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Manufactured goods		
	Chemicals	472.54	-
	Total	472.54	-

Note: Total Sales during the year Rs 1574.24 lakhs out of which sales Rs 1101.70 lakhs transferred to Trial Run Expenses.

17 Other Income

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Interest Received	66.87	-
	Misc Income	4.01	-
	Jobwork charges received	80.13	-
	Exchange rate gain loss	3.91	-
	Gain on Investment (MF)	179.85	61.76
	Total	334.77	61.76

18 Cost of Material Consumed

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
a)	Opening Stock		
	-Raw materials	67.64	-
	-Packing materials	1.44	-
	Transferred :- Trial Run Expenses		
	-Raw materials	(67.64)	-
	-Packing materials	(1.44)	-
	Sub-total (a)	(0.00)	-
b)	**Add: Purchase of materials**		
	Raw Materials	436.80	-
	Packing Materials	13.06	-
	Sub-total (b)	449.86	-
c)	**Less: Closing Stock of Materials**		
	-Rawmaterials	136.58	-
	-Packingmaterials	4.62	-
	Transferred to Trial Run Expenses		
	-Raw materials	(136.58)	-
	-Packing materials	(4.62)	-
	Sub-total (c)	-	-
	Less : Loss By Fire		
	-Raw materials	-	-
	-Packing materials	-	-
		-	-
d)	**Cost of Material Consumed** **Sub-total(a+b-c)**	449.86	-
	Total	449.86	-

Note 1: The Opening Stock of Raw Material and Packing Material related to "Privi Organics Limited" merged into "Privi Fine Sciences Private Limited" vide NCLT order dt. 19th December, 2023, effective from 01st April, 2023.

Note 2: The Total Purchases of Raw Material and Packing Material amounting to Rs 2,108.41 lakhs out of which Rs 1,658.55 lakhs transferred to Trial Run expenses.

M.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE

PRIVI FINE SCIENCES PRIVATE LIMITED
CIN:U24110MH2021PTC358857

Notes Forming Part of the Profit & Loss Accounts for the year ended 31st March ,2024

19 Changes in Inventories

Sr No.	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
1	**Closing Stock:**		
	Finished Goods	99.70	-
	Work In Process	502.65	-
	Less By Fire	-	-
	Transferred to Trial run expense:-		
	Finished Goods	(99.70)	-
	Work In Process	(502.65)	-
		-	-
2	**Opening Stock:**		
	Finished Goods	25.46	-
	Work In Process	71.98	-
	Transferred to Trial run expense:-		
	Finished Goods	(25.46)	-
	Work In Process	(71.98)	-
		-	-
		-	-

Note: The Opening stock of Finished Goods and Work In Process of "Privi Organics Limited" merged into "Privi Fine Sciences Private Limited" vide NCLT order dt. 19 December, 2023 effective from 1st April, 2023

20 Employee Benefits Expenses

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Salary,wages and bonus	91.01	-
	Contribution to Provident and other funds	4.00	-
	Staff Welfare expenses	8.12	0.17
	Total	103.14	0.17

21 Financial Cost

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Interest on Loan	40.68	58.68
	Other Finance Cost	-	0.002
	Total	40.68	58.69

22 Depreciation & Amortised Cost

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Depreciation on Tangible Assets	96.66	5.34
	Total	96.66	5.34

23 Other Expenses

Sr. No	Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
	Consumption of Stores and Spares	2.80	-
	Power,Fuel & water	14.22	-
	Jobwork charges	1.80	-
	Repairs & Maintenance- Machinery	0.48	-
	Repairs & Maintenance Others	1.20	-
	Contract Labour Charges	0.48	-
	Lab Expenses	2.58	-
	Other Factory Expenses	11.93	-
	Insurance	9.19	-
	Postage and Telephone Expenses	0.23	-
	Rates and Taxes	1.21	-
	Auditor Remuneration	0.88	-
	Selling & Distribution expenses	10.10	-
	Printing & Stationery	0.77	-
	Legal and Professional Fees	26.11	0.68
	Travelling and Conveyance	0.46	-
	Bank Charges	2.70	-
	Office & admin Exp	4.21	0.90
	Total	91.13	1.57

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE Navi Mumbai-400709

Notes to the financial statements *(Continued)*

(Currency: Indian Rupees In Lakhs)

24 Earnings per share

Particulars	Year Ended 31st March 2024	Year Ended 31st March 2023
Basic and diluted earnings per share		
Net profit after tax attributable to equity shareholders (A)	**(223.81)**	(3.99)
Number of equity shares outstanding at the end of the year	**20,48,93,496**	10,000
The weighted average number of equity shares outstanding during the year (B)	**20,48,93,496**	10,000
Earnings per share	**(0.11)**	(39.99)

25 Related party disclosure

1 List of related parties

a) Enterprises owned or significantly influenced by

Privi Speciality Chemicals Limited
Privi Life Sciences Private Limited
Privi Biotechnologies Private Limited
Privi Organics Limited (upto 31st March, 2023)
Prigiv Specialties Private Limited
Babani Investment And Trading Private Limited
Moneymart Securities Private Limited
Vivira Investment And Trading Private Limited
MM infra & Leasing Pvt. Ltd
Vivira Chemicals Industries
Satellite *Chemicals LLP*
Satellite Technologies Private Limited
Snejyo Agro LLP
SNEJYO Ventures Pvt. Ltd.
Prasad Organics Pvt.Ltd.
Babani Brothers LLP
Empee Constructions
Satguru Constructions
Alum And Chemical Corporation (upto 27th March,2023)

MM Speciality Chemicals Pvt. Ltd.

b) *Key Management Personnel (KMP)*

Ms. Snehal Mahesh Babani (Managing Director)
Mr. Mahesh P. Babani (Director)
Ms. Jyoti Mahesh Babani (Director)
Mr. Arun Newalkar (Chief Financial Officer)
Mr. Ramesh Kathuria (Company Secretary)

c) Relatives of Key Management Personnel

Mrs. Seema Mahesh Babani
Mahesh Purshottam Babani (HUF)

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE 400709

Notes to the financial statements *(Continued)*

(Currency: Indian Rupees in Lakhs)

2 During the year, following transactions were carried out with the related parties :

	Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	31st March 2024	31st March 2023	**31st March 2024**	31st March 2023
Purchase of Assets/Chemicals				
Privi Life Sciences Pvt.Ltd.	2.61	-	-	-
Prasad Organics Pvt.Ltd.	12.75	-	-	-
Rent Paid				
Privi Speciality Chemicals Ltd	0.90	-	-	-
Sale of Chemicals				
Privi Speciality Chemicals Ltd.	33.17	-	-	-
Privi Speciality Chemicals Ltd. USA	383.34	-	-	-
Salary Paid				
Snehal Babani	-	-	6.00	-
Job Work Chgs. Received				
Privi Speciality Chemicals Ltd.	80.13	-	-	-
Interest Paid:-				
Vivira Investment and Trading Pvt. Ltd.	25.77	146.40	-	-
Moneymart Securities Pvt. Ltd.	1.64	16.60	-	-
Equity shares Issued				
		-	-	-
Vivira Investment and Trading Pvt. Ltd. (No. of Shares 1,76,29,000+4,94,80,450= 6,71,09,450 of Rs.10 each)	6,710.95	-	-	-
Moneymart Securities Pvt. Ltd. Shares 26,64,200 Issued at Rs.10 Each	266.42	-	-	-
Deposit for Rent				
Privi Speciality Chemicals Ltd.	0.50	-	-	-
Loan taken				
Vivira Investment and Trading Pvt. Ltd.(#) (#) Loan Amount converted into Equity Shares Fully Paid	2,025.00	4,195.10	-	-
Privi Fine Sciences Pvt.Ltd.(Unit 2 Gujarat)	-	-	-	-
Moneymart Securities Pvt. Ltd.	-	250.00	-	-
Loan Repaid				
Vivira Investment and Trading Pvt. Ltd.(#) (#) Loan Amount converted into Equity Shares Fully Paid(Rs.6025 lakhs)	11,570.00	-	-	-
Receivables /Other assets				
Privi Speciality Chemicals Ltd.	40.08	-	-	-
Privi Speciality Chemicals Ltd. USA	216.64	-	-	-
Payables / Other Labilities				
Privi Fine Sciences Pvt.Ltd.(Unit 2 Gujarat)	-	-	-	-
Snehal Babani	-	-	0.50	-
Vivira Investment and Trading Pvt. Ltd.	-	4,926.86	-	-
Moneymart Securities Pvt. Ltd.	-	264.94	-	-

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PVT. LTD. REGD. OFFICE

(Currency: Indian Rupees in Lakhs)

Notes to the financial statements (Continued)

26 Segmental Reporting

a) Primary Business Segment

In accordance with the requirements of Accounting Standard 17 'Segment Reporting' ('AS17'), the Company has determined its business segment as "Aromatic chemicals/Industrial chemicals" since the entire business of the Company is from Aromatic chemicals. As the Company is engaged only in one business segment, the segment revenue, segment result, total carrying amount of segment assets, total carrying amount of segment liabilities, the total cost incurred to acquire segment assets, the total amount of charge for depreciation and amortization during the year are as reflected in the financial statements for the year ended 31 March 2024

b) **Secondary Geographical Segment**

In respect of secondary segment information, the company has identified its geographical segments as Domestic and Overseas. The Secondary Segment information has been disclosed accordingly.

	Year	Domestic	Overseas	Total
Revenue	**31st March 2024**	1,045.20	529.04	1,574.24
	31st March 2023	61.76	-	61.76
Carrying amount of segment asset	**31st March 2024**	13,230.42	-	13,230.42
	31st March 2023	1,772.08	-	1,772.08
Capital expenditure during the year	**31st March 2024**	15,489.21	-	15,489.21
	31st March 2023	414.23	-	414.23

27 CSR activities

As per Section 135 of the Companies Act, 2013, the Company has constituted a Corporate Social Responsibility (CSR) Committee. The total amount spent by the Company on CSR activities during the year is Rs. Nil (FY 2022-23: NIL), as the company incurred, a loss during the year.

28 Trial run expenses capitalized.

During the year company started the manufacturing of the product wef 30th September, 2023. However the company could not achieve its production capacity intended for. As a result, the cost of operations net of sales revenue during the period, treated as the trial run expenses & has been included in Capital WIP. Given below are the details of expenses during the year.

	Year Ended 31st March 2024	Year Ended 31st March 2023
Revenue:-		
Sales of Privial/Lilial	1,101.70	-
Other Income (including forex and duty drawback	-	-
Total (A)	1,101.70	-
Expenses		
Consumption of Material	1,081.62	-
Other expenses	1,688.83	-
Total (B)	2,770.45	-
Pre-operative expenses (Trial Run expenses) included in CWIP. Total (C) = (B-A)	**1,668.75**	-

(Currency: Indian Rupees in Lakhs)

29 Note On Amalgmation of "Privi Organics Ltd." with" Privi Fine Sciences Pvt. Ltd.":

During the year "Privi Organics Ltd." a company manufacturer, exporter, and trader in Specialty chemicals (aroma chemicals) and other Chemicals products, vide the NCLT order dt. 19th December,2023 amalgmated & merged with "Privi Fine Sciences Pvt. Ltd." wef 01st April, 2023, under section 230 to 232 & other applicable provisions of the Company's Act, 2013. The Company commenced it's manufacturing from 30th Septemeber,2023 in factory located at Plot No. C-39 & C-39 (Part), MIDC Lote, Tq.-Khed, Dist.- Ratnagiri. Further the purchase consideration is settled by way of issue of shares in the ratio of 3.25 shares of "Privi Fine Sciences Pvt. Ltd." for every share of "Privi Organics Ltd." held on 31.3.2024. As a result the Goodwill of Rs. 6301.43 lakhs was generated in the process of merger.

30 Fire Insurance claim:

On April 17, 2022, a fire broke out at the Company's Plant located at MIDC Lote. There has been a loss to assets comprising Inventories, Buildings, Stores and spares and other Fixed Assets, etc amounting to Rs.397.98 lakhs. The company had adequately insured. The Company has received a total claim of Rs 300.66 lakhs including the fire scrap sale of Rs.28.51 lakhs). The net loss on fire was Rs.97.32 lakhs has been shown in the profit and loss account under the head extraordinary items.

31 Prior year comparative

Figures for the previous year have been reclassified and regrouped wherever considered necessary to conform to the current year's presentation.

As per our report of even date attached

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : 20th June, 2024

For and on behalf of the Board of
Privi Fine Sciences Private Limited
CIN:U24110MH2021PTC358857

Shehal Babani
DIN: 07672706
Managing Director

Mahesh Babani
DIN: 00051162
Director

Ramesh Kathuria
Company Secretary
A-11214

Arun Newalkar
Chief Financial Officer

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

AUDITOR'S REPORT

To the Members of PRIVI FINE SCIENCES PRIVATE LIMITED.

Report on the Financial Statements

We have audited the accompanying financial statements of **PRIVI FINE SCIENCES PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at March 31, 2023, and the statement of Profit and Loss for the year ended 31st March 2023 and a summary of significant accounting policies and other explanatory information.

Management's Responsibility for the Financial Statements

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation and presentation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these standalone financial statements based on our audit. We have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on whether the Company has in place an adequate internal financial controls system over financial reporting and the operating effectiveness of such controls. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the standalone financial statements.

Opinion

In our opinion and to the best of our information and according to the explanations given to us, the financial statements give the information required by the act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India:

(a) In the case of the Balance Sheet, of the state of affairs of the Company as at March 31, 2023, and
(b) In the case of the statement of Profit and Loss, loss for the year ended on that date.

Report on Other Legal and Regulatory Requirements

1. Since the Company has not Commences its Business activities requirement of the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, is not applicable.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

2. **As required by section 143 (3) of the Act, we report that:**

   a. We have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit;

   b. In our opinion proper books of account as required by law have been kept by the Company so far as appears from our examination of those books [and proper returns adequate for the purposes of our audit have been received from branches not visited by us];

   c. The Balance Sheet and Statement of Profit and Loss dealt with by this Report are in agreement with the books of account ;

   d. In our opinion, the Balance Sheet and Statement of Profit and comply with the Accounting Standards referred to in Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014

   e. On the basis of the written representations received from the Directors as on 31 March 2023 taken on record by the Board of Directors, none of the directors is disqualified as on 31 March 2023 from being appointed as a director in terms of Section 164 (2) of the Act; and.

   f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate report in "Annexure B"

FOR E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS

Place: Mumbai
Date: 5TH May 2023

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

ESMAIL SITABKHAN
PROPRIETOR
M. No. O-30721
Firm Reg. No.110300W
UDIN: 23030721BGVGVX7248

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Fine Sciences Private Limited

Annexure B to the Independent Auditors' report - 31 March 2023

(Referred to in paragraph A (f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Fine Sciences Private Limited ("the Company") as of 31 March 2023 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls system with reference to financial statements and such internal financial controls were operating effectively as at 31 March, 2023, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the 'Guidance Note').

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as 'the Act').

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Fine Sciences Private Limited

Annexure B to the Independent Auditors' Report (Continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial controls with Reference to financial statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : MAY 05,2023

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Balance Sheet as at March 31,2023
(Currency : Indian Rupees)

Particulars	Refer to Note No.	As at March 31,2023	As at March 31,2022
I. EQUITY AND LIABILITIES			
(1) Shareholder's Funds			
(a) Share Capital	3	**1,00,000**	1,00,000
(b) Reserves and Surplus	4	**(3,99,860)**	-
(2) Share Application money pending allotment		-	-
(2) Non-Current Liabilities			
(a) Long-Term Borrowings	5	**50,45,10,425**	6,00,00,000
(c) Other Long Term Liabilities		-	-
(d) Long Term Provisions		-	-
(3) Current Liabilities			
(a) Short-Term Borrowings		-	-
(a) Trade Payables	6	**49,50,271**	-
(b) Other Current Liabilities	7	**1,78,36,769**	12,90,616
(c) Short-Term Provisions		-	-
Total Equity & Liabilities		**52,69,97,605**	6,13,90,616
II.ASSETS			
(1) Non-Current Assets			
(a) Fixed Assets			
(i) Tangible Assets	8	**17,72,08,351**	-
(ii) Intangible Assets		-	-
(ii) Capital Work-in-Progress	8	**4,14,23,132**	13,26,687
(iv) Intangible Assets Under Developments		-	-
(b) Non-Current Investments	9	**28,54,59,178**	5,00,000
(c) Deferred Tax Assets (Net)		-	-
(d) Long term Loans and Advances		-	-
(c) Other Non-Current Assets		-	-
(2) Current Assets			
(a) Current Investments		-	-
(b) Inventories		-	-
(c) Trade Receivables		-	-
(a) Cash and Cash Equivalents	10	**4,00,734**	5,63,929
(b) Short-Term Loans and Advances	11	**2,25,00,000**	5,90,00,000
(c) Other Current Assets	12	**6,210**	-
Total Assets		**52,69,97,605**	6,13,90,616
Significant Accounting Policies	2		
Notes Forming Integral Part of the Financial Statement	18-22		

This is the Balance Sheet referred to in our Report of even date.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : May 05, 2023

For and on behalf of the Board of
Privi Fine Sciences Private Limited

Snehal Babani
Director
DIN: 07672706

Mahesh Babani
Director
DIN: 00051162

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Profit & Loss Statement for the period ended 31 st March 2023.
(Currency : Indian Rupees)

Sr. No	Particulars	Refer to Note No.	For the year ended March 31,2023	For the Year ended March 31,2022
I	Other Income	13	61,76,201	-
	Total Revenue (I)		61,76,201	-
II	**Expenses:**			
	Employee Benefit Expenses	14	16,570	-
	Financial Costs	15	58,68,670	-
	Depreciation and Amortization Expense	16	5,33,760	-
	Other Expenses	17	1,57,060	-
	Total Expenses (II)		65,76,060	-
			-	
III	Profit before exceptional and extraordinary items and tax	(I-II)	(3,99,860)	-
IV	Exceptional Item		-	-
V	Profit before extraordinary items and tax (III -IV)		(3,99,860)	-
VI	Extraordinary Items		-	-
VII	(Loss)/Profit before tax (V - VI)		(3,99,860)	-
VIII	***Tax expense:***			
	(1) Current Tax		-	-
	(2) Deferred Tax		-	-
	(2) Deferred Tax		-	-
IX	(Loss)/Profit before tax from the perid from continuing operations	(VII-VIII)	(3,99,860)	-
X	(Loss)/Profit before tax from discontinuing operations		-	-
XI	Tax expense of discounting operations		-	-
XII	(Loss)/Profit from Discontinuing operations (XII - XIII)		-	-
X	(Loss)/Profit for the period		(3,99,860)	-
XI	Earning per equity share:			
	(1) Basic		(39.99)	
	(2) Diluted		(39.99)	-
Significant Accounting Policies		2		
Notes Forming Integral Part of the Financial Statement		18-22		

This is the statement of Profit & Loss referred to in our Report of even date.

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : May 05, 2023

For and on behalf of the Board of
Privi Fine Sciences Private Limited

Snehal Babani
Director
DIN: 07672706

Mahesh Babani
Director
DIN: 00051162

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857

Cash Flow Statement for the year ended March 31, 2023
(Currency : Indian Rupees)

Particulars	Year ended March 31, 2023	Year ended March 31,2022
(a) Cash flow from operating activities :		
(Loss)/Profit before tax:	(3,99,860)	-
Adjustments for Depreciation	5,33,760	-
Operating cash flow before working capital changes	1,33,900	-
Movements in Working Capital		
(Increase)/decrease in short term loans and advances	3,64,93,790	-
Increase in trade payables & other payables	49,50,271	-
Increase/(decrease) in other current liabilities	1,65,46,153	-
	5,79,90,214	-
Cash generated from operations	5,81,24,114	-
Less : Interest paid	-	-
Less : Income taxes paid (net of refunds)	-	-
Net cash generated from operating activities (a)	5,81,24,114	-
(b) Cash flow from investing activities :		
Purchase of Fixed asset including leasehold land	(21,78,38,556)	-
Purchase/Sale of Investment (Net)	(28,49,59,178)	-
Net cash (outflow) from investing activities (b)	(50,27,97,734)	-
(c) Cash flow from financing activities :		
Proceeds from long term borrowings	44,45,10,425	-
Net cash inflow from financing activities (c)	44,45,10,425	-
Net (decrease)/ increase in cash and bank balances (a + b+ c)	(1,63,195)	-
Add : cash and cash equivalents at the beginning of the year	5,63,929	-
Cash and cash equivalents at end of the year	4,00,734	-

The cashflow statement has been prepared under the indirect method as set out in Accounting Standard (AS-3) on cashflow statement issued by Companies (Accounting Standards) Rules, 2006.

Notes Forming Integral Part of the Financial Statement 18-22

As per our report of even date attached

For E.E.Sitabkhan & Company
Chartered Accountants

E.E.Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : May 05,2023

For and on behalf of the Board of
Privi Fine Sciences Private Limited

Snehal Babani
Director
DIN: 07672706

Mahesh Babani
Director
DIN: 00051162

Privi Fine Sciences Private Limited

Notes to the financial statements

for the year ended March 31, 2023

(Currency in Indian rupees)

1 Company overview

Corporate Information:

Privi Fine Sciences Private limited incorporated on April 14, 2021 under the provisions of the Companies Act, 1956 is a private company domiciled in India.

Privi Fine Sciences Private limited ('Privi' or 'the Company') is a Manufacturer of natural Ethanol & Industrial Chemicals. The company is in the process of putting up the manufacturing facilities in Jhagadiya, GIDC industrial area, Dist.-Bharuch.

2 Significant accounting policies

The accounting policies set out below have been applied consistently to the periods presented in these financial statements.

A. Basis of preparation of financial statements

The financial statements have been prepared and presented under the historical cost convention on an accrual basis of accounting and in accordance with the accounting principles generally accepted in India and comply with the accounting standards referred in the Companies (Accounting Standards) Rules, 2006 which continue to apply under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Account) Rules, 2014 and other relevant provision of the Companies Act, 1956 to the extent applicable.

B. Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) in India requires management to make estimates and assumptions that affect the reported amount of assets, liabilities and the disclosure of contingent liabilities on the date of the financial statements. Actual results could differ from those estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Any revision to accounting estimates is recognised prospectively in current and future periods.

C. Current and non-current classification

Schedule III to the Companies Act, 2013 requires assets and liabilities to be classified as either Current or Non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realised in, or is intended for sale or consumption in, the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE Navi Mumbai-400705

Significant accounting policies (Continued)

D. Current and non-current classification (Continued)

(c) it is expected to be realised within 12 months after the reporting date; or

(d) it is cash or cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the reporting date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current.

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is due to be settled within 12 months after the reporting date; or

(d) the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the reporting date. Terms of a liability that could, at the option of the counterparty, result in its settlement by the issue of equity instruments do not affect its classification.

Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realisation in cash or cash equivalents and is 12 months for the Company.

E. Inventories

Inventories which comprise of Raw material, packing material, stock-in trade and work in process are carried at the lower of cost and net realisable value. Costs are determined on FIFO basis. Costs include purchase price (net of refundable taxes and levies) and other costs incurred in bringing the inventories to their present location and condition. The closing stock of finished goods is valued at estimated cost or net realizable value, whichever is lower.

F. Revenue Recognition

Revenue from sale of goods in the course of ordinary activities is recognised when property in the goods or all significant risks and rewards of their ownership are transferred to the customer and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of the goods and regarding its collection.

Significant accounting policies (Continued)

G. Fixed Asset

Tangible assets are stated at cost less accumulated depreciation and net of impairment, if any. The cost of an asset comprises its purchase price (net of taxes if any) and directly attributable cost of bringing asset to working condition for its intended use.

Lease hold land is amortized at a rate, which will reduce the lease amount to "Nil" at the expiry of the remaining period of lease.

Depreciation is provided on Straight line method at the rate specified in Schedule II and provisions made there in, of the Companies Act, 2013 on the Original Cost of the assets. The rate of depreciation is charges as per single shift of working. Asset cost individually deprecated up to 95% of the cost of each individual assets only.

H. Depreciation and Amortization

Depreciation is calculated using straight line method to allocate cost of Property Plant and equipment net of residual values, over their estimated useful lives as per the useful lives prescribed in Schedule II of the Companies Act, 2013.

Depreciation on additions/ deletions during the year is provided from the month in which the asset is capitalized up to the month in which the asset is disposed off.

The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with effect of any changes in estimate accounted for on a prospective basis.

I. Retirement Benefits

Provident Fund: Provident Fund contributions are made to the Government Provident Fund Authority

J. Provisions and contingent liabilities

A provision is recognised if, as a result of a past event, the Company has a present obligation that can be estimated reliably, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are recognised at the best estimate of the expenditure required to settle the present obligation at the balance sheet date. The provisions are measured on an undiscounted basis.

Significant accounting policies (Continued)

K. Provisions and contingent liabilities (Continued)

A contingent liability exists when there is a possible but not probable obligation, or a present obligation that may, but probably will not, require an outflow of resources, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions, but are disclosed unless the possibility of outflow of resources is remote. Contingent assets are neither recognised nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic benefits will arise, the asset and related income are recognised in the period in which the change occurs.

L. Taxes on Income

Current Tax:- Provision for Income Tax is determined in accordance with the provision of the Income Tax Act 1961.

Deferred Taxation:- Income tax expense comprised current tax and deferred tax charge or release. The deferred tax charge or credit is recognized using current tax rates. Deferred tax assets arising from unabsorbed depreciation or carry forward losses are recognized only if there is virtual certainty of realization of such amounts. Other deferred tax assets are recognized only to the extent there is reasonable certainty of realization in future.

M. Earnings per share ('EPS')

Basic EPS is computed using the weighted average number of equity shares outstanding during the year. Diluted EPS is computed using the weighted average number of equity and dilutive equity equivalent shares outstanding during the year except where the results would be anti-dilutive.

N. Cash and cash equivalent

Cash comprises cash on hand and demand deposits with banks. Cash equivalents are short term (with an original maturity of three months or less from the date of acquisition), highly liquid investments that are readily convertible into known amounts of cash and which are subject to an insignificant risk of changes in value.

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Notes to the financial statement as at March 31, 2023
(Currency : Indian Rupees)

Note : 3 - Share Capital:

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Authorized Capital 10,000 equity shares of Rs. 10 each (PY 10,000 equity shares of Rs. 10 each)	**1,00,000**	1,00,000
		1,00,000	1,00,000
	Total	**1,00,000**	1,00,000

Note : 3(A) - Reconciliation of no. of Shares outstanding:

Particulars	Equity Shares		Equity Shares	
	As At March 31,2023		As At March 31,2022	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**10,000**	**1,00,000**	10,000	1,00,000
Shares Issued during the year	**-**	**-**	-	-
Share Premium		**-**	-	-
Shares bought back during the year	**-**	**-**	-	-
Shares outstanding at the end of the year	**10,000**	**1,00,000**	10,000	1,00,000

Note : 3(B) - Details of shareholders holding of more than 5% shares:

Sr. No.	Name of Shareholder	As At March 31,2023		As At March 31,2022	
		No. of Shares held	% of Holding	No. of Shares held	% of Holding
1	Mahesh P Babani	**2,500**	**25%**	2,500	25%
2	Seema Mahesh Babani	**2,500**	**25%**	2,500	25%
3	Jyoti Mahesh Babani	**2,500**	**25%**	2,500	25%
4	Snehal Mahesh Babani	**2,500**	**25%**	2,500	25%
		10,000		10,000	

Note : 4 - Reserve & Surplus:

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	**Surplus (Profit & Loss Account)**		
	Balance brought forward from previous year	**-**	-
	Add: Profit / (Loss) for the period	**(3,99,860)**	-
	Less: Utilised during the year	**-**	-
	Less: Transfer to reserve	**-**	-
	Closing Balance	**(3,99,860)**	-
	Total	**(3,99,860)**	

Note : 5 - Non-Current Liabilities

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Long-Term Borrowings	**50,45,10,425**	6,00,00,000
	Total	**50,45,10,425**	6,00,00,000

Note : 6- Trade Payable#:

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Sundry Creditors For Goods	**-**	-
2	Sundry Creditors- Others	**49,50,271**	-
	Total (A + B)	**49,50,271**	-

The Company has not received any intimation from the "Supplier" regarding their status under the Micro, Small and Medium Enterprises Development Act, 2006 and hence the disclosure relating to amount unpaid as at the end of the year together with interest paid / payable as required under the said Act has not been furnished and provision for interest, if any, on delayed payments, is not ascertainable at this stage.

Note : 7 - Other Current Liabilities:

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Other liabilities- expenses	**1,58,68,671**	11,63,055
2	Statutory liabilities	**19,68,097**	1,27,561
	Total	**1,78,36,769**	12,90,616

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Notes to the financial statement as at March 31, 2023
(Currency : Indian Rupees)

Note : 8 Fixed Asset

Sr. No	Particulars	Gross Block				Depreciaton				Net Block	
		April 01,2022	Addition/ Revaluation during the year	Deduction during the year	March 31,2023	April 01,2022	Addition during the year	Deduction during the year	March 31,2023	WDV as on March 31,2023	WDV as on March 31,2022
I	**Tangible Assets**										
1	Leasehold land	-	17,77,42,111	-	17,77,42,111	-	5,33,760	-	5,33,760	17,72,08,351	
	Total Tangible Assets I	-	17,77,42,111	-	17,77,42,111	-	-	-	5,33,760	17,72,08,351	-
II	**CAPITAL WORKING PROGRESS**										
1	CWIP(Building)	13,26,687	1,42,96,445	-	1,56,23,132	-	-	-	-	1,56,23,132	13,26,687
2	CWIP(Plant & Machinery)	-	2,58,00,000	-	2,58,00,000	-	-	-	-	2,58,00,000	-
	Total Capital Working Progress I	13,26,687	4,00,96,445	-	4,14,23,132	-	-	-	-	4,14,23,132	13,26,687
	Grand Total I+II	13,26,687	21,78,38,556		21,91,65,243	-	-	-	5,33,760	21,86,31,483	13,26,687
	Fixed Assets-Year 2021-2022	-	-	-	-	-	-	-	-	-	-
	CWIP- Year 2021-2022	-	13,26,687	-	13,26,687	-	-	-	-	-	13,26,687

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Notes to the financial statement as at March 31, 2023
(Currency : Indian Rupees)

Note : 9 Non Current Investment

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Mutual Fund	**28,54,59,178**	**5,00,000**
	Total	**28,54,59,178**	5,00,000

Note : 10 Cash & Cash Equivalent

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	**Cash-in-Hand**		
	Cash Balance	-	-
	Sub Total (A)	-	-
2	**Bank Balance**		
	With Banks	**4,00,734**	5,63,929
	Sub Total (B)	**4,00,734**	5,63,929
	Total [A + B]	**4,00,734**	5,63,929

Note:11 Short Term Loans & Advances

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Advance against purchase of Fixed Assets	**2,25,00,000**	5,90,00,000
	Total	**2,25,00,000**	5,90,00,000

Note:12 Other Current Assets

Sr. No	Particulars	As At March 31,2023	As At March 31,2022
1	Input Tax Credit (Indirect Taxes)	**6,210**	-
	Total	**6,210**	-

Privi Fine Sciences Private Limited

CIN: U24110MH2021PTC358857

Notes to the financial statement as at 31st March ,2023

(Currency : Indian Rupees)

Note : 13 Other Income

Sr. No	Particulars	For the year ended March 31,2023	For the Year ended March 31,2022
1	Gain on Investment	**61,76,201**	-
	Total	**61,76,201**	-

Note : 14 Employee Benefits Expenses

Sr. No	Particulars	For the year ended March 31,2023	For the Year ended March 31,2022
1	Staff Welfare	**16,570**	-
	Total	**16,570**	-

Note :15 Financial Cost

Sr. No	Particulars	For the year ended March 31,2023	For the Year ended March 31,2022
1	Interest on Other loans	**58,68,493**	-
2	Bank Charges	**177**	-
	Total	**58,68,670**	-

Note : 16 Depreciation & Amortised Expense

Sr. No	Particulars	For the year ended March 31,2023	For the Year ended March 31,2022
1	Depreciation & Amortisation	**5,33,760**	-
	Total	**5,33,760**	-

Note : 17 Other Expenses

Sr. No	Particulars	For the year ended March 31,2023	For the Year ended March 31,2022
1	Professional Fees	**67,500**	-
2	Office & Administrative Expenses	**89,560**	-
	Total	**1,57,060**	-

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI FINE SCIENCES PRIVATE LIMITED REGD. OFFICE Navi Mumbai

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Notes to the financial statement as at March 31, 2023
(Currency : Indian Rupees)

Note: 18 Related party disclosures
Details of transactions between the Company and other related party are disclosed below.

a) **List of Related Parties**

Enterprises owned by key management personnel or their relatives

Privi Speciality Chemicals Limited.
Privi Life Sciences Private Limited
Privi Organics Limited
Prigiv Specialties Private Limited
Babani Investment And Trading Private Limited
Privi Biotechnologies Private Limited
Satellite Technologies Private Limited
Moneymart Securities Private Limited
MM Infra & Leasing Pvt. Ltd.
Vivira Chemicals Industries
Babani Brothers LLP
Empee Constructions
Satguru Constructions
Alum And Chemical Corporation (upto 27th March, 2023)
Vivira Investment And Trading Private Limited

Key Management Personnel (KMP)
Mr. Mahesh P. Babani
Ms.Jyoti Mahesh Babani

Relatives of Key Management Personnel
Mahesh Purshottam Babani HUF
Mrs. Seema Mahesh Babani
Ms. Snehal Mahesh Babani

b) **During the year, following transactions were carried out with the related parties :**

Transactions	Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2023	March 31, 2022	**March 31, 2023**	March 31, 2022
Loan taken from Vivira Investment And Trading Private Limited	**41,95,10,425**	6,00,00,000	-	-
Loan taken from Moneymart Securities Private Limited	**2,50,00,000**	-	-	-
Interest on loan taken from Vivira Investment And Trading Private Limited	**1,46,40,411**	12,75,616	-	-
Interest on loan taken from Moneymart Securities Private Limited	**16,60,274**	-	-	-

Privi Fine Sciences Private Limited
CIN: U24110MH2021PTC358857
Notes to the financial statement as at March 31, 2023
(Currency : Indian Rupees)

Related party disclosures continues

c) **Outstanding Balance**

	Enterprises owned by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31, 2023	March 31, 2022	**March 31, 2023**	March 31, 2022
Payables / Other Labilities				
Vivira Investment And Trading Private Limited	**49,26,86,795**	6,11,48,055	**-**	-
Moneymart Securities Private Limited	**2,64,94,247**	-	**-**	-

19 **Earnings per share**

	As at March 31, 2023	As at March 31, 2022
Profit/(Loss) after tax attributable to equity shareholders [A]	**(3,99,860)**	-
Number of equity shares at the beginning of the year [B]	**10,000**	10,000
Number of equity shares outstanding at the end of the year [C]	**10,000**	10,000
Weighted average number of equity shares outstanding during the year [D]	**10,000**	10,000
Basic & Diluted earnings (in rupees) per share of face value Rs. 10 [A]/[D]	**(39.99)**	-

20 **Segmental Reporting**

(a) Primary Business Segment:

In accordance with the requirements of Accounting Standard 17 'Segment Reporting' ('AS17'), the Company has determined its business segment as Manufacturer of natural Ethanol & Industrial Chemicals. As the Company is engaged only in one business segment, the segment revenue, segment result, total carrying amount of segment assets, total carrying amount of segment liabilities, total cost incurred to acquire segment assets, the total amount of charge for depreciation and amortization during the year are as reflected in the financial statements for the year ended 31 March 2023.

(b) Secondary Geographical Segment:

In respect of secondary segment information, the company has identified its geographical segments as Domestic and Overseas. The Secondary Segment information has been disclosed accordingly.

	Year	Domestic	Overseas	Total
Revenue	**March 31,2023**	**61,76,201**	**NIL**	**61,76,201**
	March 31,2022	NIL	NIL	NIL
Carrying amount of segment asset	**March 31,2023**	**17,72,08,351**	**NIL**	**17,72,08,351**
	March 31,2022	NIL	NIL	NIL
Capital expenditure during the year	**March 31,2023**	**4,14,23,132**	**NIL**	**4,14,23,132**
	March 31,2022	NIL	NIL	NIL

21 During the year, company has acquired the leasehold land for the purpose of construction of manufacturing facilities at Jhagadia, dist.- Bharuch in the state of Gujarat. The expenses incurred during the construction period have been treated as Capital Work in progress.

22 Previous Year figures have been regrouped wherever necessary.

As per our report of even date attached

For M/S.E.E Sitabkhan & Co.
Chartered Accountants

E E Sitabkhan
Proprietor
Membership No. 30721

Place : Mumbai
Date : May 05, 2023

For and on behalf of the Board of
Privi Fine Sciences Private Limited

Shehal Babani
Director
DIN: 07672706

Mahesh Babani
Director
DIN: 00051162

F. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

F. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Privi Biotechnologies Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Biotechnologies Private Limited ('the Company'), which comprise the standalone balance sheet as at 31st March 2025, and the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as 'standalone financial statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2025, its Loss (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's Annual Report but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

F. E. SITABKHAN & CO. MUMBAI Chartered Accountants

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the standalone financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

F. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

(A) As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The standalone balance Sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement dealt with by this report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on 31st March 2025 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2025 from being appointed as a director in terms of Section 164(2) of the Act: and

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer our separate Report in 'Annexure B'.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI

DATE :APRIL 28,2025
UDIN: 25030721BMJAAH1326

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Biotechnologies Private Limited

"Annexure A" to the Independent Auditors' Report – 31 March 2025

(Referred to in our report of even date)

(i) **(a)** (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) All fixed assets are physically verified by the management in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. The physical verification of fixed assets was done in previous financial year 2024-25 and No material discrepancies were noticed on such verification.

(c) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favor of the lessee) are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a)The company is involved in activity of research & development of aroma products therefore does not have significant inventory, however few of the store spares , consumables and machinery spare parts which are taken and consumed. Regarding the unused item at the end of the year inventory is taken as on 31st March 2025 and same has been valued on Average Price Basis. The Expenses on account of Consumables Stores & spare items is shown in Profit & Loss A/c net off inventory value. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.

(b)According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has no sanctioned working capital facility from banks or financial institutions.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company has not made during the year any investments or given any guarantee or security or granted any loans or advances which are characterized as loans, unsecured or secured, to LLPs, firms or companies or any other person.

(a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has not provided loans or provided advances in the nature of loans, or given guarantee, or provided security to any other entity during the year.

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the investments made is, prima facie, not prejudicial to the interest of the company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loans are given during the year further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loans given. Further, the Company has not given any advances in the nature of loans to any party during the year. Accordingly, clause 3(iii) (d) of the Order is not applicable.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted. Accordingly, clause 3(iii) (e) of the Order is not applicable.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans. Accordingly, clause 3(iii) (f) of the Order is not applicable.

(iv) According to the Information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any security as specified under section 185 and 186 of the Companies Act, 2013. According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and guarantees given by the Company, the provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) In our opinion since the company is not engaged in manufacturing activities , the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013 is not applicable to Company.

(vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues have been generally regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable.

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
T. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to banks or financial institutions during the year. Further, the Company did not have any outstanding loans or borrowings from any other lender during the year

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, Company does not have any term loans.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, its associates, subsidiaries or joint ventures as defined under Companies Act, 2013.

(f) According to the information and explanations given to us and procedures performed by us, we report that the company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under Companies Act, 2013).

(x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Biotechnologies Private Limited

Annexure A to the Independent Auditors' Report – 31 March 2025 (Continued)

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) (a) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has internal audit system commensurate with the size and nature of its business as The Company is engaged in R&D activity.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has incurred cash losses in the current year amounting to Rs. 529.64 Lakhs.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : APRIL 28,2025

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721
UDIN: 25030721BMJAAH1326

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
F. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Biotechnologies Private Limited

Annexure B to the Independent Auditors' report - 31 March 2025

(Referred to in paragraph A (f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Biotechnologies Private Limited ("the Company") as of 31 March 2025 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls system with reference to financial statements and such internal financial controls were operating effectively as at 31 March, 2025, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the 'Guidance Note').

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as 'the Act').

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

F. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial controls with Reference to financial statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : APRIL 28,2025

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721
UDIN: 25030721BMJAAH1326

E.E. SITABKHAN & CO. Chartered Accountants MUMBAI

PRIVI BIOTECHNOLOGIES PRIVATE LIMITED

Registered / Corporate Office : A-71, MIDC, TTC, THANE BELAPUR ROAD, NAVI MUMBAI - 400 710

BALANCE SHEET &

PROFIT & LOSS ACCOUNT

(ALONGWITH NOTES)

March-2025

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : U74220MH1985PTC037534

Audited standalone statement of assets and liabilities as at March 31, 2025

(Rs in Lakhs)

Particulars	As at March 31, 2025 (Audited)	As at March 31, 2024 (Audited)
Assets		
Non-current assets		
Property, plant and equipment	1,364.51	1,518.66
Capital work-in-progress	24.20	74.23
Intangible assets	103.80	121.48
Intangible assets under development	-	-
Right of use of assets	614.63	629.32
Financial assets		
Loans and Advances	20.14	16.67
Non-current tax assets (net)	-	2.35
Other non current assets	-	-
Total non-current assets (A)	**2,127.28**	2,362.71
Current assets		
Financial assets		
Inventories	37.57	49.62
Investment in mutual fund	-	-
Trade receivables	164.77	-
Loans and Advances	250.00	900.00
Cash and Cash equivalents	1.63	101.55
Bank Balances other than cash and cash equivalents	35.92	35.59
Other current assets	80.21	51.99
Total current assets (B)	**570.10**	**1,138.75**
Total assets (A+B)	**2,697.38**	**3,501.46**
Equity and liabilities		
Equity		
Equity share capital	3,627.47	3,627.47
Other equity	(1,194.28)	(411.64)
Total equity (C)	**2,433.19**	**3,215.83**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	-	-
Deferred tax liabilities (Net)	83.03	72.92
Provisions	45.84	35.03
Total non current liabilities (D)	**128.87**	**107.95**
Current liabilities		
Financial liabilities		
Trade Payable		
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small	61.04	91.00
Other financial liabilities	58.74	73.97
Provisions	2.90	2.24
Current tax liabilities (net)	2.07	2.07
Other current liabilities	10.57	8.40
Total current liabilities (E)	**135.32**	**177.68**
Total equity and liabilities (C+D+E)	**2,697.38**	**3,501.46**

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date: April 28,2025

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on Behalf of Board of Directos of
Privi Biotechnologies Pvt. Ltd

Mahesh Babani
Director
DIN: 00051162

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India

Statement of audited Standalone Financial results for the quarter and year ended March 31, 2025 (Rs In Lakhs)

CIN: U74220MH1985PTC037534

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2025 (Audited)	Decemebr 31, 2024 (Unaudited)	March 31, 2024 (Audited)	March 31, 2025 (Audited)	March 31, 2024 (Audited)
1	Revenue from operations	120.00	120.00	120.00	480.00	555.00
2	Other income	29.54	32.91	41.46	134.64	348.16
3	**Total income (1 + 2)**	**149.54**	**152.91**	**161.46**	**614.64**	**903.16**
4	**Expenses**					
	(d) Employee benefits expense	114.07	80.41	89.87	349.82	288.81
	(e) Finance cost	-	-	-	-	0.02
	(f) Depreciation and amortisation expense	54.49	55.06	51.13	219.30	221.16
	(g) Other expenses	178.04	304.40	55.73	794.46	384.95
	Total expenses (4)	**346.60**	**439.87**	**196.73**	**1,363.58**	**894.94**
5	**Profit /(Loss) before exceptional items and tax (3 - 4)**	**(197.06)**	**(286.96)**	**(35.27)**	**(748.94)**	**8.22**
6	**Exceptional Income/(Expenses)**	-		-		-
7	**Profit /(Loss) before tax (5 -6)**	**(197.06)**	**(286.96)**	**(35.27)**	**(748.94)**	**8.22**
8	**Tax expense**					
	Current tax	-		2.07		2.07
	Tax adjustment of earlier years	-		-		-
	Deferred tax	2.05	3.08	2.46	11.28	12.30
9	**Net profit /(Loss) for the period (7 - 8)**	**(199.11)**	**(290.04)**	**(39.80)**	**(760.22)**	**(6.15)**
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
	Remeasurements of post employment benefit obligations	(1.15)	(1.15)	(2.63)	(4.61)	(4.61)
	Income tax related to above	0.29	0.29	0.66	1.16	1.16
	(ii) Items that will be reclassified to Profit or loss	-	-	-		-
	Total other comprehensive income (11)	**(0.86)**	**(0.86)**	**(1.97)**	**(3.45)**	**(3.45)**
11	**Total comprehensive income/(Loss) for the period (10+11)**	**(199.96)**	**(290.89)**	**(41.77)**	**(763.66)**	**(9.60)**
12	Paid up equity share capital (face value od Rs.10/- each)			3,627.47		3,627.47
13	Earnings per share (EPS) of Rs.10/- each *(not anualised) (in Rs.)					
	Basic Diluted	*1.55	*(0.80)	*(0.12)	*(2.10)	(0.02)

Notes:

1 The Audited standalone financial results for the quarter and year cneded March 31,2025 were reviewed and approved by the Board of Directors of Privi Biotechnologies Private Limited ("the Company") at its meeting held on April ,28 2025. The above results have been subjected to reviewby the statutory auditors of the comapny.The statutory auditors have expressed an unqualified review opinion .

2 The unaudited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI circular dated July 5, 2016.

3 The Financial Results has been prepared solely to enable Privi Speciality Chemicals Limited (Holding company) to prepare consolidated financial results and not to report on the Company as a separate entity.

4 As the Company's business activity falls within a single segment viz. 'Aroma Chemical ', the disclosure requirements of the Ind AS 108 'Operating Segments' notified under Section 133 of the Companies Act, 2013 are not applicable.

5 The figures for the quarter ended March 31,2025 and March 31, 2024 are arrived at as a difference between audited figures in respect of the full financial year and the unaudited figures up to nine months of the relavent financial year.

6 Previous period figures have been regrouped and reclassified wherever necessary.

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date: April 28,2025

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of Director
Privi Biotechnologies Private Limited

Mahesh Babani
Director
DIN: 00051162

Privi Biotechnologies Private Limited

Regd.Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India

PRIVI

CIN: U74220MH1985PTC037534

Audited standalone statement of cash flow

(Rs in Lakhs)

		Year ended March 31, 2025	Year ended March 31,2024
A	**Cash flow from operating activities**		
	Profit before tax after exceptional items	(748.94)	8.22
	Adjustment for:		
	Depreciation and amortisation	219.30	221.16
	Sundry balances Written Off	(0.01)	1.97
	Profit on sale of fixed assets	-	(218.81)
	Interest Income	(3.19)	(2.41)
	Finance costs	-	0.02
	Operating cash flow before working capital changes	(532.84)	10.15
	Movements in working Capital		
	Increase in trade receivables	(164.77)	279.77
	Decrease / (increase) in inventories	12.05	(10.00)
	Increase /(decrease) in other assets	618.31	(929.86)
	Increase in trade payables and other current liabilities and provisions	(36.17)	62.81
	Cash generated / (used in) from operatation	429.42	(597.28)
	Income taxes paid	-	(2.35)
	Net cash generated / (used in) from operating activities [A]	**(103.42)**	(589.48)
B	**Cash flow from investing activities**		
	Purchase of property, plant & equipment	(0.02)	(127.12)
	Proceeds from sale of Property, Plant & Equipment	-	811.00
	Purchase of business (Refer Note No. 30)	-	-
	Realisation / (investment) of fixed deposits	-	-
	Sale / (purchase) of investments	-	-
	Investment in fixed deposits	0.33	0.14
	Interest received	3.19	2.41
	Net cash (used in)/ generated by investing activities [B]	3.50	686.44
C	**Cash flow from financing activities**		
	Repayment of long term borrowings	-	-
	Interest paid	-	(0.02)
	Net cash (used in)/ generated from financing activities [C]	-	(0.02)
	Net increase/ (decrease) in cash and cash equivalents (A+B+C)	**(99.92)**	96.94
	Cash and cash equivalents at the beginning of the year	101.55	4.61
	Cash and cash equivalents at end of the year	1.63	101.55

Note A: The above statement of cash flows has been prepared under 'Indirect Method' as set out in Ind AS 7,'statement of Cash Flows'

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date: April 28,2025

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on Behalf of Board of Directos of
Privi Biotechnologies Pvt. Ltd

Mahesh Babani
Director
DIN: 00051162

Privi Biotechnologies Private Limited

Balance Sheet

As at March 31, 2025

(Currency: Indian Rupees in lakhs)

		As at March 31, 2025	As at March 31, 2024
Assets			
Non-current assets			
Property, plant and equipment	4	1,364.51	1,518.66
Capital work-in-progress	4	24.20	74.23
Intangible assets	5	103.80	121.48
Intangible assets under development	5	-	-
Right of use of assets	5a	614.63	629.32
Other financial assets	7	20.14	16.67
Non-current tax assets (net)		-	2.35
Other non current assets	11	-	-
Total non current Assets		2,127.28	2,362.71
Current assets			
Financial assets			
Inventory	6	37.57	49.62
Investments	7	-	-
Trade receivables	8	164.77	
Loans and Advances	7	250.00	900.00
Cash and cash Equivalents	9	1.63	101.55
Bank balances other than cash and cash equivalents	10	35.92	35.59
Other Financial Assets	7	-	-
Other current assets	11	80.21	51.99
Total current assets		570.10	1,138.75
Total assets		2,697.38	3,501.46
Equity and liabilities			
Equity			
Equity share capital	3	3,627.47	3,627.47
Other equity	3a	(1,194.28)	(411.64)
Total equity		2,433.19	3,215.83
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings		-	-
Other financial liabilities	15	-	-
Provisions	12	45.84	35.03
Deferred tax liabilities (Net)	13	83.03	72.92
Total non-current liabilities		128.87	107.95
Current liabilities			
Financial liabilities			
Trade payable			
a) Total outstanding dues of micro and small enterprises	14	-	-
b) Total outstanding dues of creditors other than micro and small enterprise	14	61.04	91.00
Other financial liabilities	15	58.74	73.97
Other current liabilities	16	10.57	8.40
Provisions	12	2.90	2.24
Current tax liabilities (net)		2.07	2.07
Total current liabilities		135.32	177.68
Total equity and liabilities		2,697.38	3,501.46
Notes to the financial statements	3 to 27		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Mumbai
Date: April 28,2025

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Privi Biotechnologies Private Limited

Statement of Profit and Loss

for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2025	Year ended March 31,2024
Revenue from operations	17	480.00	555.00
Other income	18	134.64	348.16
Total income (I)		614.64	903.16
Expenses			
Employee benefits expense	19	349.82	296.19
Finance costs	20	-	0.02
Depreciation and amortisation expenses	21	219.30	221.16
Other expenses	22	794.46	384.95
Total expenses (II)		1,363.58	902.32
Profit / (loss) before tax expenses (I)-(II)		(748.94)	0.84
Tax expenses			
Current tax		-	2.07
Deferred tax credit / (charge)		11.28	12.30
Income tax expense		11.28	14.37
Profit / (loss) for the year (III)		(760.22)	(13.53)
Other comprehensive income / (loss)		(4.61)	(4.61)
Income tax related to above		1.16	1.16
Total comprehensive income / (loss) for the year (III)+(IV)		(763.66)	(16.98)
Earnings per equity share: nominal value of share Rs.10/- each (March 31, 2024: Rs. 10/-)			
Basic and diluted (Rs.)	25	(2.10)	(0.02)
Notes to the financial statements	3 to 27		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Mumbai
Date: April 28,2025

For and on behalf of the Board of Directors of Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Bubani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Privi Biotechnologies Private Limited

Statement of Cash Flow

for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2025	Year ended March 31,2024
A	**Cash flows from operating activities**		
	Profit/ (Loss) before tax	(748.94)	8.22
	Adjustment for:		
	Depreciation and amortisation	219.30	221.16
	Sundry balances Written Off	(0.01)	1.97
	Profit on sale of assets	-	(218.81)
	Interest income	(3.19)	(2.41)
	Finance costs	-	0.02
		(532.84)	10.15
	Operating cash flows before working capital changes		
	Adjustment for:		
	Increase in trade receivables	(164.77)	279.77
	Decrease/(increase) in inventories	12.05	(10.00)
	Increase /(Decrease) in other assets	618.31	(929.86)
	Increase in trade payables and other current liabilities and provisions	(36.17)	62.81
	Cash generated from operations	429.42	(597.28)
	Income taxes paid	-	(2.35)
	Net cash generated / (used in) from operating activities [A]	(103.42)	(589.48)
B	**Cash flows from investing activities**		
	Purchase of property, plant & equipment	(0.02)	(127.12)
	Proceeds from sale of Property, Plant & Equipment	-	811.00
	Investment in fixed deposits	0.33	0.14
	Interest received	3.19	2.41
	Net cash (used in)/ generated by investing activities [B]	3.50	686.44
C	**Cash flow from financing activities**		
	Proceeds from long-term borrowings	-	-
	Interest paid	-	(0.02)
	Net cash (used in)/ generated by financing activities [C]	-	(0.02)
	Net increase in cash and equivalents [A +B +C]	(99.92)	96.94
	Cash and cash equivalents at the beginning of year	101.55	4.61
	Cash and cash equivalents at the end of year (refer note no. 9)	1.63	101.55

The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard - 7 on cash flow statements specified under Section 133 of the Companies Act, 2013.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountant

(E.E. Sitabkhan)
Proprietor, M.No.30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Mumbai
Date: April 28,2025

Privi Biotechnologies Private Limited

Statement of Changes in Equity

As at March 31,2025

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	As at March 31, 2025	As at March 31, 2024
Balance at the beginning of the year	3,627.47	3,627.47
Changes in equity share capital during the year	-	-
Balance at the end of the year	3,627.47	3,627.47

B. Other equity

	Reserves and surplus			
	Revaluation reserve	Retained earnings	Other comperhensive income	Total
Total comprehensive profit / (loss) for the year ended April 01, 2023				
Opening balance of profit and loss account	783.96	(1,154.09)	(12.95)	(383.08)
(Loss) for the year	-	(6.15)	(3.45)	(9.60)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	765.00	(1,160.24)	(16.40)	(411.64)
Balance as at Apr 01,2024	765.00	(1,160.24)	(16.40)	(411.64)
Total comprehensive profit / (loss) for the year ended April 01,2024				
Profit/(Loss) for the year	-	(760.22)	(3.45)	(763.67)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	(18.96)	(760.22)	(3.45)	(783.63)
Balance as at March 31,2025	746.03	(1,920.46)	(19.85)	(1,194.28)

Notes to the financial statements 3 to 27
Significant accounting policies 2

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached
For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Mumbai
Date: April 28,2025

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

Mahesh Babani
Director
DIN: 00054162

D. B. Rao
Managing Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58578

Privi Biotechnologies Private Limited

Notes to financial statements *(Continued)*

for the financial year ended 31 March 2025

(Currency: Indian Rupees in Lakhs)

1 Corporate Information

Privi Biotechnologies Private Limited (The Company) is incorporated on September 20, 1985, under the provision of the companies act 2013. The Company is a 100% subsidiary of Privi Specialty Chemicals Limited.

The Company's Pilot Plant is located at Nerul, Navi Mumbai, Maharashtra, and its Registered office is situated at Koparkhairne. Navi Mumbai, Maharashtra

2 Significant accounting policies

Statement of Compliance

These standalone financial statements (hereinafter referred to as "financial statements") are prepared in accordance with the Indian Accounting Standards ("Ind AS") as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of the Companies Act, 2013 ("the Act"), amendments thereto and other relevant provisions of the Act. The standalone financial statements of the Company were approved for issue in accordance with the resolution of the Board of Directors on April 20, 2023.

i. Basis of Preparation

The standalone financial statements have been prepared on a historical cost basis, except for the following assets and liabilities:

(i) Derivative Financial Instruments measured at fair value.
(ii) Certain financial assets and liabilities measured at fair value (refer to accounting policy regarding financial instruments)
(iii) Employee's Defined Benefit Plan as per actuarial valuation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company considers the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

Functional and Presentation Currency

The financial statements are presented in Indian Rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

ii. Use of estimates

The preparation of financial statements requires management to make judgments, estimates, and assumptions in the application of accounting policies that affect the reported amounts of assets, liabilities, income, and expenses. Actual results may differ from these estimates. Estimates and judgments are continuously evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future period affected.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are included in the following notes:

(a) Measurement of defined benefit obligations for any actuarial assumption
(b) Recognition of deferred tax assets

iii. Current and non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realized in, or is intended for sale or consumption in, the company's normal operating cycle;

(b) it is held primarily for the purpose of being traded;

(c) it is expected to be realized within 12 months after the balance sheet date; or

(d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the balance sheet date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in, the company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is due to be settled within 12 months after the balance sheet date; or

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

iii. Current and non-current classification (Continued)

(d) the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Terms of a liability that could, at the option of the counter party, result in its settlement by issue of equity instruments do not affect its classification. Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalents.

iv. Property, Plant, and Equipment ("PPE") and depreciation

Freehold land is carried at historical cost. All other items of property, plant, and equipment are stated at historical cost, less accumulated depreciation/amortization and impairments, if any. Historical costs include taxes, duties, freight, and other incidental expenses related to acquisition and installation. Indirect expenses during the construction period, which are required to bring the asset in the condition for its intended use by the management and are directly attributable to bringing the asset to its position, are also capitalized.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE.

Material items such as spare parts, stand-by equipment and service equipment are classified as PPE when they meet the definition of PPE as specified in Ind AS 16 – Property, Plant and Equipment.

The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in the Statement of Profit and Loss.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

iv. Property, Plant, and Equipment ("PPE") and depreciation (Continued)

Depreciation and amortization

Depreciation is calculated using the straight-line method to allocate the cost of property plant equipment, net of residual values, over their estimated useful lives as per the useful life prescribed in schedule II of the Companies Act, 2013 except in the case of the following class of assets where the useful life is based on technical evaluation of the management:

Asset Class	Years
Plant and Machinery	10
Furniture & Fixtures	16
Electrical Installation	10
Office Equipment	10
Computer	6

Fixtures in leasehold premises are amortized over the primary period of the lease or the useful life of the fixtures, whichever is lower.

Depreciation on additions/deletions during the year is provided from the month in which the asset is capitalized up to the month in which the asset is disposed of.

The estimated useful lives, residual values, and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets required under finance leases are depreciated over the shorter of the lease term and their useful lives (not being greater than the useful life envisaged in Schedule II of the Companies Act, 2013) unless it is reasonably certain that the company will obtain ownership by the end of lease term, in which case the depreciation rates applicable for similar assets owned by the company are applied.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amounts. These are included in profit or loss within other gains/(losses).

v. Intangible assets and amortization

Intangible assets with finite useful life are stated at the cost of acquisition, less accumulated depreciation/ amortization, and impairment loss, if any. Cost includes taxes, duties, and other incidental expenses related to the acquisition and other incidental expenses.

S. S. SHAIKHANI & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

v. Intangible assets and amortization (Continued)

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

Asset Class	Years
Patent	5 Years
Computer & Software's	5 Years

Regarding internally generated intangible assets:

Expenditure on research activities, undertaken with the prospect of developing new products or gaining new technical knowledge and understanding, is recognized in profit or loss as incurred.

Capital expenditure on research and development is capitalized and depreciated as per the accounting policy mentioned above. Revenue expenditure is charged off in the year in which it is incurred.

Development activities involve a plan or design for the production of new or substantially improved products or processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of tangible fixed assets). Another development expenditure is recognized in profit or loss as incurred.

Intangible assets are amortized in profit or loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the asset.

Gains or losses arising from the recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is derecognized.

Research and Development:

Capital expenditure on research and development is capitalized and depreciated as per the accounting policy mentioned in para h and I above. Revenue expenditure is charged off in the year in which it is incurred.

Gains or losses arising from the de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is de-recognized.

The useful life of intangible assets of the company comprising of Patents & Know-how, Licenses & Certificates, and Software are considered finite and estimated at five years.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

vi. Impairment of assets

The Company assesses at each balance sheet date whether there is any indication that an asset or a group of assets (cash-generating unit) may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset or a group of assets.

The recoverable amount of an asset or CGU is greater than its value in use and its net selling price. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. If the recoverable amount of the asset or the recoverable amount of the cash-generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the Statement of profit and loss. If at the

balance sheet date there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed, and the asset is reflected at the recoverable amount subject to a maximum of depreciable historical cost.

vii. Inventories

Inventories that comprise Raw material, packing material, stores, and spares stock-in-trade, and work-in-process are carried at a lower cost and net realizable value. Costs are determined on a periodic unit price basis.

Costs include purchase price (net of refundable taxes and levies) and other costs incurred in bringing the inventories to their present location and condition. The closing stock of finished goods is valued at estimated cost or net realizable value, whichever is lower. The net realizable value of work in progress is determined by reference to the selling prices of related finished products.

Obsolete, defective, and unserviceable inventories are duly provided for. The comparison of cost and net realizable value is made on an item-to-item basis. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

viii. Revenue Recognition

Revenue from the sale of services is recognized on the basis of approved contracts regarding the transfer of services to a customer as per agreed terms of service, recovery of consideration is probable, the associated costs and possible return of services can be estimated reliably, there is no continuing effective control over or managerial involvement with the services, for an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those services. Revenue from the service is measured at the fair value of the consideration received or receivable, net of return of discounts and rebates, and Goods and Service tax. The Company does not provide any warranties or maintenance contracts to its customers.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

viii. Revenue Recognition (Continued)

Significant financing component - Generally, the Company receives short-term advances from its customers. Using the practical expedient in Ind AS 115, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if it expects, at contract inception, that the period between the transfer of the promised good or service to the customer and when the customer pays for that good or service will be one year or less.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortized cost.

Dividend Income

Dividend income is recognized when the right to receive payment is established.

ix. Borrowing costs

Borrowing costs are interest and other costs that the Group incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing. Borrowing costs include interest costs measured at EIR and exchange differences arising from foreign currency borrowings (other than long-term foreign currency borrowings) to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction/development of the qualifying asset up to the date of capitalization of such asset are added to the cost of the assets. Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognized as an expense in the period in which they are incurred.

x. Financial Instruments

a. Financial assets

Initial recognition and initial measurement

All financial assets are initially recognized at fair value plus, for an item not at fair value through profit or loss, transaction costs that are directly attributable to its acquisition or issue.

Classification and subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

3 Significant accounting policies (Continued)

x. Financial Instruments (Continued)

Financial assets at amortized cost

A financial asset is classified as subsequently measured at the amortized cost if both the following conditions are met:

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

The losses arising from impairment are recognized in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through Other Comprehensive Income ("FVTOCI")

A financial asset is classified as subsequently measured at fair value through Other Comprehensive Income if both the following conditions are met:

- The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

Financial assets included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in other comprehensive income (OCI). However, the Company recognizes interest income, impairment losses & reversals, and foreign exchange gain or loss in the P&L. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified from equity to P&L. The company did not have any financial assets at FVTOCI during the current year as well as the previous year.

Financial assets at fair value through Profit and loss ("FVTPL")

Financial assets at FVTPL are a residual category for financial assets. Any financial asset which does not meet the criteria of categorizing it at amortized cost or at FVTOCI is classified as at FVTPL.

Financial assets included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement; and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

Significant accounting policies (Continued)

x. ***Financial Instruments (Continued)***

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset nor transferred control of the asset,

the Company continues to recognize the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognizes an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of Financial Assets

In view of its past experience of having no bad debts/write-offs during the past two years and based on management's estimate that this trend would continue for the foreseeable future, the Company has determined that no impairment of Financial assets is required to be recognized based on Expected Credit Loss model.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at amortized cost and financial liabilities at FVTPL. Derivative liabilities are classified as FVTPL. All financial liabilities are recognized initially at fair value. The Company's financial liabilities include trade and other payables, loans, and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes

derivative financial instruments entered into by the Company that is not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognized in the profit or loss. Except for derivative instruments, the Company has not designated any financial liability at FVTPL.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

x. Financial Instruments (Continued)

Financial liabilities at amortized cost

All financial liabilities except for derivatives are classified as measured at amortized cost. This category includes bank and other borrowings, trade payables, and other financial liabilities.

De-recognition

A financial liability is derecognized when the obligation under the liability is discharged or cancelled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss.

c. Offsetting of Financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

xi. Cash and Cash equivalents

Cash and cash equivalent in the balance sheet and for the statement cash flow comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortized cost.

xii. Government grants

Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the company will comply with all attached conditions.

Government grants relating to income are deferred and recognized in the profit or loss over the period necessary to match them with the costs that they are intended to compensate and reduce from the corresponding cost.

S. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

xii. Government grants (Continued)

Income from export incentives such as a premium on the sale of import licenses, duty drawback, etc. is recognized on an accrual basis to the extent the ultimate realization is reasonably certain.

Government grants relating to the purchase of property, plant, and equipment are included in non-current liabilities as deferred income and are credited to profit or loss on a straight-line basis over the expected lives of the related assets and presented within other operating income.

xiii. Employee Benefits

(a) Short-Term Employee Benefits

Employee benefits are payable wholly within twelve months of receiving employees' services and are classified as short-term employee benefits. These benefits include salaries and wages, bonuses, ex-gratia, etc. These are recognized as an expense at an undiscounted amount in the Statement of Profit and Loss of the year in which the related service is rendered.

(b) Post-employment Benefits

(i) Provident Fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's contribution is recognized as an expense in the statement of profit and loss during the period in which the employee renders the related.

(ii) Gratuity

The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary using the projected unit credit method. The Company recognizes all actuarial gains and losses arising from the defined benefit plan immediately in the Statement of Profit and Loss. All expenses related to the defined benefit plan are recognized in employee benefits expense in the Statement of Profit and Loss.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

xiii. Employee Benefits (Continued)

(iii) Compensated Absences

The Company provides for encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/availment. The Company makes provisions for compensated absences based on an independent external actuarial valuation carried out at the end of the year. Actuarial gains and losses are recognized in the Statement of Profit and Loss.

xiv. Taxation

Income tax expense comprises current tax and deferred tax charges or credits.

Current Income Tax

Provision for current tax is determined as the amount of tax payable in respect of taxable income for the year in accordance with the provisions of the Income Tax Act, 1961. Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the enacted or substantively enacted tax rates and tax laws. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred Tax

Deferred tax is recognized in respect of temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax liabilities are recognized for all taxable temporary differences.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits, and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

xiv. Taxation (Continued)

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum Alternative tax ('MAT') under the provisions of the Income Tax Act, 1961 is recognized as the current tax in the Statement of Profit Loss. The credit available under the Act in respect of MAT paid is recognized as an asset only when and to the extent it is probable that the company will pay normal income tax during the year for which the MAT credit can be carried forward for set-off against the normal tax liability. MAT credit recognized as an asset is reviewed at each balance sheet date and written down to the extent the aforesaid convincing evidence no longer exists.

xv. Earnings per share

Basic earnings per share are calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share are the net profit for the year attributable to equity shareholders. The weighted average number of equities shares outstanding during the year end for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equities shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares.

xvi. Provisions and contingent liabilities

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

A provision in respect of loss contingencies relating to claims litigation, assessment, fines, penalties, etc. are recognized when it is probable that a liability has been incurred, and the amount can be estimated reliably.

2 Significant accounting policies (Continued)

xvi. Provisions and contingent liabilities (Continued)

A contingent liability exists when there is a possible but not probable obligation or a present obligation that may, probably will not, require an outflow of resources embodying economic benefits, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of an outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic resources embodying economic benefits will arise, related income is recognized in the year in which the change occurs.

xvii. Fair value measurement

The Company measures financial instruments, such as derivatives, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

xvii. Fair value measurement (Continued)

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

As at March 31,2025

(Currency: Indian Rupees in lakhs)

	As at March 31, 2025	As at March 31, 2024
3 Share Capital		
Authorised:		
4,00,00,000 (as at March 31, 2024 : 4,00,00,000) Equity Shares of Rs. 10/- each.	**4,000.00**	4,000.00
Issued, Subscribed and Paid up:		
3,62,74,728 (as at March 31, 2024: 3,62,74,728) Equity Shares of Rs.10/- each fully paid up	**3,627.47**	3,627.47
	3,627.47	3,627.47

a) Reconciliation of the number of shares

Description	As at March 31, 2025		As at March 31, 2024	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	**3,62,74,728**	**3,627.47**	3,62,74,728	3,627.47
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	**3,62,74,728**	**3,627.47**	3,62,74,728	3,627.47

b) Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.
Failure to pay any amount called up on shares may lead to forfeiture of the shares.
On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

c) Shares held by holding company

	As at March 31, 2025		As at March 31, 2024	
	Number	Amount	Number	Amount
Privi Speciality Chemicals Limited	**3,62,74,728**	**3,627.47**	3,62,74,728	3,627.47

d) Details of shareholders holding more than 5% of shares

	As at March 31, 2025		As at March 31, 2024	
	Number	%	Number	%
Privi Speciality Chemicals Limited	**3,62,74,728**	**100.00%**	3,62,74,728	100.00%

	As at March 31, 2025	As at March 31,
4 Other equity		
Retained Earnings	**(1,194.28)**	**(411.64)**
	(1,194.28)	**(411.64)**

F.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Privi Biotechnologies Private Limited REGD. OFFICE

4 Property, plant and equipment

Description	Gross Block				Depreciation				Net Block	
	As at April 01,2024	Addition during the year	Deletion during the year	As at March 31,2025	As at April 01,2024	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2025	As at March 31,2025
At Cost :										
Building	876.75	-	-	876.75	208.24	22.26	5.26	-	235.76	640.99
Plant & Machinery	1,453.69	51.74	-	1,505.43	752.44	151.64	-	-	904.08	601.34
Electricals	194.84	-	-	194.84	104.94	20.15	-	-	125.09	69.75
Furniture and fixtures	77.33	-	-	77.33	25.55	4.83	-	-	30.38	46.95
Computers	13.34	-	-	13.34	8.72	1.38	-	-	10.10	3.24
Office equipments	3.63	-	-	3.63	1.03	0.36	-	-	1.39	2.24
	2,619.58	51.74	-	2,671.32	1,100.92	200.62	5.26	-	1,306.80	1,364.51
Capital Work in Progress	74.23	1.71	51.74	24.20	-	-		-	-	24.20

Description	Gross Block				Depreciation				Net Block	
	As at April 01,2023	Addition during the period	Deletion during the period	As at March 31,2024	As at April 01,2023	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2024	As at March 31,2024
At Cost :										
Building	876.75	-	-	876.75	180.72	22.26	5.26	-	208.24	668.51
Plant & Machinery	1,398.80	54.89	-	1,453.69	607.79	144.65	-	-	752.44	701.25
Electricals	194.84	-	-	194.84	84.79	20.15	-	-	104.94	89.90
Furniture and fixtures	77.33		-	77.33	20.72	4.83	-	-	25.55	51.78
Computers	13.34		-	13.34	6.61	2.11	-	-	8.72	4.62
Office equipments	3.63		-	3.63	0.67	0.36	-	-	1.03	2.60
	2,564.69	54.89	-	2,619.58	901.30	194.36	5.26	-	1,100.92	1,518.66
Capital Work in Progress	14.47	114.65	54.89	74.23	-	-		-	-	74.23

E.E. SITABKHAN & CO. Chartered Accountants MUMBAI
Privi Biotechnologies Private Limited REGD. OFFICE Navi Mumbai

5 Intangible assets

Description	Gross Block				Amortisation				Net Block
	As at April 01,2024	Addition during the year	Deletion during the year	As at March 31, 2025	As at April 01,2024	For the year	Deletion during the year	As at March 31, 2025	As at March 31, 2025
Patents	182.70	-	-	182.70	61.59	17.49	-	79.08	103.62
Computers & softwares	0.98	-	-	0.98	0.61	0.20	-	0.81	0.17
Total intangible assets	183.68	-	-	183.68	62.20	17.69	-	79.88	103.80
Intangible Asset Under Development	-	-	-	-	-	-	-	-	-
	183.68			183.68	62.20	17.69	-	79.88	103.80

Description	Gross Block				Amortisation				Net Block
	As at April 01,2023	Addition during the year	Deletion during the year	As at March 31,2024	As at April 01,2023	For the year	Deletion during the year	As at March 31,2024	As at March 31,2024
Patents	101.22	81.48	-	182.70	51.45	10.14	-	61.59	121.11
Computer software	0.98	-	-	0.98	0.41	0.20	-	0.61	0.37
Intangible assets	102.20	81.48	-	183.68	51.86	10.34	-	62.20	121.48
Intangible Asset Under Development	60.29	-	(60.29)	-	-	-	-		-
	162.49	81.48	-	183.68	51.86	10.34	-	62.20	121.48

SITABKHAN & CO. MUMBAI
Privi Biotechnologies Private Limited REGD. OFFICE Navi Mumbai - 400705

5a Right of use assets

Description	Gross carrying amount				Accumulated Amortisation					Net carrying amount
	As at April 01, 2024	Addition during the year	Disposal during the year	As at March 31, 2025	As at April 01, 2024	Amortisation for the year	*Depreciation on revaluation	Deletion during the year	As at March 31, 2025	As at March 31, 2025
Land	754.74	-	-	754.74	125.42	0.99	13.70	-	140.11	614.63
Total intangible assets	754.74	-	-	754.74	125.42	0.99	13.70	-	140.11	614.63

Description	Gross carrying amount				Accumulated Amortisation					Net carrying amount
	As at April 01, 2023	*Addition during the year	Disposal during the year	As at March 31, 2024	As at April 01, 2022	Amortisation for the year	*Depreciation on revaluation	Deletion during the year	As at March 31, 2023	As at March 31, 2024
Land	1,387.40	-	632.66	754.74	129.55	16.46	13.70	34.30	125.42	629.32
Total intangible assets	1,387.40	-	632.66	754.74	129.55	16.46	13.70		125.42	629.32

		March 31,2025	March 31, 2024
6	**Inventories**		
	(valued at lower of cost and net realisable value)		
	Stores and spares	**37.57**	49.62
		37.57	49.62

7 **Other financial assets**
(Unsecured, considered good unless otherwise stated)

	Non-current portion		Current Portion	
	March 31,2025	March 31, 2024	March 31,2025	March 31, 2024
Inter Corporate deposit (PSCL)	-	-	**250.00**	900.00
Security deposits	**20.14**	16.67	-	-
	20.14	16.67	**250.00**	900.00

8 **Trade Receivables**
(Unsecured unless otherwise stated)

	March 31,2025	March 31, 2024
Considered good- Secured		
Dues from related party (refer note 25)	**164.77**	-
Dues from others	-	-
Credit impaired	-	-
Less: Allowance for expected credit loss and credit impairment	-	-
	164.77	-

Particulars	Outstanding for following periods from due date of payments					
	Less than 6 months		6 months - 1 year		Total	
	March 31,202	March 31, 202	March 31,2025	March 31, 2024	March 31,2025	March 31, 2024
Undisputed Trade receivbales-considered good	164.77	-	-	-	**164.77**	-
Undisputed Trade Receivables- which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivables-Credit impaired	-	-	-	-	-	-
Undisputed Trade Receivables Considered good	-	-	-	-	-	-
Disputed Trade Receivables-which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivables- credit impaired	-	-	-	-	-	-
	-	-	-	-	-	-

9 **Cash and cash equivalent**

	March 31,2025	March 31, 2024
Cash on hand	**0.12**	0.24
Balances with Banks		
In current accounts	**1.51**	101.31
	1.63	101.55

10 **Bank balances other than cash and cash equivalents**

	March 31,2025	March 31, 2024
Fixed deposit with bank (with original maturity of more than three months but less than twelve months)	**35.92**	35.59
	35.92	35.59

11 **Other Assets**
(Unsecured, considered good)

	Non-current portion		Current Portion	
	March 31,2025	March 31,2024	March 31,2025	March 31,2024
Capital advances	-	-	**11.50**	-
Advance to vendors	-	-	**1.70**	0.62
Prepaid Expenses	-	-	**25.46**	16.84
Tds Receivable	-	-	**25.06**	23.29
Receivable from government authorities	-	-	-	4.35
Loans and advances to employees	-	-	**16.49**	6.89
	-	-	**80.21**	51.99

(Currency: Indian Rupees in lakhs)

12 Provisions

	Non Current		Current	
	March 31,2025	March 31, 2024	March 31,2025	March 31, 2024
Provisions for employee benefits				
Gratuity	31.74	25.20	1.11	0.93
Compensated absences	14.10	9.83	1.78	1.30
	45.84	35.03	2.90	2.24

13 Income tax

	March 31,2025	March 31, 2024
Current income tax:		
Current income tax expenses	-	2.07
Tax Adjustment of earlier years	-	-
Deferred tax:		
Relating to origination and reversal of temporary differences	(11.28)	(74.31)
Income tax expense reported in the statement of profit or loss	(11.28)	(72.24)
Income tax recognised in other comprehensive income		
Tax expense related to items recognised in OCI during the year:		
Actuarial loss on defined benefit plan	1.16	1.16
Income tax charged to OCI	1.16	1.16

	As at 1 April 2024	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	March 31,2025
Deferred tax (assets)/liabilities				
Expenses allowable for tax purposes when paid	17.98		1.16	19.14
Tax depreciation	(90.90)	(11.28)	-	(102.18)
	(72.92)	(11.28)	1.16	(83.03)

	As at 1 April 2023	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	As at 31 March 2024
Deferred tax (assets)/liabilities				
Expenses allowable for tax purposes when paid	16.82		1.16	17.98
Tax depreciation	(78.60)	(12.30)	-	(90.90)
	(61.78)	(12.30)	1.16	(72.92)

14 Trade Payable

	March 31,2025	March 31, 2024
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small enterprises	-	-
i) Payable to Related parties : (Refer note no: 25)	-	-
ii) Other Payable	61.04	91.00
	61.04	91.00

Particulars	Less Than 1 years	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	61.04	-	-	-	-
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-
	61.04	-	-	-	-

Particulars	Less Than 1 years	1-2 years	2-3 years	More than 3 years	Total
(i) MSME	-	-	-	-	-
(ii) Others	91.00	-	-	-	91.00
(iii) Disputed dues - MSME	-	-	-	-	-
(iv) Disputed dues-Others	-	-	-	-	-
	91.00	-	-	-	91.00

15 Other financial liabilities

	March 31,2025	March 31, 2024
Advance from Customer	-	11.93
Payable for capital expenditure	-	-
Employee's Expenses Payable	33.74	37.04
Other Current Borrowings (Refer Note 12)	-	-
Deposits	25.00	25.00
	58.74	73.97

16 Other Current Liabilities

	March 31,2025	March 31, 2024
Statutory dues (including provident fund, tax deducted at source and others)	10.57	8.40
	10.57	8.40

SITABKHAN & CO. MUMBAI Chartered Accountants

Privi Biotechnologies Private Limited REGD. OFFICE Navi Mumbai

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2025	Year ended March 31,2024
17	**Revenue from Operations**		
	Techincal Services	**480.00**	555.00
		480.00	555.00
18	**Other Income**		
	Interest income from fixed deposits	**2.34**	1.98
	Interest received on income tax refund	**0.85**	0.43
	Profit on sale of investments (net)	**-**	1.27
	Rent received	**90.00**	90.00
	Unrealized gain on investment	**-**	
	Miscelleneous Income	**0.03**	-
	Interest received ICD Loan	**41.42**	35.67
	Profit on Sale of Land	**-**	218.81
		134.64	348.16
19	**Employee benefits expense**		
	Salaries, wages and bonus	**304.68**	252.69
	Contribution to provident and other funds	**15.49**	13.63
	Staff welfare expenses	**29.65**	29.65
		349.82	295.97
20	**Finance Cost**		
	Interest on other loans	-	0.02
	Amortisation of premium on forward exchange contracts	-	-
	Other Finance cost	-	-
	Interest on delayed payment of income tax	-	-
		-	0.02
21	**Depreciation and amortisation**		
	Depreciation on tangible assets	**200.62**	194.36
	Amortisation of intangible assets	**17.69**	10.34
	Amortisation right of use assets	**0.99**	16.46
		219.30	221.16

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2025	Year ended March 31,2024
22	**Other Expenses**		
	Power and fuel	**163.24**	146.14
	Buildings	**0.46**	0.34
	Plant and machinery	**90.98**	15.35
	others	**5.09**	3.59
	Consumables	**129.01**	29.32
	Contract Labour Charges	**50.40**	31.05
	Insurance	**0.45**	1.88
	Rates and taxes	**138.60**	3.31
	Training Expenses	**1.35**	0.30
	Auditors remuneration:		
	Stututory audit	**1.00**	1.00
	Printing and stationery	**13.98**	9.91
	Legal and professional fees	**83.23**	41.87
	Travelling and conveyance	**18.91**	18.92
	Bank charges	**0.87**	0.64
	CSR expenses	-	-
	Laboratory & Analytical Expenses	**56.52**	45.09
	Sundry balances w/off	-	-
	Management support services	-	-
	Rounding Off	-	-
	Sundry Bal. Written Off	-	-
	Other Admin Expenses	**40.36**	36.24
		794.46	384.95

(Currency: Indian Rupees in lakhs)

23 Employee benefits - Post-employment benefit plans

a) **Defined contribution plans**

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund, Super annuation fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the Note 17 under "Contribution to provident & other funds":

	Year ended March 31, 2025	Year ended **March 31, 2024**
Contribution to employees provident fund	**15.49**	13.63
Contribution to ESI	-	-

b) **Defined benefit plans**

The Company operates one post-employment defined benefit plan (funded plan) that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

	As at March 31, 2025	As at March 31, 2024
Amount recognised in the Balance Sheet in respect of Gratuity		
Present value of the funded defined benefit obligation at the	**32.84**	26.12
Net liability/(asset)	**32.84**	26.12
Movement in present value of defined benefit obligation		
Obligation taken over under BTA (Refer Note No. 30)	-	0.00
Opening Defined Benefit Obiligations	**26.12**	18.59
Current service cost	**4.91**	3.93
Interest cost	**1.88**	1.38
Actuarial (gain)/loss	**(0.07)**	**4.13**
Benefits paid	-	(1.91)
Closing defined benefit obligation	**32.84**	**26.12**

23 Employee benefits - Post-employment benefit plans *(Continued)*

	As at March 31, 2025	As at March 31, 2024
b) **Defined benefit plans *(Continued)***		
Expense recognised in statement of profit and loss		
Current service cost	**4.91**	**3.93**
Interest on defined benefit obligations	**1.88**	**1.38**
Total	**6.79**	**5.31**
Remeasurements recognised in Other comprehensive income		
Change in Demographic Assumption	-	-
Change in Financial Assumption	1.51	0.74
Experience adjustments	(1.58)	3.39
Total	**(0.07)**	**4.13**
Total expense recognised	**6.72**	**9.45**

	March 31, 2025	March 31, 2024
Principal actuarial assumptions at the balance sheet date		
Discount rate (p.a.)	7.21%	7.47%
Expected rate of Salary increase (p.a.)	8.25%	8.25%
Attrition Rate	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%
Mortality Tables	Indian Assured Lives Mortality (2012-14)	Indian Assured Lives Mortality (2012-14)

The estimates of future salary increase , considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

Estimated rate of return on plan assets is based on average long term rate of return expected on investments of the Fund during the estimated term of the obligations.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
Impact on defined benefit obligation due to:	**March 31, 2025**	March 31, 2024	**March 31, 2025**	March 31, 2024
a. 1% increase	**3.96**	3.17	**3.96**	3.17
b. 1% decrease	**(3.34)**	(2.68)	**(3.34)**	(2.68)

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment

	March 31, 2025	March 31, 2024
Defined benefit obligation	**32.84**	26.12
Plan assets	-	-
Surplus/(deficit)	**(32.84)**	(26.12)
Experience adjustment on plan liabilities	**(1.58)**	3.39
Experience adjustment on plan assets	-	-

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the Period ended March 31,2025

(Currency: Indian Rupees in lakhs)

24 Related party disclosures

a) List of Related Parties

Related parties where control exist:

Holding Company

Privi Speciality Chemicals Limited

Enterprises owned or significantly influenced by key management personnel or their relatives

Privi Life Sciences Pvt. Ltd.

Prasad Organics Pvt. Ltd.

Privi Fine Sciences Private Limited

Vivira Investment and Trading Pvt. Ltd.

Satellite Technologies Private Limited

Key Management Personnel (KMP)

Mr. D. B. Rao (Managing Director)

Mr. Mahesh P. Babani (Director)

b) During the year, following transactions were carried out with the related parties :

	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31,2025	31 March 2024	March 31,2025	31 March 2024	March 31,2025	31 March 2024
Transactions						
Purchase of raw materials						
Privi Speciality Chemicals Ltd	-	-	-	-	-	-
Privi Fine Sciences Pvt.Ltd.	-	-	-	-	-	-
Vivira Investment and Trading Pvt Ltd	-	-	-	-	-	-
Purchase of Consumable						
Prasad Organics Pvt Ltd	-	-	-	-	-	-
Privi Life Science Pvt Ltd	-	-	-	-	-	-
Technical services						
Privi Speciality Chemicals Ltd	**480.00**	420.00	-	-	-	-
Rent						
Privi Speciality Chemicals Ltd	**90.00**	60.00	-	-	-	-
Interest Received	**41.42**	35.67	-	-	-	-

Particulars	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31,2025	31 March 2024	March 31,2025	31 March 2024	March 31,2025	31 March 2024
Trade Receivable						
Privi Speciality Chemicals Ltd	**164.77**	129.16	-	-	-	-
Trade Payables						
Privi Speciality Chemicals Ltd	-	-	-	-	-	-
Privi Life Science Pvt Ltd	-	-	-	-	-	-
Prasad Organics Pvt Ltd	-	-	-	-	-	-
Other Payables						
Privi Speciality Chemicals Ltd	**25.00**	25.00	-	-	-	-

(Currency: Indian Rupees in lakhs)

		March 31,2025	March 31, 2024
25	**Earnings per share**		
	Profit/(Loss) after tax attributable to equity shareholders [A]	**(760.22)**	(13.53)
	Number of equity shares at the beginning of the year [B]	**3,62,74,728**	3,62,74,728
	Number of equity shares outstanding at the end of the year [C]	**3,62,74,728**	3,62,74,728
	Weighted average number of equity shares outstanding during the year	**3,62,74,728**	3,62,74,728
	Basic & Diluted earnings (in rupees) per share of face value Rs. 10	**(2.10)**	(0.04)

26 Previous year comparative

The previous year figures have been regrouped and reclassified, wherever required.

27 Information with regard to other additional information and other disclosures to be disclosed by way of notes to Statement of Profit and Loss as specified in Schedule III to the Act is either 'nil ' or ' not applicable ' to the Company for the year.

For For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Mumbai
Date: April 28,2025

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Privi Biotechnologies Private Limited REGD OFFICE Navi Mumbai

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Privi Biotechnologies Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Biotechnologies Private Limited ('the Company'), which comprise the standalone balance sheet as at 31st March 2024, and the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as 'standalone financial statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2024, its Loss (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's Annual Report but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the standalone financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

(A) As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The standalone balance Sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement dealt with by this report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on 31st March 2024 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2024 from being appointed as a director in terms of Section 164(2) of the Act: and

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer our separate Report in 'Annexure B'.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

PLACE : MUMBAI

DATE :APRIL 25,2024

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721
UDIN: 24030721BKAOVX3833

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Priyi Biotechnologies Private Limited

"Annexure A" to the Independent Auditors' Report – 31 March 2024

(Referred to in our report of even date)

(i) **(a)** (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) All fixed assets are physically verified by the management in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. The physical verification of fixed assets was done in previous financial year 2023-24 and No material discrepancies were noticed on such verification.

(c) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favor of the lessee) are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a)The company is involved in activity of research & development of aroma products therefore does not have significant inventory, however few of the store spares , consumables and machinery spare parts which are taken and consumed. Regarding the unused item at the end of the year inventory is taken as on 31st March 2024 and same has been valued on Average Price Basis. The Expenses on account of Consumables Stores & spare items is shown in Profit & Loss A/c net off inventory value. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.

(b)According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has no sanctioned working capital facility from banks or financial institutions.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company has not made during the year any investments or given any guarantee or security or granted any loans or advances which are characterized as loans, unsecured or secured, to LLPs, firms or companies or any other person.

(a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has not provided loans or provided advances in the nature of loans, or given guarantee, or provided security to any other entity during the year.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the investments made is, prima facie, not prejudicial to the interest of the company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loans are given during the year further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loans given. Further, the Company has not given any advances in the nature of loans to any party during the year. Accordingly, clause 3(iii) (d) of the Order is not applicable.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted. Accordingly, clause 3(iii) (e) of the Order is not applicable.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans. Accordingly, clause 3(iii) (f) of the Order is not applicable.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any security as specified under section 185 and 186 of the Companies Act, 2013. According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and guarantees given by the Company, the provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) In our opinion since the company is not engaged in manufacturing activities , the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013 is not applicable to Company.

(vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues have been generally regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2024 for a period of more than six months from the date they became payable.

E. E. SITABKHAN & CO. * Chartered Accountants * MUMBAI

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to banks or financial institutions during the year. Further, the Company did not have any outstanding loans or borrowings from any other lender during the year

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, Company does not have any term loans.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, its associates, subsidiaries or joint ventures as defined under Companies Act, 2013.

(f) According to the information and explanations given to us and procedures performed by us, we report that the company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under Companies Act, 2013).

(x) (a) The Company has not raised any money by way of initial public offer or further public offer (including debt instruments) Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Priyi Biotechnologies Private Limited

Annexure A to the Independent Auditors' Report – 31 March 2024 (Continued)

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) (a) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has internal audit system commensurate with the size and nature of its business as The Company is engaged in R&D activity.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : APRIL 25,2024

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

UDIN : 24030721BKAOVX3833

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Biotechnologies Private Limited

Annexure B to the Independent Auditors' report - 31 March 2024

(Referred to in paragraph A (f) under 'Report on Other Legal and Regulatory Requirements' section of our report of even date)

Opinion

We have audited the internal financial controls with reference to financial statements of Privi Biotechnologies Private Limited ("the Company") as of 31 March 2024 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

In our opinion, the Company has, in all material respects, adequate internal financial controls system with reference to financial statements and such internal financial controls were operating effectively as at 31 March, 2024, based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India (the 'Guidance Note').

Management's Responsibility for Internal Financial Controls

The Company's management and the Board of Directors are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to financial statements criteria established by the Company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013 (hereinafter referred to as 'the Act').

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls with reference to financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls with reference to financial statements and their operating effectiveness. Our audit of internal financial controls with reference to financial statements included obtaining an understanding of such internal financial controls, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the standalone financial statements, whether due to fraud or error.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Priyi Biotechnologies Private Limited

Annexure B to the Independent Auditors' Report (Continued)

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls with reference to financial statements.

Meaning of Internal Financial controls with Reference to financial statements

A company's internal financial controls with reference to financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls with reference to financial statements include those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial controls with Reference to financial statements

Because of the inherent limitations of internal financial controls with reference to financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls with reference to financial statements to future periods are subject to the risk that the internal financial controls with reference to financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : APRIL 25,2024

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI BIOTECHNOLOGIES PRIVATE LIMITED

Registered / Corporate Office : A-71, MIDC, TTC, THANE BELAPUR ROAD, NAVI MUMBAI - 400 709.

BALANCE SHEET &

PROFIT & LOSS ACCOUNT

(ALONGWITH NOTES)

March - 2024

462

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71 TTC Industrial Area,Thane Belapur Road, Kopar Khairane, Navi Mumabi -400710
Email : Investors@privi.co.in Phone +91 22 33043500/3343600 Fax: + 91 22 27783049 Website : www.privi.com

CIN : U74220MH1985PTC0377534

Audited Standalone statement of assets and liabilities as at March,31 2024

(Rs in Lakhs)

Particulars	As at March 31,2024 (Audited)	As at March 31, 2023 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,518.66	1,663.39
Capital work-in-progress	74.23	14.47
Intangible assets	121.48	50.34
Intangible assets under development	-	60.29
Right of use of assets	629.32	1,257.85
Other financial assets	16.67	15.91
Non-current tax assets (net)	2.35	-
Other non current assets	-	5.13
Total non-current assets (A)	**2,362.71**	**3,067.39**
Current assets		
Financial assets		
Inventories	49.62	39.62
Investments	-	-
Trade receivables	-	279.77
Loans	900.00	-
Cash and Cash equivalents	101.55	4.61
Bank Balances other than cash and cash equivalents	35.59	35.45
Other current assets	51.99	24.52
Total current assets (B)	**1,138.75**	**383.97**
TOTAL (A+B)	**3,501.46**	**3,451.36**
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	3,627.47	3,627.47
Other equity	(411.64)	(383.08)
Total equity (C)	**3,215.83**	**3,244.39**
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Borrowings	-	-
b) Other financial liabilities		
Provisions	35.03	27.97
Deferred tax liabilities (Net)	72.92	61.78
Total non current liabilities (D)	**107.95**	**89.75**
Current liabilities		
Financial liabilities		
Trade payables		
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small enterprises	91.00	52.60
Other financial liabilities	73.97	52.97
Other current liabilities	8.40	9.58
Provisions	2.24	2.07
Current tax liabilities (net)	2.07	
Total current liabilities (E)	**175.61**	**117.22**
Total liabilities F = (D + E)	**285.63**	**206.97**
TOTAL (C + F)	**3,501.46**	**3,451.36**

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710. India

Statement of audited Standalone Financial results for the quarter and year ended March 31, 2024 (Rs in Lakhs)

CIN: U74220MH1985PTC037534

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2024 (Audited)	December 31, 2023 (Unaudited)	March 31, 2023 (Audited)	March 31, 2024 (Audited)	March 31, 2023 (Audited)
1	Revenue from operations	120.00	120.00	157.50	555.00	622.50
2	Other income	41.46	33.13	24.35	348.16	109.15
3	**Total income (1 + 2)**	**161.46**	**153.13**	**181.85**	**903.16**	**731.65**
4	**Expenses**					
	(d) Employee benefits expense	89.87	68.93	66.76	288.81	237.54
	(e) Finance cost	-	0.02	(0.40)	0.02	-
	(f) Depreciation and amortisation expense	51.13	51.68	58.53	221.16	237.37
	(g) Other expenses	55.73	157.67	80.75	384.95	349.28
	Total expenses (4)	**196.73**	**278.30**	**205.64**	**894.94**	**844.19**
5	**Profit /(Loss) before exceptional items and tax (3 - 4)**	**(35.27)**	**(125.17)**	**(23.79)**	**8.22**	**(112.54)**
6	**Exceptional Income/(Expenses)**	-	-	-	-	-
7	**Profit /(Loss) before tax (5 -6)**	**(35.27)**	**(125.17)**	**(23.79)**	**8.22**	**(112.54)**
8	**Tax expense**					
	Current tax	2.07	-	-	2.07	-
	Tax adjustment of earlier years	-			-	-
	Deferred tax	2.46	(4.92)	(2.57)	12.30	(10.28)
9	**Net profit /(Loss) for the period (7 - 8)**	**(39.80)**	**(120.25)**	**(21.22)**	**(6.15)**	**(102.26)**
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
	Remeasurements of post employment benefit obligations	(2.63)	(0.66)	2.07	(4.61)	(2.64)
	Income tax related to above	0.66	0.17	(0.53)	1.16	0.66
	(ii) Items that will be reclassified to Profit or loss	-	-	-	-	-
	Total other comprehensive income (10)	**(1.97)**	**(0.49)**	**1.55**	**(3.45)**	**(1.97)**
11	**Total comprehensive income/(Loss) for the period (9+10)**	**(41.77)**	**(120.74)**	**(19.67)**	**(9.60)**	**(104.23)**
12	**Paid up equity share capital (Face value of Rs. 10/- each)**	3,627.47	3,627.47	3,627.47	3,627.47	3,627.47
13	**Earnings per share (EPS) of Rs. 10/- each (* not annualised) (in Rs.) Basic / Diluted**	(0.12)	(0.33)	(0.05)	(0.02)	(0.28)

Notes:

1 The Audited standalone financial results for the quarter and year ended March 31, 2024, were reviewed and approved by the Board of Directors of Privi Biotechnologies Private Limited ("the Company") at its meeting held on April 25, 2024. The above results have been subjected to review by the statutory auditors of the company. The statutory auditors have expressed an unqualified review opinion.

2 The Audited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015and SEBI circular dated July 5, 2016.

3 The audited standalone Financial Results has been prepared solely to enable Privi Speciality Chemicals Limited (Holding company) to prepare consolidated financial results and not to report on the Company as a separate entity.

4 As the company's business activity falls within a single segment viz. 'Aroma Chemical', the disclosure requirements of the Ind AS 108 'Operating Segments' notified under Section 133 of the Companies Act, 2013 are not applicable.

5 The figures for the quarter ended March 31, 2024, and March 31,2023 are arrived at as a difference between audited figures in respect of the full financial year and the unaudited figures up to nine months of the relevent financial year.

6 Previous period figures have been regrouped and classified wherever necessary.

For M/S. E E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor M.No.38721

Place: Mumbai
Date: April 25,2024

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

Mahesh Babani
Director
DIN: 00051106

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India

CIN: U74220MH1985PTC037534

Anaudited standalone statement of cash flow

(Rs in Lakhs)

		Year ended March 31, 2024	Year Ended March 31,2023
A	**Cash flow from operating activities**		
	Profit before tax after exceptional items	8.22	(112.54)
	Adjustment for:		
	Depreciation and amortisation	221.16	237.37
	Sundry balances Written Off	1.97	-
	Profit on sale of fixed assets	(218.81)	-
	Interest Income	(2.41)	(1.97)
	Finance costs	0.02	-
	Operating cash flow before working capital changes	10.15	122.86
	Movements in working Capital		
	Increase in trade receivables	279.77	(176.76)
	Decrease / (increase) in inventories	(10.00)	1.57
	Increase /(decrease) in other assets	(929.86)	58.31
	Increase in trade payables and other current liabilities and provisions	62.81	-
	Cash generated / (used in) from operatation	(597.28)	10.18
	Income taxes paid	(2.35)	-
	Net cash generated / (used in) from operating activities [A]	**(589.48)**	10.18
B	**Cash flow from investing activities**		
	Purchase of property, plant & equipment	(127.12)	(13.37)
	Proceeds from sale of Property, Plant & Equipment	811.00	-
	Purchase of business (Refer Note No 30)	-	-
	Realisation / (investment) of fixed deposits	-	-
	Sale / (purchase) of investments	-	-
	Investment in fixed deposits	0.14	0.59
	Interest received	2.41	1.97
	Net cash (used in)/ generated by investing activities [B]	686.44	(10.81)
C	**Cash flow from financing activities**		
	Repayment of long term borrowings	-	(3.00)
	Interest paid	(0.02)	0.70
	Net cash (used in)/ generated from financing activities [C]	(0.02)	(2.30)
	Net increase/ (decrease) in cash and cash equivalents (A+B+C)	**96.94**	(2.94)
	Cash and cash equivalents at the beginning of the year	4.61	7.55
	Cash and cash equivalents at end of the year	101.55	4.61

Note A: The above statement of cash flows has been prepared under 'Indirect Method' as set out in Ind AS 7,'statement of Cash Flows'

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date : ~~November 02 2023~~ April -25-2024

For on Behalf of Board of Directos of
Privi Biotechnologies Pvt. Ltd

Mahesh Bajani
Director

DIN: 00051162

Privi Biotechnologies Private Limited

Balance Sheet

As at March 31, 2024

(Currency: Indian Rupees in lakhs)

		As at March 31, 2024	As at March 31, 2023
Assets			
Non-current assets			
Property, plant and equipment	4	1,518.66	1,663.39
Capital work-in-progress	4	74.23	14.47
Intangible assets	5	121.48	50.34
Intangible assets under development	5	-	60.29
Right of use of assets	5a	629.32	1,257.85
Other financial assets	7	16.67	15.91
Non-current tax assets (net)		3.35	-
Other non current assets	11	-	5.13
Total non current Assets		2,363.71	3,067.39
Current assets			
Financial assets			
Inventory	6	49.62	39.62
Investments	7	-	-
Trade receivables	8	-	279.77
Loans and Advances	7	900.00	-
Cash and cash Equivalents	9	101.55	4.61
Bank balances other than cash and cash equivalents	10	35.59	35.45
Other Financial Assets	7	-	-
Other current assets	11	51.99	24.52
Total current assets		1,138.75	383.97
Total assets		3,501.46	3,451.36
Equity and liabilities			
Equity			
Equity share capital	3	3,627.47	3,627.47
Other equity	3a	(411.64)	(383.08)
Total equity		3,215.83	3,244.39
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings		-	-
Other financial liabilities	15	-	-
Provisions	12	35.03	27.97
Deferred tax liabilities (Net)	13	72.92	61.78
Total non-current liabilities		107.95	89.75
Current liabilities			
Financial liabilities			
Trade payable			
a) Total outstanding dues of micro and small enterprises	14	-	-
b) Total outstanding dues of creditors other than micro and small enterprise	14	91.00	52.60
Other financial liabilities	15	73.97	52.97
Other current liabilities	16	8.40	9.58
Provisions	12	2.24	2.07
Current tax liabilities (net)		2.07	-
Total current liabilities		177.68	117.22
Total equity and liabilities		3,501.46	3,451.36
Notes to the financial statements	3 to 27		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No 30721

Mumbai
Date: April 25,2024

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Dahanukar
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 165320

Ashwini Shah
Company Secretary
Membership No: A-58348

Privi Biotechnologies Private Limited

Statement of Profit and Loss

for the Period ended March 31,2024

(Currency: Indian Rupees in lakhs)

	Note	Year ended March 31, 2024	Year Ended March 31,2023
Revenue from operations	17	**555.00**	622.50
Other income	18	**348.16**	109.15
Total income (I)		**903.16**	731.65
Expenses			
Employee benefits expense	19	**288.81**	257.54
Finance costs	20	**0.02**	-
Depreciation and amortisation expenses	21	**221.16**	237.37
Other expenses	22	**384.95**	349.28
Total expenses (II)		**894.94**	844.19
Profit / (loss) before tax expenses (I)-(II)		**8.22**	(112.54)
Tax expenses			
Current tax		**2.07**	-
Deferred tax charge/(credit)		**12.30**	(10.28)
Income tax expense		**14.37**	(10.28)
Profit / (loss) for the year (III)		**(6.15)**	(102.26)
Other comprehensive income / (loss)	(IV)	**(4.61)**	(2.64)
Income tax related to above	(V)	**1.16**	0.66
Total comprehensive income / (loss) for the year (III)+(IV)		**(9.60)**	**(104.23)**
Earnings per equity share: nominal value of share Rs.10/- each (March 31, 2020: Rs. 10/-)			
Basic and diluted (Rs.)	25	**(0.02)**	(0.28)
Notes to the financial statements	3 to 27		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No 30721

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

Mumbai
Date. April 25,2024

For and on behalf of the Board of Directors of Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-[illegible]8 8

Privi Biotechnologies Private Limited

Statement of Cash Flow

for the Period ended March 31,2024

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2024	Year Ended March 31,2023
A	**Cash flows from operating activities**		
	Profit/ (Loss) before tax	**8.22**	(112.54)
	Adjustment for:		
	Depreciation and amortisation	**221.16**	237.37
	Sundry balances Written Off	**1.97**	-
	Profit on sale of assets	**(218.81)**	-
	Interest income	**(2.41)**	(1.97)
	Finance costs	**0.02**	-
		10.15	122.86
	Operating cash flows before working capital changes		
	Adjustment for:		
	Increase in trade receivables	**279.77**	(176.76)
	(Increase)/Decrease in inventories	**(10.00)**	1.57
	(Increase) /Decrease in other assets	**(929.86)**	58.31
	Increase in trade payables and other current liabilities and provisions	**62.81**	4.20
	Cash generated from operations	**(597.28)**	(112.68)
	Income taxes paid	**(2.35)**	-
	Net cash generated / (used in) from operating activities [A]	**(589.48)**	10.18
B	**Cash flows from investing activities**		
	Purchase of property, plant & equipment	**(127.12)**	(13.37)
	Proceeds from sale of Property, Plant & Equipment	**811.00**	-
	Investment in fixed deposits	**0.14**	0.59
	Interest received	**2.41**	1.97
	Net cash (used in)/ generated by investing activities [B]	**686.44**	(10.81)
C	**Cash flow from financing activities**		
	Proceeds from long-term borrowings	-	(3.00)
	Interest paid	**(0.02)**	0.70
	Net cash (used in)/ generated by financing activities [C]	**(0.02)**	(2.30)
	Net increase in cash and equivalents [A +B +C]	**96.94**	(2.94)
	Cash and cash equivalents at the beginning of year	**4.61**	7.55
	Cash and cash equivalents at the end of year (refer note no. 9)	**101.55**	**4.61**

The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard - 7 on cash flow statements specified under Section 133 of the Companies Act, 2013

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountant

(E.E. Sitabkhan;
Proprietor. M.No 30721

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58878

Mumbai
Date: April 25.2024

468

Privi Biotechnologies Private Limited

Statement of Changes in Equity

As at March 31, 2024

(Currency: Indian Rupees in lakhs)

A. **Equity share capital**

	As at March 31, 2024	As at March 31, 2023
Balance at the beginning of the year	3,627.47	3,627.47
Changes in equity share capital during the year	-	-
Balance at the end of the year	3,627.47	3,627.47

B. Other equity

	Reserves and surplus			
	Revaluation reserve	Retained earnings	Other comprehensive income	Total
Total comprehensive profit / (loss) for the year ended April 01, 2022				
Opening balance of profit and loss account	802.92	(1,051.83)	(10.98)	(259.89)
(Loss) for the year	-	(102.26)	(1.97)	(104.23)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	783.96	(1,154.09)	(12.95)	(383.10)
Balance as at Apr 01,2023	783.96	(1,154.09)	(12.95)	(383.10)
Total comprehensive profit / (loss) for the year ended April 01,2023				
Profit/(Loss) for the year	-	(6.15)	(3.45)	(9.60)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	(18.96)	(6.15)	(3.45)	(28.56)
Balance as at March 31,2024	765.00	(1,160.24)	(16.40)	(411.64)

Notes to the financial statements 3 to 27
Significant accounting policies 2

The notes referred to above form an integral part of the financial statements

As per our report of even date attached
For *M/S K.K Sitabkhan & Co.*
Chartered Accountants

(K.K. Sitabkhan)
Proprietor M.No.30721

Mumbai
Date: April 25,2024

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

Mahesh Babani
Director
DIN: 00031162

D. B. Rao
Managing Director
DIN: 00356218

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A56378

Privi Biotechnologies Private Limited

Notes to financial statements *(Continued)*

for the financial year ended 31 March 2024

(Currency: Indian Rupees in Lakhs)

1 Corporate Information

Privi Biotechnologies Private Limited (The Company) is incorporated on September 20,1985 under the provision of the companies act 2013. The Company is 100% subsidiary of Privi Specialty Chemicals Limited.

The Company's Pilot Plant is located at Nerul, Navi Mumbai, Maharashtra and its Registered office is situated at Koparkhairne. Navi Mumbai, Maharashtra

2 Significant accounting policies

Statement of Compliance

These standalone financial statements (hereinafter referred to as "financial statements") are prepared in accordance with the Indian Accounting Standards ("Ind AS") as per the Companies (Indian Accounting Standards) Rules, 2015 notified under Section 133 of Companies Act, 2013 ("the Act''), amendments thereto and other relevant provisions of the Act. The standalone financial statements of the Company were approved for issue in accordance with the resolution of the Board of Directors on May 05, 2023.

i. Basis of Preparation

The standalone financial statements have been prepared on a historical cost basis, except for the following assets and liabilities:

(i) Derivative Financial Instruments measured at fair value.
(ii) Certain financial assets and liabilities measured at fair value (refer accounting policy regarding financial instruments)
(iii) Employee's Defined Benefit Plan as per actuarial valuation.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date under current market conditions, regardless of whether that price is directly observable or estimated using another valuation technique. In determining the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

Functional and Presentation Currency

The financial statements are presented in Indian Rupees, which is the functional currency of the Company and the currency of the primary economic environment in which the Company operates.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

2 Significant accounting policies (Continued)

ii. Use of estimates

The preparation of financial statements requires management to make judgements, estimates and assumptions in the application of accounting policies that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and judgements are continuously evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable. Revisions to accounting estimates are recognized in the period in which the estimate is revised and in any future period affected.

Information about critical judgments in applying accounting policies, as well as estimates and assumptions that have the most significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year, are included in the following notes:

(a) Measurement of defined benefit obligations for any actuarial assumption
(b) Recognition of deferred tax assets

iii. Current and non-current classification

All assets and liabilities are classified into current and non-current.

Assets

An asset is classified as current when it satisfies any of the following criteria:

(a) it is expected to be realized in, or is intended for sale or consumption in, the company's normal operating cycle:

(b) it is held primarily for the purpose of being traded;

(c) it is expected to be realized within 12 months after the balance sheet date; or

(d) it is cash or a cash equivalent unless it is restricted from being exchanged or used to settle a liability for at least 12 months after the balance sheet date.

Current assets include the current portion of non-current financial assets.

All other assets are classified as non-current

Liabilities

A liability is classified as current when it satisfies any of the following criteria:

(a) it is expected to be settled in, the company's normal operating cycle.

(b) it is held primarily for the purpose of being traded.

(c) it is due to be settled within 12 months after the balance sheet date; or

2 Significant accounting policies (Continued)

iii. Current and non-current classification (Continued)

(d) the company does not have an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date.

Terms of a liability that could, at the option of the counter party, result in its settlement by issue of equity instruments do not affect its classification. Current liabilities include current portion of non-current financial liabilities.

All other liabilities are classified as non-current.

Operating cycle

Operating cycle is the time between the acquisition of assets for processing and their realization in cash or cash equivalents.

iv. Property, Plant, and Equipment ("PPE") and depreciation

Freehold land is carried at historical cost. All other items of property, plant, and equipment are stated at historical cost, less accumulated depreciation/amortization and impairments, if any. Historical costs include taxes, duties, freight, and other incidental expenses related to acquisition and installation. Indirect expenses during the construction period, which are required to bring the asset in the condition for its intended use by the management and are directly attributable to bringing the asset to its position, are also capitalized.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Company and the cost of the item can be measured reliably.

If significant parts of an item of PPE have different useful lives, then they are accounted for as separate items (major components) of PPE.

Material items such as spare parts, stand-by equipment and service equipment are classified as PPE when they meet the definition of PPE as specified in Ind AS 16 – Property, Plant and Equipment.

The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to profit or loss during the reporting period in which they are incurred.

Any gain or loss on disposal of an item of property, plant and equipment is recognized in the Statement of Profit and Loss.

2 Significant accounting policies (Continued)

iv. Property, Plant, and Equipment ("PPE") and depreciation (Continued)

Depreciation and amortization

Depreciation is calculated using the straight-line method to allocate the cost of property plant equipment, net of residual values, over their estimated useful lives as per the useful life prescribed in schedule II of the Companies Act, 2013 except in the case of the following class of assets where the useful life is based on technical evaluation of the management:

Asset Class	Years
Plant and Machinery	10
Furniture & Fixtures	16
Electrical Installation	10
Office Equipment	10
Computer	6

Fixtures in leasehold premises are amortized over the primary period of the lease or the useful life of the fixtures, whichever is lower.

Depreciation on additions/deletions during the year is provided from the month in which the asset is capitalized up to the month in which the asset is disposed of.

The estimated useful lives, residual values, and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis.

Assets required under finance leases are depreciated over the shorter of the lease term and their useful lives (not being greater than the useful life envisaged in Schedule II of the Companies Act, 2013) unless it is reasonably certain that the company will obtain ownership by the end of lease term, in which case the depreciation rates applicable for similar assets owned by the company are applied.

An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

Gains and losses on disposals are determined by comparing proceeds with carrying amounts. These are included in profit or loss within other gains/(losses).

v. Intangible assets and amortization

Intangible assets with finite useful life are stated at the cost of acquisition, less accumulated depreciation/ amortization, and impairment loss, if any. Cost includes taxes, duties, and other incidental expenses related to the acquisition and other incidental expenses.

2 Significant accounting policies (Continued)

v. Intangible assets and amortization (Continued)

Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of respective intangible assets.

Asset Class	Years
Patent	5 Years
Computer & Software's	5 Years

Regarding internally generated intangible assets:

Expenditure on research activities, undertaken with the prospect of developing new products or gaining new technical knowledge and understanding, is recognized in profit or loss as incurred.

Capital expenditure on research and development is capitalized and depreciated as per the accounting policy mentioned above. Revenue expenditure is charged off in the year in which it is incurred.

Development activities involve a plan or design for the production of new or substantially improved products or processes. Development expenditure is capitalized only if development costs can be measured reliably, the product or process is technically and commercially feasible, future economic benefits are probable, and the Company intends to and has sufficient resources to complete development and to use the asset. The expenditure capitalized includes the cost of materials, direct labor, overhead costs that are directly attributable to preparing the asset for its intended use, and directly attributable borrowing costs (in the same manner as in the case of tangible fixed assets). other development expenditure is recognized in profit or loss as incurred.

Intangible assets are amortized in profit or loss over their estimated useful lives, from the date that they are available for use based on the expected pattern of consumption of economic benefits of the asset.

Gains or losses arising from the recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is derecognized.

Research and Development:

Capital expenditure on research and development is capitalized and depreciated as per the accounting policy mentioned in para h and I above. Revenue expenditure is charged off in the year in which it is incurred.

Gains or losses arising from the de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the statement of profit or loss when the asset is de-recognized.

The useful life of intangible assets of the company comprising of Patents & Know-how, Licenses & Certificates, and Software are considered finite and estimated at five years.

2 Significant accounting policies (Continued)

vi. Impairment of assets

The Company assesses at each balance sheet date whether there is any indication that an asset or a group of assets (cash-generating unit) may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset or a group of assets.

The recoverable amount of an asset or CGU is greater of its value in use and its net selling price. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset or CGU. If the such recoverable amount of the asset or the recoverable amount of the cash-generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the Statement of profit and loss. If at the

balance sheet date there is an indication that a previously assessed impairment loss no longer exists, the recoverable amount is reassessed, and the asset is reflected at the recoverable amount subject to a maximum of depreciable historical cost.

vii. Inventories

Inventories that comprise Raw material, packing material, stock-in-trade, and work-in-process are carried at a lower cost and net realizable value. Costs are determined on a periodic unit price basis.

Costs include purchase price (net of refundable taxes and levies) and other costs incurred in bringing the inventories to their present location and condition. The closing stock of finished goods is valued at estimated cost or net realizable value, whichever is lower. The net realizable value of work in progress is determined by reference to the selling prices of related finished products.

Obsolete, defective, and unserviceable inventories are duly provided for. The comparison of cost and net realizable value is made on an item-to-item basis. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated cost of completion and the estimated costs necessary to make the sale.

viii. Revenue Recognition

Revenue from the sale of services is recognized on the basis of approved contracts regarding the transfer of services to a customer as per agreed terms of service, recovery of consideration is probable, the associated costs and possible return of services can be estimated reliably, there is no continuing effective control over or managerial involvement with the services, for an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those services. Revenue from the service is measured at the fair value of the consideration received or receivable, net of return of discounts and rebates, and Goods and Service tax. The Company does not provide any warranties or maintenance contracts to its customers.

2 Significant accounting policies (Continued)

viii. Revenue Recognition (Continued)

Significant financing component - Generally, the Company receives short-term advances from its customers. Using the practical expedient in Ind AS 115, the Company does not adjust the promised amount of consideration for the effects of a significant financing component if it expects, at contract inception, that the period between the transfer of the promised good or service to the customer and when the customer pays for that good or service will be one year or less.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortized cost.

Dividend Income

Dividend income is recognized when the right to receive payment is established

ix. Borrowing costs

Borrowing costs are interest and other costs that the Group incurs in connection with the borrowing of funds and is measured with reference to the effective interest rate applicable to the respective borrowing. Borrowing costs include interest costs measured at EIR and exchange differences arising from foreign currency borrowings (other than long-term foreign currency borrowings) to the extent they are regarded as an adjustment to the interest cost.

Borrowing costs, allocated to qualifying assets, pertaining to the period from commencement of activities relating to construction/development of the qualifying asset up to the date of capitalization of such asset are added to the cost of the assets. Capitalization of borrowing costs is suspended and charged to the Statement of Profit and Loss during extended periods when active development activity on the qualifying assets is interrupted.

All other borrowing costs are recognized as an expense in the period in which they are incurred.

x. Financial Instruments

a. Financial assets

Initial recognition and initial measurement

All financial assets are initially recognized at fair value plus, for an item not at fair value through profit or loss, transaction costs that are directly attributable to its acquisition or issue

Classification and subsequent measurement

For purposes of subsequent measurement, financial assets are classified in three categories:

Financial assets at amortized cost

A financial asset is classified as subsequently measured at the amortized cost if both the following conditions are met:

2 **Significant accounting policies (Continued)**

x. ***Financial Instruments (Continued)***

- The asset is held within a business model whose objective is to hold assets for collecting contractual cash flows, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

The losses arising from impairment are recognized in the profit or loss. This category generally applies to trade and other receivables.

Financial assets at fair value through Other Comprehensive Income ("FVTOCI")

A financial asset is classified as subsequently measured at fair value through Other Comprehensive Income if both the following conditions are met:

- The objective of the business model is achieved both by collecting contractual cash flows and selling the financial assets, and
- Contractual terms of the asset give rise on specified dates to cash flows that are solely payments of principal and interest (SPPI) on the principal amount outstanding.

Financial assets included within the FVTOCI category are measured initially as well as at each reporting date at fair value. Fair value movements are recognized in other comprehensive income (OCI). However, the Company recognizes interest income, impairment losses & reversals, and foreign exchange gain or loss in the P&L. On de-recognition of the asset, cumulative gain or loss previously recognized in OCI is reclassified from equity to P&L. The company did not have any financial assets at FVTOCI during the current year as well as the previous year.

Financial assets at fair value through Profit and loss ("FVTPL")

Financial assets at FVTPL are a residual category for financial assets. Any financial asset which does not meet the criteria of categorizing it at amortized cost or at FVTOCI is classified as at FVTPL.

Financial assets included within the FVTPL category are measured at fair value with all changes recognized in the P&L.

De-recognition

A financial asset (or, where applicable, a part of a financial asset or part of a group of similar financial assets) is primarily derecognized (i.e. removed from the Company's balance sheet) when:

- The rights to receive cash flows from the asset have expired, or
- The Company has transferred its rights to receive cash flows from the asset or has assumed an obligation to pay the received cash flows in full without material delay to a third party under a 'pass-through' arrangement: and either (a) the Company has transferred substantially all the risks and rewards of the asset, or (b) the Company

has neither transferred nor retained substantially all the risks and rewards of the asset, but has transferred control of the asset.

2 Significant accounting policies (Continued)

x. Financial Instruments (Continued)

When the Company has transferred its rights to receive cash flows from an asset or has entered into a pass-through arrangement, it evaluates if and to what extent it has retained the risks and rewards of ownership. When it has neither transferred nor retained substantially all of the risks and rewards of the asset, nor transferred control of the asset,

the Company continues to recognise the transferred asset to the extent of the Company's continuing involvement. In that case, the Company also recognises an associated liability. The transferred asset and the associated liability are measured on a basis that reflects the rights and obligations that the Company has retained.

Continuing involvement that takes the form of a guarantee over the transferred asset is measured at the lower of the original carrying amount of the asset and the maximum amount of consideration that the Company could be required to repay.

Impairment of Financial Assets

In view of its past experience of having no bad-debts / write-offs during the past two years and based on management's estimate that this trend would continue for the foreseeable future, the Company has determined that no impairment of Financial assets is required to be recognised based on Expected Credit Loss model.

b. Financial liabilities

Initial recognition and measurement

Financial liabilities are classified, at initial recognition, as financial liabilities at amortized cost and financial liabilities at FVTPL. Derivative liabilities are classified as FVTPL. All financial liabilities are recognized initially at fair value. The Company's financial liabilities include trade and other payables, loans, and borrowings including bank overdrafts and derivative financial instruments.

Subsequent measurement

The measurement of financial liabilities depends on their classification, as described below:

Financial liabilities at FVTPL

Financial liabilities at fair value through profit or loss include financial liabilities held for trading and financial liabilities designated upon initial recognition as at fair value through profit or loss. Financial liabilities are classified as held for trading if they are incurred for the purpose of repurchasing in the near term. This category also includes

derivative financial instruments entered into by the Company that is not designated as hedging instruments in hedge relationships as defined by Ind AS 109.

Gains or losses on liabilities held for trading are recognized in the profit or loss. Except for derivative instruments, the Company has not designated any financial liability at FVTPL.

2 Significant accounting policies (Continued)

x. Financial Instruments (Continued)

Financial liabilities at amortized cost

All financial liabilities except for derivatives are classified as measured at amortized cost. This category includes bank and other borrowings, trade payables, and other financial liabilities.

De-recognition

A financial liability is derecognized when the obligation under the liability is discharged or canceled or expires. When an existing financial liability is replaced by another from the same lender on substantially different terms, or the terms of an existing liability are substantially modified, such an exchange or modification is treated as the de-recognition of the original liability and the recognition of a new liability. The difference in the respective carrying amounts is recognized in the statement of profit or loss.

c. Offsetting of Financial instruments

Financial assets and financial liabilities are offset, and the net amount is reported in the balance sheet if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

xi. Cash and Cash equivalents

Cash and cash equivalent in the balance sheet and for the statement cash flow comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

Interest

Interest revenue is calculated by using the effective interest method for financial assets measured at amortized cost.

xii. Government grants

Grants from the government are recognized at their fair value where there is a reasonable assurance that the grant will be received, and the company will comply with all attached conditions.

Government grants relating to income are deferred and recognized in the profit or loss over the period necessary to match them with the costs that they are intended to compensate and reduce from the corresponding cost.

2 Significant accounting policies (Continued)

xii. Government grants (Continued)

Income from export incentives such as a premium on the sale of import licenses, duty drawback, etc. is recognized on an accrual basis to the extent the ultimate realization is reasonably certain.

Government grants relating to the purchase of property, plant, and equipment are included in non-current liabilities as deferred income and are credited to profit or loss on a straight-line basis over the expected lives of the related assets and presented within other operating income.

xiii. Employee Benefits

(a) Short-Term Employee Benefits

Employee benefits are payable wholly within twelve months of receiving employees' services and are classified as short-term employee benefits. These benefits include salaries and wages, bonuses, ex-gratia, etc. These are recognized as an expense at an undiscounted amount in the Statement of Profit and Loss of the year in which the related service is rendered.

(b) Post-employment Benefits

(i) Provident Fund

A defined contribution plan is a post-employment benefit plan under which an entity pays specified contributions to a separate entity and has no obligation to pay any further amounts. The Company makes specified monthly contributions towards employee provident fund to Government administered provident fund scheme which is a defined contribution plan. The Company's contribution is recognized as an expense in the statement of profit and loss during the period in which the employee renders the related.

(ii) Gratuity

The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned in return for their service in the current and prior periods; that benefit is discounted to determine its present value. The calculation of the Company's obligation under the plan is performed annually by a qualified actuary using the projected unit credit method. The Company recognizes all actuarial gains and losses arising from the defined benefit plan immediately in the Statement of Profit and Loss. All expenses related to the defined benefit plan are recognized in employee benefits expense in the Statement of Profit and Loss.

2 Significant accounting policies (Continued)

xiii. Employee Benefits (Continued)

(iii) Compensated Absences

The Company provides for encashment of leave or leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits for future encashment/availment. The Company makes provisions for compensated absences based on an independent external actuarial valuation carried out at the end of the year. Actuarial gains and losses are recognized in the Statement of Profit and Loss.

xiv. Taxation

Income tax expense comprises current tax and deferred tax charges or credits.

Current Income Tax

Provision for current tax is determined as the amount of tax payable in respect of taxable income for the year in accordance with the provisions of the Income Tax Act, 1961. Current tax is measured at the amount expected to be paid to (recovered from) the taxation authorities, using the enacted or substantively enacted tax rates and tax laws. Management periodically evaluates positions taken in the tax returns with respect to situations in which applicable tax regulations are subject to interpretation and establishes provisions where appropriate.

Deferred Tax

Deferred tax is recognized in respect of temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date

Deferred tax liabilities are recognized for all taxable temporary differences.

Deferred tax assets are recognized for all deductible temporary differences, the carry forward of unused tax credits, and any unused tax losses. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred tax asset to be utilized. Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the year when the asset is realized or the liability is settled, based on tax rates (and tax laws) that have been enacted or substantively enacted at the reporting date.

Deferred tax relating to items recognized outside profit or loss is recognized outside profit or loss (either in other comprehensive income or in equity). Deferred tax items are recognized in correlation to the underlying transaction either in OCI or directly in equity.

2 Significant accounting policies (Continued)

xiv. Taxation (Continued)

Deferred tax assets and deferred tax liabilities are offset if a legally enforceable right exists to set off current tax assets against current tax liabilities and the deferred taxes relate to the same taxable entity and the same taxation authority.

Minimum Alternative tax ('MAT') under the provisions of the Income Tax Act, 1961 is recognized as the current tax in the Statement of Profit Loss. The credit available under the Act in respect of MAT paid is recognized as an asset only when and to the extent it is probable that the company will pay normal income tax during the year for which the MAT credit can be carried forward for set-off against the normal tax liability. MAT credit recognized as an asset is reviewed at each balance sheet date and written down to the extent the aforesaid convincing evidence no longer exists.

xv. Earnings per share

Basic earnings per share are calculated by dividing the net profit for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the year. Earnings considered in ascertaining the Company's earnings per share are the net profit for the year attributable to equity shareholders. The weighted average number of equities shares outstanding during the year end for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equities shares outstanding, without a corresponding change in resources.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year is adjusted for the effects of all dilutive potential equity shares.

xvi. Provisions and contingent liabilities

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. The expense relating to a provision is presented in the statement of profit and loss.

If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost.

A provision in respect of loss contingencies relating to claims litigation, assessment, fines, penalties, etc. are recognized when it is probable that a liability has been incurred, and the amount can be estimated reliably.

2 Significant accounting policies (Continued)

xvi. Provisions and contingent liabilities (Continued)

A contingent liability exists when there is a possible but not probable obligation or a present obligation that may, probably will not, require an outflow of resources embodying economic benefits, or a present obligation whose amount cannot be estimated reliably. Contingent liabilities do not warrant provisions but are disclosed unless the possibility of an outflow of resources is remote. Contingent assets are neither recognized nor disclosed in the financial statements. However, contingent assets are assessed continually and if it is virtually certain that an inflow of economic resources embodying economic benefits will arise, related income is recognized in the year in which the change occurs.

xvii. Fair value measurement

The Company measures financial instruments, such as derivatives, at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

xvii. Fair value measurement (Continued)

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

	As at March 31, 2024	As at March 31, 2023
3 Share Capital		
Authorised:		
4,00,00,000 (as at March 31, 2024 : 4,00,00,000) Equity Shares of Rs. 10/- each.	**4,000.00**	4,000.00
Issued, Subscribed and Paid up:		
3,62,74,728 (as at March 31, 2024: 3,62,74,728) Equity Shares of Rs.10/- each fully paid up	**3,627.47**	3,627.47
	3,627.47	3,627.47

a) Reconciliation of the number of shares

Description	As at March,31 2024		As at March 31, 2023	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,62,74,728	3,627.47	3,62,74,728	3,627.47
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	**3,62,74,728**	**3,627.47**	3,62,74,728	3,627.47

b) Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.
Failure to pay any amount called up on shares may lead to forfeiture of the shares.
On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

c) Shares held by holding company

	As at March,31 2024		As at March 31, 2023	
	Number	Amount	Number	Amount
Privi Speciality Chemicals Limited (formerly known as Fairchem Specialty Limited)	**3,62,74,728**	3,627.47	3,62,74,728	3,627.47

d) Details of shareholders holding more than 5% of shares

	As at March,31 2024		As at March 31, 2023	
	Number	%	Number	%
Privi Speciality Chemicals Limited (formerly known as Fairchem Specialty Limited)	**3,62,74,728**	**100.00%**	3,62,74,728	100.00%

4 Other equity	As at March 31, 2024	As at March 31,
Retained Earnings	**(411.64)**	**(383.10)**
	(411.64)	(383.10)

E. E. SITABKHAN & CO. Chartered Accountants MUMBAI

4 Property, plant and equipment

Description	Gross Block				Depreciation					Net Block
	As at April 01,2023	Addition during the year	Deletion during the year	As at March 31,2024	As at April 01,2023	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2024	As at March 31,2024
At Cost :										
Building	876.75	-	-	876.75	180.72	22.26	5.26	-	208.24	668.51
Plant & Machinery	1,398.80	54.89	-	1,453.69	607.79	144.65	-	-	752.44	701.25
Electricals	194.84	-	-	194.84	84.79	20.15	-	-	104.94	89.90
Furniture and fixtures	77.33	-	-	77.33	20.72	4.83	-	-	25.55	51.78
Computers	13.34	-	-	13.34	6.61	2.11	-	-	8.72	4.62
Office equipments	3.63	-	-	3.63	0.67	0.36	-	-	1.03	2.60
	2,564.69	54.89	-	2,619.58	901.30	194.36	5.26	-	1,100.92	1,518.66
Capital Work in Progress	14.47	114.65	54.89	74.23	-	-		-	-	74.23

Description	Gross Block				Depreciation					Net Block
	As at April 01,2022	Addition during the period	Deletion during the period	As at March 31,2023	As at April 01,2022	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2023	As at March 31,2023
At Cost :										
Building	876.75	-	-	876.75	153.20	22.26	5.26	-	180.72	696.03
Plant & Machinery	1,398.80	-	-	1,398.80	463.15	144.64	-	-	607.79	791.01
Electricals	194.84	-	-	194.84	64.64	20.15	-	-	84.79	110.05
Furniture and fixtures	77.33	-	-	77.33	15.89	4.83	-	-	20.72	56.61
Computers	13.34	-	-	13.34	4.39	2.22	-	-	6.61	6.73
Office equipments	3.09	0.54	-	3.63	0.34	0.33	-	-	0.67	2.96
	2,564.15	0.54	-	2,564.69	701.61	194.43	5.26	-	901.30	1,663.39
Capital Work in Progress	-	15.00	0.54	14.47	-	-		-	-	14.47

*Note: i) Gross value of Leasehold land as on 31 March 2024 includes Rs 735 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 630.40 lacs is actual cost of Asset.
ii) Gross value of Building as on 31 March 2024 includes Rs 175.36 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 123.09 lacs is actual cost of Asset.
iii) Depreciation on revluataion on Leasehold Land and Building is adjusted with the Revaluation Reserve.

E. S. SITABKHAN MUMBAI Chartered Accountants

485

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

As at March 31,2024

(Currency: Indian Rupees in lakhs)

5 Intangible assets

Description	Gross Block				Amortisation				Net Block
	As at April 01,2023	Addition during the year	Deletion during the year	As at March 31,2024	As at April 01,2023	For the year	Deletion during the year	As at March 31,2024	As at March 31,2024
Patents	101.22	81.48	-	182.70	51.45	10.14	-	61.59	121.11
Computers & softwares	0.98	-	-	0.98	0.41	0.20	-	0.61	0.37
Total intangible assets	102.20	81.48	-	183.68	51.86	10.34	-	62.20	121.48
Intangible Asset Under Development	60.29	21.19	81.48	-	-	-	-	-	-
	162.49	102.67	81.48	183.68	51.86	10.34	-	62.20	121.48

Description	Gross Block				Amortisation				Net Block
	As at April 01,2022	Addition during the year	Deletion during the year	As at March 31,2023	As at April 01,2022	For the year	Deletion during the year	As at March 31,2023	As at March 31,2023
Patents	101.22	-	-	101.22	41.33	10.12	-	51.45	49.77
Computer software	0.98	-	-	0.98	0.21	0.20	-	0.41	0.57
Intangible assets	102.20	-	-	102.20	41.54	10.32	-	51.86	50.34
Intangible Asset Under Development	13.91	46.38	-	60.29	-	-	-		60.29
	116.11	46.38	-	162.49	41.54	10.32	-	51.86	110.63

SITABKHAN & CO. Chartered Accountants MUMBAI

486

5a Right of use assets

Description	Gross carrying amount				Accumulated Amortisation					Net carrying amount
	As at April 01, 2023	Addition during the year	Disposal during the year	As at March 31,2024	As at April 01, 2023	Amortisation for the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2024	As at March 31,2024
Land	1,387.40	-	632.66	754.74	129.55	16.46	13.70	34.30	125.42	629.32
Total intangible assets	1,387.40	-	632.66	754.74	129.55	16.46	13.70	34.30	125.42	629.32

The aggregate depreciation expense on right-of-use asset is included under depreciation and amortisation expense in the Statement of Profit and Loss.
The Company has not recognised any impairment loss during the current year (31 March, 2023 - Nil).
*Note: i) Gross value of Leasehold land as on 31 March 2024 includes Rs 735 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 630.40 lacs is actual cost of Asset.

Description	Gross carrying amount				Accumulated Amortisation					Net carrying amount
	As at April 01, 2022	*Addition during the year	Disposal during the year	As at March 31, 2023	As at April 01, 2022	Amortisation for the year	*Depreciation on revaluation	Deletion during the year	As at March 31, 2023	As at March 31, 2023
Land	1,387.40	-	-	1,387.40	83.23	32.62	13.70		129.55	1,257.85
Total intangible assets	1,387.40	-	-	1,387.40	83.23	32.62	13.70		129.55	1,257.85

*Note: i) Gross value of Leasehold land as on 31 March 2023 includes Rs 735 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 652.40 lacs is actual cost of Asset.

SITABKHAN & CO. MUMBAI Chartered Accountants

		March 31,2024	March 31, 2023
6	**Inventories**		
	(valued at lower of cost and net realisable value)		
	Stores and spares	49.62	39.62
		49.62	39.62

7 **Other financial assets**
(Unsecured, considered good unless otherwise stated)

	Non-current portion		Current Portion	
	March 31,2024	March 31, 2023	March 31,2024	March 31, 2023
Inter Corporate deposit	-	-	900.00	-
Security deposits	16.67	15.91	-	-
	16.67	15.91	900.00	-

8 **Trade Receivables**
(Unsecured unless otherwise stated)

	March 31,2024	March 31, 2023
Considered good- Secured		
Dues from related party (refer note 25)	-	279.77
Dues from others	-	-
Credit impaired	-	-
Less: Allowance for expected credit loss and credit impairment	-	-
	-	279.77

Particulars	Outstanding for following periods from due date of payments					
	Less than 6 months		6 months - 1 year		Total	
	March 31,202	March 31, 202	March 31,2024	March 31, 2023	March 31,2024	March 31, 2023
Undisputed Trade receivbales-considered good	-	279.77	-	-	-	279.77
Undisputed Trade Receivables- which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivables-Credit unpaired	-	-	-	-	-	-
Undisputed Trade Receivables Considered good	-	-	-	-	-	-
Disputed Trade Receivables-which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivables- credit impaired	-	-	-	-	-	-
	-	-	-	-	-	-

9 **Cash and cash equivalent**

	March 31,2024	March 31, 2023
Cash on hand	0.24	0.07
Balances with Banks		
In current accounts	101.31	4.54
	101.55	4.61

10 **Bank balances other than cash and cash equivalents**

	March 31,2024	March 31, 2023
Fixed deposit with bank (with original maturity of more than three months but less than twelve months)	35.59	35.45
	35.59	35.45

11 **Other Assets**
(Unsecured, considered good)

	Non-current portion		Current Portion	
	March 31,2024	March 31,2023	March 31,2024	March 31,2023
Capital advances	-	6.76	-	-
Advance to vendors	-	-	0.62	4.10
Prepaid Expenses	-	-	16.84	5.71
Tds Receivable	-	-	23.29	6.19
Receivable from government authorities	-	20.69	4.35	-
Loans and advances to employees	-	-	6.89	8.53
	-	27.45	51.99	24.52

P. E. SITABKHAN & Co. Chartered Accountants MUMBAI

488

12 **Provisions**

	Non Current		Current	
	March 31,2024	March 31, 2023	March 31,2024	March 31, 2023
Provisions for employee benefits				
Gratuity	25.20	17.99	0.93	0.63
Compensated absences	9.83	10.00	1.30	1.44
	35.03	27.99	2.24	2.07

13 Income tax

	March 31,2024	March 31, 2023
Current income tax		
Current income tax expenses	2.93	-
Tax Adjustment of earlier years	-	-
Deferred tax		
Relating to origination and reversal of temporary differences	(12.30)	(10.28)
Income tax expense reported in the statement of profit or loss	(10.28)	(10.28)
Income tax recognised in other comprehensive income		
Tax expense related to items recognised in OCI during the year		
Actuarial loss on defined benefit plan	1.16	0.66
Income tax charged to OCI	1.16	0.66

	As at 1 April 2023	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	March 31,2024
Deferred tax (assets)/liabilities				
Expenses allowable for tax purposes when paid	16.82		1.16	17.98
Tax depreciation	(78.60)	(12.30)	-	(90.90)
	(61.78)	(12.30)	1.16	(72.92)

	As at 1 April 2022	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	As at 31 March 2023
Deferred tax (asset)/liabilities				
Expenses allowable for tax purposes when paid	16.13		0.66	16.82
Tax depreciation	(88.88)	10.28	-	(78.60)
	(72.75)	10.28	0.66	(61.78)

14 **Trade Payable**

	March 31,2024	March 31, 2023
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small enterprises		
i) Payable to Related parties (refer note no. 35)	-	-
ii) Other Payable	91.00	52.07
	91.00	52.07

Particulars	Less Than 1 years	1-2 years	2-3 years	More than 3 years	Total
i) MSME	-	-	-	-	-
ii) Others	91.00	-	-	-	-
iii) Disputed dues - MSME	-	-	-	-	-
iv) Disputed dues - Others	-	-	-	-	-
	91.00	-	-	-	-

Particular	Less Than 1 years	1-2 years	2-3 years	More than 3 years	Total
i) MSME	-	-	-	-	-
ii) Others	91.00	-	-	-	91.00
iii) Disputed dues - MSME	-	-	-	-	-
iv) Disputed dues - Others	-	-	-	-	-
	91.00	-	-	-	91.00

15 **Other financial liabilities**

	March 31,2024	March 31, 2023
Advance from Customer	11.93	-
Payable for capital expenditure	-	-
Employee's Expenses Payable	37.04	27.99
Other Current Borrowings (Refer Note 12)	-	-
Deposits	25.00	25.00
	73.97	52.97

16 Other Current Liabilities

	March 31,2024	March 31, 2023
Statutory dues including provident fund, tax deduction at source and others	8.40	9.58
	8.40	9.58

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the Period ended March 31,2024

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2024	Year Ended March 31,2023
17	**Revenue from Operations**		
	Techincal Services	**555.00**	622.50
		555.00	622.50
18	**Other Income**		
	Interest income from fixed deposits	**1.98**	1.97
	Interest received on income tax refund	**0.43**	
	Profit on sale of investments (net)	**1.27**	-
	Rent received	**90.00**	105.00
	Miscelleneous Income	**35.67**	2.18
	Profit on Sale of Land	**218.81**	-
		348.16	109.15
19	**Employee benefits expense**		
	Salaries, wages and bonus	**252.91**	237.77
	Contribution to provident and other funds	**13.63**	13.91
	Staff welfare expenses	**22.27**	5.86
		288.81	257.54
20	**Finance Cost**		
	Interest on other loans	**0.02**	-
	Amortisation of premium on forward exchange contracts	-	-
	Other Finance cost	-	-
	Interest on delayed payment of income tax	-	-
		0.02	-
21	**Depreciation and amortisation**		
	Depreciation on tangible assets	**194.36**	194.43
	Amortisation of intangible assets	**10.34**	10.32
	Amortisation right of use assets	**16.46**	32.62
		221.16	237.37

E. SITABKHAN & CO. MUMBAI Chartd.

490

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the Period ended March 31,2024

(Currency: Indian Rupees in lakhs)

		Year ended March 31, 2024	Year Ended March 31,2023
22	**Other Expenses**		
	Power and fuel	**146.14**	102.13
	Repairs and maintenance of:		
	Buildings	**0.34**	1.73
	Plant and machinery	**15.35**	40.85
	others	**3.59**	5.64
	Consumables	**29.32**	63.64
	Contract Labour Charges	**31.05**	38.96
	Research & Development Material Expenses	**45.09**	-
	Insurance	**1.88**	2.12
	Rates and taxes	**3.31**	0.57
	Training Expenses	**0.30**	0.61
	Auditors remuneration:		
	Statutory audit	**1.00**	0.75
	Printing and stationery	**9.91**	7.90
	Selling and distribution		
	Legal and professional fees	**41.87**	18.98
	Travelling and conveyance	**18.92**	12.79
	Bank charges	**0.64**	-
	Other Admin Expenses	**36.24**	54.88
		384.95	349.28

SITABKHAN & CO. MUMBAI Chartered Accountants

(Currency: Indian Rupees in lakhs)

23 Employee benefits - Post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund, Super annuation fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the Note 19 under "Contribution to provident & other funds":

	Year ended March 31, 2024	Year ended March 31, 2023
Contribution to employees provident fund	13.63	13.75
Contribution to ESI	-	0.16

b) Defined benefit plans

The Company operates one post-employment defined benefit plan (funded plan) that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

	As at March 31, 2024	As at March 31, 2023
Amount recognised in the Balance Sheet in respect of Gratuity		
Present value of the funded defined benefit obligation at the	26.12	18.59
Net liability/(asset)	26.12	18.59
Movement in present value of defined benefit obligation		
Opening Defined Benefit Obligations	18.59	15.95
Current service cost	3.93	4.14
Interest cost	1.38	1.14
Actuarial (gain)/loss	4.13	(2.64)
Benefits paid	(1.91)	-
Closing defined benefit obligation	26.12	18.59

E. SITABKHAN & CO. MUMBAI Chartered Accountants

23 Employee benefits - Post-employment benefit plans *(Continued)*

	As at March 31, 2024	As at March 31, 2023
b) **Defined benefit plans *(Continued)***		
Expense recognised in statement of profit and loss		
Current service cost	3.93	4.14
Interest on defined benefit obligations	1.39	1.14
Total	5.32	5.28
Remeasurements recognised in Other comprehensive income		
Change in Demographic Assumption	-	-
Change in Financial Assumption	0.74	(0.70)
Experience adjustments	3.39	(1.93)
Total	4.13	(2.62)
Total expense recognised	9.45	2.67

	March 31, 2024	March 31, 2023
Principal actuarial assumptions at the balance sheet date		
Discount rate (p.a.)	7.47%	7.15%
Expected rate of Salary increase (p.a.)	8.25%	8.25%
Attrition Rate	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%
Mortality Tables	Indian Assured Lives Mortality (2012-14)	Indian Assured Lives Mortality (2012-14)

The estimates of future salary increase , considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

Estimated rate of return on plan assets is based on average long term rate of return expected on investments of the Fund during the estimated term of the obligations.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
Impact on defined benefit obligation due to:	**March 31, 2024**	March 31, 2023	**March 31, 2024**	March 31, 2023
a. 1% increase	3.17	2.34	3.17	2.34
b. 1% decrease	(2.68)	(1.97)	(2.68)	(1.97)

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment

	March 31, 2024	March 31, 2023
Defined benefit obligation	26.12	18.59
Plan assets	-	-
Surplus/(deficit)	(26.12)	(18.59)
Experience adjustment on plan liabilities	3.39	-1.93
Experience adjustment on plan assets	-	-

24 Related party disclosures

a) List of Related Parties

Related parties where control exist:

Holding Company

Privi Speciality Chemicals Limited

Enterprises owned or significantly influenced by key management personnel or their relatives

Privi Life Sciences Pvt. Ltd.
Prasad Organics Pvt. Ltd
Privi Organics Ltd (Upto 31.03.2023)
Privi Fine Sciences Private Limited
Vivira Investment and Trading Pvt. Ltd.
Satellite Technologies Private Limited

Key Management Personnel (KMP)

Mr. D. B. Rao (Managing Director)
Mr. Mahesh P. Babani (Director)

b) During the year, following transactions were carried out with the related parties :

	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31,2024	31 March 2023	March 31,2024	31 March 2023	March 31,2024	31 March 2023
Transactions						
Purchase of raw materials						
Privi Speciality Chemicals Ltd	-	5.09	-	-	-	-
Privi Fine Sciences Private Limited	-	-	2.81	-	-	-
Vivira Investment and Trading Pvt Ltd	-	-	-	-	-	-
Purchase of Consumable						
Prasad Organics Pvt Ltd	-	-	-	5.90	-	-
Privi Life Science Pvt Ltd	-	-	-	1.46	-	-
Technical servicer						
Privi Speciality Chemicals Ltd	555.00	420.00	-	-	-	-
Rent						
Privi Speciality Chemicals Ltd	90.00	60.00	-	-	-	-

Particulars	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31,2024	31 March 2023	March 31,2024	31 March 2023	March 31,2024	31 March 2023
Trade Receivable						
Privi Speciality Chemicals Ltd	(11.93)	129.16	-	-	-	-
Trade Payables						
Privi Speciality Chemicals Ltd	-	-	-	-	-	-
Privi Life Science Pvt Ltd	-	-	-	-	-	-
Prasad Organics Pvt Ltd	-	-	-	-	-	-
Other Payables						
Privi Speciality Chemicals Ltd	25.00	25.00	-	-	-	-

For SITABKHAN & CO. MUMBAI

(Currency: Indian Rupees in lakhs)

		March 31,2024	March 31, 2023
25	**Earnings per share**		
	Profit/(Loss) after tax attributable to equity shareholders [A]	**(6.15)**	(102.26)
	Number of equity shares at the beginning of the year [B]	**3,62,74,728**	3,62,74,728
	Number of equity shares outstanding at the end of the year [C]	**3,62,74,728**	3,62,74,728
	Weighted average number of equity shares outstanding during the year	**3,62,74,728**	3,62,74,728
	Basic & Diluted earnings (in rupees) per share of face value Rs. 10	**(0.02)**	(0.28)

26 **Previous year comparative**
The previous year figures have been regrouped and reclassified, wherever required.

27 Information with regard to other additional information and other disclosures to be disclosed by way of notes to Statement of Profit and Loss as specified in Schedule III to the Act is either 'nil ' or ' not applicable ' to the Company for the year.

For For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor. M.No.30721

Mumbai
Date: April 25,2024

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

INDEPENDENT AUDITORS' REPORT

To the Board of Directors
Privi Biotechnologies Private Limited

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of Privi Biotechnologies Private Limited ('the Company'), which comprise the standalone balance sheet as at 31st March 2023, and the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement for the year then ended, and notes to the standalone Ind AS financial statements, including a summary of the significant accounting policies and other explanatory information (herein after referred to as 'standalone financial statements').

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Companies Act, 2013 ('the Act') in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March 2023, its profit (including other comprehensive income), changes in equity and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under Section 143(10) of the Act. Our responsibilities under those SAs are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Other Information

The Company's management and Board of Directors are responsible for the other information. The other information comprises the information included in the Company's Annual Report but does not include the standalone financial statements and our auditors' report thereon.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Management's Responsibility for the Standalone Financial Statements

The Company's management and Board of Directors are responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these standalone financial statements that give a true and fair view of the state of affairs, profit/loss and other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under Section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the standalone Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management and Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Auditor's Responsibilities for the Audit of the standalone financial statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.

- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditors' Report) Order, 2016 ('the Order') issued by the Central Government in terms of Section 143 (11) of the Act, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

(A) As required by Section 143(3) of the Act, we report that:

a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.

b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

c) The standalone balance Sheet, the standalone statement of profit and loss (including other comprehensive income), the standalone statement of changes in equity and the standalone cash flow statement dealt with by this report are in agreement with the books of account.

d) In our opinion, the aforesaid standalone financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act.

e) On the basis of the written representations received from the directors as on 31st March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31ST March 2022 from being appointed as a director in terms of Section 164(2) of the Act: and

f) With respect to the adequacy of the internal financial controls with reference to financial statements of the Company and the operating effectiveness of such controls, refer our separate Report in 'Annexure B'.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI

DATE : MAY 05,2023

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721
UDIN: 23030721BGVGUQ3409

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

Privi Biotechnologies Private Limited

"Annexure A" to the Independent Auditors' Report – 31 March 2023
(Referred to in our report of even date)

(i) **(a)** (A) The Company has maintained proper records showing full particulars, including quantitative details and situation of Property, Plant and Equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) All fixed assets are physically verified by the management in our opinion, is reasonable having regard to the size of the Company and the nature of its assets. The physical verification of fixed assets was done in previous financial year 2022-23 and No material discrepancies were noticed on such verification.

(c) In our opinion and according to the information and explanations given to us and based on our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the leases agreements are duly executed in favor of the lessee) are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, Plant and Equipment (including Right of Use assets) or intangible assets or both during the year.

(e) According to information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

(ii) (a)The company is involved in activity of research & development of aroma products therefore does not have significant inventory, however few of the store spares & consumables which are taken and consumed. Regarding the unused item at the end of the year inventory is taken as on 31st March 23 and same has been valued on Average Price Basis. The Expenses on account of Consumables Stores and spare items is shown in Profit & Loss A/c net off inventory value. No discrepancies were noticed on verification between the physical stocks and the book records that were more than 10% in the aggregate of each class of inventory.

(b)According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has no sanctioned working capital facility from banks or financial institutions.

(iii) According to the information and explanations given to us and on the basis of our examination of the records of the Company has not made during the year any investments or given any guarantee or security or granted any loans or advances which are characterized as loans, unsecured or secured, to LLPs, firms or companies or any other person.

(a) Based on the audit procedures carried on by us and as per the information and explanations given to us the Company has not provided loans or provided advances in the nature of loans, or given guarantee, or provided security to any other entity during the year.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

500

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(b) According to the information and explanations given to us and based on the audit procedures conducted by us, we are of the opinion that the investments made is, prima facie, not prejudicial to the interest of the company.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, no loans are given during the year further, the Company has not given any advance in the nature of loan to any party during the year.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loans given. Further, the Company has not given any advances in the nature of loans to any party during the year. Accordingly, clause 3(iii) (d) of the Order is not applicable.

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there is no loan or advance in the nature of loan granted. Accordingly, clause 3(iii) (e) of the Order is not applicable.

(f) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not granted any loans or advances in the nature of loans. Accordingly, clause 3(iii) (f) of the Order is not applicable.

(iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any security as specified under section 185 and 186 of the Companies Act, 2013. According to the information and explanations given to us and on the basis of our examination of records of the Company, in respect of investments made and guarantees given by the Company, the provisions of section 185 and 186 of the Companies Act, 2013 have been complied with.

(v) In our opinion and according to the information and explanations given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.

(vi) In our opinion since the company is not engaged in manufacturing activities , the rules prescribed by the Central Government for maintenance of cost records under Section 148(1) of the Companies Act, 2013 is not applicable to Company.

(vii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, amounts deducted/accrued in the books of account in respect of undisputed statutory dues including Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues have been generally regularly deposited during the year by the Company with the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of Provident Fund, Employees' State Insurance, Income-tax, Goods and Service Tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2023 for a period of more than six months from the date they became payable.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income Tax Act, 1961 as income during the year.

(ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not defaulted in repayment of loans and borrowing or in the payment of interest thereon to banks or financial institutions during the year. Further, the Company did not have any outstanding loans or borrowings from any other lender during the year

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the company, we report that no funds raised on short-term basis have been used for long-term purposes by the company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the company, we report that the company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, its associates, subsidiaries or joint ventures as defined under Companies Act, 2013.

(f) According to the information and explanations given to us and procedures performed by us, we report that the company has not raised loans during the year on the pledge of securities held in its subsidiaries (as defined under Companies Act, 2013).

(x) (a) The Company has not raised any moneys by way of initial public offer or further public offer (including debt instruments) Accordingly, clause 3(x)(a) of the Order is not applicable.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year. Accordingly, clause 3(x)(b) of the Order is not applicable.

(xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) According to the information and explanations given to us, no report under sub-section (12) of Section 143 of the Companies Act, 2013 has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government.

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.
CHARTERED ACCOUNTANTS
E. E. Sitabkhan B.Com., F.C.A.
Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.
Tel. : 9967315153 / 9322530507 • Email : e.e.sitabkhan@hotmail.com

(c) As represented to us by the management, there are no whistle blower complaints received by the Company during the year.

(xii) (a) According to the information and explanations given to us, the Company is not a Nidhi Company. Accordingly, clause 3(xii) of the Order is not applicable.

(xiii) In our opinion and according to the information and explanations given to us, the transactions with related parties are in compliance with Section 177 and 188 of the Companies Act, 2013, where applicable, and the details of the related party transactions have been disclosed in the financial statements as required by the applicable accounting standards.

(xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has no internal audit system commensurate with the size and nature of its business as The Company is engaged in R&D activity.

(b) Since there is no internal audit system, the question of considering the internal audit report of the company does not arise.

(xv) In our opinion and according to the information and explanations given to us, the Company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence, provisions of Section 192 of the Companies Act, 2013 are not applicable to the Company.

(xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(b) of the Order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) The Company is not part of any group. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

(xvii) The Company has not incurred cash losses in the current and in the immediately preceding financial year.

(xviii) There has been no resignation of the statutory auditors during the year. Accordingly, clause 3(xviii) of the Order is not applicable.

(xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realisation of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our

E. E. SITABKHAN & CO. MUMBAI Chartered Accountants

E. E. SITABKHAN & CO.

CHARTERED ACCOUNTANTS

E. E. Sitabkhan B.Com., F.C.A.

Office #17, Ground Floor, Mubarak CHSL, Church Road, Marol, Andheri East, Mumbai - 400059.

Tel. : 9967315153 / 9322530507• Email : e.e.sitabkhan@hotmail.com

examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

(xx) a) In our opinion and according to the information and explanations given to us, there is no unspent amount under sub-section (5) of section 135 of the Companies Act, 2013 pursuant to any project. Accordingly, clauses 3(xx)(a) and 3(xx)(b) of the Order are not applicable.

FOR M/S.E.E SITABKHAN & CO.
CHARTERED ACCOUNTANTS

PLACE : MUMBAI
DATE : MAY 05,2023

E.E. SITABKHAN
PROPRIETOR
M.No: 0-30721

UDIN : 23030721BGVGUQ3409

PRIVI BIOTECHNOLOGIES PRIVATE LIMITED

Registered / Corporate Office : A-71, MIDC, TTC, THANE BELAPUR ROAD, NAVI MUMBAI - 400 709.

BALANCE SHEET &

PROFIT & LOSS ACCOUNT

(ALONGWITH NOTES)

March-2023

505

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71 TTC Industrial Area,Thane Belapur Road, Kopar Khairane, Navi Mumabi -400710
Email : Investors@privi.co.in Phone +91 22 33043500/3343600 Fax: + 91 22 27783049 Website : www.privi.com

CIN : U74220MH1985PTC0377534

Audited Standalone statement of assets and liabilities as at March,31 2023

(Rs in Lakhs)

Particulars	As at March 31,2023 (Audited)	As at March 31, 2022 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	1,663.39	1,862.55
Capital work-in-progress	14.47	-
Intangible assets	50.34	60.66
Intangible assets under development	60.29	60.29
Right of use of assets	1,257.85	1,304.18
Financial assets		
Other financial assets	15.91	9.93
Other non current assets	5.13	27.45
Total non-current assets (A)	**3,067.39**	**3,325.06**
Current assets		
Financial assets		
Inventories	39.62	41.19
Investments	-	-
Trade receivables	279.77	103.01
Loans	-	-
Cash and Cash equivalents	4.61	7.55
Bank Balances other than cash and cash equivalents	35.45	34.86
Other current assets	24.52	68.12
Total current assets (B)	**383.97**	**254.73**
TOTAL (A+B)	**3,451.36**	**3,579.79**
EQUITY AND LIABILITIES		
EQUITY		
Equity share capital	3,627.47	3,627.47
Other equity	(383.08)	(259.89)
Total equity (C)	**3,244.39**	**3,367.58**
LIABILITIES		
Non-current liabilities		
Financial liabilities		
Borrowings	-	-
Provisions	27.97	27.47
Deferred tax liabilities (Net)	61.78	72.73
Total non current liabilities (D)	**89.75**	**100.20**
Current liabilities		
Financial liabilities		
Trade payables		
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small enterprises	52.60	39.67
Other financial liabilities	52.97	67.99
Other current liabilities	9.58	2.66
Provisions	2.07	1.69
Total current liabilities (E)	**117.22**	**112.01**
Total liabilities F = (D + E)	**206.97**	**212.21**
TOTAL (C + F)	**3,451.36**	**3,579.79**

SITABKHAN & CO. MUMBAI Chartered Accountants

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India

Statement of audited Standalone Financial results for the quarter and year ended March 31, 2023 (Rs in Lakhs)

CIN: U74220MH1985PTC037534

Sr. No.	Particulars	Quarter ended			Year ended	
		March 31, 2023 (Audited)	December 31, 2022 (Unaudited)	March 31, 2022 (Unaudited)	March 31, 2023 (Audited)	March 31, 2022 (Audited)
1	Revenue from operations	157.50	157.50	150.00	622.50	510.00
2	Other income	24.35	23.98	31.87	109.15	94.25
3	**Total Income (1 + 2)**	**181.85**	**181.48**	**181.87**	**731.65**	**604.25**
4	**Expenses**					
	(a) Employee benefits expense	66.76	55.01	64.08	257.54	283.76
	(b) Finance cost	(0.40)	-	-	-	0.57
	(c) Depreciation and amortisation expense	58.53	57.98	53.68	237.37	211.60
	(d) Other expenses	80.75	89.78	80.82	349.28	346.60
	Total expenses (4)	**205.64**	**202.77**	**198.58**	**844.19**	**842.53**
5	**Profit /(Loss) before exceptional items and tax (3 - 4)**	**(23.79)**	**(21.29)**	**(16.71)**	**(112.54)**	**(238.28)**
6	**Exceptional Income/(Expenses)**	-			-	-
7	**Profit /(Loss) before tax (5 -6)**	**(23.79)**	**(21.29)**	**(16.71)**	**(112.54)**	**(238.28)**
8	Tax expense					
	Current tax	-			-	-
	Tax adjustment of earlier years	-			-	-
	Deferred tax	(2.57)	(2.57)	14.79	(10.28)	74.31
9	**Net profit /(Loss) for the period (7 - 8)**	**(21.22)**	**(18.72)**	**(31.50)**	**(102.26)**	**(312.59)**
10	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
	Remeasurements of post employment benefit obligations	2.07	(1.57)	(1.57)	(2.64)	(6.28)
	Income tax related to above	(0.53)	0.40	0.40	0.66	1.58
	(ii) Items that will be reclassified to Profit or loss	-			-	-
	Total other comprehensive income (10)	**1.55**	**(1.17)**	**(1.17)**	**(1.97)**	**(4.70)**
11	**Total comprehensive income/(Loss) for the period (9+10)**	**(19.67)**	**(19.89)**	**(32.67)**	**(104.23)**	**(317.29)**
12	**Paid up equity share capital (Face value of Rs. 10/- each)**	3,627.47	3,627.47	3,627.47	3,627.47	3,627.47
13	Earnings per share (EPS) of Rs. 10/- each (* not annualised) (In Rs.) Basic / Diluted	(0.05)	(0.05)	(0.09)	(0.28)	(0.86)

Notes:

1 The Audited standalone financial results for the quarter and year ended March 31, 2023, were Audit and approved by the Board of Directors of Privi Biotechnologies Private Limited ("the Company") at its meeting held on May 05, 2023. The above results have been subjected to audit by the statutory auditors of the company. The statutory auditors have expressed an unqualified review opinion.

2 The Audited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015and SEBI circular dated July 5, 2016.

3 The audited standalone financial Results has been prepared solely to enable Privi Speciality Chemicals Limited (Holding company) to prepare consolidated financial results and not to report on the Company as a separate entity.

4 As the company's business activity falls within a single segment viz. 'Aroma Chemical' , the disclosure requirements of the Ind AS 108 'Operating Segments' notified under Section 133 of the Companies Act, 2013 are not applicable.

5 The figures for the quarter ended March 31, 2023, and March 31,2022 are arrived at as a difference between audited figures in respect of the full financial year and the unaudited figures up to nine months of the relevent financial year.

6 Previous period figures have been regrouped and classifie wherever necessary.

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date : May 05 2023

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

For Privi Biotechnologies Pvt.Ltd.

Mahesh Babani
Director

DIN: 00051162

PRIVI

Privi Biotechnologies Private Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India

CIN: U74220MH1985PTC037534

Unaudited standalone statement of cash flow

(Rs in Lakhs)

		Year ended March,31,2023	Year ended March,31,2022
A	**Cash flow from operating activities**		
	Profit before tax after exceptional items	(102.26)	(238.28)
	Adjustment for:	-	
	Depreciation and amortisation	237.37	211.60
	Profit on sale of investments	-	-
	Interest Income	(1.97)	(3.35)
	Finance costs	-	0.57
	Operating cash flow before working capital changes	133.14	(29.46)
	Movements in working Capital		
	(Increase) / decrease in trade receivables	(176.76)	26.15
	(Increase) / decrease in inventories	1.57	(5.34)
	(Increase) / decrease in other assets	58.31	76.79
	Increase / (decrease) in trade payables and other current liabilities and provisions	(6.08)	12.93
	Cash generated / (used in) from operatation	(122.96)	110.53
	Income taxes paid	-	-
	Net cash generated / (used in) from operating activities [A]	10.18	81.07
B	**Cash flow from investing activities**		
	Purchase of property, plant & equipment	(13.37)	(73.82)
	Realisation / (investment) of fixed deposits	0.59	1.97
	Sale / (purchase) of investments	-	-
	Investment in fixed deposits		-
	Interest received	1.97	3.35
	Net cash (used in)/ generated by investing activities [B]	(10.81)	(68.50)
C	**Cash flow from financing activities**		
	Repayment of long term borrowings	(3.00)	(6.00)
	Interest paid	0.70	(0.92)
	Net cash (used in)/ generated from financing activities [C]	(2.30)	(6.92)
	Net increase/ (decrease) in cash and cash equivalents (A+B+C)	(2.94)	5.65
	Cash and cash equivalents at the beginning of the year	7.55	1.90
	Cash and cash equivalents at end of the year	4.61	7.55

Note A: The above statement of cash flows has been prepared under 'Indirect Method' as set out in Ind AS 7,'statement of Cash Flows'

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Place: Mumbai
Date : May 05 2023

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

By order of the Board
For Privi Biotechnologies Pvt. Ltd

Mahesh Babani
Director

DIN: 00051162

Privi Biotechnologies Private Limited

Balance Sheet

As at March 31, 2023

(Currency: Indian Rupees in lakhs)

		As at March 31, 2023	As at March 31, 2022
Assets			
Non-current assets			
Property, plant and equipment	4	1,663.39	1,862.55
Capital work-in-progress	4	14.47	-
Intangible assets	5	50.34	60.66
Intangible assets under development	5	60.29	60.29
Right of use of assets	5a	1,257.85	1,304.18
Other financial assets	7	15.91	9.93
Other Financial Assets	6	-	-
Other non current assets	11	5.13	27.45
Total non current Assets		3,067.39	3,325.06
Current assets			
Financial assets			
Inventory	6	39.62	41.19
Trade receivables	8	279.77	103.01
Cash and cash Equivalents	9	4.61	7.55
Bank balances other than cash and cash equivalents	10	35.45	34.86
Other Financial Assets		-	-
Other current assets	11	24.52	68.12
Total current assets		383.97	254.73
Total assets		3,451.36	3,579.79
Equity and liabilities			
Equity			
Equity share capital	3	3,627.47	3,627.47
Other equity	4	(383.08)	(259.89)
Total equity		3,244.39	3,367.58
Liabilities			
Non-current liabilities			
Financial liabilities			
Borrowings	12	-	-
Provisions	13	27.97	27.47
Deferred tax liabilities (Net)	14	61.78	72.73
Total non-current liabilities		89.75	100.20
Current liabilities			
Financial liabilities			
Trade payable			
a) Total outstanding dues of micro and small enterprises	15	-	-
b) Total outstanding dues of creditors other than micro and small enterpris	15	52.60	39.67
Other financial liabilities	16	52.97	67.99
Other current liabilities	17	9.58	2.66
Provisions	13	2.07	1.69
Total current liabilities		117.22	112.01
Total equity and liabilities		3,451.36	3,579.79
Notes to the financial statements	3 to 28		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Mumbai
Date : May 05 2023

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Privi Biotechnologies Private Limited

Statement of Profit and Loss

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

	Note	Year Ended March 31,2023	Year Ended March 31,2022
Revenue from operations	18	622.50	510.00
Other income	19	109.15	94.25
Total income (I)		731.65	604.25
Expenses			
Employee benefits expense	20	257.54	283.76
Finance costs	21	-	0.57
Depreciation and amortisation expenses	22	237.37	211.60
Other expenses	23	349.28	346.60
Total expenses (II)		844.19	842.53
Profit / (loss) before tax expenses (I)-(II)		(112.54)	(238.28)
Tax expenses			
Current tax		-	-
Deferred tax credit / (charge)		(10.28)	74.31
Income tax expense		(10.28)	74.31
Profit / (loss) for the year (III)		(102.26)	(312.59)
Other comprehensive income / (loss)		(2.64)	(6.28)
Income tax related to above		0.66	1.58
Total comprehensive income / (loss) for the year (III)+(IV)		(104.23)	(317.29)
Earnings per equity share: nominal value of share Rs.10/- each (March 31, 2020: Rs. 10/-)			
Basic and diluted (Rs.)	26	(0.28)	(0.86)
Notes to the financial statements	3 to 28		
Significant accounting policies	2		

The notes referred to above form an integral part of the financial statements.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Mumbai
Date : May 05 2023

For and on behalf of the Board of Directors of Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer

Ashwini Shah
Company Secretary
Membership No: 105320 Membership No: A-58378

Privi Biotechnologies Private Limited

Statement of Cash Flow

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

		Year Ended March 31,2023	Year Ended March 31,2022
A	**Cash flows from operating activities**		
	Profit/ (Loss) before tax	(112.54)	(238.28)
	Adjustment for:		
	Depreciation and amortisation	237.37	211.60
	Interest income	(1.97)	(3.35)
	Finance costs	-	0.57
		122.86	(29.46)
	Operating cash flows before working capital changes		
	Adjustment for:		
	Increasein trade receivables	(176.76)	26.15
	Decrease in inventories	1.57	(5.34)
	Decrease in other assets	58.31	76.79
	Increase in trade payables and other current liabilities and provisions	4.20	16.17
	Cash generated from operations	(112.68)	113.77
	Income taxes paid	-	-
	Net cash generated / (used in) from operating activities [A]	10.18	84.31
B	**Cash flows from investing activities**		
	Purchase of property, plant & equipment	(13.37)	(73.60)
	Investment in fixed deposits	0.59	1.97
	Interest received	1.97	3.35
	Net cash (used in)/ generated by investing activities [B]	(10.81)	(68.28)
C	**Cash flow from financing activities**		
	Proceeds from long-term borrowings	(3.00)	(3.00)
	Interest paid	0.70	(0.92)
	Net cash (used in)/ generated by financing activities [C]	(2.30)	(3.92)
	Net increase in cash and equivalents [A +B +C]	(2.94)	12.11
	Cash and cash equivalents at the beginning of year	7.55	(4.56)
	Cash and cash equivalents at the end of year (refer note no. 9)	4.61	7.55

The cash flow statement has been prepared under the indirect method as set out in Indian Accounting Standard - 7 on cash flow statements specified under Section 133 of the Companies Act, 2013.

As per our report of even date attached

For M/S. E.E Sitabkhan & Co.
Chartered Accountant

(E.E. Sitabkhan)
Proprietor, M.No.30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Mumbai
Date : May 05 2023

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

Privi Biotechnologies Private Limited

Statement of Changes in Equity

As at March 31,2023

(Currency: Indian Rupees in lakhs)

A. Equity share capital

	As at March 31, 2023	As at March 31, 2022
Balance at the beginning of the year	3,627.47	3,627.47
Changes in equity share capital during the year	-	-
Balance at the end of the year	3,627.47	3,627.47

B. Other equity

	Reserves and surplus			
	Revaluation reserve	Retained earnings	Other comperhensive income	Total
Total comprehensive profit / (loss) for the year ended April 01, 2021				
Opening balance of profit and loss account	821.89	(739.24)	(6.28)	76.37
(Loss) for the year	-	(312.59)	(4.70)	(317.29)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	802.92	(1,051.83)	(10.98)	(259.89)
Balance as at Apr 01,2022	802.92	(1,051.83)	(10.98)	(259.89)
Total comprehensive profit / (loss) for the year ended April 01,2021				
(Loss) for the year	-	(102.26)	(1.97)	(104.23)
Revaluation charge for the year	(18.96)	-	-	(18.96)
Total comprehensive income / (loss) for the year	(18.96)	(102.26)	(1.97)	(123.20)
Balance as at March 31,2023	783.96	(1,154.09)	(12.95)	(383.08)

Notes to the financial statements 3 to 28
Significant accounting policies 2

The notes referred to above form an integral part of the financial statements

As per our report of even date attached
For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

Mumbai
Date May 05 2023

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D.B. Rao
Managing Director
DIN: 00356218

Mahesh Upkar
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

3 Share Capital

	As at March 31, 2023	As at March 31, 2022
Authorised:		
4,00,00,000 (as at March 31, 2022 : 4,00,00,000) Equity Shares of Rs. 10/- each.	4,000.00	4,000.00
Issued, Subscribed and Paid up:		
3,62,74,728 (as at March 31, 2022: 3,62,74,728) Equity Shares of Rs.10/- each fully paid up	3,627.47	3,627.47
	3,627.47	3,627.47

a) Reconciliation of the number of shares

Description	As at March 31, 2023		As at March 31, 2022	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,62,74,728	3,627.47	3,62,74,728	3,627.47
Add: Shares issued during the year	-	-	-	-
Shares outstanding at the end of the year	3,62,74,728	3,627.47	3,62,74,728	3,627.47

b) Rights, preferences and restrictions attached to equity shares

The Company has a single class of equity shares. Accordingly, all equity shares rank equally with regards to dividends and share in the company's residual assets. The equity shares are entitled to receive dividend as declared from time to time. The voting rights of an equity shareholder on a poll (not on show of hands) are in proportion to its share of the paid-up equity capital of the Company. Voting rights cannot be exercised in respect of shares on which any call or other sums presently payable have not been paid.
Failure to pay any amount called up on shares may lead to forfeiture of the shares.
On winding up of the Company, the holders of equity shares will be entitled to receive the residual assets of the Company, remaining after distribution of all preferential amounts in proportion to the number of equity shares held.

c) Shares held by holding company

	As at March 31, 2023		As at March 31, 2022	
	Number	Amount	Number	Amount
Privi Speciality Chemicals Limited (formerly known as Fairchem Speciality Limited)	3,62,74,728	3,627.47	3,62,74,728	3,627.47

d) Details of shareholders holding more than 5% of shares

	As at March 31, 2023		As at March 31, 2022	
	Number	%	Number	%
Privi Speciality Chemicals Limited (formerly known as Fairchem Speciality Limited)	3,62,74,728	100.00%	3,62,74,728	100.00%

4 Other equity

	As at March 31, 2023	As at March 31,
Retained Earnings	(383.08)	(259.89)
	(383.08)	(259.89)

E.E. SITABKHAN & CO. Chartered Accountants MUMBAI

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

As at March 31,2023

(Currency: Indian Rupees in lakhs)

4 Property, plant and equipment

Description	Gross Block				Depreciation					Net Block
	As at April 01,2022	Addition during the year	Deletion during the year	As at March 31,2023	As at April 01,2022	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2023	As at March 31,2023
At Cost :										
Building	876.75	-	-	876.75	153.20	22.26	5.26	-	180.72	696.03
Plant & Machinery	1,398.80	-	-	1,398.80	463.15	144.64	-	-	607.79	791.01
Electricals	194.84	-	-	194.84	64.64	20.15	-	-	84.79	110.05
Furniture and fixtures	77.33	-	-	77.33	15.89	4.83	-	-	20.72	56.61
Computers	13.34	-	-	13.34	4.39	2.22	-	-	6.61	6.73
Office equipments	3.09	0.54	-	3.63	0.34	0.33	-	-	0.67	2.96
	2,564.15	0.54	-	2,564.69	701.61	194.43	5.26	-	901.30	1,663.39
Capital Work in Progress	-	15.00	0.54	14.47	-	-		-	-	14.47

Description	Gross Block				Depreciation					Net Block
	As at April 01,2021	Addition during the period	Deletion during the period	As at March 31,2022	As at April 01,2021	For the year	*Depreciation on revaluation	Deletion during the year	As at March 31,2022	As at March 31,2022
At Cost :										
Building	876.75	-	-	876.75	120.37	27.57	5.26	-	153.20	723.55
Plant & Machinery	1,398.80	-	-	1,398.80	318.51	144.65	-	-	463.15	935.65
Electrical:	194.84	-	-	194.84	44.49	20.15	-	-	64.64	130.20
Furniture and fixtures	77.33		-	77.33	11.00	4.89	-	-	15.89	61.44
Computers	6.14	7.20	-	13.34	2.65	1.74	-	-	4.39	8.95
Office equipments	0.79	2.30	-	3.09	0.16	0.18	-	-	0.34	2.75
	2,554.65	9.50	-	2,564.15	497.17	199.17	5.26	-	701.61	1,862.55
Capital Work in Progress	-	9.50	9.50	-	-	-		-	-	-

*Note: i) Gross value of Leasehold land as on 31 March 2022 includes Rs 735 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 652.40 lacs is actual cost of Asset.

ii) Gross value of Building as on 31 March 2022 includes Rs 175.36 lacs on account of revaluation of asset done in the year 2015-16 and remaining amount of Rs 701.39 lacs is actual cost of Asset.

iii Depreciation on revluataion on Leasehold Land and Building is adjusted with the Revaluation Reserve.

6 **Inventories**

	March 31,2023	March 31, 2022
(valued at lower of cost and net realisable value)		
Stores and spares	39.62	41.19
	39.62	41.19

7 **Other financial assets**
(Unsecured, considered good unless otherwise stated)

	Non-current portion		Current Portion	
	March 31,2023	March 31, 2022	March 31,2023	March 31, 2022
Security deposits	15.91	9.93	-	-
	15.91	9.93	-	-

8 **Trade Receivables**
(Unsecured unless otherwise stated)

	March 31,2023	March 31, 2022
Considered good- Secured		
Dues from related party (refer note 25)		
Dues from others	279.77	103.01
Credit impaired	-	-
Less: Allowance for expected credit loss and credit impairment	-	-
	-	-
	279.77	103.01

Particulars	Outstanding for following periods from due date of payments					
	Less than 6 months		6 months - 1 year		Total	
	March 31,202	March 31, 202	March 31,2023	March 31, 2022	March 31,2023	March 31, 2022
Undisputed Trade receivbales-considered good	279.77	103.01	-	-	279.77	103.01
Undisputed Trade Receivables- which have significant increase in credit risk	-	-	-	-	-	-
Undisputed Trade Receivables-Credit impaired	-	-	-	-	-	-
Undisputed Trade Receivables Considered good	-	-	-	-	-	-
Disputed Trade Receivables-which have significant increase in credit risk	-	-	-	-	-	-
Disputed Trade Receivables- credit impaired	-	-	-	-	-	-

9 **Cash and cash equivalent**

	March 31,2023	March 31, 2022
Cash on hand	0.07	0.40
Balances with Banks		
In current accounts	4.54	7.15
	4.61	7.55

10 **Bank balances other than cash and cash equivalents**

	March 31,2023	March 31, 2022
Fixed deposit with bank (with original maturity of more than three months but less than twelve months)	35.45	34.86
	35.45	34.86

11 Other Assets
(Unsecured, considered good)

	Non-current portion		Current Portion	
	March 31,2023	March 31,2022	March 31,2023	March 31,2022
Capital advances	5.13	6.76	-	-
Advance to vendors	-	-	4.10	-
Prepaid Expenses	-	-	5.71	2.79
Tds Receivable	-	-	6.19	
Receivable from government authorities	-	20.69	-	62.80
Loans and advances to employees	-	-	8.53	2.53
	5.13	27.45	24.52	68.12

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

(Currency: Indian Rupees in lakhs)

12 Borrowings

Non-current borrowings (Secured)

	Non-current portion (*)		Current portion (*)	
Loans	March 31,2023	March 31, 2022	March 31,2023	March 31, 2022
Indo-German Science And Technology Center	-	-	-	3.00
	-	-	-	3.00

(*) Amount disclosed under the head ' Other Financials Liabilities' refer Note 16

Privi Biotechnologies Private limited taken loan from Indo-German Science and Technology Center (for the project on design of selective nanoporous membrane bioreactor for efficient production of bio-butanol from lignocellulosic sugars.) amounting Rs. 30 Lakhs which is repayable in ten equal half yearly installment starting from March 2018 and year maturity of Loan is Sep - 2022.

13 Provisions

	Non Current		Current	
Provisions for employee benefits	March 31,2023	March 31, 2022	March 31,2023	March 31, 2022
Gratuity	17.97	15.62	0.63	1.36
Compensated absences	10.00	11.85	1.44	0.33
	27.97	27.47	2.07	1.69

14 Income tax

	March 31,2023	March 31,2022
Current income tax		
Current income tax expenses	-	-
Tax Adjustment of earlier years	-	-
Deferred tax		
Relating to origination and reversal of temporary differences		
Income tax expense reported on the statement of profit or loss	10.28	(74.31)
	10.28	(74.31)
Income tax recognised in other comprehensive income		
Tax expense related to items recognised in OCI during the year:		
Actuarial loss on defined benefit plan	0.66	1.58
Income tax charged to OCI	0.66	1.58

Deferred tax (assets)/liabilities	As at 1 April 2022	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	March 31,2023
Expenses allowable for tax purposes when paid	16.15		0.66	16.82
Tax depreciation	(88.88)	10.28	-	(78.60)
	(72.73)	10.28	0.66	(61.78)

Deferred tax (assets)/liabilities	As at 1 April 2021	Credit/(charge) in the statement of profit and Loss	Credit/(charge) in other comprehensive income	As at 31 March 2022
Expenses allowable for tax purposes when paid	-	14.57	1.58	16.15
Tax depreciation	-	(88.88)	-	(88.88)
	-	(74.31)	1.58	(72.73)

15 Trade Payable

	March 31,2023	March 31, 2022
a) Total outstanding dues of micro and small enterprises	-	-
b) Total outstanding dues of creditors other than micro and small enterprises		
i) Payable to Related parties (Refer note no. 33)	-	-
ii) Other Payable	-	-
	52.60	39.67
	52.60	39.67

Particulars	Less Than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	-	-	-	-	-
ii) Others	-	-	-	-	-
iii) Disputed dues - MSME	52.60	-	-	-	-
iv) Disputed dues-Others	-	-	-	-	-
	-	-	-	-	-
	52.60	-	-	-	-

Particulars	Less Than 1 year	1-2 years	2-3 years	More than 3 years	Total
i) MSME	-	-	-	-	-
ii) Others	-	-	-	-	-
iii) Disputed dues - MSME	52.60	-	-	-	52.60
iv) Disputed dues-Others	-	-	-	-	-
	-	-	-	-	-
	52.60	-	-	-	52.60

16 Other financial liabilities

	March 31,2023	March 31, 2022
Interest accrued but not due on borrowings	-	-
Payable for capital expenditure	-	0.70
Employee's Expenses Payable	-	-
Other Current Borrowings (Refer Note 12)	27.97	39.29
Deposits	-	3.00
	25.00	25.00
	52.97	67.99

17 Other Current Liabilities

	March 31,2023	March 31, 2022
Statutory dues (including provident fund, tax deducted at source and others)	9.58	2.68
	9.58	2.68

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

		Year Ended March 31,2023	Year Ended March 31,2022
18	**Revenue from Operations**		
	Techincal Services	622.50	510.00
		622.50	510.00
19	**Other Income**		
	Interest income from fixed deposits	1.97	3.35
	Rent received	105.00	90.00
	Miscelleneous Income	2.18	0.90
	Profit on Sale of Investment	-	-
		109.15	94.25
20	**Employee benefits expense**		
	Salaries, wages and bonus	237.77	251.82
	Contribution to provident and other funds	13.91	15.14
	Staff welfare expenses	5.86	16.80
		257.54	283.76
21	**Finance Cost**		
	Interest on other loans	-	0.57
	Amortisation of premium on forward exchange contracts	-	-
	Other Finance cost		-
	Interest on delayed payment of income tax	-	-
		-	0.57
22	**Depreciation and amortisation**		
	Depreciation on tangible assets	194.43	199.17
	Amortisation of intangible assets	10.32	10.32
	Amortisation right of use assets	32.62	2.11
		237.37	211.60

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Privi Biotechnologies Private Limited

Notes to the Standalone Financial Statements ***(Continued)***

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

		Year Ended March 31,2023	Year Ended March 31,2022
23	**Other Expenses**		
	Power and fuel	102.13	124.82
	Repairs and maintenance of:		
	Buildings	1.73	2.73
	Plant and machinery	40.85	59.10
	others	5.64	55.21
	Consumables	63.64	15.20
	Contract Labour Charges	38.96	20.69
	Insurance	2.12	1.98
	Rates and taxes	0.57	0.74
	Training Expenses	0.61	-
	Auditors remuneration:		
	Statutory audit	0.75	1.10
	Printing and stationery	7.90	11.13
	Selling and distribution		
	Legal and professional fees	16.71	8.16
	Travelling and conveyance	12.79	8.26
	Bank charges	-	0.49
	Other Admin Expenses	54.88	36.99
		349.28	346.60

(Currency: Indian Rupees in lakhs)

24 Employee benefits - Post-employment benefit plans

a) Defined contribution plans

The Company makes contributions, determined as a specified percentage of employee salaries, in respect of qualifying employees towards Provident Fund, Super annuation fund and ESI which are defined contribution plans. The Company has no obligations other than to make the specified contributions. The contributions are charged to statement of profit and loss as they accrue.

The Company has recognised the following amount as an expense and included in the Note 17 under "Contribution to provident & other funds":

	Year ended March 31, 2023	Year ended March 31, 2022
Contribution to employees provident fund	13.75	7.75
Contribution to ESI	0.16	0.12

b) Defined benefit plans

The Company operates one post-employment defined benefit plan (funded plan) that provides gratuity. The gratuity plan entitles an employee, who has rendered at least five years of continuous service, to receive one-half month's salary for each year of completed service at the time of retirement. In case of employees completing longer service periods, the Company's scheme is more favourable as compared to the obligation under Payment of Gratuity Act, 1972.

	As at March 31, 2023	As at March 31, 2022
Amount recognised in the Balance Sheet in respect of Gratuity		
Present value of the funded defined benefit obligation at the	18.59	15.95
Net liability/(asset)	18.59	15.95
Movement in present value of defined benefit obligation		
Opening Defined Benefit Obligations	15.95	11.45
Current service cost	4.14	3.68
Interest cost	1.14	0.74
Actuarial (gain)/loss	(2.64)	0.09
Benefits paid	-	-
Closing defined benefit obligation	18.59	15.95

(Currency: Indian Rupees in lakhs)

24 Employee benefits - Post-employment benefit plans *(Continued)*

b) Defined benefit plans *(Continued)*	As at March 31, 2023	As at March 31, 2022
Expense recognised in statement of profit and loss		
Current service cost	4.14	3.68
Interest on defined benefit obligations	1.14	0.74
Total	5.28	4.42
Remeasurements recognised in Other comprehensive income		
Change in Demographic Assumption	-	0.01
Change in Financial Assumption	(0.70)	(1.48)
Experience adjustments	(1.93)	1.56
Total	(2.64)	0.09
Total expense recognised	2.64	4.51

Principal actuarial assumptions at the balance sheet date	March 31, 2023	March 31, 2022
Discount rate (p.a.)	7.15%	6.44%
Expected rate of Salary increase (p.a.)	8.25%	8.25%
Attrition Rate	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%	For service 2 years and below : 20% For service 3 to 4 Years : 10% For service 5 Years and above: 5%
Mortality Tables	Indian Assured Lives Mortality (2012-14)	Indian Assured Lives Mortality (2006-08)

The estimates of future salary increase , considered in actuarial valuation, take account of inflation, seniority, promotion and other relevant factors such as supply and demand in the employment market.

Estimated rate of return on plan assets is based on average long term rate of return expected on investments of the Fund during the estimated term of the obligations.

A quantitative sensitivity analysis for significant assumption is as shown below:

	Discount rate		Future salary increase	
Impact on defined benefit obligation due to:	**March 31, 2023**	March 31, 2022	**March 31, 2023**	March 31, 2022
a. 1% increase	2.34	2.14	2.30	2.10
b. 1% decrease	(1.97)	(1.79)	(1.97)	(1.79)

The sensitivity analyses above have been determined based on a method that extrapolates the impact on defined benefit obligation as a result of reasonable changes in key assumptions occurring at the end of the reporting period, as calculated by Actuary.

Experience adjustment

	March 31, 2023	March 31, 2022
Defined benefit obligation	18.59	15.95
Plan assets	-	-
Surplus/(deficit)	(18.59)	(15.95)
Experience adjustment on plan liabilities	(1.93)	0.01
Experience adjustment on plan assets	-	-

E.E. SHAIKH & CO. MUMBAI Chartered Accountants

Notes to the Standalone Financial Statements *(Continued)*

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

25 Related party disclosures

a) List of Related Parties

Related parties where control exist:

Holding Company
- Privi Speciality Chemicals Limited
  (formerly known as Fairchem Speciality Limited)

Enterprises owned or significantly influenced by key management personnel or their relatives
- Privi Life Sciences Pvt. Ltd.
- Prasad Organics Pvt. Ltd
- Privi Organics Ltd
- Privi Fine Sciences Private Limited
- Vivira Investment and Trading Pvt. Ltd
- Satellite Technologies Private Limited

Key Management Personnel (KMP)
- Mr. D. B. Rao (Managing Director)
- Mr. Mahesh P. Babani (Director)

b) During the year, following transactions were carried out with the related parties :

	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
Transactions	March 31,2023	31 March 2022	March 31,2023	31 March 2022	March 31,2023	31 March 2022
Purchase of raw materials						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	-	5.09	-	-	-	-
Privi Organics Ltd	-	-	2.81	-	-	-
Vivira Investment and Trading Pvt Ltd	-	-	-	-	-	-
Purchase of Consumable						
Prasad Organics Pvt Ltd	-	-	-	5.90	-	-
Privi Life Science Pvt Ltd	-	-	-	1.46	-	-
Technical services						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	622.50	420.00	-	-	-	-
Rent						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	105.00	60.00	-	-	-	-

Particulars	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives		Key Management Personnel and their relatives	
	March 31,2023	31 March 2022	March 31,2023	31 March 2022	March 31,2023	31 March 2022
Trade Receivable						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	279.77	129.16	-	-	-	-
Trade Payables						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	-	-	-	-	-	-
Privi Life Science Pvt Ltd	-	-	-	-	-	-
Prasad Organics Pvt Ltd	-	-	-	-	-	-
Other Payables						
Privi Speciality Chemicals Ltd (formerly known as Fairchem Speciality Limited)	25.00	25.00	-	-	-	-

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

(Currency: Indian Rupees in lakhs)

24 Related party disclosures

a) List of Related Parties

Related parties where control exist:

Holding Company
Privi Speciality Chemicals Limited

Enterprises owned or significantly influenced by key management personnel or their relatives:
Privi Life Sciences Pvt. Ltd.
Prasad Organics Pvt. Ltd.

Key Management Personnel
Mr. D. B. Rao (Managing Director)
Mr. Mahesh P. Bahuai (Director)

b) During the year, following transactions were carried out with the related parties :

	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives						Key Management Personnel					
	Privi Speciality Chemicals Limited		Privi Life Sciences Pvt. Ltd.		Prasad Organics Pvt. Ltd.		Vivira Investment and Trading Pvt Ltd		Privi Organics Ltd		D.B.Rao		Mahesh P Bahuai	
	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22
Equity Share Capital	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of raw materials	-	5.09	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of Consumables	-	-	-	-	-	-	-	0.27	-	-	-	-	-	-
Technical Services	622.50	420.00	-	3.46	-	5.50	-	-	2.81	-	-	-	-	-
Rent	180.00	60.00	-	-	-	-	-	-	-	-	-	-	-	-
Security Deposit	-	-	-	-	-	-	-	-	-	-	-	-	-	-

*Remuneration does not include charge for gratuity and leave encashment as employee wise break up not available

c) Outstanding balances

Particulars	Holding Company		Enterprises owned or significantly influenced by key management personnel or their relatives						Key Management Personnel					
	Privi Speciality Chemicals Limited		Privi Life Sciences Pvt. Ltd.		Prasad Organics Pvt. Ltd.		Vivira Investment and Trading Pvt Ltd		Privi Organics Ltd		D.B.Rao		Mahesh P Bahuai	
	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22	March 31,2023	2021-22
Trade Payables	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Payables	25.00	25.00	-	-	-	-	-	-	-	-	-	-	-	-
Trade Receivables	379.72	129.16	-	-	-	-	-	-			-	-	-	-

E.E. SIYABKHAN & CO. MUMBAI Chartered Accountants

Notes to the Standalone Financial Statements ***(Continued)***

for the year ended March 31,2023

(Currency: Indian Rupees in lakhs)

		March 31,2023	March 31, 2022
26	**Earnings per share**		
	Profit/(Loss) after tax attributable to equity shareholders [A]	**(102.26)**	(312.59)
	Number of equity shares at the beginning of the year [B]	**3,62,74,728**	3,62,74,728
	Number of equity shares outstanding at the end of the year [C]	**3,62,74,728**	3,62,74,728
	Weighted average number of equity shares outstanding during the year	**3,62,74,728**	3,62,74,728
	Basic & Diluted earnings (in rupees) per share of face value Rs. 10	**(0.28)**	(0.86)

27 Previous year comparative

The previous year figures have been regrouped and reclassified, wherever required.

28 Information with regard to other additional information and other disclosures to be disclosed by way of notes to Statement of Profit and Loss as specified in Schedule III to the Act is either 'nil ' or ' not applicable ' to the Company for the year.

For For M/S. E.E Sitabkhan & Co.
Chartered Accountants

(E.E. Sitabkhan)
Proprietor, M.No.30721

E.E. SITABKHAN & CO. MUMBAI Chartered Accountants

Mumbai
Date : May 05 2023

For and on behalf of the Board of Directors of
Privi Biotechnologies Private Limited

D. B. Rao
Managing Director
DIN: 00356218

Mahesh Babani
Director
DIN: 00051162

Narayan S Iyer
Chief Financial Officer
Membership No: 105320

Ashwini Shah
Company Secretary
Membership No: A-58378

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Independent Auditor's Report

To the Board of Directors of Privi Speciality Chemicals Limited

Report on the audit of the Standalone Annual Financial Results

Opinion

We have audited the accompanying standalone annual financial results of Privi Speciality Chemicals Limited (hereinafter referred to as the "Company") for the year ended 31 March 2025, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone annual financial results:

a. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

b. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of the net profit and other comprehensive loss and other financial information for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results* section of our report. We are independent of the Company, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion on the standalone annual financial results.

Management's and Board of Directors' Responsibilities for the Standalone Annual Financial Results

These standalone annual financial results have been prepared on the basis of the standalone annual financial statements.

The Company's Management and the Board of Directors are responsible for the preparation and presentation of these standalone annual financial results that give a true and fair view of the net profit/ loss and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and

presentation of the standalone annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone annual financial results, the Management and the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the standalone annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the standalone annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone annual financial results, including the disclosures, and whether the standalone annual financial results represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

525

Other Matter

a. The standalone annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar

Partner

Membership No.: 113959

UDIN:25113959BMLXBP9137

Mumbai

03 May 2025

Privi Speciality Chemicals Limited

PRIVI

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC286828

Audited standalone statement of assets and liabilities as at March 31, 2025 (Rs. In Lakhs)

Particulars	As at March 31, 2025 Audited	As at March 31, 2024 Audited
Assets		
Non-current assets		
Property, plant and equipment	93,563.23	95,334.72
Capital work-in-progress	5,628.57	1,658.58
Right of use assets	3,407.56	3,777.31
Other Intangible assets	930.42	834.61
Intangible assets under development	1,386.82	1,008.56
Financial assets		
Investments	6,170.54	6,163.14
Other financial assets	1,808.64	1,656.56
Income tax assets (net)	1,512.94	2,343.19
Other non-current assets	3,544.22	1,349.42
Total non-current assets	**1,17,952.94**	**1,14,126.09**
Current assets		
Inventories	72,267.11	60,282.56
Financial assets		
Trade receivables	40,076.14	36,108.27
Cash and cash equivalents	4,058.45	1,575.08
Bank balances other than cash and cash equivalents	6.79	444.78
Other financial assets	629.74	-
Other current assets	12,352.44	6,333.96
Total current assets	**1,29,390.67**	**1,04,744.65**
Total assets	**2,47,343.61**	**2,18,870.74**
Equity and liabilities		
Equity		
Equity share capital	3,906.27	3,906.27
Other equity	1,06,213.00	88,141.61
Total equity	**1,10,119.27**	**92,047.88**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	27,913.38	38,350.20
Lease liabilities	274.12	820.04
Provisions	2,254.17	1,778.96
Deferred tax liabilities (net)	2,221.95	2,355.03
Total non-current liabilities	**32,663.62**	**43,304.23**
Current liabilities		
Financial liabilities		
Borrowings	56,862.93	50,462.91
Lease liabilities	542.84	373.86
Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	1,243.11	1,275.87
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	39,269.08	27,060.55
Other financial liabilities	6,045.94	2,339.34
Other current liabilities	316.42	509.16
Provisions	280.40	198.92
Current tax liabilities (net)	-	1,298.02
Total current liabilities	**1,04,560.72**	**83,518.63**
Total liabilities	**1,37,224.34**	**1,26,822.86**
Total equity and liabilities	**2,47,343.61**	**2,18,870.74**

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

527

Privi Speciality Chemicals Limited

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC286828

Statement of audited standalone financial results for the quarter and year ended March 31, 2025 (Rs. in lakhs)

Sr. No.	Particulars	Quarter ended March 31, 2025 (Note no.5)	Quarter ended December 31, 2024	Quarter ended March 31, 2024 (Note no.5)	Year ended March 31, 2025	Year ended March 31, 2024
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue from operations	58,072.85	49,819.56	47,561.41	2,03,834.26	1,71,206.12
2	Other income	1,417.08	104.93	653.25	1,790.47	2,161.63
3	**Total income (1+2)**	**59,489.93**	**49,924.49**	**48,214.66**	**2,05,624.73**	**1,73,367.75**
4	**Expenses**					
	(a) Cost of materials consumed	30,349.39	30,351.65	22,758.14	1,14,132.73	93,197.62
	(b) Changes in inventories of finished goods and work-in-progress	1,883.30	(4,762.27)	4,107.26	(3,574.49)	5,442.38
	(c) Employee benefits expense	1,944.06	1,931.38	1,590.66	7,515.05	6,544.46
	(d) Finance costs	2,137.31	2,044.83	2,356.06	8,379.31	9,502.36
	(e) Depreciation and amortisation expense	3,177.72	3,169.04	3,076.76	12,667.94	12,195.37
	(f) Power and fuel expense	3,798.44	3,807.41	3,533.75	15,183.00	13,802.14
	(g) Exchange rate difference (net)	-	354.59	-	-	-
	(h) Other expenses	7,375.13	7,060.80	6,164.12	25,934.28	19,485.74
	Total expenses (4)	**50,665.35**	**43,957.43**	**43,586.75**	**1,80,237.82**	**1,60,170.07**
5	**Profit before tax (3-4)**	**8,824.58**	**5,967.06**	**4,627.91**	**25,386.91**	**13,197.68**
6	**Tax expenses**					
	Current tax	2,358.79	1,515.57	1,020.86	6,563.27	3,080.18
	Deferred tax (Credit) / Charge	(146.50)	14.38	172.81	(106.61)	329.01
7	**Net profit for the period / year (5-6)**	**6,612.29**	**4,437.11**	**3,434.24**	**18,930.25**	**9,788.49**
8	**Other comprehensive income**					
	(i) Items that will not be reclassified to profit or loss					
	-Remeasurements of the net defined benefit plans	(54.75)	(7.97)	17.58	(104.08)	15.81
	-Income tax related to above	13.83	2.04	(4.54)	26.47	(4.08)
	Total other comprehensive income / (loss) (8)	**(40.92)**	**(5.93)**	**13.04**	**(77.61)**	**11.73**
9	**Total comprehensive income (7+8)**	**6,571.37**	**4,431.18**	**3,447.28**	**18,852.64**	**9,800.22**
10	Paid up equity share capital (Face value of Rs. 10/- each)	3,906.27	3,906.27	3,906.27	3,906.27	3,906.27
11	Other equity				1,06,213.00	88,141.61
12	Earnings per share (EPS) of Rs. 10/- each (*not annualised) (In Rs.)					
	Basic and Diluted (In Rs.)	*16.93	*11.36	*8.79	48.46	25.06

Please see accompanying notes to the standalone financial results.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE

Privi Speciality Chemicals Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC286828

PRIVI

Audited standalone statement of cash flows for the year ended March 31, 2025 (Rs. In lakhs)

Sr No.	Particulars	Year ended March 31, 2025	Year ended March 31, 2024
		Audited	Audited
A	**Cash flows from operating activities**		
	Profit before tax	25,386.91	13,197.68
	Adjustment for:		
	Depreciation and amortisation expenses	12,298.19	11,635.31
	Amortisation of right of use assets	369.75	560.06
	(Gain) on write-back of financial liabilities	(54.92)	-
	Sundry balances written off	11.53	0.78
	Unrealised foreign exchange (gain) / loss (net)	1,963.92	(680.84)
	Interest income	(14.08)	(29.38)
	Finance costs	8,379.31	9,502.36
	Loss on sale of property, plant and equipment	18.53	25.60
	(Gain) on disposal of Other Intangible assets	(63.78)	-
	(Gain) on sale of investments (net)	(1.01)	(8.70)
	Allowance for expected credit loss and credit impairment	41.20	-
	Operating cash flows before working capital changes	**48,335.55**	**34,202.87**
	Changes in working capital:		
	(Increase) in trade receivables	(4,009.07)	(4,659.48)
	(Increase) / Decrease in inventories	(11,984.55)	14,213.69
	(Increase) / Decrease in other current and non current assets (non financial assets)	(6,556.61)	2,769.78
	(Increase) in financial assets	(781.82)	(149.37)
	Increase / (Decrease) in trade payables	12,175.77	(1,435.87)
	Decrease / (Increase) in financial liabilities	36.45	(882.02)
	Decrease / (Increase)in non financial liabilities and provisions	219.89	(5,231.44)
		(10,899.94)	**4,625.29**
	Cash generated from operating activities	**37,435.61**	**38,828.16**
	Income taxes paid	(7,031.04)	(2,649.71)
	Net cash generated from operating activities [A]	**30,404.57**	**36,178.45**
B	**Cash flows from investing activities**		
	Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital	(15,127.05)	(10,261.43)
	Proceeds from sales of property, plant & equipment and Other Intangible assets	344.96	2.65
	Investment in subsidiaries	-	(1,020.00)
	Investment in structured entity	-	(499.50)
	Fixed deposit placed	-	(32.83)
	Proceeds on maturity of Fixed deposit	356.72	7.30
	Interest received	14.08	29.38
	Net cash (used in) investing activities [B]	**(14,411.29)**	**(11,774.43)**
C	**Cash flows from financing activities**		
	Proceeds from Non-current borrowings	14,900.00	17,400.00
	Repayment of Non-current borrowings	(25,716.76)	(15,987.10)
	Current borrowings (net)	6,771.79	(15,530.33)
	Payment of lease liabilities including interest on lease	(463.26)	(558.40)
	Dividend paid	(781.25)	-
	Interest paid	(8,220.11)	(9,178.38)
	Net cash (used in) financing activities [C]	**(13,509.59)**	**(23,854.21)**
	Net increase in cash and cash equivalents (A+B+C)	**2,483.69**	**549.81**
	Cash and cash equivalents at the beginning of the year	**1,575.08**	**1,025.27**
	Exchange differences on translation of foreign currency cash and cash equivalents	**(0.32)**	-
	Cash and cash equivalents at the end of the year	**4,058.45**	**1,575.08**

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063.
Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710.

Notes:

1 The audited standalone financial results for the quarter and year ended March 31, 2025 were reviewed by the audit committee and approved by the Board of Directors of Privi Speciality Chemicals Limited ("the Company") at its meeting held on May 03, 2025. The above results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion.

2 The audited standalone financial results of the Company have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The Company's business activity falls within a single segment viz. 'Aroma Chemical'. There is single operating segment as per Ind AS 108 "operating segment".

4 The Board of Directors at its meeting held on May 03, 2025 has recommended a final dividend of Rs. 5/- per equity share of face value of Rs.10/- each aggregating to Rs.1,953.13 lakhs for the financial year ended March 31, 2025, subject to approval of the shareholders at the ensuing 40th annual general meeting of the company.

5 The figures for the quarter ended March 31, 2025 and March 31, 2024, are arrived at as difference between audited figures in respect of the financial year and the unaudited figures upto nine months of the relevant financial year.

6 The financial results of the Company are available for investors at **www.privi.com, www.nseindia.com** and **www.bseindia.com**

Place: Navi Mumbai
Date : May 03, 2025

B R & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

For and on behalf of the Board of Directors
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710.

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Independent Auditor's Report

To the Board of Directors of Privi Speciality Chemicals Limited

Report on the audit of the Consolidated Annual Financial Results

Opinion

We have audited the accompanying consolidated annual financial results of Privi Speciality Chemicals Limited (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its subsidiaries together referred to as "the Group"), for the year ended 31 March 2025, attached herewith, being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditor on financial results of the subsidiaries, the aforesaid consolidated annual financial results:

a. include the annual financial results of the entities mentioned in Annexure I to the aforesaid consolidated annual financial results.

b. are presented in accordance with the requirements of Regulation 33 of the Listing Regulations in this regard; and

c. give a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards, and other accounting principles generally accepted in India, of consolidated net profit and other comprehensive loss and other financial information of the Group for the year ended 31 March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing ("SAs") specified under section 143(10) of the Companies Act, 2013 ("the Act"). Our responsibilities under those SAs are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results* section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act, and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, along with the consideration of reports of the other auditor referred to in sub paragraph no. (a) of the "Other Matters" paragraph below, is sufficient and appropriate to provide a basis for our opinion on the consolidated annual financial results.

Management's and Board of Directors' Responsibilities for the Consolidated Annual Financial Results

These consolidated annual financial results have been prepared on the basis of the consolidated annual financial statements.

The Holding Company's Management and the Board of Directors are responsible for the preparation and presentation of these consolidated annual financial results that give a true and fair view of the consolidated net profit/ loss and other comprehensive income and other financial information of the Group in accordance with the recognition and measurement principles laid down in Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting

principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Management and Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of each company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the consolidated annual financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated annual financial results by the Management and the Board of Directors of the Holding Company, as aforesaid.

In preparing the consolidated annual financial results, the respective Management and the Board of Directors of the companies included in the Group are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Annual Financial Results

Our objectives are to obtain reasonable assurance about whether the consolidated annual financial results as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated annual financial results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated annual financial results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures in the consolidated annual financial results made by the Management and Board of Directors.
- Conclude on the appropriateness of the Management's and Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the appropriateness of this assumption. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated annual financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated annual financial results, including the disclosures, and whether the consolidated annual financial results represent the

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park 3, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063
Chartered Accountants

underlying transactions and events in a manner that achieves fair presentation.

- Obtain sufficient appropriate audit evidence regarding the financial results of the entities within the Group to express an opinion on the consolidated annual financial results. We are responsible for the direction, supervision and performance of the audit of financial results of such entities included in the consolidated annual financial results of which we are the independent auditor. For the other entities included in the consolidated annual financial results, which have been audited by other auditor, such other auditor remain responsible for the direction, supervision and performance of the audits carried out by them. We remain solely responsible for our audit opinion. Our responsibilities in this regard are further described in sub paragraph no. (a) of the "Other Matter" paragraph in this audit report.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated annual financial results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

We also performed procedures in accordance with the circular No CIR/CFD/CMD1/44/2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

Other Matter

a. The consolidated annual financial results include the audited financial results of 3 subsidiaries, whose financial results reflects total assets (before consolidation adjustments) of Rs. 51,471.34 lakhs as at 31 March 2025, total revenue (before consolidation adjustments) of Rs. 49,525.84 lakhs and total net loss after tax (before consolidation adjustments) of Rs. 507.55 lakhs and cash inflows (before consolidation adjustments) of Rs 94.38 lakhs for the year ended on that date, as considered in the consolidated annual financial results, which have been audited by their respective independent auditor. The independent auditor's reports on financial results of these entities have been furnished to us by the management.

   Our opinion on the consolidated annual financial results, in so far as it relates to the amounts and disclosures included in respect of these entities, is based solely on the reports of such auditor and the procedures performed by us are as stated in paragraph above.

   Our opinion on the consolidated annual financial results is not modified in respect of the above matter with respect to our reliance on the work done and the reports of the other auditor.

b. The consolidated annual financial results include the results for the quarter ended 31 March 2025 being the balancing figure between the audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the current financial year which

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

were subject to limited review by us.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Jayesh T Thakkar
Partner
Membership No.: 113959
UDIN:25113959BMLXBQ5147

Mumbai
03 May 2025

Independent Auditor's Report *(Continued)*

Privi Speciality Chemicals Limited

Annexure I

List of entities included in consolidated annual financial results.

Sr. No	Name of component	Relationship
1	Privi Speciality Chemicals Limited	Holding Company
2	Privi Biotechnologies Private Limited	Wholly Owned Subsidiary
3	Privi Speciality Chemicals USA Corporation	Wholly Owned Subsidiary
4	Prigiv Specialties Private Limited	Subsidiary

BSR & Co. LLP
14th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

Privi Speciality Chemicals Limited

PRIVI

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC286828

Audited consolidated statement of assets and liabilities as at March 31, 2025 (Rs. In Lakhs)

Particulars	As at March 31, 2025	As at March 31, 2024
	Audited	Audited
Assets		
Non-current assets		
Property, plant and equipment	1,09,788.80	96,886.98
Capital work-in-progress	12,747.22	8,873.56
Right of use assets	4,748.55	5,557.01
Other Intangible assets	1,064.28	997.81
Intangible assets under development	1,386.82	1,008.56
Financial assets		
Investments	83.23	75.83
Other financial assets	5,425.83	1,918.83
Income tax assets (net)	1,535.47	2,345.62
Other non-current assets	5,940.83	2,406.90
Total non-current assets	**1,42,721.03**	**1,20,071.10**
Current assets		
Inventories	78,844.58	65,938.52
Financial assets		
Investments	754.01	3,955.90
Trade receivables	39,414.59	34,750.22
Cash and cash equivalents	4,976.40	2,398.65
Bank balances other than cash and cash equivalents	42.71	480.37
Other financial assets	136.01	-
Other current assets	12,161.29	6,659.92
Total Current Assets	**1,36,329.59**	**1,14,183.58**
Total assets	**2,79,050.62**	**2,34,254.68**
Equity and liabilities		
Equity		
Equity share capital	3,906.27	3,906.27
Other equity - Equity attributable to owners of the company	1,06,436.75	88,532.70
Equity attributable to shareholders of the Company	**1,10,343.02**	**92,438.97**
Non-controlling interest	1,449.11	1,673.68
Total equity	**1,11,792.13**	**94,112.65**
Liabilities		
Non-current liabilities		
Financial liabilities		
Borrowings	51,113.38	44,450.20
Lease liabilities	946.45	1,853.71
Provisions	2,450.86	1,914.52
Deferred tax liabilities (net)	2,411.30	2,319.57
Total non-current liabilities	**56,921.99**	**50,538.00**
Current liabilities		
Financial liabilities		
Borrowings	61,155.79	53,631.12
Lease liabilities	1,067.51	883.31
Trade payables		
a) Total outstanding dues of micro enterprises and small enterprises	1,243.11	1,275.87
b) Total outstanding dues of creditors other than micro enterprises and small enterprises	38,981.95	26,975.55
Other financial liabilities	6,707.68	4,443.22
Other current liabilities	552.69	835.34
Provisions	294.84	208.69
Current tax liabilities (net)	332.93	1,350.93
Total current liabilities	**1,10,336.50**	**89,604.03**
Total liabilities	**1,67,258.49**	**1,40,142.03**
Total equity and liabilities	**2,79,050.62**	**2,34,254.68**

BSR & Co. LLP Chartered Accountants 14th Floor, Central B Wing and North B Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Mumbai - 400 710.

526

Privi Speciality Chemicals Limited

Regd. Office : Privi House, A-71, TTC Industrial Area, Thane Belapur Road, Kopar Khairane, Navi Mumbai-400 710. India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC786828

Statement of audited consolidated financial results for the quarter and year ended March 31, 2025 (Rs. in Lakhs)

Sr. No.	Particulars	Quarter ended March 31, 2025 (Note no 6)	Quarter ended December 31, 2024	Quarter ended March 31, 2024 (Note no.6)	Year ended March 31, 2025	Year ended March 31, 2024
		Audited	Unaudited	Audited	Audited	Audited
1	Income from operations	61,355.03	49,087.12	48,434.84	2,10,119.08	1,75,223.47
2	Other income	1,481.85	218.66	758.39	2,064.56	2,829.96
3	Total income (1+2)	62,836.88	49,305.78	49,193.23	2,12,183.64	1,77,053.43
4	Expenses					
	(a) Cost of materials consumed	31,865.77	29,034.48	24,028.81	1,17,195.15	95,450.68
	(b) Purchase of stock in trade	1.20	0.50	-	148.64	225.53
	(c) Changes in inventories of finished goods, stock in trade and work in progress	2,181.88	(6,125.22)	4,507.01	(4,194.61)	5,262.07
	(d) Employee benefits expense	2,354.26	2,197.81	1,800.15	8,651.13	7,273.57
	(e) Finance cost	2,257.09	2,175.08	2,505.99	8,788.33	9,793.85
	(f) Depreciation and amortisation expense	3,491.75	3,233.64	2,956.04	13,175.83	12,341.43
	(g) Power and fuel expense	3,894.23	3,823.40	3,557.86	15,327.37	13,826.23
	(h) Exchange rate difference (net)	-	359.20	-	-	-
	(i) Other expenses	7,797.63	7,671.10	6,432.48	27,640.08	20,688.12
	Total expenses (4)	53,843.81	43,214.14	44,797.34	1,68,731.17	1,64,867.50
5	Profit before tax (3-4)	8,993.07	6,091.64	4,395.89	25,452.28	12,185.93
6	Tax expense					
	Current tax	2,920.09	1,638.28	1,024.12	6,857.89	3,115.75
	Deferred tax	75.06	5.91	174.92	119.36	611.23
7	Net profit for the periods / year (5-6)	6,997.92	4,447.45	3,196.85	18,475.03	8,542.96
	Attributable to :					
	Owners of the Holding Company	6,852.46	4,449.70	3,102.19	18,699.60	9,490.72
	Non-controlling interest	(254.54)	3.75	84.66	(224.57)	52.24
8	Other comprehensive income					
	(i) Items that will not be reclassified to profit or loss					
	-Remeasurements of the net defined benefit plans	(55.90)	(9.12)	14.95	(108.69)	81.28
	-Income tax related to above	14.12	2.33	(3.88)	27.63	(2.82)
	(ii) Items that will be reclassified to profit or loss					
	Exchange differences in translating financial statements of foreign operations	1.24	54.60	1.65	66.76	33.00
	-Income tax related to above	-	-	-	-	-
	Total other comprehensive income / (loss) (8)	(40.54)	47.81	12.72	(14.30)	111.26
	Attributable to :-					
	Owners of the Holding Company	(40.54)	47.81	12.72	(14.30)	111.26
	Non-controlling interest	-	-	-	-	-
9	Total comprehensive income (7+8)	6,957.38	4,495.26	3,209.57	18,460.73	8,654.24
	Attributable to :-					
	Owners of the Holding Company	6,611.92	4,497.51	3,114.91	18,685.30	9,602.00
	Non-controlling interest	(254.54)	3.75	84.66	(224.57)	52.24
10	Paid up equity share capital (Face value of Rs. 10/- each)	3,906.27	3,906.27	3,906.27	3,906.27	3,906.27
11	Other equity				1,06,436.75	88,532.70
12	Earnings per share (EPS) of Rs. 10/- each (*not annualised) (in Rs.)					
	Basic and Diluted (in Rs.)	*17.03	*11.38	*8.16	47.87	24.49

Please see accompanying notes to the consolidated financial results.

BSR & Co. LLP Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710.

Privi Speciality Chemicals Limited

Regd. Office : Privi House, A-71,TTC Industrial Area,Thane Belapur Road,Kopar Khairane, Navi Mumbai - 400 710, India
Email : investors@privi.co.in Phone : +91 22 33043500 / 33043600 Fax : +91 22 27783049 Website : www.privi.com
CIN : L15140MH1985PLC286828

Audited consolidated statement of cash flows for the year ended March 31, 2025 (Rs. in lakhs)

Sr No.	Particulars	Year ended March 31, 2025	Year ended March 31, 2024
		Audited	Audited
A	**Cash flows from operating activities**		
	Profit before tax	25,452.28	12,990.93
	Adjustment for:		
	Depreciation and amortisation expenses	12,720.22	11,843.88
	Amortisation of right of use assets	455.11	497.55
	(Gain) on writen-back of financial liabilities	(54.92)	-
	Sundry balances written off	11.53	0.78
	Unrealised foreign exchange (gain) / loss (net)	1,963.92	(680.84)
	Interest Income	(186.53)	(32.23)
	Finance costs	8,788.33	9,793.85
	Loss on sale of property, plant and equipment (net)	18.53	(193.21)
	(Gain) on disposal of Other Intangible assets	(63.78)	-
	(Gain) on sale of investments (net)	(72.24)	(172.98)
	Change in fair value of investments at FVTPL (mutual fund)	(40.85)	(81.51)
	Allowance for expected credit loss and credit impairment	41.20	-
	Operating cash flows before working capital changes	**49,032.80**	**33,966.22**
	Changes in working capital:		
	(Increase) in trade receivables	(4,705.57)	(5,191.54)
	(Increase) / Decrease in inventories	(12,906.06)	13,999.42
	(Increase) / Decrease in other current and non current assets (non financial assets)	(8,264.31)	2,441.99
	(Increase) / Decrease in financial assets	(266.02)	(289.48)
	Increase/ (Decrease) in trade payables	11,973.64	(1,140.88)
	Decrease / (Increase) in financial liabilities	30.15	(872.95)
	Decrease / (Increase)in non financial liabilities and provisions	282.15	(4,872.76)
		(13,856.02)	**4,073.80**
	Cash generated from operating activities	**35,176.78**	**38,040.02**
	Income taxes paid	(7,065.74)	(2,591.63)
	Net cash generated from operating activities [A]	**28,111.04**	**35,448.39**
B	**Cash flows from investing activities**		
	Purchase of property, plant and equipment including CWIP, intangible assets, intangible assets under development and capital advances, net of capital creditors	(29,913.72)	(15,050.84)
	Proceeds from sales of property, plant & equipment and Other Intangible assets	68.38	819.82
	Investment in structured entity	-	(499.50)
	Investment in mutal fund (net)	-	(3,283.14)
	Proceeds from redemption of investments (mutual fund)	3,201.89	-
	Fixed deposit placed	(3,278.42)	(58.68)
	Proceeds on maturity of Fixed deposit	339.09	7.30
	Interest received	186.53	32.23
	Net cash (used in) investing activities [B]	**(29,396.25)**	**(18,032.81)**
C	**Cash flows from financing activities**		
	Proceeds from Non-current borrowings	31,100.00	23,500.00
	Repayment of Non-current borrowings	(25,066.76)	(15,987.10)
	Current borrowings (net)	8,154.61	(15,403.20)
	Equity contribution received from non controlling interest	-	980.11
	Payment of lease liabilities including interest on lease	(987.93)	(675.89)
	Dividend paid	(781.25)	-
	Interest paid	(8,555.39)	(9,475.76)
	Net cash generated / (used in) from financing activities [C]	**3,863.28**	**(17,061.84)**
	Net increase in cash and cash equivalents (A+B+C)	**2,578.07**	**353.74**
	Cash and cash equivalents at the beginning of the year	**2,398.65**	**2,044.91**
	Exchange differences on translation of foreign currency cash and cash equivalents	**(0.32)**	-
	Cash and cash equivalents at the end of the year	**4,976.40**	**2,398.65**

Note A : The above Statement of Cash Flows has been prepared under the 'Indirect Method' as set out in Ind AS 7, 'Statement of Cash Flows'.

BSR & Co. LLP 14th Floor, Central B Wing and Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063 Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD. REGD. OFFICE Navi Mumbai - 400 710

538

Notes:

1 The audited consolidated financial results for the quarter and year ended March 31, 2025 were reviewed by the audit committee and approved by the Board of Directors of Privi Speciality Chemicals Limited ("the Company") at its meeting held on May 03, 2025. These audited consolidated financial results have been subjected to audit by the statutory auditors of the Company. The statutory auditors have expressed an unmodified audit opinion.

2 The audited consolidated financial results of Privi Speciality Chemicals Limited ("the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") have been prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and in terms of the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

3 The audited consolidated financial results for the quarter and year ended March 31, 2025 comprise results of the following entities as a group :

Name of the Entity
Privi Speciality Chemicals Limited
Privi Biotechnologies Private Limited
Privi Speciality Chemicals USA Corporation
Prigiv Specialties Private Limited

4 The Group's business activity falls within a single segment viz. 'Aroma Chemical '. There is single operating segment as per Ind AS 108 "operating segment" .

5 The Board of Directors at its meeting held on May 03, 2025 has recommended a final dividend of Rs. 5/- per equity share of face value of Rs.10/- each aggregating to Rs.1,953.13 lakhs for the financial year ended March 31, 2025, subject to approval of the shareholders at the ensuing 40th annual general meeting of the company.

6 The figures for the quarter ended March 31, 2025 and March 31, 2024, are arrived at as difference between audited figures in respect of the financial year and the unaudited figures upto nine months of the relevant financial year.

7 The financial results of the Group are available for investors at **www.privi.com, www.nseindia.com and www.bseindia.com**

BSR & Co. LLP
5th Floor,
Central B Wing and
North C Wing,
Nesco IT Park4,
Nesco Center,
Western Express Highway,
Goregaon (East),
Mumbai - 400 063
Chartered Accountants

PRIVI SPECIALITY CHEMICALS LTD.
REGD. OFFICE
Navi Mumbai - 400 710

For and on behalf of the Board of Directors
Privi Speciality Chemicals Limited

Mahesh Babani
Chairman & Managing Director
DIN: 00051162

Place: Navi Mumbai
Date : May 03, 2025